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Abstract 
 
Opioid-mediated pain relief, currently the gold standard treatment for many types of pain, 
has been inextricably associated with negative side effects including analgesic tolerance and 
physical dependence. These side effects have perpetuated the rising rates of opioid addiction across 
the United States. Several investigators have shown that activating the mu opioid receptor (MOR) 
while blocking the delta opioid receptor (DOR) can provide pain relief devoid of tolerance or 
dependence, laying the foundation for the work presented here. This dissertation is focused on the 
design and synthesis of bifunctional ligands that both activate MOR and block DOR while binding 
to both targets with equal affinity. Specifically, this work investigates how substitutions at the N-
1, C-6, and C-8 positions of the tetrahydroquinoline (THQ) scaffold impact pharmacological 
activity. Through these investigations, we have identified two distinct chemical motifs that 
produce the desired MOR agonist/DOR antagonist efficacy profile. Furthermore, multiple 
analogues bearing this advantageous efficacy profile also display similar affinity for both targets, 
improve drug-like properties such as ClogP, and effectively block pain responses in mice after 
peripheral administration. Additionally, combining those chemical motifs in a hybrid ligand 
achieved optimal in vitro binding and efficacy, laying a foundation for further exploration. The 
work discussed herein has yielded 13 novel ligands displaying robust antinociceptive activity; 
evaluation of tolerance and dependence for select compounds is ongoing.  
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Chapter 1: Introduction 
 
1.1 The History of Opioids 
“Here was a panacea, a pharmakon nepenthes, for all human woes. Here was the secret of 
happiness, about which philosophers had disputed for so many ages, at once discovered.” 
— Thomas de Quincey 
“The Pleasures of Opium” in Confessions of 
an English Opium-Eater, 1856. 
 
The earliest evidence of human cultivation of the opium poppy, Papaver somniferum, was 
discovered in the submerged Neolithic settlement of La Marmotta near modern-day Rome, dating 
back to 5,700 BCE.1,2 The opium poppy appears to have been known throughout the eastern 
Mediterranean, as the Sumerian civilization of modern-day Iraq provides the first written example 
of opium preparation as early as the third millennium BCE. P. sominferum was depicted in the 
ancient Sumerian cuneiform script as “hul gil” or the “joy plant,” though this translation is the 
subject of some debate.3,4 The use of the opium poppy has appeared repeatedly throughout the 
history of the eastern Mediterranean civilizations.1,5,6 Spreading north from La Marmotta, over 33 
settlements in Switzerland and nearby France and Germany indicate cultivation of P. somniferum, 
dating back to the Neolithic, Copper, and Bronze Ages, as has been documented in a thorough 
review by ethnobotanist Mark Merlin in 2003.1 
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Galen (130 – 210 CE), in his writing De Compositione Medicamentorum Localium, 
described the “antidote of Hippocrates,” an opium-containing elixir, as a “panacea” or a cure for 
all that ails.7 Experimenting in the 16th century, the Swiss physician Paracelsus discovered that the 
active alkaloids in opium can be extracted much more effectively with alcohol than previous warm-
water preparations described by the Greeks. This tincture of opium he named “laudanum” was 
described as an effective analgesic, which was modified and popularized by English physician 
Thomas Sydenham in the 1660s in his seminal work Medical Observations Concerning the History 
and Cure of Acute Diseases. Laudanum became a popular drug of abuse in the Romantic and 
Victorian eras among both the working and artistic classes.8 Some notable opium users of this era 
include Samuel Taylor Coleridge, Thomas de Quincey, Charles Dickens, and Percy Shelley among 
others.8,9 It was around this time that opium first appeared as a public health threat, though orally 
ingested opium lacked many of the risk factors associated with modern intravenous opioid use.  
The early 1800s saw the isolation of a major active alkaloid from opium by the German 
pharmacist Friedrich Sertürner, which he named morphine after Morpheus, the Greek god of 
dreams. The isolation of morphine allowed for more standardized and predictable dosing, as 
laudanum preparations varied widely in potency.10 Sertürner’s crystallization of morphine is 
recognized as the first isolation of an active plant alkaloid. Following the invention of the 
hypodermic syringe and hollow needle in the 1850s, morphine use expanded to operating rooms 
across Europe.3 However, the advent of the hypodermic needle combined with the discovery of 
diacetylmorphine (heroin) in the late 1800s set the stage for the opioid crisis that is presently 
devastating large swaths of the United States. Other technological, legal, and cultural changes 
connecting morphine of the 1800s to the opioid crisis of 2018 are examined in depth in Johann 
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Hari’s Chasing the Scream (2015),11 Sam Quinones’ Dreamland (2015),12 and Beth Macy’s 
Dopesick (2018).13  
1.2 The Opioid Receptors 
“Pharmacological evidence for the existence of a specific opiate receptor is compelling, 
but heretofore it has not been directly demonstrated biochemically. We report here a direct 
demonstration of opiate receptor binding, its localization in nervous tissue, and a close parallel 
between the pharmacologic potency of opiates and their affinity for receptor binding.” 
— Candace B. Pert & Solomon H. Snyder 
“Opiate Receptor: Demonstration in Nervous 
Tissue” in Science, 1973. 
Throughout the 19th and 20th centuries, the library of known opioid ligands expanded 
significantly. With an increasing number of known opioid ligands, it had become apparent that 
changes in chemical structure and stereochemistry could modulate the pharmacological responses 
to these ligands. The existence of a structure-activity relationship (SAR) among the morphinan 
ligands suggested a specific binding site upon which these ligands must act.14–17 As early as the 
1950s, it had been proposed that one or multiple opioid receptors must exist,14 though they were 
not demonstrated experimentally until 1973.16–20 Due to the low concentration of opioid receptors 
in the brain and limited sensitivity for low specific activity radioligands, early [14C]-based probes 
failed to identify specific opioid binding sites.17 The implementation of [3H]naloxone by Pert and 
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Snyder,18 [3H]dihydromorphine by Terenius,19,20 and [3H]etorphine by Simon et al,21 enabled three 
laboratories to almost simultaneously identify what would later be termed the mu opioid receptor.  
Shortly after the discovery of the opioid receptors, some of the endogenous peptides for 
the opioid receptors, enkephalins and endorphins, were discovered.22,23 By the 1990s, three types 
of opioid receptors had been cloned—the mu opioid receptor (MOR),24,25 delta opioid receptor 
(DOR),26,27 and kappa opioid receptor (KOR).28,29 MOR is the most widely studied of the three 
and is the primary binding site of morphine and the endorphins. DOR is known to bind the 
endogenous enkephalin peptides and the prototypical DOR agonist SNC-80 is known to stimulate 
antinociception as well as antidepressant and anxiolytic effects.30,31 Unfortunately, SNC-80 is also 
associated with epileptic seizures in mice, limiting the therapeutic potential of selective DOR 
agonists.32 KOR, named after the synthetic benzomorphan derivative ketazocine, binds 
endogenous peptides known as dynorphins.33 Activation of KOR is associated with hallucinations 
and dysphoria, as is induced by the exogenous KOR agonist salvinorin A, found in the Salvia 
divinorum plant.34,35 The endorphins, enkephalins, and dynorphins all feature a conserved N-
terminal Tyr1-Gly2-Gly3-Phe4-X5 sequence, with the phenol and amine of Tyr1 participating in 
crucial H-bonds and ionic interactions. Most morphinan, peptide, and peptidomimetic ligands 
feature similar phenol and amine moieties, taking advantage of these endogenous H-bond partners.  
It is of note that the morphinan ligands such as morphine achieve high binding affinity by 
conformationally restricting the Tyr1 pharmacophore into a bridged phenanthrene ring system 
while truncating other pharmacophore elements of the endogenous peptides completely. The added 
rigidity of morphinan ligands reduces the entropic loss associated with binding, necessitating fewer 
receptor-ligand interactions to achieve similar affinity. Due to the conformational restriction and 
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rigidity of the morphinan scaffold, small changes often result in dramatic shifts in affinity or 
activity. Depicted in Fig. 1 are the structures, potencies, and functional activities of the highly 
homologous morphinan ligands morphine, codeine, and nalorphine as well as the enantiomeric 
pair levorphanol and dextrorphan. These data were reported by Pert and Snyder in the seminal 
work that described the first characterization of the opioid receptors.18  
Figure 1. SAR of the Morphinan Scaffold Adapted from Pert and Snyder, 1973a 
 
a Relative potencies of drugs in reducing [3H]naloxone binding to rat brain homogenate and guinea pig intestine. 
 
As demonstrated by the drastic reduction in potency induced by phenolic methylation of 
morphine (see codeine, Fig. 1), modification of the Tyr1 pharmacophore—especially at sites of 
critical H-bonds—is poorly tolerated. Additionally, extending the N-methyl group of morphine to 
an allyl substitution converts the opioid agonist activity of morphine to an antagonist profile in 
nalorphine. Other modifications to the stereochemistry of the Tyr1 moiety, as demonstrated by the 
pair of enantiomers levorphanol and dextrorphan, provides further validation that the receptors 
show preference for the endogenous tyrosine-like stereochemical orientation of levorphanol over 
the inverted orientation of the phenol and amine found in dextrorphan. This stereospecific binding 
provided some of the first concrete evidence of a specific opiate (opioid) receptor.  
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1.3  Opioid Receptor Signaling 
The opioid receptors belong to the Class A (rhodopsin-like) family of G protein-coupled 
receptors (GPCRs). GPCRs feature seven transmembrane alpha-helices and associate with a G 
protein at the intracellular surface. The opioid peptides and exogenous ligands bind to a large, 
solvent-exposed36–38 extracellular pocket and stabilize a particular conformation of the receptor. 
These are typically classified into the “inactive” and “active” states in relation to whether or not 
they stimulate the dissociation of a G protein, though there are nearly infinite conformations that 
a receptor might sample.39,40 Multiple investigators have engaged in molecular dynamics, NMR, 
and spectroscopic studies to probe the nature of events that relate the binding of an agonist to the 
dissociation of a heterotrimeric G protein from the membrane-bound GPCR.38–45 The shift from 
an inactive to an active state entails multiple translocations and rotations in domains, hydrogen 
bond network rearrangements, and ion cofactor and substrate exchanges. Simplistically speaking, 
binding of an agonist stabilizes a series of changes in the receptor that promotes G protein binding 
and subsequent dissociation of its Ga and its Gbg subunits.  
Classical ligand binding models consider two primary factors: the ligand and the receptor. 
An emerging concept in GPCR modeling and structural biology is that of a highly conserved water 
network as a third major factor (or cofactor) in ligand binding and receptor activation.40,46–52 The 
groups of Bryan Roth and Brian Kobilka, who combined have solved the crystal structures of  
MOR, DOR, and KOR at high resolution in both active and inactive states, have noted the 
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significance of water networks and their importance to GPCR activation, both in the orthosteric 
site and through the core of the receptor (see Fig. 2).40,46,47 Quoting the Kobilka group in 2018:   
The [high-resolution crystal structures] highlight the contribution of many hydrogen bonds 
in stabilizing both the inactive and active states of opioid receptors. These hydrogen bonds 
represent many low-energy molecular switches that have to be broken and reformed in a 
concerted manner to achieve the active conformation.46 
Figure 2. Active- and Inactive-State Water-Mediated Polar Networks of Opioid Receptorsa 
 
a Distinct networks of polar interactions extending through the transmembrane domains of the active- and inactive-
state crystal structures from Kobilka et al.46(Left) MOR 2.1 Å, PDB ID: 5C1M. (right) DOR 1.8 Å, PDB ID: 4N6H. 
The emerging structural biology studies in this area continue to add layers of detail to our 
understanding of how small modifications to ligands that bind at the extracellular orthosteric  
(ligand-binding) site can propagate through the transmembrane domains, facilitated by a 
membrane-spanning polar network, to modulate intracellular G protein interactions,.40,46,52–54 
Crystallographic, spectroscopic, and computational investigations into receptor activation indicate 
a critical role for an allosteric sodium ion in the inactive state,40,54 whereas the active state is more 
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solvated and features a continuous channel of waters extending through the core of the GPCR.52,53 
At present, computational models of GPCRs lack a comprehensive understanding and 
incorporation of the many factors involved in the transmission of a signal from the orthosteric 
binding site to the intracellular G protein interface. Thus, a reliable in silico determination of the 
efficacy or affinity of a ligand, especially when probing minor structural changes, still eludes 
computational models. Therefore, we rely primarily on radioligand assays to accurately report a 
compound’s in vitro affinity, potency, and efficacy, which can be further explained in some 
instances through computational modeling of the active or inactive states of the opioid receptors. 
These assays measure affinity through competitive displacement of an orthosteric radioligand, 
[3H]diprenorphine, and measure potency and efficacy via incorporation of a radiolabeled GTP 
analogue, [35S]GTPgS into Ga proteins. 
As depicted in Fig 3-1 the inactive-state G protein, which holds a GDP molecule between 
its Ga and its Gbg subunits, binds to an active-state GPCR intracellularly. GDP is displaced from 
the G protein when the active-state GPCR allosterically disrupts the G protein’s nucleotide-binding 
site (Fig. 3-2).38,42,45,55 A high intracellular GTP concentration drives the binding of GTP to the 
nucleotide-free binding site on the Ga subunit of the G protein.56 With GTP bound, the Gbg 
subunits dissociate from Ga (Fig. 3-3) and both subunits go on to promote intracellular 
signaling.56,57 The GTP is hydrolyzed following activation of downstream effectors (Fig. 3-4), 
shifting Ga to an inactive GDP-bound state. The Gbg subunits then re-associate with Ga (Fig. 3-
5), recycled for further intracellular signaling. In the [35S]GTPgS assay, the hydrolysis step (Fig. 
3-4) is blocked by replacement of an oxygen on the terminal phosphate with 35S, causing an 
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accumulation of radioactivity in the membrane connected to Ga activation that can be quantified 
by scintillation counting.  
 
Figure 3. GPCR-Stimulated G Protein Activation and Signalinga 
 
a Green outline indicates an activated G protein or GPCR, while blue indicates an inactive state. GDP is depicted as 
purple and GTP is shown in light blue. 1. Agonist binds to the GPCR, recruiting GDP-bound heterotrimeric G protein; 
GPCR-binding promotes dissociation of GDP from the nucleotide-binding site. 2. GTP binds the G protein nucleotide-
binding site. 3. Ga and its Gbg subunits dissociate in activated form and interact with downstream effectors such as 
cAMP, GIRK, and Ca2+ channels 4. GTP is hydrolyzed to GDP + Pi, inactivating Ga 5. GDP-bound Ga and Gbg re-
associate.  
Of the G protein subtypes, the opioid receptors selectively interact with the inhibitory G 
protein family. The Gai/o subunit inhibits adenylyl cyclase and production of cAMP. Meanwhile, 
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the Gbg subunit activates G protein-coupled inwardly-rectifying potassium channels (see Fig. 4), 
allowing outward K+ diffusion and inducing a hyperpolarized state in the neuron.56–59 Additionally, 
the dissociated Gbg subunit interacts with Ca2+ channels following GPCR activation, reducing the 
voltage-gated pore opening of Ca2+ channels thereby decreasing the Ca2+ concentration within the 
cell. The hyperpolarizing effects of decreased intracellular K+, paired with the decreased Ca2+ 
signaling, serves to further reduce neural firing.56,57 Through these mechanisms depicted in Fig. 4, 
as well as other downstream effectors, the opioid receptors act to quiet neural transmission. 
Figure 4. Downstream Effectors Following GPCR Activation of Inhibitory G Proteina 
 
a Inhibitory Ga, following GPCR activation, GTP binding, and dissociation from Gbg, activates K+ channels while 
inhibiting adenylyl cyclase and its downstream product cAMP. Gbg acts on Ca2+ channels to reduce influx of Ca2+. 
Because the opioid receptors are often found in cell populations responsible for pain 
transmission, opioid agonists (especially MOR agonists such as morphine) function to decrease 
the afferent pain signaling, resulting in analgesia. Of note, while agonism at MOR, DOR, and KOR 
all induce some antinociception, the euphoric and rewarding effects of MOR agonists such as 
morphine are not observed for agonists of DOR and KOR. In fact, DOR agonists are established 
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to be non-rewarding and non-euphoric whereas KOR agonists are known to be aversive and 
dysphoric. As such, it may be possible to combine these differential opioid effects to mitigate some 
negative side effects associated with MOR agonists, including tolerance and dependence.  
 
1.4  Bifunctional Opioid Ligands 
The idea that the opioid receptors may interact and modulate the activities of one another 
has been a subject of interest to many researchers aiming to improve opioid treatments. Of 
particular interest in the field of pain and analgesia is the observation that DOR agonists have been 
shown to potentiate the analgesic activity of MOR agonists60–63 while DOR antagonists are 
associated with a reduction in tolerance and dependence toward MOR agonists including 
morphine.64–66 In 1991, a landmark study by Abdelhamid, Sultana, Portoghese and Takemori 
demonstrated that the selective DOR antagonist naltrindole (NTI) reduced both tolerance and 
dependence toward morphine in mice.64  
Following a single subcutaneous (s.c.) injection of morphine (100 mg/kg), mice show acute 
antinociceptive tolerance, indicated by an increase in the effective dose (ED50) of morphine, 
meaning more of the drug must be administered to elicit the same antinociceptive effect. 
Abdelhamid et al. demonstrated that when mice are pretreated with NTI intracerebroventricularly 
(i.c.v.), morphine tolerance is suppressed as illustrated in Fig. 5. Furthermore, a subcutaneous 
implantation of a morphine pellet caused a dramatic increase in chronic tolerance, which was 
similarly suppressed by once-daily injections of NTI (Fig. 6). 
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Figure 5. Acute Morphine Tolerance Following a Single Injection of Morphine Sulfatea, b 
 
a Figure taken from Abdelhamid, Sultana, Portoghese and Takemori, 1991 (reference 64). b Effect of naltrindole (NTI) 
on morphine tolerance. NTI was administered i.c.v. 5.5 hr prior and immediately preceding anti-nociceptive testing. 
Morphine (100 mg/kg) was administered 4 hr prior to testing. Bars represent 95% CI of the values. 
Figure 6. Chronic Morphine Tolerance Following Subcutaneous Implantation of Morphine 
Sulfate Pellet after 3 Daysa, b 
 
a Figure taken from Abdelhamid, Sultana, Portoghese and Takemori, 1991 (reference 64). b Effect of NTI on chronic 
morphine tolerance. Mice were implanted with placebo or morphine pellet (75 mg free base) for 3 days. NTI (10 pmol) 
was administered i.c.v. 1.5 hr before, 24 hr after, and 48 hr after pellet implantation. Bars represent 95% CI of the 
values.  
In this same study, the amount of naloxone (NLX), an opioid antagonist, required to 
precipitate withdrawal was measured under various conditions. Mice given a single s.c. injection 
(100 mg/kg) of morphine needed only 2 µmol/kg NLX to precipitate withdrawal jumping, whereas 
opioid-naïve mice demonstrated no withdrawal after 250 µmol/kg NLX. When pre-treated with 
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NTI (10 pmol, i.c.v.) 90 min before, then co-treated with morphine (100 mg/kg) and NTI again 
(10 pmol, i.c.v.), these mice showed a 45-fold increase in NLX (90 µmol/kg) required to induce 
withdrawal, suggesting a dramatic decrease in acute physical dependence. These results were 
further substantiated by studies in rats,65 with DOR-1 antisense oligonucleotides,67 and DOR-1 
knockout mice,66 implicating a role for DOR in the development of tolerance and dependence 
toward MOR agonists.  
 Based on the DOR antagonist co-administration and DOR-1 knockout studies discussed 
above, much interest has been focused on the development of a single agent that can achieve both 
the MOR agonist and DOR antagonist components.68–85 Some labs have used a bivalent ligand 
approach, predicated on the existence of MOR/DOR heterodimers, which link a MOR agonist and 
DOR antagonist through a flexible linker.72–76,86,87 While work in this area has shown some 
promise, a single-agent approach features a ligand that can reproduce the MOR agonist/DOR 
antagonist profile independent of whether or not MOR/DOR heterodimers exist in a meaningful 
context in vivo—a subject that is still contested within the field of opioid pharmacology.88 Our lab 
has been interested in developing ligands that bind to both MOR and DOR with high affinity, and 
act as an agonists at MOR and antagonists at DOR. Early work in the Mosberg lab focused on 
peptides and pseudopeptides,82,84,85,89–91 though recent work has seen the development of several 
peptidomimetic series exploring the MOR agonist/DOR antagonist profile.80,83,92–100 These 
peptidomimetic series primarily build around a tetrahydroquinoline (THQ) core, which replaces 
the cyclic peptide scaffold that was initially used to develop the structure-activity relationship 
(SAR) and pharmacophore models for the MOR agonist/DOR antagonist profile. Both series take 
key pharmacophore elements from the endogenous opioid peptides which feature the previously 
described Tyr1-Gly2-Gly3-Phe4-X5 sequence. It was determined through SAR studies and 
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computational modeling that the Tyr1 and Phe4 residues (separated by a flexible di-glycine spacer) 
are important pharmacophores to achieve high opioid affinity for flexible, peptide-like ligands. In 
contrast to the rigid morphinan scaffold, the relatively flexible peptide/peptidomimetic scaffold is 
less responsive to minute structural modifications, allowing us to fine-tune our desired 
pharmacological profile.  
In 2018, the Kobilka lab obtained a cryo-EM structure of the high-affinity, MOR selective 
peptide DAMGO (H-Tyr1-D-Ala2-Gly3-N(Me)Phe4-Gly5-ol) bound to MOR with a resolution of 
3.5Å.38 They reported the active 3D conformation for the peptide depicted in Fig. 7A. Comparison 
between the structures of DAMGO (Fig. 7B) and our lead THQ-based peptidomimetic 1 (Fig. 7C) 
suggests our small-molecule scaffold can position the key pharmacophores—Tyr1 and Phe4—
similarly to the opioid peptides while reducing flexibility and rotatable bonds through 
conformational restriction. 
Figure 7. Active 3D Conformation of the Opioid Peptide Agonist DAMGO and Comparison to 
the THQ Lead 1 
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One minor difference between DAMGO (and the endogenous peptides) and the 
peptidomimetic series is the replacement of the Tyr1 residue with a 2’,6’-dimethyl-L-tyrosine 
residue (Dmt) shown at bottom in Fig. 7C. Since its introduction in 1985,101 Dmt has been widely 
used as a mimetic of the endogenous Tyr1 residue across the field of opioid ligand design.78,97,102,103 
The Dmt residue maintains the critical phenolic H-bond donor and has demonstrated widespread 
bioavailability, and in many contexts displays superior MOR affinity relative to unsubstituted 
tyrosine. As can be seen in Fig. 7A, the bioactive conformation of the Tyr1 residue shows the ring 
to be out-of-plane with the peptide backbone, with the phenol and amine pointing in opposite 
directions. The steric influence of the methyl groups on Dmt favor this anti-planar orientation, 
reducing the entropic loss associated with binding and thus decreasing the binding energy. The 
compounds presented in this work have held constant the Dmt section of the THQ scaffold constant 
while probing modifications around the THQ core. 
Initial exploration of the peptidomimetic series focused primarily on modifications to the 1- 
and 6-positions. Chapter 2 departs from past SAR campaigns and explores the effects of 
substitutions at the 8-position of the THQ core. This previously unexplored chemical space is 
probed with a diverse set of substitutions, leading to unique in vitro SAR observations as well as 
several novel analogues displaying antinociceptive activity in vivo. Chapter 3 returns to the past 
1- and 6-position SAR campaigns, taking advantageous substitutions from both positions and 
combining them in a series of dually-substituted analogues with fine-tuned in vitro profiles. Trends 
from this campaign are visualized via a two-dimensional matrix, providing novel insights into the 
effects of various pharmacophore elements on binding and efficacy. In Chapter 4, a collection of 
short series and side-projects are presented, with concluding remarks and future direction 
presented in Chapter 5. The following chapters represent the collaborative efforts of several 
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chemists and pharmacologists spanning several years of work. In some cases, analogues designed 
and synthesized by other chemists will be presented to provide context for the novel chemical 
exploration done in this dissertation. Unless otherwise noted, compounds presented here are the 
work of the author of this dissertation.  
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Chapter 2: Exploration of the THQ Core at the C-8 Position 
 
2.1  Introduction 
 Research on opioid peptides performed by the Mosberg lab and others led to the 
development of pharmacophore models highlighting the importance of two key pharmacophores—
a tyrosine and an aryl ring—separated by an appropriate linker region.89,93 As discussed previously, 
modifications to the tyrosine functionality caused significant changes in pharmacology, though 
conversion to the Dmt analogue was well-tolerated. The second aryl pharmacophore was more 
tolerant to modification, and much peptide work went into probing the effects of various unnatural 
amino acids in the Phe4 position.82,84,85,89 To increase metabolic stability and restrict rotational 
freedom, the peptide core was cyclized through disulfide and di-thioether bridges. This peptide 
scaffold was later replaced with a more drug-like tetrahydroquinoline (THQ) core, resulting in the 
first peptidomimetic small molecule developed by our lab based on the aforementioned series of 
peptide ligands.93 Subsequent development of small molecules, which largely mirror the changes 
initially probed in the peptide series, was explored with renewed interest in 2013.83 Some of these 
early analogues showed selectivity for MOR and DOR over KOR, and these were carried forward 
for further development with the MOR agonist/DOR antagonist profile in mind.  
In vitro pharmacology data obtained by Nicholas Griggs, Thomas Fernandez, Tyler Trask, Jessica Anand, and others 
in the lab of John Traynor. In vivo data were obtained by Jessica Anand and others in the lab of Emily Jutkiewicz. 
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 Computational models and ligand overlays indicated that placement of the benzyl pendant 
at the C-6 position of the THQ ring (see Fig. 8 compound 1) offered optimal overlay with the Phe4 
residue of the peptide series of ligands that showed high affinity for MOR and DOR.83,93 Our lab 
then went on to probe the effects of linker length (Fig. 8 compound 2), ring fusion (3), connection 
point (4), and saturation (5) with regard to the C-6 aryl pharmacophore, providing some of our 
first leads for THQ-based SAR development of MOR and DOR selective ligands.83  
Figure 8. Leads for the Design of Mixed-Efficacy MOR Agonist/DOR Antagonist Ligandsa 
 
a Figure adapted from reference 83. Synthesis of analogues 1-5 was performed by L.Y.M., A.A.H., and A.M.B. 
 These ligands displayed high MOR efficacy and little to no DOR efficacy, however all five 
ligands in Fig. 8 showed 8- to 120-fold binding selectivity for MOR over DOR. As such, further 
development of the MOR agonist/DOR antagonist profile required optimization in reducing MOR 
selectivity while optimizing MOR and DOR efficacy profiles (compounds 1 and 3 displayed some 
DOR efficacy whereas 2 was only a partial MOR agonist). Furthermore, only compound 1 
displayed full antinociceptive activity in vivo after peripheral administration in mice. In order to 
determine what degree of MOR selectivity is tolerable while maintaining the favorable profile 
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established by prior DOR blocking studies,64–67 it was important to develop a library of in vivo 
active MOR agonist/DOR antagonist analogues with varying degrees of selectivity. With this goal 
in mind, further exploration about the THQ core was undertaken with the aim of maintaining 
bioavailability while varying MOR selectivity. The results of this chapter were described in part 
in a 2018 manuscript published by the journal ACS Chemical Neuroscience.96 
2.2 Translocation of the Phe4 Pharmacophore 
While prior pharmacophore and computational models suggested that the C-6 position 
offered optimal overlap with the Phe4 position of the peptide series, empirical evidence of such a 
conclusion had not yet been established. To test this hypothesis, the C-6 benzyl pendant of our 
lead peptidomimetic 1 (Table 1) was translocated to C-7 and C-8 in analogues 6 and 7 respectively. 
 
 
a Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [3H]-diprenorphine in membrane 
preparations. Functional data were obtained using agonist induced stimulation of [35S]-GTPγS binding. Potency is 
represented as EC50 (nM) and efficacy as percent maximal stimulation relative to standard agonist DAMGO (MOR), 
DPDPE (DOR), or U69,593 (KOR) at 10 μM. All values are expressed as the mean of three separate assays performed 
in duplicate with standard error of the mean in parentheses. “dns” = does not stimulate (<10% stim). “---" = not tested. 
Analogue 6 was synthesized by A.A.H.. 
Ki (nM) EC50 (nM) % stim
# R position MOR DOR KOR DOR Ki / MOR Ki
MOR DOR KOR MOR DOR KOR
1 C-6 0.22
(0.02)
9.4
(0.8)
68
(2)
43 1.6
(0.3)
110
(6)
>500
(70)
81
(2)
16
(2)
22
(2)
6 C-7 0.8
(0.3)
26
(2)
92
(n=1)
33 25
(20)
dns --- 18
(5)
dns ---
7 C-8 48
(9)
360
(60)
1500
(400)
7.5 1200
(300)
dns dns 37
(4)
dns dns
8 C-6 & C-8 1.0
(0.1)
1.6
(0.4)
23
(5)
1.6 4
(2)
380
(80)
dns 96
(4)
42
(7)
dns
NH2
HN
N
H
OH
O
1
2
3
45
6
7
8R R = benzyl
Table 1. Probing the Effects of Translocating the Phe4
Aryl Pharmacophore to C-7 and C-8 of the THQ Corea
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Both analogues 6 (C-7 benzyl) and 7 (C-8 benzyl) showed significant decreases in efficacy 
at MOR, while compound 7 showed a 100-fold decrease in MOR potency and affinity at both 
MOR and DOR (Table 1). We then questioned whether this reduction in MOR activity was due 
to the loss of the C-6 pharmacophore, or to unfavorable ligand-receptor interactions at C-8. To 
examine this, we incorporated both the C-6 and C-8 benzyl substitutions in compound 8. The 
binding affinity as well as potency and efficacy of 8 at MOR were restored (Ki = 1 nM; EC50 = 4 
nM; 96% stimulation), while the DOR binding affinity increased 6-fold compared to 1, not only 
validating the importance of the C-6 pharmacophore for MOR activity, but also identifying a key 
role for the C-8 position in modulating DOR affinity.  The moderate loss in MOR affinity and 
increase in DOR affinity for 8 shifted the MOR/DOR binding ratio (DOR Ki/MOR Ki) from 43 
for compound 1 to a more balanced 1.6 for compound 8 (Table 1). Consequently, this 6-,8-
disubstituted THQ analogue 8 established C-8 as a region of interest for future SAR. 
2.3  Design and Synthesis of C-8 Substituted Analogues 
 The synthesis of final compounds 8-31 began with the aniline derivatives depicted in 
Schemes 1 and 2, which differ only by R-group and the presence or absence of an aryl bromide at 
C-6 (THQ numbering depicted in Table 1 is used throughout this synthesis for consistency). 
Likewise, Scheme 3 follows many of the same steps but features a benzyl C-6 substitution in the 
starting aniline.  
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Scheme 1. Synthesis of C-8 Alkyl and Trifluoromethyl Analogue Intermediates from Anilines 
 
a (A) 3-bromopropionyl chloride & K2CO3 in DCM. (B) NaOtBu in DMF. (C) TfOH in DCE. (D) NBS in DCM. 
(E) benzyl boronic acid pinacol ester, Pd(dppf)Cl2 & K2CO3 in 3:1 acetone/H2O, 80°C. 
 
 
Scheme 2. Synthesis of C-8 Ethyl and Fluoro Analogue Intermediates from 6-Bromo Anilines 
 
a (A) 3-bromopropionyl chloride & K2CO3 in DCM. (B) NaOtBu in DMF. (C) TfOH in DCE. (D) benzyl boronic 
acid pinacol ester, Pd(dppf)Cl2 & K2CO3 in 3:1 acetone/H2O, 80°C. 
 
The synthesis of the THQ core in three steps—A, B, and C in Schemes 1-3—was 
developed by Dr. Larisa Yeomans, though these transformations had been previously reported in 
the literature independently. In step A, the aniline is substituted in a simple, high-yielding amide 
formation reaction with the acid chloride 3-bromopropionyl chloride. Step B involves an 
intramolecular b-lactam cyclization, catalyzed by the powerful base sodium tert-butoxide.104 In 
step C, this b-lactam intermediate undergoes an intramolecular Friedel-Crafts-like acylation (Fries 
rearrangement) facilitated by the ring strain of the 4-membered b-lactam in the presence of the 
superacid trifluoromethanesulfonic (triflic) acid, which is proposed to both protonate the amide 
while also coordinating the carbonyl to promote acylium ion formation.105 Though breaking 
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aromaticity is energetically unfavorable, the establishment of a more conjugated, less-strained 
bicyclic 6-membered ring system (the THQ core) makes this reaction exergonic. If not already 
present as in Scheme 2, an aryl bromide was next installed with N-bromosuccinimide in a highly 
regioselective addition at the C-6 (Scheme 1) or C-8 (Scheme 3) positions, directed by the ortho-
/para-directing aniline and meta-directing ketone. The final step in Schemes 1-3 (step E in 1 and 
2, D in Scheme 3) involves palladium-catalyzed functionalization of the aryl bromide. In Schemes 
1 and 2, this involves a simple Suzuki cross-coupling with a benzyl boronic acid pinacol ester in 
the presence of potassium carbonate and heat.  
 
Scheme 3. Synthesis of C-8 Bromo, Aryl, and Carbonyl Analogue Intermediates from 6-Benzyl 
Aniline 
 
 
 
 
a (A) 3-bromopropionyl chloride & K2CO3 in DCM. (B) NaOtBu in DMF. (C) TfOH in DCE. (D) NBS in DCM. 
(E) Suzuki conditions: 3-furanyl, benzyl, ethylphenyl, or 2-benzofuranyl boronic acid pinacol ester, Pd(dppf)Cl2 & 
K2CO3 in 3:1 acetone/H2O, 80°C. Carbonylation conditions: carbon monoxide gas, Pd(dppf)Cl2 & K2CO3 in 3:1 
DMF/H2O, MeOH, or IPA, 80°C. Amide coupling conditions: amine, PyBOP & DIPEA in DMF. 
 
In Scheme 3, Suzuki conditions could be used to install the 3-furan, 2-benzofuran, benzyl, 
or ethylphenyl substitutions. However, different functionalization was required to further diversify 
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the SAR at the C-8 position beyond simple aryl modifications. Heretofore unreported on a 
heterocyclic substrate, a method was developed for aryl carbonylation at the C-8 position using 
carbon monoxide generated in situ from the decomposition of oxalyl chloride in 2M sodium 
hydroxide. The decomposition side products carbon dioxide and hydrochloric acid are readily 
absorbed in the degassed aqueous media while carbon monoxide is liberated as a gas. CO is 
cannulated or balloon-transferred to a mixture of aryl bromide, Pd(dppf)Cl2, and potassium 
carbonate in an argon-sparged solution of DMF and water or alcohol. Through a proposed Suzuki-
type mechanism shown in Fig. 9, the carboxylic acid or ester (corresponding to which alcohol is 
used) can be installed at C-8. The carboxylic acid could then be substituted with amide coupling 
conditions (using DIPEA and the peptide coupling reagent PyBOP) to achieve the carboxamide as 
well as the dimethyl, ethyl, benzyl, and phenyl amides in modest yields (Scheme 3 step E). 
Figure 9. Suzuki-Type Palladium-Catalyzed Carbonylation Mechanism 
 
 
 
 In addition to alkyl, halo, aryl and carbonyl substitutions at C-8, a series of basic amine 
heterocycles were also explored. These ligands started with a 6-bromo-8-methyl THQ 
intermediate, the synthesis of which can be found in Scheme 1 prior to Suzuki coupling. As laid 
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out in Scheme 4, the THQ amine was first substituted with a trifluoroacetyl group in step A. This 
protecting group was selected as it would be least likely to sterically inhibit subsequent benzylic 
bromination at the C-8 methyl position, yet also offered facile removal under mild conditions 
compared to the fairly robust acetyl alternative. Unprotected amines are poorly tolerated in the 
subsequent radical bromination reaction. In step B of Scheme 4, benzylic bromine insertion was 
catalyzed by the radical initiator benzoyl peroxide and heat. The benzylic bromide could then be 
substituted with a secondary amine such as piperidine, morpholine, or mono-Boc piperazine. Due 
to the use of potassium carbonate as a base, some loss of the trifluoroacetyl group was observed. 
However, the unprotected amine was sterically hindered by the C-8 substitution and caused no 
adverse side-reactions during subsequent Suzuki coupling. With the C-8 amine installed, the C-6 
aryl bromide underwent Suzuki coupling as described previously. The use of potassium carbonate 
in aqueous solvent during Suzuki coupling, heated at 80°C for several hours, provided full 
trifluoroacetyl removal affording the 6-benzyl-8-R THQ intermediate desired to begin Scheme 5. 
 
Scheme 4. Synthesis of C-8 Amine Analogue Intermediates from 6-Bromo-8-Methyl THQ 
 
 
a (A) Trifluoroacetic acid anhydride in DCM. (B) NBS & benzoyl peroxide in CCl4, 80°C. (C) amine & K2CO3 in 
DMF. (D) benzyl boronic acid pinacol ester, Pd(dppf)Cl2 & K2CO3 in 3:1 acetone/H2O, 80°C.  
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 To complete the synthesis of analogues 8-31 as shown in Scheme 5, the 6-benzyl-8-R THQ 
intermediates underwent reductive amination in step A to install the desired stereochemistry at the 
C-4 position. Using the chiral Ellman auxiliary (R)-(+)-2-methyl-2-propanesulfinamide and 
Ti(OEt)4, the ketone was converted to an N-sulfinyl imine, which was then reduced 
stereoselectively in situ with sodium borohydride to provide the (R) sulfinamide at C-4. During 
this reaction, it was observed that methyl, isopropyl, and phenyl esters were all converted to an 
ethyl ester. The excess titanium, which is used to coordinate the ketone to facilitate transamination, 
could also coordinate the ester functionality. The ester coordination catalyzed nucleophilic attack 
by excess ethoxide liberated from Ti(OEt)4 during the 48-hour reaction. To synthesize the 
isopropyl analogue 27, Ti(OiPr)4 was used instead of Ti(OEt)4. The methyl and phenyl esters were 
not re-synthesized, though use of TiCl4 or another suitable Lewis acid would likely achieve 
transamination without the unwanted nucleophilic attack. Additionally, NMR indicated 
conversion of the carboxamide to a nitrile under reductive amination conditions, demonstrated by 
a downfield shift in 13C-NMR and loss of 18 mass units for the major peak by LC-MS.  
 
Scheme 5. Completing the Synthesis of Analogues 8-31a 
 
a (A) (R)-(+)-2-methyl-2-propanesulfinamide & Ti(OEt)4 in THF, 0°C to 70°C, then NaBH4 in THF, -78°C to r.t. (e) 
HCl, 1,4-dioxane, r.t., then diBoc 2,6-dimethyl-L-tyrosine, PyBOP, DIPEA, DMF, r.t., then TFA, DCM, r.t. 
 
8 - 31
8 R = Bn
9 R = Me
10 R = Et
11 R = n-Pr
16 R = Br
17 R = 3-furan
18 R = ethylphenyl
19 R = 2-benzofuran
20 R = dimethyl amide
21 R = ethyl amide
22 R = benzyl amide
23 R = phenyl amide
28 R = piperidine
29 R = morpholine
30 R = piperazine
31 R = piperazine-Dmt
12 R = n-Bu
13 R = t-Bu
14 R = F
15 R = CF3
24 R = nitrile *
25 R = carboxylic acid
26 R = ethyl ester **
27 R = isopropyl ester
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*carboxamide was unintentionally converted to a nitrile in step B under reductive amination conditions. **methyl ester was converted to an ethyl ester
during step A via nucleophilic attack by excess ethoxide ion, catalyzed by coordination of the ester carbonyl with Ti, both effects of Ti(OEt)4 reagent.
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In step B of Scheme 5, the sulfinamide was cleaved with hydrochloric acid giving the chiral 
amine salt, which was typically carried forward without characterization. Previously, this amine 
intermediate has been fully characterized by 1D and 2D NMR as well as X-ray crystallography, 
confirming that the stereoselectivity and chirality at C-4 that results from the described reductive 
transamination. During the synthesis of analogue 30 which featured a Boc-piperazine at C-8, the 
Boc group was removed during the sulfinamide cleavage of step B. Subsequent amide coupling to 
N-,O-diBoc-2’,6’-dimethyl-L-tyrosine, followed by Boc deprotection with trifluoroacetic acid, 
gave title compounds 8-30. In the case of analogue 30, some double insertion of Dmt at both the 
C-4 and piperazine amine was observed, yielding 31 by accident. A depiction of the C-8 
substitutions analyzed in analogues 8-31 is provided below in Fig. 10. 
 
 
Figure 10. Final C-8 R Groups of Analogues 8-31  
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2.4 In Vitro Pharmacology and SAR Analysis 
Following the promise of the initial C-8 benzyl substituted analogue 8 for modulating MOR 
selectivity, the SAR around C-8 was further expanded with the diverse substitutions represented 
in Fig. 10. Subsequent compounds in the C-8 series explored the steric environment and depth of 
the C-8 binding pocket with various alkyl substitutions, ranging from methyl to t-butyl (Table 2). 
We extended this series to include halogens (F, CF3, Br), which largely fit the same trend as the 
alkyl set.  
 
a Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [3H]-diprenorphine in membrane 
preparations. Functional data were obtained using agonist induced stimulation of [35S]-GTPγS binding. Potency is 
represented as EC50 (nM) and efficacy as percent maximal stimulation relative to standard agonist DAMGO (MOR), 
DPDPE (DOR), or U69,593 (KOR) at 10 μM. All values are expressed as the mean of three separate assays performed 
in duplicate with standard error of the mean in parentheses. dns = does not stimulate. † indicates n=2. 
Ki (nM) EC50 (nM) % stim
# C-8 R Group MOR DOR KOR DOR Ki / MOR Ki
MOR DOR KOR MOR DOR KOR
1 H 0.22(0.02)
9.4
(0.8)
68
(2)
43 1.6
(0.3)
110
(6)
>500 81
(2)
16
(2)
22
(2)
9 Me 0.24
(0.08)
1.9
(0.4)
17
(0.7)
8 4.2
(1.6)
110
(24)
>500 91
(1)
71
(3)
52
(2)
10 Et 0.09(0.04)
1.9
(0.4)
40
(5)
21 6.2
(2.9)
32
(10) dns
74
(2)
45
(4) dns
11 n-Pr 0.64(0.08)
5.9
(1.5)
98
(18)
9 23
(7)
310
(30) dns
† 90
(6)
36
(3) dns
†
12 n-Bu 0.76(0.28)
3.6
(0.5)
34
(5)
5 17
(4)
250
(39) dns
† 85
(2)
25
(4) dns
†
13 tert-Bu 0.47(0.18)
3.8
(0.7)
48
(7)
8 9.9
(3.6)
240
(40) dns
† 83
(5)
42
(2) dns
†
14 F 0.11
(0.01)
3.0
(0.3)
9
(1)
27 1.6
(0.2)
97
(19)
>500 95
(2)
28
(3)
40
(1)
15 CF3 0.26(0.10)
2.2
(0.7)
29
(10)
9 1.8
(0.9)
50
(14) >500
70
(5)
42
(2)
18
(4)
16 Br 0.23(0.14)
2.4
(0.8)
13
(1)
10 1.2
(0.5)
36
(18)
310
(95)
73
(3)
69
(4)
29
(1)
Table 2. Alkyl and Halogen Substituted C-8 Analogues
are MOR Agonists/DOR Partial Agonistsa
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The alkyl and halogenated series generally showed potent, efficacious agonism at MOR 
and partial agonism at DOR. Additionally, most alkyl-substituted analogues showed no KOR 
activation, whereas the halogenated compounds were low-potency partial agonists at KOR. In 
terms of binding, the smallest C-8 substitutions (9, 10, 14, 15, and 16) maintained high affinity for 
MOR and moderately increased affinity for DOR relative to the unsubstituted lead peptidomimetic 
1. Conversely, larger C-8 substitutions (11, 12, and 13) slightly decreased MOR affinity and 
maintained the modest increase in DOR affinity. This alkyl/halo subset provided a range of MOR 
selectivity profiles between 5 and 30, though all analogues were partial DOR agonists. 
Expanding upon the alkyl and halogen subsets, we synthesized a series of analogues 
featuring conjugated, aryl, and saturated heterocyclic substitutions, summarized in Table 3. The 
conjugated nitrile (24), furan (17), and benzofuran (19) analogues all favored MOR 10-fold or 
more, while the more flexible benzyl (8) and ethylphenyl (18) analogues displayed slightly better 
balance between MOR and DOR affinity. The flexible, saturated heterocycles offered little change 
in the MOR-selectivity profile compared to the lead compound 1. In fact, analogues 28 and 30 
were not only selective for MOR over DOR, but also displayed high affinity for KOR. Again, all 
analogues in this subset showed some DOR agonism, though these were generally less efficacious 
than the alkyl/halo subset. The lone outlier is the piperazine-Dmt analogue 31, which showed no 
DOR efficacy. Generally, analogues in Tables 2 & 3 showed only slight variation in binding 
affinities at MOR and DOR, yielding relatively flat SAR at the C-8 position. Even so, mild 
increases in DOR affinity paired with mild decreases in MOR affinity (as with compound 8) can 
serve to provide promising improvements towards balancing MOR and DOR affinities. 
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a Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [3H]-diprenorphine in membrane 
preparations. Functional data were obtained using agonist induced stimulation of [35S]-GTPγS binding. Potency is 
represented as EC50 (nM) and efficacy as percent maximal stimulation relative to standard agonist DAMGO (MOR), 
DPDPE (DOR), or U69,593 (KOR) at 10 μM. All values are expressed as the mean of three separate assays performed 
in duplicate with standard error of the mean in parentheses. dns = does not stimulate. † indicates n=2. 
 
As indicated by 18, 19, and 31, it may be possible to achieve the MOR agonist/DOR 
antagonist profile by increasing the size of substituents at C-8. However, due to the already high 
polar surface area of the analogues in this subset, further increasing the size of substituents at C-8 
seemed to offer diminishing returns.  
It was discovered in the following subset (see Table 4) that incorporation of a simple 
carbonyl bond at C-8 achieved the desired MOR agonist/DOR antagonist functional profile. 
Ki (nM) EC50 (nM) % stim
# C-8 R Group MOR DOR KOR DOR Ki / MOR Ki
MOR DOR KOR MOR DOR KOR
24 nitrile 0.16(0.06)
2.3
(0.7)
7.3
(0.7)
14 1.3
(0.5)
188
(22)
>500† 73
(6)
27
(6)
38†
(3)
17 3-furan 0.34
(0.08)
3.5
(0.6)
28
(6)
10 3.4
(0.3)
10
(4)
dns† 103
(5)
33
(5)
dns†
8 benzyl 1.0
(0.1)
1.6
(0.4)
23
(5)
2 4
(2)
380
(84)
dns 96
(4)
42
(7)
dns
18 ethylphenyl 0.37
(0.07)
1.4
(0.7)
27
(8)
4 44
(17)
33
(13) dns
† 78
(1)
15
(2) dns
†
19 2-benzofuran 3
(1)
71
(17)
>500 24 16
(7)
18†
(5) dns
† 101
(2)
13†
(2)
dns†
28 piperidine 0.07(0.03)
4.4
(1.0)
0.93
(0.18)
63 2.3
(0.2)
27
(2)
100
(33)
93
(2)
31
(4)
30
(6)
29 morpholine 0.15
(0.04)
2.3
(0.7)
7.3
(1.4)
15 1.8
(0.4)
180
(47)
dns 96
(2)
29
(5)
dns
30 piperazine 0.35(0.18)
15
(3)
1.9
(0.5)
43 8.2
(3.5)
290
(100)
170
(67)
60
(2)
18
(1)
17
(1)
31 piperazine-Dmt 0.31(0.16)
2.6
(0.5)
7
(2)
20 5.9
(0.7) dns
† dns 86(8) dns
† dns
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Table 3. Increasing Size of C-8 Substitution Moderately
Decreases DOR Efficacya
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Similar to the prior subsets, MOR selectivity persisted throughout Table 4. All analogues in this 
subset were less than 20-fold selective with four of the seven analogues displaying less than 10-
fold MOR selectivity. MOR potency showed modest improvement over past subsets, with all 
analogues showing single-digit nanomolar EC50 values. It is worth noting that the carbonyl C-8 
substituents consistently reduced MOR and DOR efficacy despite having only limited effects on 
binding. Thus, despite the relatively flat binding SAR around C-8, modifications in this region 
show a distinct ability to reliably modulate efficacy at MOR and DOR.  
 
 
a Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [3H]-diprenorphine in membrane 
preparations. Functional data were obtained using agonist induced stimulation of [35S]-GTPγS binding. Potency is 
represented as EC50 (nM) and efficacy as percent maximal stimulation relative to standard agonist DAMGO (MOR), 
DPDPE (DOR), or U69,593 (KOR) at 10 μM. All values are expressed as the mean of three separate assays performed 
in duplicate with standard error of the mean in parentheses. dns = does not stimulate. † indicates n=2. The EC50 of 27 
is listed as N/A, as the potency values vary too widely to assert a meaningful numerical value. 
Ki (nM) EC50 (nM) % stim
# C-8 R Group MOR DOR KOR DOR Ki / MOR Ki
MOR DOR KOR MOR DOR KOR
20 dimethyl amide 0.23(0.08)
1.3
(0.2)
80
(50)
6 9
(3) dns >500
58
(1) dns
25
(4)
21 ethyl amide 0.20
(0.06)
1.8
(0.4)
25
(4)
9 2.1
(0.3)
dns dns 56
(5)
dns dns
22 benzyl amide 0.17(0.03)
3.0
(0.4)
30
(2)
18 3.4
(1.4) dns dns
73
(5) dns dns
23 phenyl amide 0.32(0.08)
5.4
(0.5)
29
(5)
17 1.2
(0.7) dns dns
† 49
(4) dns dns
†
25 carboxylic acid 0.47(0.16)
2.4
(0.4)
210
(6)
5 4.4
(1.7) dns dns
67
(3) dns dns
26 ethyl ester 1.0(0.3)
3.7
(0.3)
47
(2)
4 4.9
(0.3) dns dns
† 71
(3) dns dns
†
27 isopropyl ester 0.45
(0.06)
5.9
(0.6)
77
(12)
13 N/A dns dns 58
(1)
dns dns
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Table 4. Carbonyl Substituted C-8 Analogues Consistently
Display Desired MOR Agonist/DOR Antagonist Profilea
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 Based on this diverse set of substitutions, it is apparent that the C-8 position tolerates a 
wide degree of variability in terms of binding. With few exceptions, most analogues display MOR 
affinity between 0.1 and 1.0 nM and DOR affinity ranging between 1.0 and 10 nM. KOR binding 
showed greater variability than MOR or DOR, with only the basic amines 28-31, the nitrile 24, 
and the fluoro analogue 14 displaying single-digit or sub-nanomolar affinity. The rigid, conjugated 
2-benzofuran 19 and carboxylic acid 25 were both poorly tolerated. These results are consistent 
with computational models which show a non-conserved glutamate residue near C-8 in KOR 
which is likely to prefer nitrogenous substituents over acidic residues like 25. 
 Despite the C-8 substitutions only having a minor effect on binding affinity at MOR and 
DOR, the carbonyl substitutions were functionally distinct from the alkyl, halo, aryl, or amino 
groups tested in this series. The carbonyl analogues all displayed less efficacy at MOR, DOR and 
KOR compared to other subsets, consistently affording the MOR agonist/DOR antagonist profile 
that had proven elusive in Tables 1-3. While insights gained from computational models are 
retrospective and have not been experimentally validated, the models may provide an indication 
as to why the carbonyl has proven effective at reducing efficacy across all three receptors. In Fig. 
11A are the crystal structures of MOR bound to the antagonist b-FNA (MOR inactive, lavender) 
and the agonist BU72 (MOR active, green), adapted from Huang et al.46 In Fig. 11B is an 
analogous view of DOR with the partial agonist ligand 12 (DOR active, tan) and antagonist 26 
(DOR inactive, orange) docked. Labeled “Dmt” is the primary amine and carbonyl backbone of 
the Dmt moiety of each ligand. Fig. 11C shows the same ligands and coloring schemes with a 
face-on view of the THQ core and C-8 substitutions. The DOR models are based on agonist-bound 
and antagonist-bound crystal structures.40,106 Because of the 1.8 Å resolution of the antagonist-
bound (inactive) receptor, stable water molecules were able to be placed within electron density 
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maps with high confidence. Some of these DOR-inactive water molecules were included in the 
Fig. 11B and C renderings, though these were not involved in the docking models for 12 and 26. 
 
Fig. 11. Crystallographic Models of MOR and DOR in Active and Inactive States with Partial 
DOR Agonist 12 (DOR Active) and Antagonist 26 (DOR Inactive) Computationally Dockeda 
 
 
 
aPanel A adapted from Huang et al, 2015. Panels B and C use models based on structures obtained by Granier et al, 
2012 and Fenalti et al, 2014. Ligands 12 and 26 were docked by Ira Pogozheva. 
 
  As noted by the Kobilka group in Fig. 11A with a red curved arrow, the shift from the 
inactive (lavender) to the active (green) state involves a large rotation in residue N3.35 with a 
smaller translation of residue D3.32 away from the receptor core. Fig. 11B indicates a similar shift 
in residues N3.35 and D3.32 between inactive and active states. As described previously, a distinct 
water-mediated polar network in the core of the receptor is involved in the stabilization of either 
the active or inactive state for both MOR and DOR. In Fig. 11B, one can observe a network of 
hydrogen bonds that link residue D3.32 to N3.35 and a critical sodium ion, which is believed to be 
involved in stabilizing the inactive state of the receptor. Importantly, D3.32 is also critical to ligand 
binding. This residue forms a H-bond with the amine of morphinan ligands b-FNA and BU72 and 
the Dmt amine of ligands 12 and 26. A shift in ligand binding toward helix 3 may push D3.32 away 
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from the core of the receptor, which would disrupt the water-mediated interaction with N3.35 and 
facilitate its outward swing. Through loss of this coordinating network and opening of the receptor 
core, the inactive-state sodium ion can more easily dissociate, allowing further solvation of the 
receptor’s core, which is associated with the active state as proposed by Yuan et al (see Fig. 12).52  
 
Figure 12. Agonist-Bound GPCR Models Indicate Contiguous Solvation Through the Core of the 
Receptor While Antagonist-Bound Models Display Primarily Extracellular Solvationa 
 
a Molecular dynamics simulation by Yuan et al. of agonist- and antagonist-bound receptor states, with water molecules 
depicted by yellow circles. The active-state KOR model indicates a channel of water molecules extending through the 
receptor core while the inactive-state MOR excludes water molecules primarily to the extracellular orthosteric site.52 
 
 The view of analogues 12 and 26 in Fig. 11C allows one to scrutinize what effect C-8 may 
have in receptor activation. The n-butyl and ethyl ester groups are very similar in size and occupy 
similar positions in the binding pocket of DOR, but one can see that the partial agonist 12 sits 
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“higher” or more toward helix 3 than the antagonist 26. Of note, the carbonyl in the C-8 position 
is predicted to bind near a conserved lysine residue in helix 5, K5.39. Though it is out of range for 
a direct H-bond, a stable water observed in the inactive-state structure could mediate a polar 
interaction between the C-8 carbonyl and helix 5, preventing the “upward” shift toward helix 3 
associated with activation. The decrease in efficacy across all three receptors further supports the 
proposal of a key interaction with a conserved residue such as K5.39. Further mutagenesis studies 
would be needed to confirm this hypothesis, but these models suggest a potential mechanism by 
which ligand design could predictably modulate receptor activation. 
 As a caveat, it is worth noting that the changes observed in binding modes are relatively 
small (1.0 Å or less) and retrospective modeling is poorly suited for identifying causation. 
Additionally, though the carbonyl ligands are antagonists at DOR and KOR, they maintain efficacy 
at MOR despite the inactivating mechanism being conserved. This could be due to other minor 
differences in binding-site topography, but certainly merits further investigation. As such, these 
structural insights remain hypotheses and not experimental observations at present.  
2.5 In Vivo Pharmacology 
In addition to optimizing in vitro SAR, another key aim of this project was to test the effects 
that differing MOR selectivities had on in vivo tolerance and dependence. As such, only 
compounds that displayed an in vivo antinociceptive response could be evaluated in this context. 
To determine the antinociceptive effect of each compound following peripheral administration, 
compounds were tested in the mouse warm water tail withdrawal (WWTW) assay. Briefly, the 
WWTW assay measures the response to a noxious stimulus—submersion of part of the tail in 50°C 
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water—and whether latency to tail withdrawal increases in a dose-dependent manner after 
intraperitoneal (ip) administration of a test compound. Compounds were given at doses of 1.0, 3.2 
and 10 mg/kg (cumulative) in 30-minute intervals. Fully efficacious compounds such as morphine 
reach the maximal possible effect (MPE) of a 20 s latency to tail withdrawal at 10 mg/kg. 
Compounds displaying less than a 10-second latency to tail withdrawal (<50% MPE) were 
considered not to stimulate an antinociceptive response in vivo, denoted as “dns” in Table 5.  
 
 
a Results from the mouse WWTW assay after cumulative dosing of test compound up to 10 mg/kg ip. Antinociceptive 
activity represented as percent maximum possible effect (% MPE), with MPE being a 20 s latency to tail withdrawal. 
Baseline tail withdrawal latency is ~5 s, or 25% MPE. “dns” indicates no stimulation of an antinociceptive response. 
“---” indicates the compound was not tested in the WWTW assay. 
Alkyl & Halo Analogues 
(from Table 2)
# C-8 R Group % MPE
1 H 100
9 Me 100
10 Et 100
11 n-Pr dns
12 n-Bu 100
13 tert-Bu 60
14 F dns
15 CF3 dns
16 Br 50
Table 5. Antinociceptive Activity in Mouse WWTW
Assay Following Intraperitoneal Administrationa
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Conjugated & Cyclic Analogues 
(from Table 3)
# C-8 R Group % MPE
24 nitrile dns
17 3-furan dns
8 benzyl dns
18 ethylphenyl dns
19 2-benzofuran 100
28 piperidine dns
29 morpholine dns
30 piperazine ---
31 piperazine-Dmt dns
Amide, Acid & Ester Analogues 
(from Table 4)
# C-8 R Group % MPE
20 dimethyl amide 100
21 ethyl amide dns
22 benzyl amide dns
23 phenyl amide ---
25 carboxylic acid dns
26 ethyl ester 100
27 isopropyl ester 100
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 In the alkyl series, compounds 9, 10 and 12 were fully efficacious, showing dose dependent 
antinociception and reaching the cutoff latency of 20 s at 10 mg/kg after intraperitoneal (ip) 
administration, whereas 11 showed no significant antinociceptive effect at the same dose. The tert-
butyl analogue 13 was partially active in vivo, with a latency of 10 s at 10 mg/kg. The 2-benzofuran 
analogue 19 was the only analogue from Table 3 to show any activity in vivo. The smaller 
conjugated analogues 24 and 17 as well as the larger substitutions including the cyclic amines 28 
– 31 and aryl rings 8 and 18 produced no antinociception at the doses tested. Within the carbonyl 
series, the dimethyl amide analogue 20, as well as the ethyl and isopropyl esters 26 and 27, showed 
full antinociceptive activity. Of the bioactive analogues 9, 10, 12, 19, 20, 26 and 27, the duration 
of action for 12 and 26 proved to be the longest at 2.5 hours (Table 6). This is a modest 
improvement over the lead 1 (2 hours). 
 
a Duration of action was determined by administering a 10 mg/kg bolus dose of test compound, then evaluating 
animals in the WWTW assay at 30-minute intervals until latency to tail withdrawal returned to baseline.  
 
As shown in Table 5, most compounds in this series demonstrated no antinociceptive 
activity at the doses tested in vivo. While we cannot definitively attribute a loss of activity to any 
individual factor for all compounds in the series, typical physicochemical properties such as high 
molecular weight, lipophilicity, polar surface area, and hydrogen bond partners are likely to inhibit 
Table 6. Duration of Antinociceptive Action for C-8 Analoguesa
# C-8 R Group Duration (h)
1 H 2.0
9 Me 1.5
10 Et 1.0
12 n-Bu 2.5
# C-8 R Group Duration (h)
19 2-benzofuran 1.5
20 dimethyl amide 2.0
26 ethyl ester 2.5
27 isopropyl ester 1.5
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membrane permeability and access to the CNS. Accordingly, our reported in vivo SAR was 
constrained to small C-8 modifications. Small alkyl and carbonyl substitutions were best correlated 
with in vivo antinociceptive activity, with 19 being a notable exception. However, the relatively 
small fluoro-substituted compounds (14-16) showed no activity in vivo at the doses tested, 
indicating pharmacokinetic obstacles besides polar surface area. Another pair of relatively low 
molecular weight analogues with differing in vivo effects, 21 and 26, suggest other parameters 
affecting bioavailability. Although 21 and 26 are comparable in size, 21 features an hydrogen bond 
donating amide moiety, whereas 26 bears a more lipophilic ester functionality devoid of H-bond 
donating capacity. The added hydrogen bond donating amide may affect specific interactions with 
proteins that impact CNS access (e.g. active transporters, efflux proteins, metabolizing enzymes), 
or nonspecific parameters, including polarity, and by extension, passive membrane permeability. 
To test this hypothesis, the dimethylamide analogue 20 was synthesized and evaluated in vivo. The 
antinociceptive activity of 20 supported the idea that hydrogen bond donating ability and not 
polarity is a significant factor affecting bioavailability. Analogue 20 was the only bioavailable 
analogue in this series with a ClogP less than the lead compound (ClogP = 2.2 for 20 compared to 
3.1 for 1). Whether this indicates an in vivo preference for lipophilic ligands or is simply an artifact 
of the nature of the compounds explored in this series requires further exploration. 
2.6 Conclusions 
Comprehensive evaluation of this series of compounds suggests that C-8 carbonyl moieties 
block DOR activation quite effectively while bulky groups such as the 2-benzofuran, ethylphenyl, 
and piperazine attenuate DOR activation relative to smaller alkyl, aryl, and halogen-containing 
groups. We have previously shown that a bulky C-6 pendant interacts favorably with the active-
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state MOR binding pocket, yet there is a steric clash between a large C-6 pendant and the analogous 
amino acid residues in the active-state DOR.83,89 We propose from our SAR analysis that the 
active-state binding pockets of MOR and DOR likely interact with the C-8 substitutions in a similar 
manner. Additionally, as previously proposed, computational models and SAR trends suggest that 
carbonyl moieties may participate in a conserved polar interaction with K5.39 which disfavors 
movement in the binding pocket towards transmembrane helix 3 and residue D3.32, thus reducing 
opioid receptor activation. In MOR, this translates to reduced efficacy (between 50 and 75%) 
whereas DOR and KOR typically lose all activity, providing a new avenue toward the MOR 
agonist/DOR antagonist profile.  
SAR at C-8 indicates that a wide range of substitutions at this position are fairly well 
tolerated. Though rigid substitutions such as the 2-benzofuran analogue 19 negatively impact 
binding affinity, modeling and SAR data suggest that flexible substitutions like the piperazine-
Dmt moiety of 31 can flip into a solvent-exposed region of the receptors, leading to minimal impact 
on binding (see Table 3). Throughout this SAR campaign, we observed only slight changes in 
binding affinity at MOR and DOR, with most analogues binding MOR with 0.1 to 1.0 nM affinity 
and DOR with 1.0 to 10 nM affinity. As such, our ability to reliably modulate MOR selectivity 
was very limited. However, due to the fairly mild impact of C-8 substitutions on receptor binding, 
it was believed that solubilizing substituents such as the morpholine and piperazine rings might 
improve aqueous solubility and bioavailability. Those efforts were not met with the desired 
outcomes, as indicated by Table 5. 
In terms of in vivo activity, it is apparent that C-8 can indeed be modified significantly (as 
with the 2-benzofuran analogue 19) while maintaining antinociceptive activity. Seven of the 
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twenty-four analogues synthesized in this series displayed full antinociception, while two others 
were partially active. Generally speaking, small alkyl and aprotic acyl groups are best-tolerated 
for in vivo activity, whereas halogens, protic amides, and amines were less bioavailable.  All of 
the seven analogues displaying robust antinociceptive activity were fairly short-acting, with a 
duration of action ranging between one and three hours. These bioavailable analogues span a range 
of MOR selectivity profiles—4, 5, 8, 13, 21, 22, and 24—all of which are more balanced than the 
lead peptidomimetic 1 with a 43-fold MOR selectivity profile. Further in vivo studies for tolerance 
and dependence are currently underway for the dimethyl amide 20. However, despite its very poor 
aqueous solubility and high lipophilicity (ClogP = 4.3), the ethyl ester analogue 26 may also merit 
further study, as it displayed among the best potency (5 nM), lowest MOR selectivity (4-fold), 
longest duration of action (2.5 hours), and highest MOR efficacy (71% stimulation) within the 
MOR agonist/ DOR antagonist subset. Considering the propensity of esters to be hydrolyzed in 
vivo, 26 may act as a prodrug of the carboxylic acid analogue 25. Fortunately, 25 shows an almost 
equally well-balanced MOR and DOR affinity profile while maintaining the MOR agonist/DOR 
antagonist profile. Additionally, cleavage to the carboxylic acid would boost selectivity over KOR 
from 50:1 to 450:1. Thus, despite the relatively unstable nature of the ester substitution, this moiety 
could still be useful in this specific context. 
Highlights of analogues 20 and 26 are summarized in Fig. 13. It is worth noting the high 
equilibrium constant, Ke, measured for compound 26. The Ke is used to approximate antagonist 
potency (the calculation for which can be found in the experimental procedures in section 2.7 of 
this chapter). While potency at MOR and DOR for 26 is 5- to 10-fold less than the observed 
affinities reported in Table 4, analogue 26 is still less than 10-fold selective for MOR by both 
affinity and potency metrics. The Ke has not yet been determined for analogue 20. 
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Figure 13. Summary Profiles of MOR Agonist/DOR Antagonist Analogues 20 and 26 
 
 
Going forward, the C-8 carboxylic acid could serve as a useful functionality for late-stage 
derivatization, facilitating further SAR exploration or probe development. Due to the limited 
impact on receptor binding, this position could be utilized in the development of multifunctional 
fluorescent probes, lysine-targeting covalent inhibitors,37,107 bivalent ligands,78,81 or receptor-
mediated transport substrates.82,108–113 In fact, attempts were made toward developing a 
glucoserine-linked analogue (see Chapter 5 for further discussion); however, further 
methodological development is needed to bring this project to fruition. As illustrated, the C-8 
position of the THQ scaffold has been instrumental in design and synthesis of bioavailable mixed-
efficacy MOR agonist/DOR antagonist ligands, but also has significant room for further 
development. In Chapter 4, additional projects currently underway or proposed that focus on 
functionalizing the C-8 position (among others) will be discussed in greater detail.  
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MOR agonist (71% stim, EC50 = 4.9 nM)
DOR antagonist (<10% stim, Ke = 43 nM)
MOR/DOR selectivity: 4:1
MOR/KOR selectivity: 50:1
Full antinociceptive activity (100% MPE)
Duration of action = 2.5 h; ClogP = 4.3
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NH2
HN
N
H
OH
O
N O
MOR agonist (58% stim, EC50 = 9 nM)
DOR antagonist (<10% stim), Ke not yet tested
MOR/DOR selectivity: 6:1
MOR/KOR selectivity: 350:1
Full antinociceptive activity (100% MPE)
Duration of action = 2.0 h; ClogP = 2.2
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2.7   Experimental Procedures  
 
Figure 10. Final C-8 R Groups of Analogues 8-31 (replicated from above for convenience) 
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Cell Lines and Membrane Preparations 
All tissue culture reagents were purchased from Gibco Life Sciences (Grand Island, NY, U.S.). 
C6-rat glioma cells stably transfected with a rat MOR (C6-MOR) or rat DOR (C6-DOR) and 
Chinese hamster ovary (CHO) cells stably expressing a human KOR (CHO-KOR) were used for 
all in vitro assays. Cells were grown to confluence at 37 °C in 5% CO2 in Dulbecco’s modified 
Eagle medium (DMEM) containing 10% fetal bovine serum and 5% penicillin/streptomycin. 
Membranes were prepared by washing confluent cells three times with ice cold phosphate buffered 
saline (0.9% NaCl, 0.61 mM Na2HPO4, 0.38 mM KH2PO4, pH 7.4). Cells were detached from the 
plates by incubation in warm harvesting buffer (20 mM HEPES, 150 mM NaCl, 0.68 mM EDTA, 
pH 7.4) and pelleted by centrifugation at 1600 rpm for 3 min. The cell pellet was suspended in ice-
cold 50 mM Tris- HCl buffer, pH 7.4, and homogenized with a Tissue Tearor (Biospec Products, 
Inc., Bartlesville, OK, U.S.) for 20 s. The homogenate was centrifuged at 15,000 rpm for 20 min 
at 4°C. The pellet was rehomogenized in 50 mM Tris-HCl with a Tissue Tearor for 10 s, followed 
by recentrifugation. The final pellet was resuspended in 50 mM Tris-HCl and frozen in aliquots at 
80°C. Protein concentration was determined via a BCA protein assay (Thermo Scientific Pierce, 
Waltham, MA, U.S.) using bovine serum albumin as the standard.  
Radioligand Competition Binding Assays 
Radiolabeled compounds were purchased from Perkin-Elmer (Waltham, MA, U.S.). Opioid ligand 
binding assays were performed by competitive displacement of 0.2 nM [3H]-diprenorphine (250 
μCi, 1.85 TBq/mmol) by the peptidomimetic from membrane preparations containing opioid 
receptors as described above. The assay mixture, containing membranes (20 μg protein/tube) in 
50 mM Tris-HCl buffer (pH 7.4), [3H]-diprenorphine, and various concentrations of test 
peptidomimetic, was incubated at room temperature on a shaker for 1 h to allow binding to reach 
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equilibrium. Samples were rapidly filtered through Whatman GF/C filters using a Brandel 
harvester (Brandel, Gaithersburg, MD, U.S.) and washed three times with 50 mM Tris-HCl buffer. 
Bound radioactivity on dried filters was determined by liquid scintillation counting, after saturation 
with EcoLume liquid scintillation cocktail, in a Wallac 1450 MicroBeta (Perkin-Elmer, Waltham, 
MA, U.S.). Nonspecific binding was determined using 10 μM naloxone. The results presented are 
the mean ± standard error (S.E.M.) from at least three separate assays performed in duplicate. Ki 
(nM) values were calculated using nonlinear regression analysis to fit a logistic equation to the 
competition data using GraphPad Prism, version 6.0c (GraphPad Software Inc., La Jolla, CA). 
[35S]-GTPgS Binding Assays 
Agonist stimulation of [35S]guanosine 5′-O-[γ- thio]triphosphate [35S]-GTPγS, 1250 Ci, 46.2 
TBq/mmol) binding to G protein was measured as described previously.114 Briefly, membranes 
(10–20 μg of protein/tube) were incubated for 1 h at 25°C in GTPγS buffer (50 mM Tris-HCl, 100 
mM NaCl, 5 mM MgCl2, pH 7.4) containing 0.1 nM [35S]-GTPγS, 30 μM guanosine diphosphate 
(GDP), and varying concentrations of test peptidomimetic. G protein activation following receptor 
activation with peptidomimetic was compared with 10 μM of the standard compounds [D-Ala2,N-
MePhe4,Gly-ol]enkephalin (DAMGO) at MOR, D-Pen2,5- enkephalin (DPDPE) at DOR, or 
U69,593 at KOR. The reaction was terminated by vacuum filtration of GF/C filters that were 
washed 10 times with GTPγS buffer. Bound radioactivity was measured as previously described. 
The results are presented as the mean ± standard error (S.E.M.) from at least three separate assays 
performed in duplicate; potency (EC50 (nM)) and percent stimulation were determined using 
nonlinear regression analysis with GraphPad Prism, as above.  
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Ke Determination 
Agonist stimulation of [35S]-GTPγS binding by the known standard agonist SNC80 at DOR was 
measured as described above. This was then compared to [35S]-GTPγS binding stimulated by 
SNC80 in the presence of test compound (1000 nM). Both conditions produced 100% stimulation 
relative to SNC80. The difference between the EC50 of SNC80 alone and in the presence of test 
antagonist is the shift in concentration response. The Ke was then calculated as Ke = (concentration 
of compound)/ (concentration response shift – 1). The results presented are the mean from at least 
three separate assays performed in duplicate. 
In Vivo Drug Preparation 
All compounds were administered by intraperitoneal (ip) injection in a volume of 10 mL/kg of 
body weight. Test compounds were dissolved in 5% DMSO (v/v) in sterile saline (0.9% NaCl w/v).  
Animals 
Male C57BL/6 wild type mice (Stock number 000664, Jackson Laboratory, Sacramento CA, USA) 
bred in-house from breeding pairs and weighing between 20-30 g at 8-16 weeks old, were used for 
behavioral experiments. Mice were group-housed with free access to food and water at all times. 
Experiments were conducted in the housing room, maintained on a 12 h light/dark cycle with lights 
on at 7:00 am; all experiments were conducted during the light cycle. Studies were performed in 
accordance with the University of Michigan Committee on the Use and Care of Animals and the 
Guide for the Care and Use of Laboratory Animals (National Research Council, 2011 publication). 
Antinociception 
Antinociceptive effects were evaluated in the mouse WWTW assay. Withdrawal latencies were 
determined by briefly placing a mouse into a cylindrical plastic restrainer and immersing 2-3 cm 
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of the tail tip into a water bath maintained at 50°C. The latency to tail withdrawal or rapidly flicking 
the tail back and forth was recorded with a maximum cutoff time of 20 s to prevent tissue damage. 
Antinociceptive effects were determined using a cumulative dosing procedure. Each mouse 
received an injection of saline ip and then 30 min later baseline withdrawal latencies were 
recorded. Following baseline determinations, cumulative doses of each test compound (1, 3.2, and 
10 mg/kg) were given ip at 30 min intervals. Thirty min after each injection, the tail withdrawal 
latency was measured as described above. To determine the duration of antinociceptive action, 
baseline latencies were determined as described above. Thirty minutes after baseline 
determination, animals were given a 10 mg/kg bolus injection of test compound ip. Latency to tail 
withdrawal was then determined at 5, 15, and 30 min after injections, and every 30 min thereafter 
until latencies returned to baseline values. 
HPLC Purification  
Purification of final compounds was performed using a Waters semipreparative HPLC with a 
Vydac protein and peptide C18 reverse phase column, using a linear gradient of 0% solvent B 
(0.1% TFA in acetonitrile) in solvent A (0.1% TFA in water) to 100% solvent B in solvent A at a 
rate 1% per minute, monitoring UV absorbance at 230 nm.  
Compound Characterization  
Final compounds were characterized by 1H NMR, electrospray ionizing mass spectrometry (ESI-
MS), and HPLC retention time. 1H NMR data for final compounds were obtained on a 500 MHz 
Varian spectrometer using CD3OD as the solvent. ESI-MS was obtained using an Agilent 6130 
LC–MS mass spectrometer in positive ion mode. The retention time and purity of final compounds 
were assessed using a Waters Alliance 2690 analytical HPLC instrument with a Vydac protein and 
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peptide C18 reverse phase column. Retention times were obtained by running a linear gradient 
starting at 0% solvent B (99.9% acetonitrile, 0.1% TFA) and 100% solvent A (99.9% water, 0.1% 
TFA) to 70% solvent B and 30% solvent A in 70 min, measuring UV absorbance at 230 nm. All 
final compounds used for testing were ≥95% pure, as determined by analytical HPLC. Intermediate 
compounds were characterized by 1H and 13C NMR on a Varian 500 MHz or 400 MHz NMR 
instrument.  
Synthesis – General Procedures 
General Procedure (A): Schotten-Bauman Acylation of a Commercially Available Aniline 
Starting Material. To a flame-dried round-bottom flask under Ar atmosphere was added aniline 
starting material (1.00 eq), followed by dichloromethane, then K2CO3 (1.2-3.0 eq.). After 10 
minutes, 3-bromopropionyl chloride (1.05 eq) was added slowly via syringe. Reaction was 
monitored by TLC in 40% ethyl acetate, 60% hexanes. Ninhydrin stain was used to help monitor 
disappearance of aniline starting material. After 1-3 h, reaction was quenched with deionized 
water. Organics were separated and dried over MgSO4, then filtered and concentrated under 
vacuum. Product was purified by crystallization or, when necessary, column chromatography.   
General Procedure (B): Intramolecular b-Lactam Cyclization. To a flame-dried round-bottom 
flask under Ar atmosphere was added sodium tert-butoxide (1.05 eq) followed by anhydrous DMF, 
then stirred 10 min before slowly adding a solution of  acyl bromide intermediate from step A 
(1.00 eq) dissolved in DMF at ambient temperature via syringe. Monitored reaction by TLC in 
40% ethyl acetate, 60% hexanes. Desired product showed a moderate decrease in Rf relative to 
starting material. After stirring 1-3 h, reaction mixture was concenctrated under vacuum, then 
resuspended in dichloromethane or ethyl acetate. Extracted reaction mixture with deionized water 
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and aqueous sodium bicarbonate, then separated organics and dried over MgSO4. Filtered and 
reconcentrated organics onto silica, then purified by flash chromatography. 
General Procedure (C): Fries Rearrangement to Synthesize the THQ Core. To a round-
bottom flask containing b-lactam intermediate (1 eq) dissolved in dichloroethane under inert 
atmosphere was slowly added TfOH (3 eq). After 1 hour, TLC in 40% ethyl acetate, 60% hexanes 
showed a decrease in Rf. Reaction was quenched with deionized water and neutralized with 
K2CO3, then diluted with dichloromethane. Separated organics and dried over MgSO4, then filtered 
and concentrated organics onto silica and purified by flash chromatography. 
General Procedure (D): Aryl Bromination of THQ Core. To a round-bottom flask containing 
THQ intermediate (1.00 eq), dissolved in dichloromethane under inert atmosphere was added N-
bromosuccinimide (1.05 eq) at ambient temperature. After 30 minutes, TLC in 40% ethyl acetate, 
60% hexanes showed complete conversion. Reaction was reconcentrated onto silica and was 
purified by flash chromatography. 
General Procedure (E): Suzuki Copuling of Aryl Bromide to Boronic Acid Pinacol Ester. To 
a round-bottom flask under Ar atmosphere was added 3:1 acetone/water and stirred under vacuum 
for 10 minutes. Next, Ar was bubbled through solvent for an additional 10 minutes before adding 
aryl bromide intermediate (1.0 eq), boronic acid (1.2-2.0 eq), K2CO3 (3 eq) and Pd(dppf)Cl2 (0.1 
eq). Reaction was heated to 80°C for 6-12 hours, after which the reaction mixture was cooled and 
diluted with ethyl acetate and aqueous NaHCO3. Organics were separated and dried over MgSO4, 
then filtered and concentrated in vacuo onto silica. Product was purified by silica chromatography. 
General Procedure (F): Reductive Amination of 6-benzyl-8-R-THQ Ketone to Sulfinamide 
Using Ellman’s Sulfinamide. To a round bottom flask already containing desiccated THQ 
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intermediate (1.0 eq) under Ar atmosphere was added (R)-2-methylpropane-2-sulfinamide (3.0 
eq). Meanwhile, a reflux condenser was flame-dried under vacuum, and then flooded with Ar. 
Next, anhydrous THF (5-10 mL) was added to the reaction vessel containing starting reagents via 
syringe. The round bottom flask was placed in an ice bath and allowed to equilibrate to 0°C. Next, 
Ti(OEt)4 (6.0 eq) was added slowly via syringe. Once addition was complete, the reaction vessel 
was taken out of ice bath and placed in oil bath at 70°C-75°C, affixed condenser, and stirred for 
16-48 h under Ar. The reaction was monitored by TLC for loss of ketone. Once sufficient 
conversion to the tert-butanesulfinyl imine was observed, reaction vessel was taken out of oil bath 
and cooled to ambient temperature. Meanwhile, an additional round bottom flask was flame-dried 
under vacuum, then flooded with Ar. NaBH4 (6.0 eq) was added quickly, and anhydrous THF was 
added (5-10 mL). The round bottom flask was placed in dry ice/acetone bath and allowed to 
equilibrate to -78°C. Contents from the round bottom flask containing the imine intermediate were 
transferred to round bottom flask containing NaBH4 via cannula. Imine-containing flask was 
washed twice with minimal THF, which was also transferred to reducing flask via cannula under 
Ar. Once contents were completely added, the reaction was taken out of dry ice/acetone bath and 
was allowed to warm to room temperature. The reaction stirred at ambient temperature for 2-3 h. 
To quench, sat. NaCl solution was added. Reaction mixture was diluted with ethyl acetate and DI 
H2O and separated, washing with H2O until both layers were clear, indicating sufficient removal 
of titanium oxide by-product. Organics were then isolated and dried over MgSO4 and filtered 
through a fritted funnel. Organic extract was then concentrated onto silica and purified by silica 
chromatography. 
General Procedure (G): Conversion of Sulfinamide to Final Compound. Step 1: To a round 
bottom flask containing sulfinamide (1.0 eq) was added 1,4-dioxane, followed by conc. HCl (6.0 
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eq), cleaving the sulfinamide to the primary amine. The reaction stirred at r.t. for up to 3 h. Solvent 
was removed under reduced, and residue was re-suspended in Et2O. The resultant white solid 
precipitate (the HCl salt of the amine) was isolated by decanting and washing with Et2O up to three 
times. After desiccation, the solid residue was used without further purification. Step 2: To a pear-
shaped flask under inert atmosphere containing amine salt (1.0 eq) was added di-Boc-Dmt (1.1 
eq), PyBOP (1.1 eq), and, when specified, 6-Cl HOBt (1.1 eq), followed by DMF and DIPEA (10 
eq) at ambient temperature. After stirring for 6 hours, solvent was removed under reduced pressure 
and residual oil was loaded onto silica. Boc-protected intermediate was purified by silica 
chromatography but was generally not characterized by NMR. Step 3: Boc-protected intermediate 
was suspended in DCM (10 mL), then TFA (3-5 mL) was added. After 1 hour, solvent was 
removed under vacuum. Product was resuspended in a solution of 99.9% acetonitrile, 0.1% TFA, 
then diluted with deionized water. Final products were purified by reverse-phase semi-preparative 
HPLC. Final yield not calculated.  
General Procedure (H): Palladium-Catalyzed Carbonylation of Aryl Bromide. For a 
schematic of the apparatus, see the synthesis of Compound 20. To a flame-dried 2-necked round-
bottom flask under Ar atmosphere was affixed a condenser to the verticle neck. Through the angled 
neck was added degassed, Ar-sparged 4:1 DMF/H2O (or alcohol in place of water) and stir bar. 
Next, 6-benzyl-8-bromo-THQ intermediate (1 eq), K2CO3 (1.5 eq) and Pd(dppf)Cl2 (0.1 eq) were 
added to the stirring solution. To a separate 30 mL pressure tube under Ar atmosphere was added 
2M NaOH (15 mL), then evacuated, flushed with Ar, and bubbled Ar through base solution for 15 
min. A cannula was added from the septum of the pressure tube leading into the reaction solution, 
and a vent was placed in the condenser septum. To the bottom of the tube containing stirring base 
solution was added, via syringe, oxalyl chloride (1 mL in aliquots of 0.1 to 0.2 mL). Carbon 
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monoxide generated in situ from the decomposition of oxalyl chloride bubbled through the vented 
reaction mixture 10 minutes. This process was repeated twice more at 30 minute intervals. Vent 
was replaced with a balloon filled with CO, and heated at 70-80°C for 6-10 hours, monitored by 
TLC. When TLC indicated conversion of starting material to new product, reaction was cooled to 
ambient temperature and reaction solvents were removed under vacuum. Residual oil was 
resuspended in ethyl acetate and water, and acid/base extraction was performed. Organics were 
isolated, dried with MgSO4, filtered, and reconcentrated onto silica in vacuo. Reaction was purified 
by flash chromatography. 
General Procedure (I): Amine Substitution of Benzylic Bromide. To a pear-shaped flask 
containing 6-benzyl-8-carboxylate-THQ intermediate (1.0 eq) dissolved in DMF under inert 
atmosphere was added PyBOP (1.2 eq), amine (1.2 eq) and DIPEA (5-10 eq), then stirred at 
ambient temperature. Reaction was monitored by TLC. After 3-12 hours, solvent was removed 
under reduced pressure and reconcentrated residue onto silica in vacuo. Purified by flash 
chromatography. Product was highly fluorescent under long-wave UV (285 nm) light. 
General Procedure (J): N-Trifluoroacetylation of the THQ core. To a round-bottom flask 
containing 6-bromo-8-methyl-THQ intermediate (1.0 eq) under Ar atmosphere was added DCM. 
Reaction flask was then cooled to 0°C before adding Et3N (1.2 eq), followed by trifluoroacetic 
anhydride (1.2 eq). When starting material showed complete conversion to product by TLC, 
solvent was removed under reduced pressure and reaction residue was purified by silica 
chromatography. 
General Procedure (K): Benzylic Bromination of the C-8 Methyl Group. To a round-bottom 
flask containing (1.00 eq) under Ar atmosphere was added degassed, Ar-sparged CCl4, followed 
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by N-bromosuccinimide (1.05 eq) and benzoyl peroxide (0.1 eq). Reaction was then heated to 
reflux, monitored by TLC. Quantitative conversion of starting material was generally not observed, 
so reaction was halted when side-product began to form. Reaction was halted by cooling to -20°C, 
and precipitate was filtered from solution (washing with additional cold CCl4). Filtrate was then 
concentrated onto silica and purified by silica chromatography.  
General Procedure (L): Substitution of Benzylic Bromide with Amine Heterocycle. To a 
round-bottom flask under inert atmosphere was added DMF, followed by K2CO3 (1.2 eq) and 
amine (1.2 eq), then benzylic bromide (1.0 eq) stirring at ambient temperature. After 6-12 hours, 
solvent was removed under reduced pressure and residual oil was resuspended in ethyl acetate and 
sat. NaHCO3. Organics were separated and dried over MgSO4, then filtered and concentrated in 
vacuo onto silica. Product was purified by silica chromatography. 
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Compound 8 (Notebook name: AFN-4) 
 
 
8-2. N-(4-benzylphenyl)-3-bromopropanamide. 8-2 was synthesized following General 
Procedure (A) from 4-benzylaniline 8-1 (3.65 g, 19.92 mmol, 1.00 eq), K2CO3 (3.56 g, 25.78 
mmol, 1.30 eq). and 3-bromopropionyl chloride (2.11 mL, 20.91 mmol, 1.05 eq). Yield: 6.37 g, 
100%. 1H NMR (500 MHz, CDCl3) δ 7.43 (d, J = 8.3 Hz, 2H), 7.29 (d, J = 7.5 Hz, 1H), 7.20 (d, 
J = 7.3 Hz, 1H), 7.16 (dd, J = 7.9, 5.8 Hz, 4H), 3.95 (s, 2H), 3.71 (t, J = 6.6 Hz, 2H), 2.92 (t, J = 
6.6 Hz, 2H).  
 
 
8-3. 1-(4-benzylphenyl)azetidin-2-one. 8-3 was synthesized following General Procedure (B) 
from 8-2 (6.37g, 20.02 mmol, 1.00 eq) and NaOtBu (2.02 g, 21.02 mmol, 1.05 eq). Yield: 4.25 g, 
90%. 1H NMR (500 MHz, CDCl3) δ 7.29 (d, J = 8.1 Hz, 3H), 7.20 (d, J = 7.3 Hz, 1H), 7.16 (d, J 
= 8.0 Hz, 4H), 3.95 (s, 2H), 3.60 (t, J = 4.5 Hz, 2H), 3.10 (t, J = 4.5 Hz, 2H). 
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8-4 6-benzyl-2,3-dihydroquinolin-4(1H)-one. 8-4 was synthesized following General Procedure 
(C) from 8-3 (3.75 g, 15.80 mmol, 1 eq) and TfOH (4.18 mL, 47.40 mmol, 3 eq). Yield: 3.34 g, 
90%. 1H NMR (500 MHz, CDCl3) δ 7.72 (d, J = 2.1 Hz, 1H), 7.30 – 7.23 (m, 2H), 7.20 – 7.15 (m, 
3H), 7.12 (dd, J = 8.4, 2.2 Hz, 1H), 6.60 (d, J = 8.4 Hz, 1H), 4.34 (s, 1H), 3.86 (s, 2H), 3.54 (td, J 
= 7.1, 2.0 Hz, 2H), 2.68 (t, J = 6.9 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 193.92, 150.73, 141.35, 
136.19, 130.89, 128.86, 128.59, 127.37, 126.18, 119.34, 116.35, 77.16, 42.53, 41.08, 38.30.  
 
 
8-5. 6-benzyl-8-bromo-2,3-dihydroquinolin-4(1H)-one. 8-5 was synthesized following General 
Procedure (D) from 8-4 (501 mg, 2.11 mmol, 1.00 eq) and NBS (375 mg, 2.11 mmol, 1.00 eq). 
Yield: 640 mg, 96%. 1H NMR (500 MHz, CDCl3) δ 7.70 (d, J = 2.0 Hz, 1H), 7.40 (d, J = 2.0 Hz, 
1H), 7.27 (t, J = 7.5 Hz, 2H), 7.22 – 7.17 (m, 1H), 7.15 (d, J = 7.5 Hz, 2H), 4.89 (s, 1H), 3.83 (s, 
2H), 3.60 (td, J = 7.2, 2.1 Hz, 2H), 2.69 (t, J = 6.9 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 193.10, 
147.40, 140.62, 138.57, 131.31, 128.81, 128.70, 127.07, 126.41, 120.28, 110.32, 77.16, 41.92, 
40.75, 37.55. 
 
8-6. 6,8-dibenzyl-2,3-dihydroquinolin-4(1H)-one. 8-6 was synthesized following General 
Procedure (E) from 8-5 (236 mg, 0.75 mmol, 1 eq), benzyl boronic acid pinacol ester (0.50 mL, 
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2.24 mmol, 2 eq), K2CO3 (310 mg, 2.24 mmol, 3 eq) and Pd(dppf)Cl2 (55 mg, 0.08 mmol, 0.1 eq). 
Yield: Yield: 210 mg, 86%. 1H NMR (500 MHz, CDCl3) δ 7.72 (d, J = 2.0 Hz, 1H), 7.34 – 7.24 
(m, 5H), 7.19 (dd, J = 7.7, 4.7 Hz, 3H), 7.14 (d, J = 7.5 Hz, 2H), 7.07 (d, J = 2.1 Hz, 1H), 4.20 (s, 
1H), 3.89 (s, 2H), 3.86 (s, 2H), 3.43 (t, J = 7.0 Hz, 2H), 2.63 (t, J = 7.2 Hz, 2H). 13C NMR (126 
MHz, CDCl3) δ 194.17, 149.04, 141.42, 138.31, 137.54, 130.25, 128.99, 128.85, 128.60, 128.32, 
126.91, 126.20, 126.16, 125.69, 119.86, 42.25, 41.13, 37.92, 37.68.  
 
8-7. (R)-N-((R)-6,8-dibenzyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-sulfinamide. 8-
7 was synthesized following General Procedure (F) from 8-6 (70 mg, 0.21 mmol, 1 eq), (R)-2-
methyl-2-propanesulfinamide (104 mg, 0.86 mmol, 4 eq), and Ti(OEt)4 (0.27 mL, 1.28 mmol, 6 
eq), then NaBH4 (50 mg, 1.28 mmol, 6 eq). Yield: 38 mg, 41%. 1H NMR (500 MHz, CDCl3) δ 
7.31 – 7.21 (m, 4H), 7.21 – 7.11 (m, 5H), 7.06 (d, J = 2.0 Hz, 1H), 6.81 (d, J = 2.0 Hz, 1H), 4.57 
– 4.48 (m, 1H), 3.84 (d, J = 3.0 Hz, 2H), 3.77 (s, 2H), 3.25 (td, J = 11.8, 2.7 Hz, 1H), 3.15 (dt, J = 
11.7, 3.9 Hz, 1H), 2.07 – 1.97 (m, 1H), 1.81 (tt, J = 13.2, 3.9 Hz, 1H), 1.19 (s, 9H). 13C NMR(126 
MHz, CDCl3) δ 141.97, 141.31, 139.10, 131.26, 129.81, 129.21, 128.81, 128.75, 128.53, 128.46, 
126.50, 125.91, 124.70, 121.02, 77.16, 55.42, 49.86, 41.15, 37.88, 36.68, 28.28, 22.76.   
 
N
H
O
N
H
HN S
O
F
8-6 8-7
 56 
 
8. (S)-2-amino-N-((R)-6,8-dibenzyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide. 8 was synthesized following General Procedure (G) from 8-7 (26 
mg, 0.06 mmol, 1 eq) and concentrated HCl (0.12 mL, excess). Carried forward without further 
purification or characterization. Step 2: Performed amide coupling using 8-7 amine salt (22 mg, 
0.06 mmol, 1 eq), di-Boc-Dmt (33 mg, 0.078 mmol, 1.3 eq), PyBOP (42 mg, 0.078 mmol, 1.3 eq), 
and 6-Cl HOBt (14 mg, 0.078 mmol, 1.3 eq), and DIPEA (0.13 mL, 0.71 mmol, 12 eq). Step 3: 
Boc-deprotected with TFA as described in General Procedure (G). Final products were purified 
by reverse-phase semi-preparative HPLC. Final yield not calculated. 1H NMR (500 MHz, 
Methanol-d4) δ 8.20 (dd, J = 8.0, 2.7 Hz, 1H), 7.27 – 7.21 (m, 2H), 7.21 – 7.15 (m, 3H), 7.08 (ddd, 
J = 23.4, 11.4, 7.1 Hz, 5H), 6.90 (d, J = 3.0 Hz, 1H), 6.71 (d, J = 2.7 Hz, 1H), 6.47 (d, J = 2.3 Hz, 
2H), 5.02 – 4.97 (m, 1H), 3.86 (dt, J = 11.5, 3.6 Hz, 1H), 3.78 (s, 2H), 3.76 (s, 2H), 3.24 (td, J = 
12.5, 11.4, 1.9 Hz, 1H), 3.09 (dt, J = 12.4, 4.1 Hz, 1H), 3.02 (dt, J = 13.9, 3.4 Hz, 1H), 2.55 (t, J = 
12.0 Hz, 1H), 2.26 (s, 6H), 1.75 (ddt, J = 17.8, 10.7, 3.3 Hz, 1H), 1.51 (dd, J = 12.9, 5.4 Hz, 1H). 
HPLC (gradient A): retention time = 44.3 min. ESI-MS 520.3[M + H]+ and 542.3 [M + Na]+.  
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Compound 9 (Notebook reference: AFN-18 or afn-iv-75, notebook 4 p. 75) 
 
 
9-2. 3-bromo-N-(o-tolyl)propanamide. 9-2 was synthesized following General Procedure (A) 
from o-toluidine 10-1 (1.00 g, 5.38 mmol, 1.00 eq), K2CO3 (2.23 g, 16.14 mmol, 3.00 eq) and 3-
bromopropionyl chloride (0.57 mL, 5.64 mmol, 1.05 eq). Yield: 1.72 g, 100%. 1H NMR (500 
MHz, CDCl3) δ 7.57 (d, J = 7.6 Hz, 2H), 7.16 (d, J = 7.5 Hz, 2H), 7.08 (t, J = 7.5 Hz, 1H), 3.66 
(t, J = 6.5 Hz, 2H), 2.91 (t, J = 6.5 Hz, 2H), 2.22 (s, 3H). 13C NMR(126 MHz, CDCl3) δ 168.64, 
135.16, 130.76, 130.64, 126.63, 126.03, 124.38, 40.21, 27.57, 18.02. 
 
 
9-3. 1-(o-tolyl)azetidin-2-one. 9-3 was synthesized following General Procedure (B) from 9-2 
(1.72 g, 5.36 mmol, 1.00 eq) and NaOtBu (540 mg, 5.63 mmol, 1.05 eq). Yield: 1.18 g, 92%. 1H 
NMR (500 MHz, CDCl3) δ 7.28 (td, J = 8.6, 6.9, 0.8 Hz, 1H), 7.09 (t, J = 6.9 Hz, 2H), 7.03 (td, J 
= 7.6, 7.2, 1.5 Hz, 1H), 3.60 (t, J = 4.4 Hz, 2H), 2.97 (t, J = 4.5 Hz, 2H), 2.28 (s, 3H). 13C NMR(126 
MHz, CDCl3) δ 165.27, 136.19, 131.08, 130.79, 126.06, 125.76, 125.75, 122.03, 41.04, 35.99, 
18.87. 
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9-4. 8-methyl-2,3-dihydroquinolin-4(1H)-one. 9-4 was synthesized following General Procedure 
(iii) from 9-4 (1.18 g, 4.9 mmol, 1 eq) and TfOH (1.3 mL, 14.7 mmol, 3 eq). Yield: 606 mg, 52%. 
1H NMR (500 MHz, CDCl3) δ 7.75 (d, J = 8.0 Hz, 1H), 7.18 (d, J = 7.1 Hz, 1H), 6.65 (t, J = 7.5 
Hz, 1H), 4.40 (s, 1H), 3.60 (t, J = 6.9 Hz, 2H), 2.68 (t, J = 6.9 Hz, 2H), 2.15 (s, 3H). 13C NMR(126 
MHz, CDCl3) δ 194.16, 150.47, 135.73, 125.61, 122.87, 119.10, 117.26, 77.16, 42.18, 37.92, 
16.95.  
 
9-5. 6-bromo-8-methyl-2,3-dihydroquinolin-4(1H)-one. 9-5 was synthesized following General 
Procedure (D) from 9-4 (120 mg, 0.74 mmol, 1.00 eq) and NBS (139 mg, 0.78 mmol, 1.05 eq). 
Yield: 170 mg, 95%. 1H NMR (500 MHz, CDCl3) δ 7.85 (d, J = 2.3 Hz, 1H), 7.28 (dd, J = 2.3, 
1.1 Hz, 1H), 4.34 (s, 1H), 3.61 (t, J = 7.0 Hz, 2H), 2.71 – 2.65 (m, 2H), 2.13 (s, 3H). 13C NMR(126 
MHz, CDCl3) δ 192.79, 149.26, 137.96, 127.94, 125.36, 120.28, 109.76, 42.07, 37.60, 16.80.   
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9-6. 6-benzyl-8-methyl-2,3-dihydroquinolin-4(1H)-one. 9-6 was synthesized following General 
Procedure (E) from 9-5 (300 mg, 1.25 mmol, 1 eq), benzyl boronic acid pinacol ester (0.56 mL, 
2.50 mmol, 2 eq), K2CO3 (518 mg, 3.75 mmol, 3 eq) and Pd(dppf)Cl2 (88 mg, 0.12 mmol, 0.1 eq). 
Yield: 223 mg, 71%. 1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 2.1 Hz, 1H), 7.30 – 7.23 (m, 2H), 
7.20 – 7.15 (m, 3H), 7.04 – 7.02 (m, 1H), 3.84 (s, 2H), 3.59 (t, J = 7.0 Hz, 2H), 2.68 (t, J = 6.9 Hz, 
2H), 2.10 (s, 3H). 13C NMR(126 MHz, CDCl3) δ 194.24, 149.08, 141.53, 136.80, 130.14, 128.86, 
128.59, 126.14, 125.32, 123.34, 119.11, 42.42, 41.17, 38.06, 25.00, 17.05. 
 
 
9-6. (R)-N-((R)-6-benzyl-8-methyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-
sulfinamide. 9-6 was synthesized following General Procedure (F) from 9-5 (75 mg, 0.30 mmol, 
1 eq), (R)-2-methyl-2-propanesulfinamide (106 mg, 0.90 mmol, 3 eq), and Ti(OEt)4 (0.38 mL, 
1.80 mmol, 6 eq), then NaBH4 (68 mg, 1.80 mmol, 6 eq). Yield: not calculated. 1H NMR (500 
MHz, CDCl3) δ 7.29 – 7.22 (m, 1H), 7.20 – 7.12 (m, 3H), 7.00 (d, J = 2.0 Hz, 1H), 6.80 (d, J = 
2.5 Hz, 1H), 4.54 (q, J = 3.0 Hz, 1H), 3.82 (d, J = 2.7 Hz, 2H), 3.40 (td, J = 11.8, 2.8 Hz, 1H), 3.31 
(dt, J = 11.4, 4.0 Hz, 1H), 2.12 – 2.06 (m, 1H), 2.04 (s, 3H), 1.89 (dddd, J = 16.7, 8.1, 4.1, 2.1 Hz, 
1H), 1.21 (s, 9H). 13C NMR(126 MHz, CDCl3) δ 142.09, 141.30, 130.69, 129.79, 128.86, 128.50, 
125.94, 122.12, 120.17, 116.96, 55.42, 49.71, 41.19, 36.77, 28.34, 22.80, 22.25, 17.31. 
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9. (S)-2-amino-N-((R)-6-benzyl-8-methyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide.  9 was synthesized following General Procedures (G) from 9-7 
(0.30 mmol, 1 eq) and concentrated HCl (0.03 mL, excess). Carried forward without 
characterization. Step 2: Performed amide coupling using 9-7 amine salt (20 mg, 0.070 mmol, 1 
eq), di-Boc-Dmt (31 mg, 0.076 mmol, 1.1 eq), PyBOP (40 mg, 0.076 mmol, 1.1 eq), and 6-Cl 
HOBt (13 mg, 0.076 mmol, 1.1 eq), followed by DIPEA (0.12 mL, 0.70 mmol, 10 eq). Step 3: 
Boc-deprotected with TFA as described in General Procedure (G). Final yield not calculated. 1H 
NMR (500 MHz, Methanol-d4) δ 7.22 (td, J = 7.5, 2.0 Hz, 2H), 7.13 (td, J = 8.7, 4.2 Hz, 3H), 7.01 
(s, 1H), 6.94 (s, 1H), 6.49 (s, 2H), 4.98 (m, 1H), 3.90 – 3.82 (m, 1H), 3.83 (s, 2H), 3.26 (dd, J = 
13.6, 11.6 Hz, 1H), 3.25 – 3.19 (m, 1H), 3.02 (dd, J = 13.5, 5.6 Hz, 1H), 2.76 – 2.64 (m, 1H), 2.27 
(s, 6H), 2.14 (s, 3H), 1.90 – 1.78 (m, 1H), 1.63 – 1.54 (m, 1H). HPLC (gradient A): retention time 
= 28.4 min. ESI-MS 466.3 [M + Na]+. 
 
 
Compound 10 (Notebook reference: AFN-35 or afn-v-23, notebook 5 p. 23) 
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10-2. 3-bromo-N-(4-bromo-2-ethylphenyl)propanamide. 10-2 was synthesized following General 
Procedure (A) from 4-bromo-2-ethylaniline 10-1 (1.41 g, 7.05 mmol, 1.00 eq), K2CO3 (1.95 g, 
14.10 mmol, 2.00 eq) and 3-bromopropionyl chloride (0.75 mL, 7.35 mmol, 1.05 eq). Yield: 2.36 
g, 100%. 1H NMR (500 MHz, CDCl3) δ 7.67 (d, J = 8.4 Hz, 1H), 7.37 – 7.31 (m, 2H), 7.07 (s, 
1H), 3.72 (t, J = 5.8 Hz, 2H), 2.97 (t, J = 6.3 Hz, 2H), 2.60 (q, J = 7.5 Hz, 2H), 1.24 (t, J = 7.5 Hz, 
3H). 13C NMR(126 MHz, CDCl3) δ 168.32, 137.66, 133.70, 131.62, 129.82, 125.79, 119.24, 
40.80, 27.41, 24.33, 13.93.   
 
 
10-3. 1-(4-bromo-2-ethylphenyl)azetidin-2-one. 10-3 was synthesized following General 
Procedure (B) from 10-2 (2.56 g, 7.64 mmol, 1.00 eq) and NaOtBu (734 mg, 7.64 mmol, 1.00 
eq). Yield: 1.89 g, 97%. 1H NMR (500 MHz, CDCl3) δ 7.36 (d, J = 2.1 Hz, 1H), 7.33 – 7.29 (m, 
1H), 3.75 – 3.69 (m, 2H), 3.13 (td, J = 4.5, 1.3 Hz, 2H), 2.71 (q, J = 7.5 Hz, 2H), 1.22 (td, J = 7.5, 
1.3 Hz, 3H). 13C NMR(126 MHz, CDCl3) δ 165.77, 139.73, 135.09, 132.52, 129.62, 124.88, 
119.92, 42.03, 36.81, 25.12, 14.34. 
 
10-4. 6-bromo-8-ethyl-2,3-dihydroquinolin-4(1H)-one. 10-4 was synthesized following General 
Procedure (C) from 10-3 (1.89 g, 7.42 mmol, 1 eq) and TfOH (1.31 mL, 14.85 mmol, 2 eq). 
Yield: 640 mg, 34%. 1H NMR (500 MHz, CDCl3) δ 7.88 (d, J = 2.4 Hz, 1H), 7.29 (d, J = 2.3 Hz, 
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1H), 4.40 (s, 1H), 3.61 (t, J = 7.0 Hz, 3H), 2.69 (t, J = 7.1 Hz, 3H), 2.46 (q, J = 7.5 Hz, 3H), 1.27 
(t, J = 7.5 Hz, 4H). 13C NMR(126 MHz, CDCl3) δ 192.87, 148.71, 135.93, 130.97, 127.91, 120.59, 
110.25, 42.13, 37.69, 23.30, 12.53. 
 
 
10-5. 6-benzyl-8-ethyl-2,3-dihydroquinolin-4(1H)-one. 10-5 was synthesized following General 
Procedure (E) from 10-4 (200 mg, 0.79 mmol, 1 eq), benzyl boronic acid pinacol ester (0.35 mL, 
1.57 mmol, 2 eq), K2CO3 (326 mg, 2.36 mmol, 3 eq) and Pd(dppf)Cl2 (58 mg, 0.08 mmol, 0.1 eq). 
Yield: 120 mg, 57%.1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 2.1 Hz, 1H), 7.29 – 7.23 (m, 2H), 
7.20 – 7.13 (m, 3H), 7.05 (d, J = 2.1 Hz, 1H), 4.39 – 4.31 (m, 1H), 3.86 (s, 2H), 3.57 (td, J = 7.1, 
1.7 Hz, 2H), 2.71 – 2.64 (m, 2H), 2.44 (q, J = 7.5 Hz, 2H), 1.22 (t, J = 7.5 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 194.38, 148.55, 141.51, 134.74, 134.71, 130.14, 128.99, 128.81, 128.55, 126.09, 
125.24, 125.18, 119.27, 75.12, 42.38, 41.23, 38.07, 24.98, 24.94, 23.58, 12.87, 12.85.  
 
 
10-6. (R)-N-((R)-6-benzyl-8-ethyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-
sulfinamide. 10-6 was synthesized following General Procedure (F) from 10-5 (100 mg, 0.38 
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mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (137 mg, 1.13 mmol, 3 eq), and Ti(OEt)4 (0.47 
mL, 2.26 mmol, 6 eq), then NaBH4 (85 mg, 2.26 mmol, 6 eq). Yield: not calculated. 1H NMR (500 
MHz, CDCl3) δ 7.28 – 7.23 (m, 2H), 7.21 – 7.16 (m, 2H), 7.16 – 7.14 (m, 1H), 6.99 (d, J = 2.0 
Hz, 1H), 6.83 (d, J = 2.0 Hz, 1H), 4.54 (q, J = 2.7, 2.2 Hz, 1H), 3.84 (d, J = 2.4 Hz, 2H), 3.38 (td, 
J = 11.8, 2.8 Hz, 1H), 3.33 – 3.26 (m, 1H), 2.38 (q, J = 7.5 Hz, 2H), 2.08 (dq, J = 13.6, 3.2 Hz, 
1H), 1.89 (ttd, J = 12.1, 3.9, 1.2 Hz, 1H), 1.23 (t, J = 6.3 Hz, 3H), 1.20 (s, 9H). 13C NMR(126 
MHz, CDCl3) δ 142.10, 140.76, 129.83, 128.85, 128.52, 128.49, 128.48, 127.72, 125.92, 120.36, 
55.42, 55.31, 49.81, 47.33, 41.31, 36.72, 28.35, 24.98, 23.80, 23.73, 22.80, 22.65, 12.84.   
 
 
10. (S)-2-amino-N-((R)-6-benzyl-8-ethyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide. 10 was synthesized following General Procedure (G) from 10-6 
(0.38 mmol, 1 eq) and concentrated HCl (0.03 mL, excess). Carried forward without 
characterization following step 2 of General Procedure (G) from 10-6 amine salt (45 mg, 0.15 
mmol, 1 eq), di-Boc-Dmt (67 mg, 0.16 mmol, 1.1 eq), PyBOP (85 mg, 0.16 mmol, 1.1 eq), and 6-
Cl HOBt (28 mg, 0.16 mmol, 1.1 eq), followed by DIPEA (0.26 mL, 1.50 mmol, 10 eq). Step 3: 
Boc-deprotected following General Procedure (G). Final yield not calculated. 1H NMR (500 
MHz, Methanol-d4) δ 7.21 (t, J = 7.5 Hz, 2H), 7.11 (t, J = 8.8 Hz, 3H), 6.77 (d, J = 6.1 Hz, 2H), 
6.48 (s, 2H), 4.92 (t, J = 3.9 Hz, 1H), 3.84 (dd, J = 11.6, 5.1 Hz, 1H), 3.76 (s, 2H), 3.29 – 3.22 (m, 
1H), 3.09 – 3.02 (m, 1H), 2.99 (dd, J = 13.7, 5.1 Hz, 1H), 2.48 (t, J = 11.1 Hz, 1H), 2.38 (q, J = 
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7.5 Hz, 2H), 2.27 (s, 6H), 1.70 (t, J = 12.7 Hz, 1H), 1.56 – 1.48 (m, 1H), 1.11 (td, J = 7.5, 0.9 Hz, 
3H). HPLC (gradient A): retention time = 32.1. ESI-MS 480.3 [M + Na]+. 
 
 
Compound 11 (Notebook reference: AFN-7 or afn-iii-87, notebook 3 p. 87) 
 
 
11-2. 3-bromo-N-(2-propylphenyl)propanamide. 11-2 was synthesized following General 
Procedure (A) from 2-propylaniline 11-1 (1.00 g, 7.40 mmol, 1.00 eq), K2CO3 (3.07 g, 22.2 mmol, 
3.00 eq) and 3-bromopropionyl chloride (0.78 mL, 7.77 mmol, 1.05 eq). Yield: 1.73 g, 86%. 1H 
NMR (500 MHz, CDCl3) δ 7.70 (q, J = 6.9, 5.8 Hz, 1H), 7.19 (d, J = 7.8 Hz, 2H), 7.13 (t, J = 7.5 
Hz, 1H), 3.72 (td, J = 7.0, 6.5, 3.1 Hz, 2H), 2.96 (dq, J = 7.1, 3.8, 3.3 Hz, 2H), 2.56 (t, J = 7.9 Hz, 
2H), 1.62 (h, J = 7.6 Hz, 3H), 0.97 (t, J = 7.4 Hz, 3H). 13C NMR(126 MHz, CDCl3) δ 168.28, 
134.56, 129.63, 126.67, 125.91, 124.54, 40.55, 33.47, 27.46, 23.12, 14.06.  
 
 
11-3. 1-(2-propylphenyl)azetidin-2-one. 11-3 was synthesized following General Procedure (B) 
from 11-2 (1.56 g, 5.78 mmol, 1.00 eq) and NaOtBu (583 mg, 6.07 mmol, 1.05 eq). Yield: 1.10 g, 
100%. 1H NMR (500 MHz, CDCl3) δ 7.35 (dd, J = 7.5, 1.5 Hz, 1H), 7.20 (td, J = 6.2, 5.4, 2.0 Hz, 
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2H), 7.16 (dd, J = 7.2, 1.6 Hz, 1H), 3.74 – 3.69 (m, 2H), 3.14 – 3.09 (m, 2H), 2.71 – 2.63 (m, 2H), 
1.61 (h, J = 7.4 Hz, 2H), 0.96 (t, J = 7.4 Hz, 3H). 13C NMR(126 MHz, CDCl3) δ 165.86, 136.45, 
136.02, 130.55, 126.64, 126.62, 123.68, 42.03, 36.59, 34.35, 23.64, 14.20. 
 
 
11-4. 8-propyl-2,3-dihydroquinolin-4(1H)-one. 11-4 was synthesized following General 
Procedure (C) from 11-3 (1.10 g, 5.8 mmol, 1 eq) and TfOH (1.54 mL, 17.4 mmol, 3 eq). Yield: 
1.06 g, 100%.  1H NMR (500 MHz, CDCl3) δ 7.77 (dd, J = 8.0, 1.5 Hz, 1H), 7.18 (dd, J = 7.2, 1.5 
Hz, 1H), 6.70 (t, J = 7.6 Hz, 1H), 3.72 (s, 1H), 3.60 (dd, J = 7.6, 6.3 Hz, 2H), 2.69 (dd, J = 7.5, 6.4 
Hz, 2H), 2.46 – 2.41 (m, 2H), 1.65 (h, J = 7.4 Hz, 2H), 1.01 (t, J = 7.3 Hz, 3H). 13C NMR(126 
MHz, CDCl3) δ 194.22, 149.96, 134.78, 127.18, 125.74, 119.59, 117.47, 77.16, 42.32, 38.04, 
32.84, 21.59, 14.20.  
 
 
11-5. 6-bromo-8-propyl-2,3-dihydroquinolin-4(1H)-one. 11-5 was synthesized following General 
Procedure (D) from 11-4 (294 mg, 1.55 mmol, 1.00 eq) and NBS (282 mg, 1.58 mmol, 1.02 eq). 
Yield: 350 mg, 84%. 1H NMR (500 MHz, CDCl3) δ 7.87 (d, J = 2.3 Hz, 1H), 7.26 (s, 1H), 4.42 
(s, 1H), 3.63 – 3.56 (m, 2H), 2.68 (td, J = 7.0, 1.1 Hz, 2H), 2.44 – 2.37 (m, 2H), 1.70 – 1.59 (m, 
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2H), 1.01 (td, J = 7.3, 1.1 Hz, 3H). 13C NMR(126 MHz, CDCl3) δ 192.90, 148.83, 136.97, 129.68, 
127.97, 120.67, 110.07, 77.16, 42.11, 37.68, 32.56, 21.40, 14.14.  
 
 
11-6. 6-benzyl-8-propyl-2,3-dihydroquinolin-4(1H)-one. 11-6 was synthesized following General 
Procedure (E) from 11-5 (102 mg, 0.38 mmol, 1 eq), benzyl boronic acid pinacol ester (0.17 mL, 
0.76 mmol, 2 eq), K2CO3 (157 mg, 1.14 mmol, 3 eq) and Pd(dppf)Cl2 (28 mg, 0.04 mmol, 0.1 eq), 
with the exception that the reaction was run in a microwave at 110oC for 30 minutes. Yield: 35 
mg, 32%. 1H NMR (500 MHz, CDCl3) δ 7.65 (d, J = 2.1 Hz, 1H), 7.27 (dd, J = 8.5, 6.6 Hz, 2H), 
7.20 – 7.17 (m, 3H), 7.03 (d, J = 2.1 Hz, 1H), 3.86 (s, 2H), 3.58 (t, J = 7.0 Hz, 2H), 2.68 (t, J = 6.5 
Hz, 2H), 2.41 (t, J = 3.9 Hz, 2H), 1.62 (h, J = 7.5 Hz, 2H), 0.98 (t, J = 7.3 Hz, 3H). 
 
 
11-7. (R)-N-((R)-6-benzyl-8-propyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-
sulfinamide. 11-7 was synthesized following General Procedure (F) from 11-6 (88 mg, 0.31 
mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (115 mg, 0.95 mmol, 3 eq), and Ti(OEt)4 (0.40 
mL, 1.89 mmol, 6 eq), then NaBH4 (71 mg, 1.89 mmol, 6 eq). Yield: 20 mg, 17%. 1H NMR (500 
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MHz, CDCl3) δ 7.21 – 7.18 (m, 1H), 7.16 (d, J = 2.4 Hz, 2H), 7.12 – 7.08 (m, 1H), 7.00 (d, J = 
2.3 Hz, 1H), 6.95 (s, 1H), 6.76 (d, J = 1.9 Hz, 1H), 4.45 (d, J = 3.0 Hz, 1H), 3.79 – 3.75 (m, 2H), 
3.29 (d, J = 3.0 Hz, 1H), 3.25 (dt, J = 11.5, 4.2 Hz, 2H), 2.27 (t, J = 7.8 Hz, 4H), 2.02 (dq, J = 
13.7, 3.4 Hz, 2H), 1.84 – 1.76 (m, 2H), 1.55 (qd, J = 7.2, 4.5 Hz, 3H), 1.15 (d, J = 0.9 Hz, 17H), 
0.93 (t, J = 7.3 Hz, 6H). 13C NMR(126 MHz, CDCl3) δ 141.26, 131.32, 130.35, 129.62, 128.78, 
128.67, 128.61, 128.44, 128.35, 128.26, 128.12, 125.82, 121.94, 108.32, 55.39, 49.57, 41.12, 
36.44, 32.65, 27.75, 22.64, 21.17, 14.13.   
 
 
11. (S)-2-amino-N-((R)-6-benzyl-8-propyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide.  11 was synthesized following General Procedures (G) from 11-7 
(19 mg, 0.05 mmol, 1 eq) and concentrated HCl (0.02 mL, excess). Carried forward without 
characterization. Step 2: Performed amide coupling using 11-7 amine salt (16 mg, 0.050 mmol, 1 
eq), di-Boc-Dmt (23 mg, 0.055 mmol, 1.1 eq), PyBOP (29 mg, 0.055 mmol, 1.1 eq), and 6-Cl 
HOBt (19 mg, 0.055 mmol, 1.1 eq), followed by DIPEA (0.09 mL, 0.50 mmol, 10 eq) and stirred 
18 hours. Step 3: Boc-deprotected with TFA as described in General Procedure (G). Final yield 
not calculated. 1H NMR (500 MHz, Methanol-d4) δ 7.21 (td, J = 7.3, 1.4 Hz, 2H), 7.16 – 7.08 (m, 
3H), 6.85 (dt, J = 5.3, 2.7 Hz, 2H), 6.48 (s, 2H), 4.96 (d, J = 5.1 Hz, 1H), 3.86 (ddd, J = 11.6, 5.2, 
2.3 Hz, 1H), 3.80 (d, J = 2.4 Hz, 2H), 3.25 (t, 1H), 3.11 (d, J = 4.0 Hz, 1H), 3.01 (ddd, J = 13.5, 
5.3, 2.0 Hz, 1H), 2.58 (tt, J = 10.6, 2.5 Hz, 1H), 2.39 (td, J = 7.9, 3.0 Hz, 2H), 2.27 (s, 7H), 1.76 
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(dddd, J = 17.9, 14.1, 9.1, 5.3 Hz, 1H), 1.59 – 1.48 (m, 3H), 0.93 (td, J = 7.3, 1.4 Hz, 3H). HPLC 
(gradient A): retention time = 37.1 min. ESI-MS 494.3 [M + Na]+. 
 
 
Compound 12 (Notebook reference: AFN-8 or afn-iii-91, notebook 3 p. 91) 
 
 
12-2. 3-bromo-N-(2-butylphenyl)propanamide. 12-2 was synthesized following General 
Procedure (A) from 2-butylaniline 12-1 (1.00 g, 6.70 mmol, 1.00 eq), K2CO3 (2.78 g, 20.1 mmol, 
3.00 eq) and 3-bromopropionyl chloride (0.71 mL, 7.03 mmol, 1.05 eq). Yield: 1.725 g, 91%. 1H 
NMR (500 MHz, CDCl3) δ 7.74 (d, J = 7.9 Hz, 1H), 7.20 (d, J = 8.5 Hz, 2H), 7.17 – 7.10 (m, 2H), 
3.73 (t, J = 6.5 Hz, 2H), 2.97 (t, J = 6.5 Hz, 2H), 2.59 (t, J = 7.9 Hz, 2H), 1.57 (h, J = 9.8, 8.7 Hz, 
2H), 1.39 (h, J = 7.4 Hz, 2H), 0.94 (t, J = 7.3 Hz, 3H). 13C NMR(126 MHz, CDCl3) δ 168.13, 
134.53, 134.36, 129.57, 126.67, 125.86, 124.31, 40.67, 32.10, 31.18, 27.42, 22.61, 13.96.  
 
 
12-3. 1-(2-butylphenyl)azetidin-2-one. 12-3 was synthesized following General Procedure (B) 
from 12-2 (1.725 g, 6.06 mmol, 1.00 eq) and NaOtBu (613 mg, 6.37 mmol, 1.05 eq). Yield: 1.23 
g, 100%. 1H NMR (500 MHz, CDCl3) δ 7.35 (dd, J = 7.6, 1.6 Hz, 1H), 7.20 (td, J = 8.4, 7.9, 2.1 
NH2 NH
O
Br
A
12-1 12-2
N
O
N
H
O
Br
B
12-2 12-3
 69 
Hz, 2H), 7.17 – 7.13 (m, 2H), 3.71 (td, J = 4.4, 0.9 Hz, 2H), 3.11 (td, J = 4.4, 1.0 Hz, 2H), 2.74 – 
2.65 (m, 2H), 1.56 (p, J = 7.9, 7.5 Hz, 2H), 1.37 (h, J = 7.3 Hz, 2H), 0.93 (t, J = 7.3 Hz, 3H). 13C 
NMR(126 MHz, CDCl3) δ 165.82, 136.71, 135.97, 130.49, 126.63, 126.57, 123.70, 42.02, 36.57, 
32.70, 32.00, 22.71, 14.08.   
 
12-4. 8-butyl-2,3-dihydroquinolin-4(1H)-one. 12-4 was synthesized following General 
Procedure (C) from 12-3 (1.23 g, 6.06 mmol, 1.00 eq) and TfOH (1.64 mL, 18.58 mmol, 3.07 
eq). Yield: 1.174 g, 95%. 1H NMR (500 MHz, CDCl3) δ 7.80 – 7.74 (m, 1H), 7.19 (t, J = 7.2 Hz, 
1H), 6.70 (q, J = 7.7 Hz, 1H), 4.44 (s, 1H), 3.61 (q, J = 7.3 Hz, 2H), 2.70 (q, J = 7.3 Hz, 2H), 2.47 
(q, J = 7.8 Hz, 2H), 1.61 (h, J = 7.6 Hz, 2H), 1.42 (hept, J = 7.5 Hz, 2H), 0.97 (q, J = 7.5 Hz, 3H). 
13C NMR(126 MHz, CDCl3) δ 194.23, 194.21, 149.95, 134.69, 134.67, 127.38, 125.71, 125.69, 
119.59, 117.49, 42.35, 42.33, 38.06, 38.04, 30.57, 30.56, 30.52, 30.51, 22.81, 22.80, 14.08, 14.07.  
 
 
12-5. 6-bromo-8-butyl-2,3-dihydroquinolin-4(1H)-one. 12-5 was synthesized following General 
Procedure (D) from 12-4 (485 mg, 2.46 mmol, 1.00 eq) and NBS (446 mg, 2.51 mmol, 1.05 eq). 
Yield: 575 mg, 85%. 1H NMR (500 MHz, CDCl3) δ 7.86 (dd, J = 2.5, 1.0 Hz, 1H), 7.26 (s, 1H), 
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4.44 (s, 1H), 3.63 – 3.55 (m, 2H), 2.68 (td, J = 7.0, 1.1 Hz, 2H), 2.47 – 2.38 (m, 2H), 1.64 – 1.54 
(m, 2H), 1.41 (h, J = 7.4 Hz, 2H), 0.96 (td, J = 7.3, 1.0 Hz, 3H). 13C NMR(126 MHz, CDCl3) δ 
193.15, 149.07, 137.11, 130.17, 128.14, 120.89, 110.31, 42.36, 37.92, 30.56, 30.51, 23.00, 14.29.   
 
 
12-6. 6-benzyl-8-butyl-2,3-dihydroquinolin-4(1H)-one. 12-6 was synthesized following General 
Procedure (E) from 12-5 (300 mg, 1.06 mmol, 1 eq), benzyl boronic acid pinacol ester (0.47 mL, 
2.12 mmol, 2 eq), K2CO3 (440 mg, 3.18 mmol, 3 eq) and Pd(dppf)Cl2 (81 mg, 0.11 mmol, 0.1 eq), 
except reaction was run in microwave at 110oC for 30 minutes. Yield: 78 mg, 25%. 1H NMR (500 
MHz, CDCl3) δ 7.64 (d, J = 2.1 Hz, 1H), 7.26 (s, 2H), 7.18 (td, J = 8.6, 7.8, 3.5 Hz, 3H), 7.03 (d, 
J = 2.1 Hz, 1H), 3.86 (s, 2H), 3.58 (d, J = 7.0 Hz, 2H), 2.70 – 2.67 (m, 2H), 2.41 (d, J = 7.8 Hz, 
2H), 1.59 – 1.52 (m, 2H), 1.41 – 1.35 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H). 13C NMR(126 MHz, 
CDCl3) δ 194.25, 141.53, 135.81, 134.70, 128.84, 128.58, 127.96, 126.55, 126.12, 125.76, 125.40, 
42.52, 41.23, 38.11, 30.68, 30.64, 22.83, 14.06.   
 
12-7. (R)-N-((R)-6-benzyl-8-butyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-
sulfinamide. 12-7 was synthesized following General Procedure (F) from 12-6 (78 mg, 0.27 
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mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (97 mg, 0.80 mmol, 3 eq), and Ti(OEt)4 (0.34 
mL, 1.60 mmol, 6 eq), then NaBH4 (61 mg, 1.60 mmol, 6 eq). Yield: 89 mg, 84%. 1H NMR (500 
MHz, CDCl3) δ 7.20 – 7.14 (m, 1H), 7.11 (d, J = 7.3 Hz, 2H), 7.11 – 7.03 (m, 1H), 6.92 (d, J = 
2.0 Hz, 1H), 6.73 (d, J = 2.0 Hz, 1H), 6.58 (t, J = 7.5 Hz, 1H), 4.47 (q, J = 3.8, 3.3 Hz, 1H), 3.76 
(d, J = 2.3 Hz, 2H), 3.38 – 3.17 (m, 2H), 2.31 (dt, J = 21.0, 7.9 Hz, 2H), 2.02 (ddq, J = 13.3, 6.5, 
3.2 Hz, 1H), 1.89 – 1.79 (m, 1H), 1.58 – 1.41 (m, 2H), 1.41 – 1.26 (m, 2H), 1.14 (dd, J = 5.0, 1.0 
Hz, 9H), 0.88 (ddd, J = 12.4, 7.8, 6.8 Hz, 3H). 13C NMR(126 MHz, CDCl3) δ 142.12, 131.41, 
130.49, 129.57, 128.85, 128.81, 128.53, 128.49, 128.39, 125.92, 120.50, 117.03, 55.44, 49.88, 
41.28, 36.77, 30.83, 30.67, 28.42, 23.01, 22.82, 14.11.   
 
 
12. (S)-2-amino-N-((R)-6-benzyl-8-butyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide.  12 was synthesized following General Procedure (G) from 12-7 
(82 mg, 0.21 mmol, 1 eq) and concentrated HCl (0.03 mL, excess). Carried forward without 
characterization. Step 2: Performed amide coupling using 12-7 amine salt (68 mg, 0.21 mmol, 1 
eq), di-Boc-Dmt (93 mg, 0.23 mmol, 1.1 eq), PyBOP (118 mg, 0.23 mmol, 1.1 eq), and 6-Cl HOBt 
(38 mg, 0.23 mmol, 1.1 eq), followed by DIPEA (0.40 mL, 2.1 mmol, 10 eq) and stirred 18 hours. 
Step 3: Boc-deprotected with TFA as described in General Procedure (G). Final yield not 
calculated. 1H NMR (500 MHz, Methanol-d4) δ 7.23 – 7.18 (m, 2H), 7.14 – 7.08 (m, 3H), 6.82 
(dq, J = 6.6, 2.2 Hz, 2H), 6.48 (s, 2H), 4.95 (d, J = 4.5 Hz, 1H), 3.86 (ddd, J = 11.6, 5.1, 1.9 Hz, 
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1H), 3.79 (d, J = 2.3 Hz, 2H), 3.25 (ddd, J = 13.3, 11.6, 1.2 Hz, 1H), 3.11 (dq, J = 12.2, 4.0 Hz, 
1H), 3.01 (ddd, J = 13.7, 5.2, 1.8 Hz, 1H), 2.56 (tt, J = 12.2, 3.0 Hz, 1H), 2.40 (td, J = 7.6, 2.6 Hz, 
2H), 2.27 (d, J = 1.2 Hz, 6H), 1.79 – 1.70 (m, 1H), 1.56 – 1.44 (m, 2H), 1.34 (hept, J = 7.2, 6.6 
Hz, 2H), 0.91 (td, J = 7.3, 1.2 Hz, 3H). HPLC (gradient A): retention time = 40.9 min. ESI-MS 
508.3 [M + Na]+. 
 
 
Compound 13 (Notebook reference: AFN-9 or afn-iii-93, notebook 3 p. 93) 
 
 
13-2. 3-bromo-N-(2-(tert-butyl)phenyl)propanamide. 13-2 was synthesized following General 
Procedure (A) from 2-(tert-butyl)aniline 13-1 (0.96 g, 6.41 mmol, 1.00 eq), K2CO3 (2.66 g, 19.2 
mmol, 3.00 eq) and 3-bromopropionyl chloride (0.68 mL, 6.73 mmol, 1.05 eq). Yield: 1.82 g, 
100%. 1H NMR (500 MHz, CDCl3) δ 7.54 (d, J = 7.8 Hz, 1H), 7.40 (d, J = 7.8 Hz, 1H), 7.26 – 
7.16 (m, 2H), 3.75 (t, J = 6.6 Hz, 2H), 2.98 (t, J = 6.5 Hz, 2H), 1.42 (s, 13H). 13C NMR(126 MHz, 
CDCl3) δ 168.21, 143.07, 134.64, 128.39, 127.55, 126.87, 126.65, 40.80, 34.65, 30.82, 27.24.   
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13-3. 1-(2-(tert-butyl)phenyl)azetidin-2-one. 13-3 was synthesized following General Procedure 
(B) from 13-2 (1.90 g, 6.67 mmol, 1.00 eq) and NaOtBu (673 mg, 7.00 mmol, 1.05 eq). Yield: 
1.36 g, 100%. 1H NMR (500 MHz, CDCl3) δ 7.46 (dd, J = 7.9, 1.5 Hz, 1H), 7.26 (s, 1H), 7.23 (td, 
J = 7.4, 1.5 Hz, 1H), 7.13 (dd, J = 7.6, 1.6 Hz, 1H), 3.64 (td, J = 4.3, 1.1 Hz, 2H), 3.10 (td, J = 4.3, 
1.0 Hz, 2H), 1.41 (d, J = 0.9 Hz, 9H). 13C NMR(126 MHz, CDCl3) δ 168.19, 148.84, 135.79, 
130.22, 128.65, 127.52, 127.15, 44.52, 36.68, 35.20, 31.35.   
 
 
13-4. 8-(tert-butyl)-2,3-dihydroquinolin-4(1H)-one. 13-4 was synthesized following General 
Procedure (C) from 13-3 (1.36 g, 6.71 mmol, 1.00 eq) and TfOH (1.78 mL, 20.14 mmol, 3.00 
eq). Yield: 1.02 g, 75%. 1H NMR (500 MHz, CDCl3) δ 7.83 (ddd, J = 7.8, 1.6, 0.7 Hz, 1H), 7.37 
(dd, J = 7.6, 1.7 Hz, 1H), 6.70 (td, J = 7.7, 1.6 Hz, 1H), 3.66 – 3.56 (m, 2H), 2.69 (ddd, J = 7.7, 
6.8, 1.5 Hz, 2H), 1.43 (d, J = 1.2 Hz, 9H). 13C NMR(126 MHz, CDCl3) δ 194.44, 150.68, 134.42, 
132.18, 126.36, 120.68, 117.42, 42.24, 38.03, 34.28, 30.05 
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13-5. 6-bromo-8-(tert-butyl)-2,3-dihydroquinolin-4(1H)-one. 13-5 was synthesized following 
General Procedure (D) from 13-4 (500 mg, 2.46 mmol, 1.00 eq) and NBS (460 mg, 2.58 mmol, 
1.05 eq). Yield: 570 mg, 82%. 1H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 2.4 Hz, 1H), 7.41 (d, J 
= 2.4 Hz, 1H), 4.73 (s, 1H), 3.61 (t, J = 7.0 Hz, 2H), 2.72 – 2.63 (m, 2H), 1.41 (s, 9H). 13C 
NMR(126 MHz, CDCl3) δ 192.86, 149.20, 136.79, 134.67, 128.30, 121.49, 110.17, 77.16, 41.78, 
37.37, 34.17, 29.59.   
 
13-6. 6-benzyl-8-(tert-butyl)-2,3-dihydroquinolin-4(1H)-one. 13-6 was synthesized following 
General Procedure (E) from 13-5 (300 mg, 1.06 mmol, 1 eq), benzyl boronic acid pinacol ester 
(0.47 mL, 2.12 mmol, 2 eq), K2CO3 (440 mg, 3.18 mmol, 3 eq) and Pd(dppf)Cl2 (81 mg, 0.11 
mmol, 0.1 eq), except reaction was run in microwave at 110oC for 2 hours. Yield: 87 mg, 28%. 1H 
NMR (500 MHz, CDCl3) δ 7.70 (d, J = 2.1 Hz, 1H), 7.40 – 7.37 (m, 1H), 7.30 – 7.25 (m, 2H), 
7.22 (d, J = 2.1 Hz, 1H), 7.19 (d, J = 7.7 Hz, 2H), 3.87 (s, 2H), 3.62 – 3.57 (m, 2H), 2.69 – 2.65 
(m, 2H), 1.39 (d, J = 1.0 Hz, 9H). 13C NMR(126 MHz, CDCl3) δ 194.52, 149.25, 141.50, 133.32, 
129.81, 128.83, 128.56, 126.08, 125.87, 120.60, 117.41, 42.34, 41.45, 38.10, 34.27, 30.06. 
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13-7. (R)-N-((R)-6-benzyl-8-(tert-butyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-
sulfinamide. 13-7 was synthesized following General Procedure (F) from 13-6 (87 mg, 0.30 
mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (109 mg, 0.90 mmol, 3 eq), and Ti(OEt)4 (0.38 
mL, 1.80 mmol, 6 eq), then NaBH4 (68 mg, 1.80 mmol, 6 eq). Yield: 27 mg, 23%. 1H NMR (500 
MHz, CDCl3) δ 7.18 (s, 1H), 7.14 – 7.10 (m, 2H), 7.10 – 7.06 (m, 1H), 6.93 (s, 2H), 6.57 (tt, J = 
7.7, 2.1 Hz, 1H), 4.45 (d, J = 7.2 Hz, 1H), 3.81 – 3.72 (m, 2H), 3.34 – 3.21 (m, 2H), 2.02 – 1.95 
(m, 1H), 1.81 (tdd, J = 16.7, 8.4, 4.1 Hz, 1H), 1.31 – 1.25 (m, 9H), 1.16 – 1.11 (m, 9H). 13C 
NMR(126 MHz, CDCl3) δ 142.01, 141.55, 133.25, 131.16, 129.43, 129.16, 129.13, 128.92, 
128.84, 128.71, 128.66, 128.45, 127.33, 127.17, 126.46, 126.34, 125.88, 121.13, 116.66, 77.16, 
55.40, 50.33, 41.45, 36.56, 29.91, 29.70, 28.06, 22.80.   
 
 
13. (S)-2-amino-N-((R)-6-benzyl-8-(tert-butyl)-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-
2,6-dimethylphenyl)propanamide. 13 was synthesized following General Procedure (G) from 
13-7 (27 mg, 0.068 mmol, 1 eq) and concentrated HCl (0.02 mL, excess). Carried forward without 
characterization. Step 2: Performed amide coupling using 13-7 amine salt (22 mg, 0.068 mmol, 1 
eq), di-Boc-Dmt (31 mg, 0.074 mmol, 1.1 eq), PyBOP (39 mg, 0.074 mmol, 1.1 eq), 6-Cl HOBt 
(13 mg, 0.074 mmol, 1.1 eq), and DIPEA (0.12 mL, 0.67 mmol, 10 eq). Step 3: Boc-deprotected 
as described in General Procedure (G). Final yield not calculated. 1H NMR (500 MHz, Methanol-
d4) δ 7.23 – 7.17 (m, 2H), 7.14 – 7.07 (m, 3H), 6.91 (d, J = 2.2 Hz, 1H), 6.75 (d, J = 2.2 Hz, 1H), 
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6.49 (d, J = 2.1 Hz, 2H), 4.92 (s, 1H), 3.90 – 3.81 (m, 1H), 3.75 (s, 2H), 3.25 (ddd, J = 13.7, 11.6, 
2.3 Hz, 1H), 3.09 (d, J = 12.4 Hz, 1H), 2.99 (ddd, J = 13.8, 5.3, 2.2 Hz, 1H), 2.48 (t, J = 12.1 Hz, 
1H), 2.27 (d, J = 2.2 Hz, 6H), 1.67 (t, J = 13.1 Hz, 1H), 1.47 (d, J = 13.3 Hz, 1H), 1.29 (d, J = 2.3 
Hz, 9H). HPLC (gradient A): retention time = 44.7 min. ESI-MS 486.3[M + H]+ and 508.3 [M + 
Na]+. 
 
 
Compound 14 (Notebook name: AAH-58, synthesized by Dr. Aubrie Harland) 
 
 
14-2. 3-bromo-N-(4-bromo-2-fluorophenyl)propanamide. 14-2 was synthesized following 
General Procedure (A) from 4-bromo-2-fluoroaniline 14-1 (1.0 g, 5.26 mmol, 1.00 eq), K2CO3 
(1.49 g, 10.8 mmol, 2.05 eq) and 3-bromopropionyl chloride (0.54 mL, 5.37 mmol, 1.05 eq). Yield: 
1.71 g, 100%. 1H NMR (500 MHz, CDCl3) δ 8.18 (t, J = 8.5 Hz, 1H), 7.33 (s, 1H), 7.24 – 7.18 
(m, 3H), 3.63 (t, J = 6.5 Hz, 2H), 2.93 (t, J = 6.5 Hz, 2H). 13C NMR(126 MHz, CDCl3) δ 167.85, 
152.96, 127.83, 127.80, 125.13, 122.80, 118.55, 118.37, 116.22, 40.63, 26.36.    
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14-3. 1-(4-bromo-2-fluorophenyl)azetidin-2-one. 14-3 was synthesized following General 
Procedure (B) from 14-2 (1.71 g, 5.26 mmol, 1.00 eq) and NaOtBu (530 mg, 5.30 mmol, 1.05 
eq). Yield: 1.00 g, 78%. 1H NMR (500 MHz, CDCl3) δ 7.91 (t, J = 8.6 Hz, 1H), 7.25 – 7.15 (m, 
2H), 3.87 (q, J = 4.4 Hz, 2H), 3.15 (t, J = 4.6 Hz, 2H). 13C NMR(126 MHz, CDCl3) δ 165.40, 
152.52, 150.53, 127.71, 127.68, 125.66, 125.58, 122.06, 122.03, 119.69, 119.51, 115.66, 115.59, 
42.07, 42.01, 38.39, 38.38.   
 
14-4. 6-bromo-8-fluoro-2,3-dihydroquinolin-4(1H)-one. 14-4 was synthesized following General 
Procedure (C) from 14-3 (1.0 g, 4.1 mmol, 1 eq) and TfOH (1.09 mL, 12.3 mmol, 3 eq). Yield: 
508 mg, 51%. 1H NMR (500 MHz, CDCl3) δ 7.76 (t, J = 1.7 Hz, 1H), 7.27 – 7.23 (m, 1H), 4.65 
(s, 1H), 3.64 (td, J = 7.5, 7.1, 2.0 Hz, 2H), 2.73 (t, J = 7.1 Hz, 2H). 13C NMR(126 MHz, CDCl3) 
δ 191.33, 152.16, 150.20, 140.23, 140.13, 125.60, 122.79, 122.62, 121.78, 108.04, 107.97, 41.94, 
37.80. 
 
14-5. 6-benzyl-8-fluoro-2,3-dihydroquinolin-4(1H)-one. 14-5 was synthesized following General 
Procedure (E) from 14-4 (75 mg, 0.31 mmol, 1 eq), benzyl boronic acid pinacol ester (0.14 mL, 
0.61 mmol, 2 eq), K2CO3 (128 mg, 0.92 mmol, 3 eq) and Pd(dppf)Cl2 (23 mg, 0.03 mmol, 0.1 eq). 
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Yield: 29 mg, 37%. 1H NMR (500 MHz, CDCl3) δ 7.54 – 7.51 (m, 1H), 7.32 – 7.24 (m, 2H), 7.22 
– 7.19 (m, 1H), 7.18 – 7.14 (m, 2H), 6.94 (dd, J = 11.7, 1.9 Hz, 1H), 4.52 (s, 1H), 3.86 (s, 2H), 
3.61 (td, J = 7.5, 7.1, 1.8 Hz, 2H), 2.75 – 2.68 (m, 2H). 13C NMR(126 MHz, CDCl3) δ 192.90, 
152.40, 150.47, 140.70, 139.68, 139.57, 130.23, 128.89, 128.73, 126.45, 122.43, 120.44, 120.30, 
42.29, 41.10, 38.20. 
 
14-6. (R)-N-((R)-6-benzyl-8-fluoro-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-
sulfinamide. 14-6 was synthesized following General Procedure (F) from 14-5 (25 mg, 0.10 
mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (36 mg, 0.30 mmol, 3 eq), and Ti(OEt)4 (0.12 
mL, 0.60 mmol, 6 eq), then NaBH4 (23 mg, 0.60 mmol, 6 eq). Yield: 16 mg; 53%. 1H NMR (500 
MHz, CDCl3) δ 7.27 (t, J = 7.6 Hz, 2H), 7.22 – 7.14 (m, 3H), 6.92 (s, 1H), 6.70 (dd, J = 12.0, 1.8 
Hz, 1H), 4.55 (q, J = 3.3 Hz, 1H), 4.07 (s, 1H), 3.83 (d, J = 3.7 Hz, 2H), 3.36 (td, J = 11.6, 2.9 Hz, 
1H), 3.30 (dt, J = 11.4, 4.2 Hz, 1H), 2.11 (dq, J = 13.7, 3.4 Hz, 1H), 1.97 – 1.88 (m, 1H), 1.62 (s, 
1H), 1.22 (d, J = 0.7 Hz, 9H). 13C NMR(126 MHz, CDCl3) δ 141.34, 131.91, 129.73, 128.88, 
128.62, 126.23, 125.41, 122.55, 114.87, 114.73, 110.15, 55.58, 49.28, 41.10, 36.09, 28.36, 22.79. 
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14 (S)-2-amino-N-((R)-6-benzyl-8-fluoro-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide. 14 was synthesized following General Procedure (G) from 14-6 
(19 mg, 0.05 mmol, 1 eq) and concentrated HCl (0.03 mL, excess). Carried forward without 
characterization. Step 2: Performed amide coupling using 14-6 amine salt (55 mg, 0.14 mmol, 1 
eq), di-Boc-Dmt (60 mg, 0.15 mmol, 1.1 eq), PyBOP (73 mg, 0.15 mmol, 1.1 eq), and 6-Cl HOBt 
(24 mg, 0.15 mmol, 1.1 eq), followed by DIPEA (0.25 mL, 1.4 mmol, 10 eq). Step 3: Boc-
deprotected as described in General Procedure (G). Final yield not calculated. 1H NMR (500 
MHz, Methanol-d4) δ 7.25 – 7.19 (m, 2H), 7.11 (d, J = 7.7 Hz, 2H), 6.70 (s, 1H), 6.63 (d, J = 12.1 
Hz, 1H), 6.48 (s, 2H), 4.93 (s, 1H), 3.84 (dd, J = 11.6, 4.7 Hz, 1H), 3.75 (s, 2H), 3.25 (t, J = 12.6 
Hz, 1H), 3.19 – 3.13 (m, 1H), 3.03 (d, J = 8.0 Hz, 1H), 3.00 (d, J = 11.7 Hz, 1H), 2.46 (t, J = 11.7 
Hz, 1H), 2.31 – 2.23 (m, 7H), 1.68 (t, J = 12.6 Hz, 1H), 1.50 (d, J = 13.4 Hz, 1H). HPLC (gradient 
A): retention time = 35.2 min. ESI-MS 470.2 [M + Na]+. 
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Compound 15 (Notebook reference: AFN-32 or afn-iv-285, notebook 4 p. 285) 
 
 
15-2. 3-bromo-N-(2-(trifluoromethyl)phenyl)propanamide. 15-2 was synthesized following 
General Procedure (A) from 2-(trifluoromethyl)aniline 15-1 (2.00 g, 12.4 mmol, 1.00 eq), K2CO3 
(5.14 g, 37.2 mmol, 3.00 eq) and 3-bromopropionyl chloride (1.31 mL, 13.0 mmol, 1.05 eq). Yield: 
3.68 g, 100%. 1H NMR (500 MHz, CDCl3) δ 8.17 (d, J = 8.2 Hz, 1H), 7.63 (d, J = 8.1 Hz, 1H), 7.57 
(t, J = 7.9 Hz, 1H), 7.43 (t, J = 7.7 Hz, 1H), 3.71 (t, J = 6.6 Hz, 2H), 2.99 (t, J = 6.5 Hz, 2H). 13C 
NMR(126 MHz, CDCl3) δ 168.31, 134.75, 133.71, 133.06, 127.45, 126.26, 125.10, 40.86, 26.53.   
 
 
15-3. 1-(2-(trifluoromethyl)phenyl)azetidin-2-one. 15-3 was synthesized following General 
Procedure (B) from 15-2 (3.38 g, 12.56 mmol, 1.00 eq) and NaOtBu (1.27 g, 13.19 mmol, 1.05 
eq). Yield: 1.62 g, 60%. 1H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 8.1 Hz, 1H), 7.64 (dd, J = 8.0, 
1.4 Hz, 1H), 7.52 (td, J = 7.8, 1.5 Hz, 1H), 7.30 – 7.21 (m, 1H), 3.84 (td, J = 4.6, 1.2 Hz, 2H), 3.14 
(t, J = 4.7 Hz, 2H). 13C NMR(126 MHz, CDCl3) δ 166.86, 135.88, 135.87, 132.95, 132.94, 127.00, 
126.95, 125.58, 125.55, 124.66, 122.49, 43.89, 43.86, 43.82, 43.79, 37.24.   
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15-4. 8-(trifluoromethyl)-2,3-dihydroquinolin-4(1H)-one. 15-4 was synthesized following 
General Procedure (C) from 15-3 (1.62 g, 7.52 mmol, 1.00 eq) and TfOH (2.00 mL, 22.56 mmol, 
3.00 eq). Yield: 850 mg, 52%. 1H NMR (500 MHz, CDCl3) δ 8.05 (ddd, J = 7.9, 1.7, 0.9 Hz, 1H), 
7.60 (ddd, J = 7.6, 1.7, 0.8 Hz, 1H), 6.77 (td, J = 7.7, 0.9 Hz, 1H), 5.06 (s, 1H), 3.69 – 3.63 (m, 
2H), 2.77 – 2.71 (m, 2H). 13C NMR(126 MHz, CDCl3) δ 192.59, 148.70, 132.75, 132.71, 132.66, 
132.62, 132.22, 125.64, 123.47, 120.74, 116.46, 41.72, 37.44. 
 
15-5. 6-bromo-8-(trifluoromethyl)-2,3-dihydroquinolin-4(1H)-one. 15-5 was synthesized 
following General Procedure (D) from 15-4 (850 mg, 3.95 mmol, 1.00 eq) and NBS (739 mg, 
4.15 mmol, 1.05 eq). Yield: 1.00 g, 86%. 1H NMR (500 MHz, CDCl3) δ 8.13 (d, J = 2.4 Hz, 1H), 
7.68 (d, J = 2.5 Hz, 1H), 5.07 (s, 1H), 3.70 – 3.63 (m, 2H), 2.78 – 2.70 (m, 2H). 13C NMR(126 
MHz, CDCl3) δ 191.23, 147.36, 135.24, 135.19, 135.15, 135.10, 134.57, 124.64, 122.47, 122.03, 
108.56, 41.55, 37.08.   
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15-6. 6-benzyl-8-(trifluoromethyl)-2,3-dihydroquinolin-4(1H)-one. 15-6 was synthesized 
following General Procedure (E) from 15-5 (300 mg, 1.02 mmol, 1 eq), benzyl boronic acid 
pinacol ester (0.45 mL, 2.04 mmol, 2 eq), K2CO3 (423 mg, 3.06 mmol, 3 eq) and Pd(dppf)Cl2 (73 
mg, 0.10 mmol, 0.1 eq). Yield: 110 mg, 35%. 1H NMR (500 MHz, CDCl3) δ 7.92 (d, J = 2.2 Hz, 
1H), 7.44 (d, J = 2.2 Hz, 1H), 7.29 (dd, J = 8.2, 6.9 Hz, 2H), 7.23 – 7.18 (m, 1H), 7.17 – 7.14 (m, 
2H), 4.96 (s, 1H), 3.89 (s, 2H), 3.64 (td, J = 7.0, 2.3 Hz, 2H), 2.75 – 2.67 (m, 2H). 13C NMR(126 
MHz, CDCl3) δ 192.72, 147.26, 140.45, 133.27, 132.02, 129.55, 128.81, 126.54, 120.84, 41.84, 
40.82, 37.57.   
 
15-7. (R)-N-((R)-6-benzyl-8-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-
2-sulfinamide. 15-7 was synthesized following General Procedure (F) from 15-6 (110 mg, 0.36 
mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (132 mg, 1.08 mmol, 3 eq), and Ti(OEt)4 (0.45 
mL, 2.16 mmol, 6 eq), then NaBH4 (82 mg, 2.16 mmol, 6 eq). Yield: 128 mg, 86%. 1H NMR (500 
MHz, CDCl3) δ 7.30 – 7.24 (m, 3H), 7.20 – 7.15 (m, 4H), 4.59 (s, 1H), 4.54 (q, J = 3.3 Hz, 1H), 
3.90 – 3.79 (s, 2H), 3.41 (td, J = 12.0, 3.1 Hz, 1H), 3.34 (dt, J = 7.8, 4.0 Hz, 1H), 2.10 (dq, J = 
13.8, 3.5 Hz, 1H), 1.88 (ddt, J = 17.0, 12.9, 3.9 Hz, 1H), 1.22 (s, 9H). 13C NMR(126 MHz, CDCl3) 
CF3
N
H
O
Br
CF3
N
H
O
E
15-5 15-6
CF3
N
H
O
CF3
N
H
HN S
O
F
15-6 15-7
 83 
δ 141.13, 140.96, 134.78, 128.80, 128.68, 127.21, 126.30, 122.16, 55.63, 49.84, 40.86, 36.30, 
27.23, 22.77.   
 
 
15. (S)-2-amino-N-((R)-6-benzyl-8-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide. 15 was synthesized following General Procedure (G) 
from 15-7 (128 mg, 0.31 mmol, 1 eq) and concentrated HCl (0.05 mL, excess). Carried forward 
without characterization. Step 2: Performed amide coupling using 15-7 amine salt (48 mg, 0.140 
mmol, 1 eq), di-Boc-Dmt (63 mg, 0.154 mmol, 1.1 eq), PyBOP (78 mg, 0.154 mmol, 1.1 eq), and 
6-Cl HOBt (26 mg, 0.154 mmol, 1.1 eq), followed by DIPEA (0.25 mL, 1.40 mmol, 10 eq). Step 
3: Boc-deprotected as described in General Procedure (G). Final yield not calculated. 1H NMR 
(500 MHz, Methanol-d4) δ 8.21 (d, J = 8.0 Hz, 1H), 7.26 – 7.21 (m, 2H), 7.17 – 7.13 (m, 1H), 7.13 
– 7.08 (m, 3H), 7.06 (d, J = 2.1 Hz, 1H), 6.50 – 6.46 (m, 2H), 4.95 (q, J = 4.2 Hz, 1H), 3.84 (dd, J 
= 11.6, 5.0 Hz, 1H), 3.79 (s, 2H), 3.25 (dd, J = 13.6, 11.6 Hz, 1H), 3.08 (dtd, J = 12.6, 4.3, 1.2 Hz, 
1H), 3.01 (dd, J = 13.7, 5.0 Hz, 1H), 2.50 – 2.41 (m, 1H), 1.70 – 1.60 (m, 1H), 1.50 (dq, J = 13.2, 
3.7 Hz, 1H). 13C NMR(126 MHz, cd3od) δ 168.36, 157.38, 142.65, 142.38, 140.00, 135.67, 129.64, 
129.48, 128.97, 127.69, 127.12, 123.27, 121.87, 116.46, 53.39, 46.76, 41.44, 37.53, 31.94, 28.05, 
20.44.  HPLC (gradient A): retention time = 42.1 min. ESI-MS 498.24 [M + H]+. 
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Compound 16 (Notebook reference: AFN-31 or afn-iv-287, notebook 4 p. 287) 
 
 
16-1. (R)-N-((R)-6-benzyl-8-bromo-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-
sulfinamide. 16-1 was synthesized following General Procedure (F) from 8-5 (80 mg, 0.25 mmol, 
1 eq), (R)-2-methyl-2-propanesulfinamide (92 mg, 0.76 mmol, 3 eq), and Ti(OEt)4 (0.32 mL, 1.52 
mmol, 6 eq), then NaBH4 (58 mg, 1.52 mmol, 6 eq). Yield: 71 mg, 67%. 1H NMR (500 MHz, 
CDCl3) δ 7.29 – 7.25 (m, 2H), 7.20 – 7.15 (m, 4H), 7.06 (d, J = 1.9 Hz, 1H), 4.52 (q, J = 3.2 Hz, 
1H), 4.50 (s, 1H), 3.81 (s, 2H), 3.41 (tdd, J = 11.9, 3.0, 1.1 Hz, 1H), 3.37 – 3.32 (m, 1H), 2.98 (s, 
1H), 2.13 – 2.06 (m, 1H), 1.93 – 1.84 (m, 1H), 1.21 (s, 9H). 13C NMR(126 MHz, CDCl3) δ 141.27, 
140.26, 132.57, 130.70, 129.96, 128.85, 128.62, 126.23, 121.86, 109.13, 55.58, 49.86, 40.80, 
36.61, 27.91, 22. 
 
 
16. (S)-2-amino-N-((R)-6-benzyl-8-bromo-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide.  16 was synthesized following General Procedure (G) from 16-1 
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(71 mg, 0.17 mmol, 1 eq) and concentrated HCl (0.03 mL, excess). Carried forward without 
characterization. Step 2: Performed amide coupling using 16-1 amine salt (62 mg, 0.175 mmol, 1 
eq), di-Boc-Dmt (78 mg, 0.192 mmol, 1.1 eq), PyBOP (99 mg, 0.192 mmol, 1.1 eq), and 6-Cl 
HOBt (32 mg, 0.192 mmol, 1.1 eq), followed by DIPEA (0.31 mL, 1.75 mmol, 10 eq), stirring 18 
hours before Boc-deprotecting. Step 3: Boc-deprotected as described in General Procedure (G). 
Final yield not calculated. 1H NMR (500 MHz, Methanol-d4) δ 8.16 (d, J = 8.0 Hz, 1H), 7.26 – 
7.20 (m, 2H), 7.17 – 7.12 (m, 1H), 7.12 – 7.08 (m, 3H), 6.86 (d, J = 2.0 Hz, 1H), 6.48 (s, 2H), 4.91 
(dt, J = 7.9, 4.1 Hz, 1H), 3.83 (dd, J = 11.6, 5.0 Hz, 1H), 3.74 (s, 2H), 3.25 (dd, J = 13.6, 11.6 Hz, 
1H), 3.12 – 3.04 (m, 1H), 3.00 (dd, J = 13.7, 5.0 Hz, 1H), 2.46 (td, J = 12.0, 3.0 Hz, 1H), 2.27 (s, 
6H), 1.64 (ddt, J = 13.0, 11.6, 4.1 Hz, 1H), 1.50 (dq, J = 13.3, 3.8 Hz, 1H). 13C NMR(126 MHz, 
cd3od) δ 168.28, 157.38, 142.79, 141.86, 139.99, 133.41, 131.24, 130.77, 129.66, 129.43, 127.06, 
123.26, 121.64, 116.45, 109.56, 53.39, 46.91, 41.45, 37.96, 31.94, 28.75, 20.45. HPLC (gradient 
A): retention time = 39.9 min. ESI-MS 508.16[M + H]+ and 510.16 [M + Na]+. 
 
 
Compound 17 (Notebook reference: AFN-12 or afn-iii-245, notebook 3 p. 245) 
 
 
17-1. 6-benzyl-8-(furan-3-yl)-2,3-dihydroquinolin-4(1H)-one. 17-1 was synthesized following 
General Procedure (E) from 8-5 (111 mg, 0.35 mmol, 1 eq), 3-furanylboronic acid (60 mg, 0.53 
mmol, 1.5 eq), K2CO3 (145 mg, 1.05 mmol, 3 eq) and Pd(dppf)Cl2 (26 mg, 0.035 mmol, 0.1 eq). 
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Yield: 88 mg, 83%. 1H NMR (500 MHz, Chloroform-d) δ 7.74 (d, J = 2.1 Hz, 1H), 7.60 – 7.56 
(m, 1H), 7.52 (t, J = 1.5 Hz, 1H), 7.26 (t, J = 7.7 Hz, 2H), 7.21 – 7.16 (m, 3H), 7.17 – 7.13 (m, 
1H), 6.55 – 6.52 (m, 1H), 4.75 (s, 1H), 3.88 (s, 2H), 3.50 (td, J = 7.5, 7.1, 2.0 Hz, 2H), 2.69 (t, J = 
6.9 Hz, 2H). 13C NMR (126 MHz, cdcl3) δ 194.00, 148.40, 143.83, 141.22, 140.26, 136.20, 130.38, 
128.83, 128.62, 126.94, 126.22, 121.97, 120.04, 119.68, 111.00, 42.41, 41.09, 38.05. 
 
 
17-2. (R)-N-((R)-6-benzyl-8-(furan-3-yl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-
sulfinamide. 17-2 was synthesized following General Procedure (F) from 17-1 (71 mg, 0.23 
mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (85 mg, 0.70 mmol, 3 eq), and Ti(OEt)4 (0.29 
mL, 1.40 mmol, 6 eq), then NaBH4 (53 mg, 1.40 mmol, 6 eq). Yield: 34 mg, 35%. 1H NMR (500 
MHz, Chloroform-d) δ 7.49 (d, J = 1.7 Hz, 1H), 7.41 (q, J = 1.7 Hz, 1H), 7.19 (td, J = 7.4, 6.4, 1.6 
Hz, 2H), 7.16 – 7.07 (m, 3H), 7.02 (d, J = 1.7 Hz, 1H), 6.85 (d, J = 1.8 Hz, 1H), 6.47 (d, J = 1.9 
Hz, 1H), 4.50 (d, J = 4.0 Hz, 1H), 3.78 (d, J = 2.6 Hz, 2H), 3.25 (ddd, J = 14.1, 11.0, 2.5 Hz, 1H), 
3.19 – 3.14 (m, 1H), 3.13 (s, 1H), 2.02 (dd, J = 13.6, 3.4 Hz, 1H), 1.91 – 1.80 (m, 1H), 1.14 (d, J 
= 1.5 Hz, 9H). 13C NMR (126 MHz, cdcl3) δ 143.42, 141.81, 140.90, 140.08, 130.29, 130.18, 
129.87, 128.86, 128.56, 126.04, 122.94, 120.89, 118.22, 111.19, 77.16, 55.49, 49.88, 41.14, 36.62, 
28.27, 22.80. 
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17. (S)-2-amino-N-((R)-6-benzyl-8-(furan-3-yl)-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-
2,6-dimethylphenyl)propanamide. 17 was synthesized following General Procedure (G) from 
17-2 (34 mg, 0.08 mmol, 1 eq) and concentrated HCl (0.03 mL, excess). Carried forward without 
characterization. Step 2: Performed amide coupling using 17-2 amine salt (0.08 mmol, 1 eq), di-
Boc-Dmt (38 mg, 0.09 mmol, 1.1 eq), PyBOP (48 mg, 0.09 mmol, 1.1 eq), and 6-Cl HOBt (16 
mg, 0.09 mmol, 1.1 eq), followed by DIPEA (0.14 mL, 0.80 mmol, 10 eq). Step 3: Boc-deprotected 
as described in General Procedure (G). Final yield not calculated. 1H NMR (500 MHz, Methanol-
d4) δ 8.19 (t, J = 6.5 Hz, 1H), 7.63 – 7.60 (m, 1H), 7.55 (q, J = 1.9 Hz, 1H), 7.25 – 7.19 (m, 2H), 
7.16 – 7.10 (m, 3H), 6.93 – 6.87 (m, 2H), 6.53 (d, J = 2.0 Hz, 1H), 6.47 (d, J = 1.9 Hz, 2H), 4.96 
(d, J = 6.6 Hz, 1H), 3.86 (ddt, J = 11.8, 4.8, 2.0 Hz, 1H), 3.80 (d, J = 2.3 Hz, 2H), 3.25 (ddd, J = 
13.6, 11.4, 2.0 Hz, 1H), 3.07 – 2.98 (m, 2H), 2.46 (tq, J = 11.9, 2.9, 2.0 Hz, 1H), 2.27 (d, J = 1.9 
Hz, 6H), 1.73 (td, J = 12.2, 4.0 Hz, 1H), 1.56 – 1.47 (m, 1H). 13C NMR (126 MHz, cd3od) δ 168.36, 
157.29, 144.58, 143.13, 141.24, 140.00, 131.91, 131.16, 130.88, 129.66, 129.36, 126.92, 124.06, 
123.33, 121.87, 120.62, 116.44, 111.82, 53.41, 49.00, 46.92, 41.88, 38.49, 31.92, 28.87, 20.46. 
HPLC (method 20 to 70%B in 50 min): retention time = 19..3 min, or approximately 39.3 minutes 
adjusted to gradient A. ESI-MS 496.3 [M+H] and 518.3 [M+Na]+.   
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Compound 18 (Notebook reference: AFN-16 or afn-iv-3, notebook 4 p. 3) 
 
 
18-1. 6-benzyl-8-phenethyl-2,3-dihydroquinolin-4(1H)-one. 18-1 was synthesized following 
General Procedure (E) from 8-5 (130 mg, 0.41 mmol, 1 eq), phenethyl boronic acid MIDA ester 
(161 mg, 0.62 mmol, 1.5 eq), K2CO3 (171 mg, 1.24 mmol, 3 eq) and Pd(dppf)Cl2 (30 mg, 0.04 
mmol, 0.1 eq). Yield: 65 mg, 46%. 1H NMR (500 MHz, CDCl3) δ 7.67 (d, J = 2.1 Hz, 1H), 7.26 
(s, 4H), 7.24 – 7.18 (m, 2H), 7.15 (dd, J = 9.7, 7.7 Hz, 4H), 7.02 (d, J = 2.1 Hz, 1H), 3.85 (s, 2H), 
3.39 (td, J = 7.7, 7.1, 2.1 Hz, 2H), 2.93 – 2.87 (m, 2H), 2.73 (t, J = 7.7 Hz, 2H), 2.66 – 2.60 (m, 
2H). 13C NMR(126 MHz, CDCl3) δ 194.30, 148.77, 141.43, 141.25, 136.03, 130.18, 128.79, 
128.65, 128.55, 128.48, 126.93, 126.40, 126.09, 125.71, 119.56, 42.37, 41.14, 37.97, 35.30, 32.85.   
 
18-2. (R)-N-((R)-6-benzyl-8-phenethyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-
sulfinamide. 18-2 was synthesized following General Procedure (F) from 18-1 (65 mg, 0.19 
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mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (70 mg, 0.57 mmol, 3 eq), and Ti(OEt)4 (0.24 
mL, 1.14 mmol, 6 eq), then NaBH4 (44 mg, 1.14 mmol, 6 eq). Yield: 61 mg, 72%. Carried forward 
without characterization. 
 
 
18. (S)-2-amino-N-((R)-6-benzyl-8-phenethyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide. 18 was synthesized following General Procedure (G) from 18-2 
(61 mg, 0.14 mmol, 1 eq) and concentrated HCl (0.03 mL, excess). Carried forward without 
characterization. Step 2: Performed amide coupling using 18-2 amine salt (32 mg, 0.084 mmol, 1 
eq), di-Boc-Dmt (38 mg, 0.093 mmol, 1.1 eq), PyBOP (49 mg, 0.093 mmol, 1.1 eq), and 6-Cl 
HOBt (16 mg, 0.093 mmol, 1.1 eq), followed by DIPEA (0.15 mL, 0.84 mmol, 10 eq). Step 3: 
Boc-deprotected as described in General Procedure (G). Yield after deprotection: 17 mg, 31% 
over 2 steps. 1H NMR (500 MHz, Methanol-d4) δ 8.12 (d, J = 7.9 Hz, 1H), 7.23 – 7.17 (m, 4H), 
7.16 – 7.09 (m, 4H), 7.05 – 7.02 (m, 2H), 6.79 (d, J = 2.0 Hz, 1H), 6.70 (d, J = 2.0 Hz, 1H), 6.49 
(s, 2H), 4.94 (q, J = 4.6 Hz, 1H), 3.86 (dd, J = 11.6, 5.0 Hz, 1H), 3.72 (s, 2H), 3.25 (dd, J = 13.6, 
11.6 Hz, 1H), 3.06 (dt, J = 12.2, 4.3 Hz, 1H), 3.01 (dd, J = 13.6, 5.1 Hz, 1H), 2.81 (t, J = 7.6 Hz, 
2H), 2.70 (td, J = 8.0, 7.5, 4.7 Hz, 2H), 2.51 (td, J = 11.8, 2.5 Hz, 1H), 2.28 (s, 6H), 1.76 – 1.67 
(m, 1H), 1.55 – 1.47 (m, 1H). HPLC (gradient A): retention time = 45.3 min. ESI-MS 556.3 [M + 
Na]+.   
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Compound 19 (Notebook reference: AFN-13 or afn-iii-247, notebook 5 p. 247) 
 
 
19-1. 8-(benzofuran-2-yl)-6-benzyl-2,3-dihydroquinolin-4(1H)-one. 19-1 was synthesized 
following General Procedure (E) from 8-5 (113 mg, 0.36 mmol, 1 eq), 2-benzofuranyl boronic 
acid MIDA ester (146 mg, 0.54 mmol, 1.5 eq), K2CO3 (148 mg, 1.07 mmol, 3 eq) and Pd(dppf)Cl2 
(27 mg, 0.036 mmol, 0.1 eq). Yield: 116 mg, 92%. 1H NMR (500 MHz, Chloroform-d) δ 7.85 – 
7.81 (m, 1H), 7.60 – 7.56 (m, 2H), 7.52 (d, J = 8.1 Hz, 1H), 7.33 – 7.23 (m, 4H), 7.19 (dd, J = 
14.5, 7.4 Hz, 3H), 6.90 (s, 1H), 3.92 (s, 2H), 3.66 – 3.59 (m, 2H), 2.74 (t, J = 6.9 Hz, 2H). 13C 
NMR (126 MHz, cdcl3) δ 193.69, 154.49, 154.18, 147.86, 141.04, 135.23, 130.26, 128.98, 128.85, 
128.69, 128.56, 126.32, 124.67, 123.45, 121.01, 120.48, 117.22, 111.24, 104.17, 77.16, 42.12, 
41.03, 37.92. 
 
19-2. (R)-N-((R)-8-(benzofuran-2-yl)-6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-
methylpropane-2-sulfinamide. 19-2 was synthesized following General Procedure (F) from 19-
N
H
O
Br
N
H
O
E
8-5  19-1
O
N
H
O
N
H
HN S
O
F
 19-1 19-2
O O
 91 
1 (97 mg, 0.27 mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (100 mg, 0.82 mmol, 3 eq), and 
Ti(OEt)4 (0.35 mL, 1.65 mmol, 6 eq), then NaBH4 (63 mg, 1.65 mmol, 6 eq). Yield: 62 mg, 52%. 
1H NMR (500 MHz, Chloroform-d) δ 7.50 – 7.45 (m, 1H), 7.45 – 7.40 (m, 1H), 7.27 (d, J = 2.2 
Hz, 1H), 7.23 – 7.14 (m, 5H), 7.14 (dd, J = 7.2, 1.5 Hz, 2H), 7.08 (t, J = 3.0 Hz, 1H), 6.78 (d, J = 
1.3 Hz, 1H), 4.51 (t, J = 3.0 Hz, 1H), 3.82 (s, 2H), 3.37 (td, J = 11.9, 3.0 Hz, 1H), 3.28 (dt, J = 
11.6, 3.8 Hz, 1H), 2.05 (dq, J = 13.6, 3.2 Hz, 1H), 1.92 – 1.82 (m, 1H), 1.15 (d, J = 3.1 Hz, 9H). 
13C NMR (126 MHz, cdcl3) δ 155.55, 154.36, 141.63, 141.04, 132.05, 129.57, 129.47, 128.84, 
128.58, 126.11, 124.15, 123.17, 121.70, 120.76, 115.16, 111.11, 103.46, 77.16, 55.54, 50.05, 
41.05, 36.40, 27.65, 22.78, 22.64. 
 
 
19. (S)-2-amino-N-((R)-8-(benzofuran-2-yl)-6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide. 19 was synthesized following General Procedure (G) 
from 19-2 (62 mg, 0.14 mmol, 1 eq) and concentrated HCl (0.05 mL, excess). Carried forward 
without characterization. Step 2: Performed amide coupling using 19-2 amine salt (0.14 mmol, 1 
eq), di-Boc-Dmt (61 mg, 0.15 mmol, 1.1 eq), PyBOP (78 mg, 0.15 mmol, 1.1 eq), and 6-Cl HOBt 
(26 mg, 0.15 mmol, 1.1 eq), followed by DIPEA (0.25 mL, 1.40 mmol, 10 eq). Step 3: Boc-
deprotected as described in General Procedure (G). Final yield not calculated. 1H NMR (500 
MHz, Methanol-d4) δ 8.25 (d, J = 7.9 Hz, 1H), 7.59 – 7.54 (m, 1H), 7.51 – 7.46 (m, 1H), 7.38 (d, 
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J = 2.0 Hz, 1H), 7.29 – 7.20 (m, 4H), 7.20 – 7.11 (m, 3H), 6.97 – 6.92 (m, 2H), 6.49 (d, J = 1.7 
Hz, 2H), 4.97 (p, J = 4.1 Hz, 1H), 3.91 – 3.84 (m, 1H), 3.83 (d, J = 1.7 Hz, 2H), 3.26 (ddd, J = 
13.4, 11.5, 1.8 Hz, 1H), 3.17 – 3.08 (m, 1H), 3.01 (ddd, J = 13.5, 5.1, 1.7 Hz, 1H), 2.56 – 2.47 (m, 
1H), 2.28 (d, J = 1.7 Hz, 6H), 1.78 – 1.68 (m, 1H), 1.60 – 1.51 (m, 1H). 13C NMR (126 MHz, 
cd3od) δ 168.32, 157.33, 156.26, 155.52, 143.09, 142.03, 140.02, 132.70, 130.52, 130.30, 129.96, 
129.68, 129.41, 126.98, 125.16, 124.07, 123.33, 121.76, 116.56, 116.47, 111.73, 104.17, 53.41, 
49.00, 47.22, 41.83, 37.96, 31.95, 28.59, 20.47. HPLC (method 20 to 70%B in 50 min): retention 
time = 29..0 min, or approximately 49.0 minutes adjusted to gradient A. ESI-MS 546.3 [M+H] 
and 568.3 [M+Na]+.   
 
 
Compound 20 (Notebook reference: AFN-54 or afn-v-295, notebook 5 p. 295) 
 
 
20-1. 6-benzyl-4-oxo-1,2,3,4-tetrahydroquinoline-8-carboxylic acid. 20-1 was synthesized 
following General Procedure (H) using degassed 4:1 DMF:H2O, intermediate 8-5 (305 mg, 0.97 
mmol, 1 eq), K2CO3 (200 mg, 1.45 mmol, 1.5 eq), Pd(dppf)Cl2 (71 mg, 0.097 mmol, 0.1 eq), and 
added oxalyl chloride (3 mL total volume). Yield: 150 mg, 55%. 1H NMR (500 MHz, CDCl3) δ 
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N
H
N
H
H
O
OHO
O
8-5 20-1
Cl
O
O
NaOH
+ HCl (aq)
+ CO2 (aq)
CO (g)
Cl
 93 
8.04 (s, 1H), 8.00 (d, J = 2.4 Hz, 1H), 7.98 (d, J = 2.3 Hz, 1H), 7.30 – 7.26 (m, 2H), 7.21 – 7.15 
(m, 3H), 3.88 (s, 2H), 3.65 (t, J = 7.1 Hz, 2H), 2.73 – 2.68 (m, 2H), 2.12 (s, 1H). 13C NMR(126 
MHz, CDCl3) δ 193.29, 172.27, 152.62, 140.82, 139.57, 134.93, 128.79, 128.75, 128.29, 126.41, 
120.42, 111.83, 40.83, 37.24.  
 
20-2. 6-benzyl-N,N-dimethyl-4-oxo-1,2,3,4-tetrahydroquinoline-8-carboxamide. 20-2 was 
synthesized following General Procedure (I) from intermediate 20-1 (37 mg, 0.13 mmol, 1.0 eq), 
dimethylamine hydrochloride (22 mg, 0.26 mmol, 2.0 eq), PyBOP (75 mg, 0.20 mmol, 1.1 eq) and 
DIPEA (0.32 mL, 1.81 mmol, 10 eq). Yield: quantitative. 1H NMR (500 MHz, Chloroform-d) δ 
8.02 (s, 1H), 7.79 (d, J = 2.1 Hz, 1H), 7.26 (t, J = 7.4 Hz, 2H), 7.18 (tt, J = 7.5, 1.4 Hz, 1H), 7.14 
(dd, J = 8.6, 1.3 Hz, 2H), 7.05 (d, J = 2.2 Hz, 1H), 3.87 (s, 2H), 3.54 (td, J = 7.8, 7.3, 2.1 Hz, 2H), 
2.96 (s, 3H), 2.88 (s, 3H), 2.67 (t, J = 7.0 Hz, 2H).13C NMR (126 MHz, cdcl3) δ 193.61, 170.12, 
134.94, 129.48, 128.88, 128.70, 126.37, 77.16, 41.62, 40.85, 37.72, 36.64, 31.39. 
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20-3. (R)-6-benzyl-4-(((R)-tert-butylsulfinyl)amino)-N,N-dimethyl-1,2,3,4-tetrahydroquinoline-8-
carboxamide. 20-3 was synthesized following General Procedure (F) from 20-2 (55 mg, 0.18 
mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (66 mg, 0.54 mmol, 3 eq), and Ti(OEt)4 (0.22 
mL, 1.07 mmol, 6 eq), then NaBH4 (41 mg, 1.07 mmol, 6 eq). Yield: 51 mg, 69%. 1H NMR (499 
MHz, Chloroform-d) δ 7.25 (d, J = 7.6 Hz, 1H), 7.20 – 7.16 (m, 1H), 7.16 – 7.14 (m, 2H), 7.13 (d, 
J = 2.1 Hz, 1H), 6.98 (d, J = 2.2 Hz, 0H), 6.79 (d, J = 2.1 Hz, 1H), 4.52 (q, J = 3.2 Hz, 1H), 3.83 
(d, J = 3.0 Hz, 2H), 3.36 (td, J = 12.1, 3.0 Hz, 1H), 3.21 (d, J = 11.6 Hz, 1H), 2.08 – 2.02 (m, 1H), 
1.87 (tt, J = 12.6, 3.8 Hz, 1H), 1.27 (s, 3H), 1.21 (s, 9H). 13C NMR (126 MHz, cdcl3) δ 171.06, 
142.21, 141.48, 133.27, 132.22, 128.84, 128.73, 128.61, 128.52, 128.42, 128.29, 125.99, 121.89, 
119.13, 55.41, 49.78, 40.74, 35.94, 27.65, 22.65, 22.12. 
 
 
20. (R)-4-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamido)-6-benzyl-N,N-dimethyl-
1,2,3,4-tetrahydroquinoline-8-carboxamide. 20 was synthesized following General Procedure 
(G) from 20-3 (51 mg, 0.12 mmol, 1 eq) and concentrated HCl (0.05 mL, excess). Carried forward 
without characterization. Step 2: Performed amide coupling using 20-3 amine salt (42 mg, 0.12 
mmol, 1 eq), di-Boc-Dmt (55 mg, 0.13 mmol, 1.1 eq), PyBOP (70 mg, 0.13 mmol, 1.1 eq), and 
DIPEA (0.21 mL, 1.21 mmol, 10 eq). Step 3: Boc-deprotected as described in General Procedure 
(G). Final yield not calculated. 1H NMR (500 MHz, Methanol-d4) δ 7.21 (dd, J = 8.2, 6.8 Hz, 2H), 
7.12 (ddd, J = 8.5, 7.1, 1.5 Hz, 3H), 6.94 (d, J = 2.1 Hz, 1H), 6.76 (d, J = 2.1 Hz, 1H), 6.46 (s, 
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2H), 4.91 (dt, J = 7.6, 3.9 Hz, 1H), 3.83 (dd, J = 11.6, 5.0 Hz, 1H), 3.77 (s, 2H), 3.25 (dd, J = 13.6, 
11.6 Hz, 1H), 3.02 – 2.95 (m, 3H), 2.89 (s, 3H), 2.40 (td, J = 12.0, 2.9 Hz, 1H), 2.27 (s, 6H), 1.68 
– 1.60 (m, 1H), 1.54 – 1.46 (m, 1H). HPLC (gradient A): retention time = 34.8 min. ESI-MS 
455.3[M + H]+ and 477.3 [M + Na]+. 
 
 
Compound 21 (Notebook reference: AFN-44 or afn-v-157, notebook 5 p. 157) 
 
 
21-1. 6-benzyl-N-ethyl-4-oxo-1,2,3,4-tetrahydroquinoline-8-carboxamide. 21-1 was synthesized 
following General Procedure (I) from intermediate 20-1 (78 mg, 0.28 mmol, 1.0 eq), PyBOP 
(172 mg, 0.33 mmol, 1.2 eq), ethylamine hydrochloride (27 mg, 0.33 mmol, 1.2 eq) and DIPEA 
(0.15 mL, 0.84 mmol, 3.0 eq). Product was highly fluorescent under long-wave UV (285 nm) light. 
Yield: 66 mg, 77%. 1H NMR (500 MHz, CDCl3) δ 7.86 (d, J = 2.0 Hz, 1H), 7.31 – 7.27 (m, 3H), 
7.21 (t, J = 7.3 Hz, 1H), 7.15 (d, J = 7.5 Hz, 2H), 3.87 (s, 2H), 3.59 (td, J = 7.8, 7.2, 2.3 Hz, 2H), 
3.42 (p, J = 7.1, 6.5 Hz, 2H), 2.67 (t, J = 7.1 Hz, 2H), 1.23 (t, J = 7.3 Hz, 3H). 
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21-2. (R)-6-benzyl-4-(((R)-tert-butylsulfinyl)amino)-N-ethyl-1,2,3,4-tetrahydroquinoline-8-
carboxamide. 21-2 was synthesized following General Procedure (F) from 21-1 (64 mg, 0.21 
mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (76 mg, 0.62 mmol, 3 eq), and Ti(OEt)4 (0.26 
mL, 1.24 mmol, 6 eq), then NaBH4 (47 mg, 1.24 mmol, 6 eq). Yield: 61 mg, 71%. 1H NMR (500 
MHz, CDCl3) δ 7.58 (s, 1H), 7.30 – 7.22 (m, 2H), 7.19 (dd, J = 7.5, 1.5 Hz, 1H), 7.15 (dd, J = 5.6, 
3.1 Hz, 3H), 7.04 (d, J = 2.0 Hz, 1H), 5.96 (s, 1H), 4.51 (q, J = 2.9 Hz, 1H), 3.83 (s, 2H), 3.39 (qd, 
J = 7.3, 4.9 Hz, 3H), 3.31 (ddd, J = 11.9, 5.8, 3.5 Hz, 1H), 3.09 (s, 1H), 2.07 (dt, J = 7.0, 3.7 Hz, 
1H), 1.83 (tt, J = 13.2, 4.1 Hz, 1H), 1.26 (t, J = 7.1 Hz, 3H), 1.20 (s, 9H). 13C NMR(126 MHz, 
CDCl3) δ 169.55, 144.90, 141.55, 134.37, 130.65, 129.68, 128.86, 128.76, 128.59, 128.49, 127.73, 
126.85, 126.18, 125.96, 121.93, 115.25, 115.01, 55.53, 50.17, 40.90, 35.53, 26.92, 22.78, 22.76, 
15.01. 
 
21. (R)-4-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamido)-6-benzyl-N-ethyl-
1,2,3,4-tetrahydroquinoline-8-carboxamide. 21 was synthesized following General Procedure 
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(G) from 21-2 (61 mg, 0.15 mmol, 1 eq) and concentrated HCl (0.03 mL, excess). Carried forward 
without characterization. Step 2: Performed amide coupling using 21-2 amine salt (41 mg, 0.12 
mmol, 1 eq), di-Boc-Dmt (53 mg, 0.13 mmol, 1.1 eq), PyBOP (68 mg, 0.13 mmol, 1.1 eq), and 
DIPEA (0.21 mL, 1.19 mmol, 10 eq). Step 3: Boc-deprotected as described in General Procedure 
(G). Final yield not calculated. 1H NMR (500 MHz, Methanol-d4) δ 8.21 (d, J = 7.9 Hz, 1H), 7.22 
(t, J = 7.5 Hz, 2H), 7.14 (d, J = 3.9 Hz, 1H), 7.14 – 7.11 (m, 2H), 6.94 (d, J = 2.0 Hz, 1H), 6.47 (s, 
2H), 4.92 – 4.87 (m, 0H), 3.82 (dd, J = 11.6, 5.1 Hz, 1H), 3.77 (s, 2H), 3.30 (s, 2H), 3.24 (dd, J = 
13.5, 11.6 Hz, 1H), 2.99 (dd, J = 13.4, 4.9 Hz, 2H), 2.40 (td, J = 12.0, 2.6 Hz, 1H), 2.27 (s, 6H), 
1.62 (ddt, J = 12.5, 8.3, 4.1 Hz, 1H), 1.50 (dd, J = 13.3, 3.6 Hz, 1H), 1.16 (t, J = 7.2 Hz, 3H). 
HPLC (gradient A): retention time = 32.5 min. ESI-MS 501.3[M + H]+ and 523.3 [M + Na]+. 
 
 
Compound 22 (Notebook reference: AFN-22 or afn-iv-155, notebook 4 p. 155) 
 
 
22-1. N,6-dibenzyl-4-oxo-1,2,3,4-tetrahydroquinoline-8-carboxamide. 22-1 was synthesized 
following General Procedure (I) from intermediate 20-1 (43 mg, 0.15 mmol, 1.0 eq), 
benzylamine (0.02 mL, 0.18 mmol, 1.2 eq), PyBOP (95 mg, 0.18 mmol, 1.2 eq) and DIPEA (0.13 
mL, 0.75 mmol, 5 eq). Yield: 40 mg, 70%.  1H NMR (500 MHz, CDCl3) δ 8.06 (s, 1H), 7.86 (d, 
J = 2.1 Hz, 1H), 7.38 – 7.30 (m, 5H), 7.29 – 7.23 (m, 2H), 7.18 (t, J = 7.3 Hz, 1H), 7.15 – 7.10 (m, 
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2H), 6.51 (t, J = 5.9 Hz, 1H), 4.57 (d, J = 5.7 Hz, 2H), 3.84 (s, 2H), 3.58 (td, J = 7.6, 7.2, 2.3 Hz, 
2H), 2.66 (t, J = 7.1 Hz, 2H), 1.22 (s, 1H). 13C NMR(126 MHz, CDCl3) δ 193.62, 168.60, 151.49, 
140.78, 138.05, 133.96, 132.03, 128.91, 128.74, 128.70, 127.89, 127.77, 127.73, 126.39, 120.40, 
117.30, 43.88, 40.95, 40.78, 37.40, 22.22. 
 
22-2. (R)-N,6-dibenzyl-4-(((R)-tert-butylsulfinyl)amino)-1,2,3,4-tetrahydroquinoline-8-
carboxamide. 22-2 was synthesized following General Procedure (F) from 22-1 (40 mg, 0.11 
mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (40 mg, 0.32 mmol, 3 eq), and Ti(OEt)4 (0.14 
mL, 0.65 mmol, 6 eq), then NaBH4 (25 mg, 0.65 mmol, 6 eq). Yield: 43 mg, 84%. 1H NMR (500 
MHz, CDCl3) δ 7.71 – 7.65 (m, 1H), 7.38 – 7.28 (m, 5H), 7.29 – 7.23 (m, 3H), 7.18 – 7.15 (m, 
2H), 7.15 – 7.11 (m, 2H), 7.07 (d, J = 2.0 Hz, 1H), 6.26 (s, 1H), 4.56 (dd, J = 5.7, 2.7 Hz, 2H), 
4.52 (d, J = 3.1 Hz, 1H), 3.87 – 3.74 (m, 2H), 3.45 – 3.38 (m, 1H), 3.33 (dq, J = 11.9, 4.2 Hz, 1H), 
3.09 (s, 1H), 2.11 – 2.04 (m, 1H), 1.84 (ddt, J = 16.2, 12.7, 4.1 Hz, 1H), 1.21 (s, 9H). 13C NMR(126 
MHz, CDCl3) δ 169.48, 145.21, 141.45, 134.69, 128.89, 128.79, 128.62, 127.87, 127.76, 127.67, 
126.88, 126.22, 122.10, 114.50, 55.57, 50.19, 43.81, 40.87, 35.56, 26.85, 22.78.   
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22. (R)-4-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamido)-N,6-dibenzyl-1,2,3,4-
tetrahydroquinoline-8-carboxamide. 22 was synthesized following General Procedure (G) from 
22-2 (43 mg, 0.090 mmol, 1 eq) and concentrated HCl (0.03 mL, excess). Carried forward without 
characterization. Step 2: Performed amide coupling using 22-2 amine salt (36 mg, 0.088 mmol, 1 
eq), diBoc-Dmt (40 mg, 0.097 mmol, 1.1 eq), PyBOP (51 mg, 0.097 mmol, 1.1 eq), 6-Cl HOBt 
(17 mg, 0.097 mmol, 1.1 eq), and DIPEA (0.15 mL, 0.88 mmol, 10 eq). Step 3: Boc-deprotected 
as described in General Procedure (G). Final yield not calculated. 1H NMR (500 MHz, Methanol-
d4) δ 8.20 (d, J = 7.8 Hz, 1H), 7.30 (d, J = 5.5 Hz, 4H), 7.25 – 7.19 (m, 3H), 7.16 – 7.11 (m, 3H), 
6.95 (d, J = 2.0 Hz, 1H), 6.47 (s, 2H), 4.90 (s, 1H), 4.52 – 4.42 (m, 2H), 3.83 (dd, J = 11.6, 5.1 Hz, 
1H), 3.77 (s, 2H), 3.24 (dd, J = 13.6, 11.6 Hz, 1H), 3.01 (td, J = 13.9, 4.7 Hz, 2H), 2.45 – 2.36 (m, 
1H), 2.27 (s, 6H), 1.63 (tt, J = 12.4, 4.2 Hz, 1H), 1.55 – 1.46 (m, 1H). HPLC (gradient A): retention 
time = 42.0 min. ESI-MS 563.3[M + H]+ and 585.3 [M + Na]+. 
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Compound 23 (Notebook reference: AFN-21 or afn-iv-153, notebook 4 p. 153) 
 
 
23-1. 6-benzyl-4-oxo-N-phenyl-1,2,3,4-tetrahydroquinoline-8-carboxamide. 23-1 was synthesized 
following General Procedure (I) from intermediate 20-1 (40 mg, 0.14 mmol, 1.0 eq), aniline 
(0.02 mL, 0.18 mmol, 1.2 eq), PyBOP (94 mg, 0.18 mmol, 1.2 eq) and DIPEA (0.07 mL, 0.42 
mmol, 3.0 eq). Product was highly fluorescent under 385 nm light. Yield: 30 mg, 60%. 1H NMR 
(500 MHz, CDCl3) δ 7.89 (d, J = 1.8 Hz, 1H), 7.85 (s, 1H), 7.53 (dt, J = 8.8, 1.8 Hz, 2H), 7.46 (d, 
J = 2.0 Hz, 1H), 7.37 (t, J = 7.8 Hz, 3H), 7.27 (dd, J = 7.6, 1.3 Hz, 1H), 7.23 – 7.17 (m, 1H), 7.16 
(d, J = 7.1 Hz, 3H), 3.88 (d, J = 1.8 Hz, 2H), 3.59 (tt, J = 7.8, 1.8 Hz, 2H), 2.67 (t, J = 6.8 Hz, 2H). 
13C NMR(126 MHz, CDCl3) δ 193.52, 167.11, 151.49, 140.71, 137.50, 133.96, 132.34, 129.40, 
129.21, 129.02, 128.79, 128.01, 126.51, 125.05, 120.95, 120.71, 120.51, 117.83, 77.16, 40.96, 
40.85, 37.39.   
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23-2. (R)-6-benzyl-4-(((R)-tert-butylsulfinyl)amino)-N-phenyl-1,2,3,4-tetrahydroquinoline-8-
carboxamide. 23-2 was synthesized following General Procedure (F) from 23-1 (42 mg, 0.12 
mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (43 mg, 0.36 mmol, 3 eq), and Ti(OEt)4 (0.15 
mL, 0.72 mmol, 6 eq), then NaBH4 (28 mg, 0.72 mmol, 6 eq). Yield: 45 mg, 81%. 1H NMR (500 
MHz, CDCl3) δ 7.52 (d, J = 1.3 Hz, 1H), 7.50 (t, J = 1.1 Hz, 1H), 7.37 – 7.32 (m, 2H), 7.29 (t, J 
= 7.5 Hz, 2H), 7.23 – 7.21 (m, 2H), 7.21 – 7.18 (m, 2H), 7.18 – 7.16 (m, 1H), 7.13 (ddt, J = 7.6, 
6.9, 1.1 Hz, 1H), 4.53 (t, J = 2.8 Hz, 1H), 3.87 (d, J = 2.9 Hz, 2H), 3.41 (td, J = 12.2, 3.3 Hz, 1H), 
3.33 (dq, J = 7.9, 4.0 Hz, 1H), 3.11 (t, J = 1.7 Hz, 1H), 2.08 (dd, J = 13.7, 3.5 Hz, 1H), 1.86 (td, J 
= 12.9, 6.5 Hz, 1H), 1.21 (s, 9H). 13C NMR(126 MHz, CDCl3) δ 167.95, 145.34, 141.35, 137.90, 
134.96, 129.12, 128.81, 128.68, 127.81, 127.15, 126.31, 124.62, 122.25, 120.78, 114.91, 55.60, 
50.21, 40.91, 35.59, 26.80, 22.76.   
 
 
23. (R)-4-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamido)-6-benzyl-N-phenyl-
1,2,3,4-tetrahydroquinoline-8-carboxamide. 23 was synthesized following General Procedure 
(G) from 23-2 (45 mg, 0.097 mmol, 1 eq) and concentrated HCl (0.03 mL, excess). Carried forward 
without characterization. Step 2: Performed amide coupling using 23-2 amine salt (24 mg, 0.061 
mmol, 1 eq), di-Boc-Dmt (28 mg, 0.067 mmol, 1.1 eq), PyBOP (35 mg, 0.067 mmol, 1.1 eq), 6-
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Cl HOBt (12 mg, 0.067 mmol, 1.1 eq), and DIPEA (0.10 mL, 0.61 mmol, 10 eq). Step 3: Boc-
deprotected as described in General Procedure (G). Final yield not calculated. 1H NMR (500 
MHz, Methanol-d4) δ 8.23 (d, J = 7.8 Hz, 1H), 7.59 – 7.53 (m, 2H), 7.42 (d, J = 2.1 Hz, 1H), 7.32 
(t, J = 7.8 Hz, 2H), 7.23 (t, J = 7.6 Hz, 2H), 7.19 – 7.15 (m, 2H), 7.15 – 7.09 (m, 1H), 7.00 (d, J = 
1.9 Hz, 1H), 6.48 (s, 2H), 4.96 – 4.90 (m, 1H), 3.85 (d, J = 5.1 Hz, 1H), 3.82 (s, 3H), 3.25 (dd, J 
= 13.6, 11.6 Hz, 1H), 3.09 – 2.96 (m, 2H), 2.44 (t, J = 11.7 Hz, 1H), 2.27 (s, 6H), 1.65 (tt, J = 12.2, 
4.2 Hz, 1H), 1.57 – 1.48 (m, 1H). HPLC (gradient A): retention time = 43.0 min. ESI-MS 549.3[M 
+ H]+ and 571.3 [M + Na]+. 
 
Compound 24 (Notebook reference: AFN-45 or afn-v-159, notebook 5 p. 159) 
 
 
24-1. 6-benzyl-4-oxo-1,2,3,4-tetrahydroquinoline-8-carbonitrile. 24-1 was synthesized following 
General Procedure (I) from intermediate 20-1 (51 mg, 0.18 mmol, 1.0 eq), ammonium hydroxide 
(1 mL, excess), PyBOP (104 mg, 0.20 mmol, 1.1 eq) and DIPEA (0.32 mL, 1.81 mmol, 10 eq). 
Yield: 45 mg, 89%. 1H NMR (500 MHz, Chloroform-d) δ 8.20 (s, 1H), 7.91 (d, J = 2.1 Hz, 1H), 
7.35 (d, J = 2.1 Hz, 1H), 7.31 – 7.25 (m, 2H), 7.20 (t, J = 7.5 Hz, 1H), 7.15 (dd, J = 7.0, 1.3 Hz, 
2H), 3.87 (s, 2H), 3.61 (ddd, J = 7.8, 6.7, 2.4 Hz, 2H), 2.68 (t, J = 7.1 Hz, 2H). 13C NMR (126 MHz, 
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cdcl3) δ 193.53, 170.94, 151.84, 140.75, 134.85, 132.85, 128.83, 128.79, 127.67, 126.51, 120.56, 
115.53, 40.90, 40.82, 37.39. 
 
24-2. (R)-N-((R)-6-benzyl-8-cyano-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-
sulfinamide. 24-2 was synthesized following General Procedure (F) from 24-1 (45 mg, 0.16 
mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (58 mg, 0.48 mmol, 3 eq), and Ti(OEt)4 (0.20 
mL, 0.96 mmol, 6 eq), then NaBH4 (36 mg, 0.96 mmol, 6 eq). Yield: 30 mg, 50%. NMR indicated 
conversion of the carboxamide to a nitrile, likely promoted by titanium and/or NaBH4 as described 
in Lehnert, W. Tetrahedron Lett. 1971, 12, 1501 and S. E. Ellzey, C. H. Mack and W. J. Connick. 
J. Org. Chem. 1967, 32, 846. Carbonyl peak at 170ppm corresponding to carboxamide of 24-1 is 
shifted downfield in 24-2. 1H NMR (500 MHz, Chloroform-d) δ 7.31 – 7.26 (m, 3H), 7.23 – 7.18 
(m, 1H), 7.16 – 7.13 (m, 2H), 7.11 (d, J = 2.0 Hz, 1H), 4.81 (s, 1H), 4.51 (q, J = 3.4 Hz, 1H), 3.81 
(s, 2H), 3.48 – 3.41 (m, 1H), 3.39 (dq, J = 11.9, 4.1 Hz, 1H), 3.11 (s, 1H), 2.13 (dq, J = 13.8, 3.6 
Hz, 1H), 1.93 – 1.84 (m, 1H), 1.22 (s, 9H). 13C NMR (126 MHz, cdcl3) δ 145.77, 140.59, 135.63, 
132.51, 129.61, 128.85, 128.78, 126.50, 121.55, 117.77, 95.18, 55.77, 49.67, 40.61, 36.41, 27.27, 
22.76. 
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24. (S)-2-amino-N-((R)-6-benzyl-8-cyano-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide. 24 was synthesized following General Procedure (G) from 24-2 
(30 mg, 0.08 mmol, 1 eq) and concentrated HCl (0.05 mL, excess). Carried forward without 
characterization. Step 2: Performed amide coupling using 24-2 amine salt (36 mg, 0.11 mmol, 1 
eq), di-Boc-Dmt (44 mg, 0.14 mmol, 1.2 eq), PyBOP (70 mg, 0.14 mmol, 1.2 eq), and DIPEA 
(0.20 mL, 1.13 mmol, 10 eq). Step 3: Boc-deprotected as described in General Procedure (G). 
Final yield not calculated. LC-MS indicated dehydration of the carboxamide to the nitrile as 
indicated above. 1H NMR (500 MHz, Methanol-d4) δ 8.17 (d, J = 7.9 Hz, 0H), 7.24 (t, J = 7.4 Hz, 
2H), 7.17 – 7.13 (m, 1H), 7.13 – 7.09 (m, 2H), 7.08 (s, 2H), 6.48 (s, 2H), 4.90 (t, J = 4.2 Hz, 1H), 
3.82 (dd, J = 11.6, 5.0 Hz, 1H), 3.75 (s, 2H), 3.28 – 3.21 (m, 1H), 3.10 (dt, J = 12.7, 4.3 Hz, 1H), 
3.00 (dd, J = 13.7, 5.1 Hz, 1H), 2.47 (td, J = 12.0, 3.2 Hz, 1H), 2.26 (s, 6H), 1.68 – 1.59 (m, 1H), 
1.55 – 1.47 (m, 1H). 13C NMR (126 MHz, cd3od) δ 168.42, 157.41, 149.36, 147.45, 142.32, 140.01, 
136.50, 133.60, 130.01, 129.65, 129.54, 127.22, 123.24, 121.51, 118.59, 116.46, 95.50, 53.37, 
46.45, 41.20, 37.61, 31.92, 27.98, 20.43, 18.71, 17.27. HPLC (gradient A): retention time = 34.8 
min. ESI-MS 455.3[M + H]+ and 477.3 [M + Na]+. 
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Compound 25 (Notebook name: AFN-30) 
 
 
25. (R)-4-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamido)-6-benzyl-1,2,3,4-
tetrahydroquinoline-8-carboxylic acid.  25 was synthesized following a modified version of 
General Procedure (G) from intermediate 26-2, the synthesis of which is described below. 25 
was synthesized from 26-2 (48 mg, 0.12 mmol, 1 eq) and concentrated HCl (0.03 mL, excess). 
Yield of amine salt: 40 mg, 99%. 1H NMR (500 MHz, Methanol-d4) δ 7.78 (d, J = 2.2 Hz, 1H), 
7.29 – 7.24 (m, 3H), 7.20 – 7.14 (m, 3H), 4.48 (t, J = 4.2 Hz, 1H), 4.33 – 4.26 (m, 2H), 3.86 (s, 
2H), 3.56 (dtd, J = 13.1, 4.6, 1.0 Hz, 1H), 3.45 – 3.37 (m, 1H), 2.17 – 2.10 (m, 2H), 1.34 (t, J = 
7.1 Hz, 3H). 13C NMR(126 MHz, cd3od) δ 169.20, 147.37, 142.73, 136.75, 134.04, 129.74, 129.51, 
128.39, 127.14, 117.52, 111.58, 111.41, 109.38, 61.54, 41.59, 36.22, 26.03, 14.62.  Amide 
coupling was performed using 26-2 amine salt(30 mg, 0.086 mmol, 1 eq), di-Boc-Dmt (41 mg, 
0.10 mmol, 1.15 eq), PyBOP (52 mg, 0.10 mmol, 1.15 eq), 6-Cl HOBt (17 mg, 0.10 mmol, 1.15 
eq), and DIPEA (0.16 mL, 0.92 mmol, 11 eq). Boc-protected intermediate was isolated by flash 
chromatography. 1H NMR (500 MHz, Chloroform-d) δ 7.56 (s, 2H), 7.27 (t, J = 7.5 Hz, 2H), 7.20 
– 7.13 (m, 3H), 7.03 (d, J = 2.2 Hz, 1H), 6.84 (s, 2H), 5.67 (s, 1H), 5.41 (s, 1H), 4.98 (dt, J = 8.8, 
4.4 Hz, 1H), 4.24 (tt, J = 8.6, 5.3 Hz, 1H), 4.20 – 4.10 (m, 1H), 3.78 (s, 2H), 3.23 (dt, J = 12.9, 4.2 
Hz, 1H), 3.08 (d, J = 9.4 Hz, 2H), 2.55 (s, 1H), 2.38 (s, 6H), 1.72 (t, J = 11.6 Hz, 1H), 1.57 (s, 
10H), 1.44 (s, 9H), 1.31 (t, J = 7.1 Hz, 2H). 13C NMR (126 MHz, cdcl3) δ 170.01, 168.52, 155.12, 
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152.12, 149.53, 146.47, 141.51, 138.98, 135.76, 131.62, 131.35, 128.73, 128.57, 128.55, 126.45, 
126.11, 121.15, 120.57, 109.56, 83.50, 80.03, 60.44, 54.26, 45.56, 40.85, 36.43, 33.44, 28.44, 
27.86, 26.85, 20.56, 14.41. This Boc-protected intermediate was then saponified as described here: 
To a pear-shaped flask containing diBoc-26 (34 mg, 0.048 mmol, 1 eq) under inert atmosphere 
was added 1:1 THF/H2O (6 mL), followed by LiOH (6 mg, 0.25 mmol, 5 eq) at ambient 
temperature, stirring for 6 hours. Solution was titrated to pH 1 with HCl, then organics were 
extracted with ethyl acetate. Organics were dried with MgSO4, filtered, and concentrated in vacuo. 
1H NMR (499 MHz, Methanol-d4) δ 7.97 (d, J = 8.0 Hz, 1H), 7.57 (s, 1H), 7.21 (t, J = 7.5 Hz, 2H), 
7.15 (d, J = 7.4 Hz, 2H), 7.11 (d, J = 6.1 Hz, 2H), 6.43 (s, 2H), 4.17 (dd, J = 10.1, 5.9 Hz, 1H), 
3.76 (s, 2H), 3.20 (dt, J = 11.0, 5.0 Hz, 1H), 3.04 (dd, J = 13.9, 10.2 Hz, 1H), 2.88 – 2.77 (m, 2H), 
2.26 (s, 6H), 1.60 (d, J = 37.0 Hz, 2H), 1.43 (s, 9H). 13C NMR (126 MHz, cd3od) δ 197.20, 172.02, 
139.98, 138.40, 136.09, 131.19, 128.27, 127.92, 125.41, 124.49, 120.86, 114.63, 54.34, 45.51, 
40.38, 36.33, 31.66, 27.33, 27.08, 19.16. Product was then Boc-deprotected and purified by HPLC 
as described in General Procedure (G). Final yield not calculated. 1H NMR (500 MHz, Methanol-
d4) δ 7.62 (d, J = 2.2 Hz, 1H), 7.25 – 7.20 (m, 2H), 7.16 – 7.10 (m, 3H), 7.02 (d, J = 2.3 Hz, 1H), 
6.48 (s, 2H), 4.92 (d, J = 5.4 Hz, 1H), 3.83 (dd, J = 11.6, 5.0 Hz, 1H), 3.75 (s, 2H), 3.25 (dd, J = 
13.6, 11.6 Hz, 1H), 3.10 (dt, J = 12.2, 3.9 Hz, 1H), 3.00 (dd, J = 13.6, 5.0 Hz, 1H), 2.50 – 2.41 (m, 
1H), 2.27 (s, 6H), 1.63 (tt, J = 12.0, 4.2 Hz, 1H), 1.52 (dq, J = 13.0, 3.6 Hz, 1H). HPLC (gradient 
A): retention time = 31.1 min. ESI-MS 474.3[M + H]+ and 496.3 [M + Na]+. 
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Compound 26 (Notebook reference: AFN-20 or afn-iv-133, notebook 4 p. 133) 
 
 
26-1. methyl 6-benzyl-4-oxo-1,2,3,4-tetrahydroquinoline-8-carboxylate. 26-1 was synthesized 
following General Procedure (H) from 8-5 (220 mg, 0.70 mmol, 1 eq), oxalyl chloride (1 mL, 
excess), K2CO3 (142 mg, 1.04 mmol, 1.5 eq) and Pd(dppf)Cl2 (51 mg, 0.07 mmol, 0.1 eq) in 1:1 
DMF:MeOH. Yield: 103 mg, 50%. 1H NMR (500 MHz, CDCl3) δ 7.93 (s, 2H), 7.30 – 7.26 (m, 
2H), 7.21 – 7.14 (m, 3H), 3.86 (s, 2H), 3.85 (s, 3H), 3.63 (td, J = 7.1, 2.4 Hz, 2H), 2.69 (t, J = 7.1 
Hz, 2H). 13C NMR(126 MHz, CDCl3) δ 192.93, 167.99, 152.05, 140.82, 133.83, 128.61, 128.55, 
127.84, 126.28, 120.14, 112.39, 51.81, 40.71, 40.70, 37.17.   
 
 
26-2. ethyl (R)-6-benzyl-4-(((R)-tert-butylsulfinyl)amino)-1,2,3,4-tetrahydroquinoline-8-
carboxylate. 26-2 was synthesized following General Procedure (F) from 26-1 (42 mg, 0.14 
mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (52 mg, 0.42 mmol, 3 eq), and Ti(OEt)4 (0.18 
mL, 0.85 mmol, 6 eq), then NaBH4 (32 mg, 0.85 mmol, 6 eq). NMR indicated conversion of 26-1 
methyl ester to an ethyl ester in 26-2. Yield: 48 mg, 83%. 1H NMR (500 MHz, CDCl3) δ 7.75 (d, 
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J = 3.8 Hz, 1H), 7.62 (d, J = 2.2 Hz, 1H), 7.21 – 7.16 (m, 2H), 7.15 – 7.07 (m, 4H), 4.44 (q, J = 
3.0 Hz, 1H), 4.21 (qd, J = 7.1, 1.5 Hz, 2H), 3.75 (s, 2H), 3.36  (m, 1H), 3.29 (dt, J = 12.0, 4.0 Hz, 
1H), 3.00 (s, 1H), 2.02 (dqd, J = 13.6, 3.3, 1.1 Hz, 1H), 1.81 – 1.71 (m, 1H), 1.27 (t, J = 7.1 Hz, 
3H), 1.12 (s, 9H). 13C NMR(126 MHz, CDCl3) δ 168.50, 146.63, 141.63, 136.18, 131.87, 128.72, 
128.54, 126.63, 126.08, 121.61, 109.73, 60.37, 55.52, 50.03, 40.89, 35.53, 26.55, 22.73, 14.47.   
 
 
26. ethyl (R)-4-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamido)-6-benzyl-1,2,3,4-
tetrahydroquinoline-8-carboxylate. 26 was synthesized following General Procedure (G) from 
26-2 (48 mg, 0.12 mmol, 1 eq) and concentrated HCl (0.03 mL, excess). Yield: 40 mg, 99%. 1H 
NMR (500 MHz, Methanol-d4) δ 7.78 (d, J = 2.2 Hz, 1H), 7.29 – 7.24 (m, 3H), 7.20 – 7.14 (m, 
3H), 4.48 (t, J = 4.2 Hz, 1H), 4.33 – 4.26 (m, 2H), 3.86 (s, 2H), 3.56 (dtd, J = 13.1, 4.6, 1.0 Hz, 
1H), 3.45 – 3.37 (m, 1H), 2.17 – 2.10 (m, 2H), 1.34 (t, J = 7.1 Hz, 3H). 13C NMR(126 MHz, cd3od) 
δ 169.20, 147.37, 142.73, 136.75, 134.04, 129.74, 129.51, 128.39, 127.14, 117.52, 111.58, 111.41, 
109.38, 61.54, 41.59, 36.22, 26.03, 14.62.  Step 2: Performed amide coupling as described in 
General Procedure (G) from 26-2 amine salt (30 mg, 0.086 mmol, 1 eq), di-Boc-Dmt (41 mg, 
0.10 mmol, 1.15 eq), PyBOP (52 mg, 0.10 mmol, 1.15 eq), 6-Cl HOBt (17 mg, 0.10 mmol, 1.15 
eq), and DIPEA (0.16 mL, 0.92 mmol, 11 eq). 1H NMR (500 MHz, Chloroform-d) δ 7.56 (s, 2H), 
7.27 (t, J = 7.5 Hz, 2H), 7.20 – 7.13 (m, 3H), 7.03 (d, J = 2.2 Hz, 1H), 6.84 (s, 2H), 5.67 (s, 1H), 
5.41 (s, 1H), 4.98 (dt, J = 8.8, 4.4 Hz, 1H), 4.24 (tt, J = 8.6, 5.3 Hz, 1H), 4.20 – 4.10 (m, 1H), 3.78 
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(s, 2H), 3.23 (dt, J = 12.9, 4.2 Hz, 1H), 3.08 (d, J = 9.4 Hz, 2H), 2.55 (s, 1H), 2.38 (s, 6H), 1.72 (t, 
J = 11.6 Hz, 1H), 1.57 (s, 10H), 1.44 (s, 9H), 1.31 (t, J = 7.1 Hz, 2H). 13C NMR (126 MHz, cdcl3) 
δ 170.01, 168.52, 155.12, 152.12, 149.53, 146.47, 141.51, 138.98, 135.76, 131.62, 131.35, 128.73, 
128.57, 128.55, 126.45, 126.11, 121.15, 120.57, 109.56, 83.50, 80.03, 60.44, 54.26, 45.56, 40.85, 
36.43, 33.44, 28.44, 27.86, 26.85, 20.56, 14.41. Boc-deprotected following General Procedure 
(G). Final yield not calculated. 1H NMR (500 MHz, Methanol-d4) δ 7.61 (d, J = 2.2 Hz, 1H), 7.23 
(t, J = 7.5 Hz, 2H), 7.15 (d, J = 7.4 Hz, 1H), 7.13 – 7.09 (m, 2H), 7.03 (d, J = 2.2 Hz, 1H), 6.48 (s, 
2H), 4.92 (t, J = 4.0 Hz, 1H), 4.24 (qd, J = 7.2, 1.4 Hz, 2H), 3.83 (dd, J = 11.6, 5.0 Hz, 1H), 3.76 
(s, 2H), 3.25 (dd, J = 13.6, 11.6 Hz, 1H), 3.12 (dt, J = 12.7, 4.2 Hz, 1H), 3.00 (dd, J = 13.7, 5.1 
Hz, 1H), 2.47 (td, J = 12.2, 3.2 Hz, 1H), 2.27 (s, 6H), 1.63 (tt, J = 11.9, 4.2 Hz, 1H), 1.52 (dq, J = 
13.2, 3.8 Hz, 1H), 1.31 (t, J = 7.2 Hz, 3H). 13C NMR(126 MHz, cd3od) δ 168.25, 157.41, 147.68, 
142.95, 140.00, 137.00, 135.31, 132.61, 129.62, 129.41, 127.01, 123.26, 121.33, 116.49, 61.28, 
53.35, 47.06, 36.90, 31.94, 27.77, 20.43, 14.63. HPLC (gradient A): retention time = 43.1 min. 
ESI-MS 525.3 [M + Na]+. 
 
 
Compound 27 (Notebook name: AFN-53) 
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27-1. isopropyl 6-benzyl-4-oxo-1,2,3,4-tetrahydroquinoline-8-carboxylate. 27-1 was synthesized 
following General Procedure (H) from 8-5 (166 mg, 0.52 mmol, 1 eq), oxalyl chloride (1 mL, 
excess), K2CO3 (109 mg, 0.79 mmol, 1.5 eq) and Pd(dppf)Cl2 (38 mg, 0.05 mmol, 0.1 eq) in 2:1 
DMF:isopropanol. Yield: 15 mg, 9%. 1H NMR (500 MHz, Chloroform-d) δ 8.11 (s, 1H), 7.93 (d, 
J = 2.4 Hz, 1H), 7.91 (d, J = 2.2 Hz, 1H), 7.28 (t, J = 7.5 Hz, 2H), 7.20 (d, J = 7.4 Hz, 1H), 7.17 
(d, J = 6.9 Hz, 2H), 5.19 (hept, J = 6.3 Hz, 1H), 3.88 (s, 2H), 3.63 (td, J = 7.1, 2.4 Hz, 2H), 2.68 
(t, J = 7.3 Hz, 2H), 1.36 (s, 3H), 1.34 (s, 3H). 13C NMR (126 MHz, cdcl3) δ 167.43, 164.97, 138.57, 
133.88, 128.76, 127.80, 126.33, 77.16, 40.84, 37.42, 22.07. 
 
 
27-2. isopropyl (R)-6-benzyl-4-(((R)-tert-butylsulfinyl)amino)-1,2,3,4-tetrahydroquinoline-8-
carboxylate. 27-2 was synthesized following General Procedure (F) from 27-1 (33 mg, 0.10 
mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (38 mg, 0.31 mmol, 3 eq), and Ti(OiPr)4 (0.18 
mL, 0.61 mmol, 6 eq), then NaBH4 (23 mg, 0.61 mmol, 6 eq). Yield: 18 mg, 41%. 1H NMR (500 
MHz, Chloroform-d) δ 7.86 (d, J = 4.8 Hz, 1H), 7.69 (d, J = 2.1 Hz, 1H), 7.27 (t, J = 7.6 Hz, 2H), 
7.20 – 7.15 (m, 3H), 5.16 (hept, J = 6.2 Hz, 1H), 4.51 (q, J = 3.1 Hz, 1H), 3.84 (s, 2H), 3.44 (td, J 
= 12.2, 3.3 Hz, 1H), 3.36 (dq, J = 12.2, 4.2 Hz, 1H), 3.05 (s, 1H), 2.10 (dq, J = 13.8, 3.4 Hz, 1H), 
1.83 (tt, J = 12.8, 4.0 Hz, 1H), 1.34 (d, J = 4.8 Hz, 3H), 1.32 (d, J = 4.9 Hz, 3H), 1.20 (s, 9H). 13C 
NMR (126 MHz, cdcl3) δ 168.13, 146.68, 141.70, 136.13, 131.94, 128.76, 128.58, 126.56, 126.12, 
121.62, 110.11, 77.16, 67.79, 55.56, 50.01, 40.91, 35.53, 26.51, 22.78, 22.13. 
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27. isopropyl (R)-4-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamido)-6-benzyl-
1,2,3,4-tetrahydroquinoline-8-carboxylate. 27 was synthesized following General Procedure (G) 
from 27-2 (18 mg, 0.04 mmol, 1 eq) and concentrated HCl (0.03 mL, excess). Carried forward 
without characterization. Step 2: Performed amide coupling using 27-2 amine salt (14 mg, 0.04 
mmol, 1 eq), di-Boc-Dmt (18 mg, 0.04 mmol, 1.1 eq), PyBOP (22 mg, 0.04 mmol, 1.1 eq), and 
DIPEA (0.07 mL, 0.39 mmol, 10 eq). Step 3: Boc-deprotected as described in General Procedure 
(G). Final yield not calculated. HPLC (gradient A): retention time = 45.4 min. ESI-MS 516.3[M 
+ H]+ and 538.3 [M + Na]+. 1H NMR (500 MHz, Methanol-d4) δ 8.19 (d, J = 7.8 Hz, 1H), 7.58 
(d, J = 2.2 Hz, 1H), 7.22 (dd, J = 8.1, 6.8 Hz, 2H), 7.14 (d, J = 7.5 Hz, 1H), 7.12 – 7.09 (m, 2H), 
7.01 (d, J = 2.2 Hz, 1H), 6.48 (s, 2H), 5.11 (hept, J = 6.3 Hz, 1H), 4.91 (d, J = 6.1 Hz, 1H), 3.82 
(dd, J = 11.6, 5.0 Hz, 1H), 3.75 (s, 2H), 3.24 (dd, J = 13.6, 11.6 Hz, 1H), 3.11 (dt, J = 12.3, 4.0 
Hz, 1H), 2.99 (dd, J = 13.6, 5.1 Hz, 1H), 2.46 (td, J = 12.2, 3.3 Hz, 1H), 2.26 (s, 6H), 1.63 (tt, J = 
12.2, 4.2 Hz, 1H), 1.55 – 1.48 (m, 1H), 1.29 (d, J = 2.9 Hz, 3H), 1.28 (d, J = 2.9 Hz, 3H). 13C 
NMR (126 MHz, cd3od) δ 169.05, 157.40, 140.00, 136.93, 133.79, 132.56, 129.40, 127.59, 127.00, 
116.48, 115.22, 110.96, 68.78, 49.00, 47.17, 41.63, 36.87, 31.93, 27.77, 22.15, 20.44. 
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Compound 28 (Notebook reference: AFN-15 or afn-iii-303, notebook 3 p. 303, afn-iv-5, notebook 
4 p. 5, and afn-iv-81, notebook 4 p. 81) 
 
 
28-1. 6-bromo-8-methyl-1-(2,2,2-trifluoroacetyl)-2,3-dihydroquinolin-4(1H)-one. 28-1 was 
synthesized following General Procedure (J) from intermediate 9-5 (1.17 g, 4.89 mmol, 1 eq) 
and trifluoroacetic anhydride (1.37 mL, 9.78 mmol, 2 eq). Yield: 1.54 g, 95%. 1H NMR (400 MHz, 
CDCl3) δ 7.99 (d, J = 2.2 Hz, 1H), 7.63 (d, J = 2.3 Hz, 1H), 4.52 (dd, J = 14.6, 5.2 Hz, 1H), 3.88 
(td, J = 13.9, 3.9 Hz, 1H), 3.03 – 2.79 (m, 2H), 2.17 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 
191.77, 139.79, 139.42, 139.10, 136.84, 129.86, 128.58, 128.36, 121.85, 117.65, 114.79, 77.16, 
46.17, 40.13, 39.99, 18.70, 18.48.   
 
 
28-2. 6-bromo-8-(bromomethyl)-1-(2,2,2-trifluoroacetyl)-2,3-dihydroquinolin-4(1H)-one. 28-2 
was synthesized following General Procedure (K) from 28-2 (478 mg, 1.42 mmol, 1.00 eq), NBS 
(266 mg, 1.49 mmol, 1.05 eq), and benzoyl peroxide (34 mg, 0.14 mmol, 0.1 eq). Reaction was 
then concentrated in vacuo onto silica and purified by manually-packed silica column 
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chromatography using 10% ethyl acetate, 90% hexanes, as flash chromatography did not provide 
sufficient separation. Yield: 232 mg, 40%. 1H NMR (500 MHz, CDCl3) δ 8.11 (t, J = 2.6 Hz, 1H), 
7.82 (t, J = 2.8 Hz, 1H), 4.62 – 4.52 (m, 1H), 4.41 (dd, J = 11.7, 3.0 Hz, 1H), 4.32 (dd, J = 11.8, 
3.0 Hz, 1H), 3.92 (tt, J = 14.4, 3.5 Hz, 1H), 3.00 (dddd, J = 16.7, 13.7, 5.7, 3.0 Hz, 1H), 2.94 – 
2.85 (m, 1H). 13C NMR(126 MHz, CDCl3) δ 191.09, 138.90, 136.23, 134.42, 131.08, 130.77, 
129.92, 128.99, 122.30, 77.16, 46.11, 46.08, 39.92, 28.94.   
 
 
28-3 6-bromo-8-(piperidin-1-ylmethyl)-1-(2,2,2-trifluoroacetyl)-2,3-dihydroquinolin-4(1H)-one. 
28-3 was synthesized following General Procedure (L) from 28-2 (140 mg, 0.34 mmol, 1 eq), 
K2CO3 (140 mg, 1.02 mmol, 3 eq), and piperidine (0.04 mL, 0.41 mmol, 1.2 eq). N-trifluoroacetyl 
group was partially removed during reaction, so 28-3 was carried forward as a 1:1 molar eq mixture 
of N-TFA protected (60 mg, 0.14 mmol) and deprotected (45 mg, 0.14 mmol) intermediates. Net 
yield: 0.28 mmol, 82%. Unprotected: 1H NMR (500 MHz, CDCl3) δ 7.87 (d, J = 2.6 Hz, 1H), 7.50 
(s, 1H), 7.17 (d, J = 2.6 Hz, 1H), 3.54 (t, J = 7.1 Hz, 2H), 3.44 (s, 2H), 2.63 (t, J = 7.1 Hz, 2H), 
2.34 (s, 4H), 1.54 (q, J = 5.8 Hz, 4H), 1.45 (s, 2H). 13C NMR(126 MHz, CDCl3) δ 192.97, 151.75, 
137.64, 128.90, 125.72, 120.35, 108.66, 77.16, 62.11, 54.04, 41.38, 37.47, 26.23, 24.28. TFA-
protected: 1H NMR (500 MHz, CDCl3) δ 7.97 (d, J = 2.4 Hz, 1H), 7.83 (s, 1H), 4.43 (dd, J = 14.3, 
5.4 Hz, 1H), 3.77 (d, J = 15.8 Hz, 1H), 3.27 (dd, 2H), 2.96 – 2.72 (m, 2H), 2.17 (s, 4H), 1.54 – 
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1.40 (m, 4H), 1.35 (q, J = 6.1 Hz, 2H). 13C NMR(126 MHz, CDCl3) δ 191.76, 182.72, 139.46, 
138.55, 137.67, 129.98, 129.33, 121.93, 119.74, 117.45, 115.15, 112.87, 60.76, 54.74, 45.98, 
40.04, 25.82, 24.25.   
 
 
28-4. 6-benzyl-8-(piperidin-1-ylmethyl)-2,3-dihydroquinolin-4(1H)-one. 28-4 was synthesized 
following General Procedure (E) from the mixture of 28-3 previously described (105 mg, 0.28 
mmol, 1 eq), benzyl boronic acid pinacol ester (0.10 mL, 0.43 mmol, 1.5 eq), K2CO3 (120 mg, 
0.86 mmol, 3 eq) and Pd(dppf)Cl2 (21 mg, 0.028 mmol, 0.1 eq). Yield: 88 mg, 92%.  1H NMR 
(500 MHz, CDCl3) δ 7.58 (d, J = 2.1 Hz, 1H), 7.18 (d, J = 7.0 Hz, 2H), 7.14 – 7.06 (m, 3H), 6.85 
(d, J = 2.1 Hz, 1H), 3.76 (s, 2H), 3.46 (d, J = 7.5 Hz, 2H), 3.36 (s, 2H), 2.56 (d, J = 7.0 Hz, 2H), 
2.29 – 2.20 (m, 4H), 1.46 (p, J = 5.4 Hz, 4H), 1.37 (s, 2H). 13C NMR(126 MHz, CDCl3) δ 194.42, 
151.61, 141.51, 136.59, 129.02, 128.82, 128.54, 126.33, 126.09, 119.16, 75.12, 62.58, 54.09, 
54.03, 41.75, 41.06, 37.90, 26.26, 24.97, 24.38.   
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28-5. (R)-N-((R)-6-benzyl-8-(piperidin-1-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-
methylpropane-2-sulfinamide. 28-5 was synthesized following General Procedure (F) from 28-
4 (88 mg, 0.26 mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (96 mg, 0.79 mmol, 3 eq), and 
Ti(OEt)4 (0.33 mL, 1.58 mmol, 6 eq), then NaBH4 (60 mg, 1.58 mmol, 6 eq). Yield: 85 mg, 74%. 
Carried forward without characterization.  
 
 
28. (S)-2-amino-N-((R)-6-benzyl-8-(piperidin-1-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide. 28 was synthesized following General Procedure (G) 
from 28-5 (85 mg, 0.19 mmol, 1 eq) and concentrated HCl (0.05 mL, excess). Step 2: Performed 
amide coupling using 28-5 amine salt (37 mg, 0.090 mmol, 1 eq), di-Boc-Dmt (41 mg, 0.099 
mmol, 1.1 eq), PyBOP (52 mg, 0.099 mmol, 1.1 eq), 6-Cl HOBt (17 mg, 0.099 mmol, 1.1 eq), and 
DIPEA (0.16 mL, 0.90 mmol, 10 eq). Step 3: Boc-deprotected as described in General Procedure 
(G). Final yield not calculated. 1H NMR (500 MHz, Methanol-d4) δ 7.25 – 7.20 (m, 2H), 7.16 – 
7.10 (m, 3H), 7.01 (d, J = 2.0 Hz, 1H), 6.96 (d, J = 2.1 Hz, 1H), 6.47 (s, 2H), 4.93 (dt, J = 7.9, 4.2 
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Hz, 1H), 4.15 – 4.02 (m, 2H), 3.88 (dd, J = 11.6, 5.0 Hz, 1H), 3.79 (s, 2H), 3.37 (d, J = 12.4 Hz, 
2H), 3.26 (dd, J = 13.6, 11.6 Hz, 1H), 3.07 (dt, J = 12.4, 4.2 Hz, 1H), 3.02 (dd, J = 13.7, 5.1 Hz, 
1H), 2.95 – 2.84 (m, 2H), 2.54 – 2.45 (m, 1H), 2.27 (s, 6H), 1.89 (d, J = 14.7 Hz, 2H), 1.80 (d, J 
= 12.8 Hz, 1H), 1.71 (m, 2H), 1.65 (m, 1H), 1.53 (q, J = 4.2 Hz, 1H), 1.49 (m, 1H). HPLC (gradient 
A): retention time = 27.6min. ESI-MS 527.3[M + H]+ and 549.3 [M + Na]+. 
 
 
Compound 29 (Notebook reference: AFN-17 or afn-iv-33, notebook 4 p. 33) 
 
 
29-1. 6-bromo-8-(morpholinomethyl)-1-(2,2,2-trifluoroacetyl)-2,3-dihydroquinolin-4(1H)-one. 
29-1 was synthesized following General Procedure (L) from intermediate 28-2 (250 mg, 0.60 
mmol, 1 eq), and morpholine (3 mL, excess.); K2CO3 was not used here. No loss of trifluoroacetic 
protecting group observed. Yield: 160 mg, 63% 1H NMR (500 MHz, CDCl3) δ 8.09 (d, J = 2.4 
Hz, 1H), 7.95 (d, J = 2.3 Hz, 1H), 4.53 (d, J = 14.3 Hz, 1H), 3.88 (d, J = 13.8 Hz, 1H), 3.70 (t, J = 
4.7 Hz, 4H), 3.41 (s, 2H), 2.96 (ddd, J = 18.8, 13.4, 5.5 Hz, 1H), 2.88 (ddd, J = 18.5, 3.9, 1.7 Hz, 
1H), 2.37 (s, 4H). 13C NMR(126 MHz, CDCl3) δ 191.46, 139.50, 138.53, 130.11, 129.88, 122.18, 
77.16, 66.72, 60.08, 53.72, 46.11, 40.04.  
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29-2. 6-benzyl-8-(morpholinomethyl)-2,3-dihydroquinolin-4(1H)-one. 29-2 was synthesized 
following General Procedure (E) from 29-1 (160 mg, 0.38 mmol, 1 eq), benzyl boronic acid 
pinacol ester (0.13 mL, 0.57 mmol, 1.5 eq), K2CO3 (160 mg, 1.14 mmol, 3 eq) and Pd(dppf)Cl2 
(30 mg, 0.04 mmol, 0.1 eq). Yield: 75 mg, 60%. 1H NMR (500 MHz, CDCl3) δ 7.68 (d, J = 2.1 
Hz, 1H), 7.26 (s, 2H), 7.22 – 7.13 (m, 3H), 6.96 (d, J = 2.2 Hz, 1H), 3.83 (s, 2H), 3.68 (t, J = 4.7 
Hz, 4H), 3.56 (p, J = 5.9 Hz, 2H), 3.47 (s, 2H), 2.65 (dd, J = 7.7, 6.5 Hz, 2H), 2.43 – 2.37 (m, 4H). 
13C NMR(126 MHz, CDCl3) δ 194.16, 151.08, 141.36, 136.94, 129.29, 128.78, 128.75, 128.56, 
128.53, 128.35, 126.77, 126.14, 119.35, 77.16, 67.10, 62.16, 53.22, 53.15, 41.75, 41.01, 37.83, 
24.96.   
 
 
29-3. (R)-N-((R)-6-benzyl-8-(morpholinomethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-
methylpropane-2-sulfinamide. 29-3 was synthesized following General Procedure (F) from 29-
2 (75 mg, 0.22 mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (81 mg, 0.66 mmol, 3 eq), and 
Ti(OEt)4 (0.28 mL, 1.34 mmol, 6 eq), then NaBH4 (51 mg, 1.34 mmol, 6 eq). Yield: 31 mg, 31%. 
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1H NMR (500 MHz, CDCl3) δ 7.26 (s, 2H), 7.18 – 7.13 (m, 3H), 7.07 (d, J = 2.0 Hz, 1H), 6.74 (d, 
J = 2.1 Hz, 1H), 4.52 (q, J = 3.3 Hz, 1H), 3.81 (d, J = 3.2 Hz, 2H), 3.67 (t, J = 4.7 Hz, 4H), 3.46 
(d, J = 12.8 Hz, 1H), 3.36 – 3.33 (m, 1H), 3.32 – 3.23 (m, 2H), 2.37 (t, J = 10.1 Hz, 4H), 2.10 – 
2.02 (m, 1H), 1.89 – 1.79 (m, 1H), 1.21 (s, 9H). 13C NMR(126 MHz, CDCl3) δ 143.41, 141.97, 
131.00, 129.99, 128.86, 128.79, 128.46, 125.93, 121.35, 120.64, 116.06, 67.17, 62.46, 53.22, 
49.92, 41.08, 36.19, 28.37, 22.78.   
 
 
29. (S)-2-amino-N-((R)-6-benzyl-8-(morpholinomethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide. 29 was synthesized following General Procedure (G) 
from 29-3 (31 mg, 0.070 mmol, 1 eq) and concentrated HCl (0.03 mL, excess). Carried forward 
without characterization. Step 2: Performed amide coupling using 29-3 amine salt (25 mg, 0.068 
mmol, 1 eq), di-Boc-Dmt (31 mg, 0.075 mmol, 1.1 eq), PyBOP (39 mg, 0.075 mmol, 1.1 eq), 6-
Cl HOBt (13 mg, 0.075 mmol, 1.1 eq), and DIPEA (0.13 mL, 0.70 mmol, 10 eq). Step 3: Boc-
deprotected as described in General Procedure (G). Final yield not calculated. 1H NMR (500 
MHz, Methanol-d4) δ 7.24 – 7.17 (m, 2H), 7.15 – 7.09 (m, 3H), 7.01 (d, J = 2.1 Hz, 1H), 6.98 (d, 
J = 2.1 Hz, 1H), 6.47 (s, 2H), 4.92 (m, 1H), 4.17 (m, 2H), 3.88 (m, 1H), 3.88 (broad s, 4H), 3.78 
(s, 2H), 3.26 (m, 1H), 3.19 (broad s, 4H), 3.07 (dt, J = 12.3, 4.3 Hz, 1H), 3.02 (dd, J = 13.7, 5.1 
Hz, 1H), 2.49 (td, J = 11.9, 2.9 Hz, 1H), 2.27 (s, 6H), 1.64 (ddt, J = 13.0, 11.4, 4.1 Hz, 1H), 1.55 
– 1.47 (m, 1H).  HPLC (gradient A): retention time = 24.2 min. ESI-MS 551.3 [M + Na]+. 
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Compound 30 (Notebook reference: AFN-41 or afn-v-113, notebook 5 p. 113) 
 
 
30-1. tert-butyl 4-((6-bromo-4-oxo-1-(2,2,2-trifluoroacetyl)-1,2,3,4-tetrahydroquinolin-8-
yl)methyl)piperazine-1-carboxylate. 30-1 was synthesized following General Procedure (L) 
from 28-1 (280 mg, 0.67 mmol, 1 eq), K2CO3 (251 mg, 1.35 mmol, 2 eq), and monoBoc-piperazine 
(187 mg, 1.35 mmol, 2 eq). Some loss of trifluoroacetic protecting group observed, but not 
isolated. Yield: 212 mg, 75%. 1H NMR (500 MHz, CDCl3) δ 7.99 (d, J = 2.2 Hz, 1H), 7.85 (d, J 
= 2.4 Hz, 1H), 4.51 – 4.38 (m, 1H), 3.77 (t, J = 14.0 Hz, 1H), 3.38 – 3.29 (m, 4H), 2.91 – 2.84 (m, 
1H), 2.79 (ddd, J = 18.6, 3.7, 1.7 Hz, 1H), 2.21 (t, J = 5.0 Hz, 4H), 1.38 (s, 9H). 13C NMR(126 
MHz, CDCl3) δ 191.48, 154.81, 139.39, 138.36, 136.59, 130.05, 129.69, 122.08, 119.68, 117.38, 
115.09, 79.88, 59.83, 53.09, 46.02, 43.33, 39.99, 28.51.  
 
 
30-2. tert-butyl 4-((6-benzyl-4-oxo-1,2,3,4-tetrahydroquinolin-8-yl)methyl)piperazine-1-
carboxylate. 30-2 was synthesized following General Procedure (E) from 30-1 (212 mg, 0.50 
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mmol, 1 eq), benzyl boronic acid pinacol ester (0.22 mL, 1.00 mmol, 2 eq), K2CO3 (207 mg, 1.50 
mmol, 3 eq) and Pd(dppf)Cl2 (37 mg, 0.05 mmol, 0.1 eq). Yield: 84 mg, 39%. 1H NMR (500 MHz, 
CDCl3) δ 7.69 (d, J = 2.1 Hz, 1H), 7.29 – 7.24 (m, 2H), 7.20 – 7.14 (m, 3H), 6.94 (d, J = 2.2 Hz, 
1H), 6.83 (s, 1H), 3.84 (s, 2H), 3.55 (ddd, J = 7.7, 5.3, 2.0 Hz, 2H), 3.48 (s, 2H), 3.45 – 3.36 (m, 
4H), 2.68 – 2.61 (m, 2H), 2.35 (s, 4H), 1.45 (s, 9H). 13C NMR(126 MHz, CDCl3) δ 194.18, 178.30, 
154.82, 151.11, 141.40, 136.90, 129.39, 128.83, 128.61, 126.84, 126.19, 122.69, 119.45, 80.00, 
61.88, 52.54, 41.79, 41.05, 37.88, 28.54.   
 
 
30-3. tert-butyl 4-(((R)-6-benzyl-4-(((R)-tert-butylsulfinyl)amino)-1,2,3,4-tetrahydroquinolin-8-
yl)methyl)piperazine-1-carboxylate. 30-2 was synthesized following General Procedure (F) from 
30-2 (84 mg, 0.19 mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (71 mg, 0.58 mmol, 3 eq), 
and Ti(OEt)4 (0.24 mL, 1.16 mmol, 6 eq), then NaBH4 (44 mg, 1.16 mmol, 6 eq). Yield: 83 mg, 
80%. 1H NMR (500 MHz, CDCl3) δ 7.27 – 7.23 (m, 2H), 7.20 – 7.12 (m, 3H), 7.07 (d, J = 2.0 Hz, 
1H), 6.72 (d, J = 2.0 Hz, 1H), 4.53 (q, J = 3.3 Hz, 1H), 3.82 (d, J = 3.3 Hz, 2H), 3.52 – 3.43 (m, 
1H), 3.39 (q, J = 6.7, 4.9 Hz, 4H), 3.33 (d, J = 13.1 Hz, 2H), 3.27 (ddd, J = 11.7, 8.1, 3.4 Hz, 1H), 
2.35 – 2.30 (m, 4H), 2.13 – 2.02 (m, 1H), 1.85 (tt, J = 13.0, 12.5, 4.0 Hz, 1H), 1.45 (s, 9H), 1.22 
(s, 9H). 13C NMR(126 MHz, CDCl3) δ 154.87, 143.41, 141.97, 130.94, 129.99, 128.92, 128.81, 
128.49, 125.95, 121.54, 120.68, 79.81, 62.11, 55.45, 52.53, 49.92, 41.10, 36.18, 28.52, 28.36, 
22.80, 22.63.   
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30. (S)-2-amino-N-((R)-6-benzyl-8-(piperazin-1-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide. 30 was synthesized following General Procedure (G) 
from 30-3 (43 mg, 0.080 mmol, 1 eq) and concentrated HCl (0.015 mL, 0.18 mmol, 2 eq). Reaction 
was monitored by TLC for disappearance of 30-3, and solvent was removed after 12 minutes. 
Recovered 40 mg crude product. Carried forward without characterization. Step 2: Performed 
amide coupling using 30-3 amine salt (40 mg, 0.079 mmol, 1 eq), diBoc-Dmt (36 mg, 0.087 mmol, 
1.1 eq), PyBOP (46 mg, 0.087 mmol, 1.1 eq), 6-Cl HOBt (15 mg, 0.087 mmol, 1.1 eq), and DIPEA 
(0.14 mL, 0.79 mmol, 10 eq). Step 3: Boc-deprotected as described in General Procedure (G). 
Final yield not calculated.  1H NMR (500 MHz, Methanol-d4) δ 7.20 (t, J = 7.4 Hz, 2H), 7.14 – 
7.07 (m, 3H), 6.88 (s, 1H), 6.74 (s, 1H), 6.48 (s, 2H), 4.94 (s, 1H), 3.84 (d, J = 10.0 Hz, 1H), 3.76 
(s, 2H), 3.47 – 3.44 (m, 2H), 3.26 (m, 1H), 3.21 – 3.15 (m, 4H), 3.09 (d, J = 12.5 Hz, 1H), 3.01 
(dd, J = 13.8, 5.0 Hz, 1H), 2.53 (m, 1H), 2.28 (s, 6H), 1.66 (t, J = 12.2 Hz, 1H), 1.56 – 1.47 (m, 
1H), 1.29 (s, 4H). HPLC (gradient A): retention time = 21.7 min. ESI-MS 528.3[M + H]+ and 
550.3 [M + Na]+. 
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Compound 31 (Notebook reference: AFN-14E or afn-iii-301, notebook 3 p. 301) 
 
 
31. (S)-2-amino-N-((R)-8-((4-((S)-2-amino-3-(4-hydroxy-2,6-
dimethylphenyl)propanoyl)piperazin-1-yl)methyl)-6-benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-
(4-hydroxy-2,6-dimethylphenyl)propenamide. 31 was synthesized following General Procedure 
(G) from 30-3 (65 mg, 0.14 mmol, 1 eq) and concentrated HCl (0.05 mL, excess). Boc group likely 
removed during this step. Carried forward without characterization. Step 2: Performed amide 
coupling using 30-3 amine salt (45 mg, 0.09 mmol, 1 eq), diBoc-Dmt (43 mg, 0.09 mmol, 1.1 eq), 
PyBOP (52 mg, 0.10 mmol, 1.1 eq), 6-Cl HOBt (17 mg, 0.10 mmol, 1.1 eq), and DIPEA (0.16 
mL, 0.91 mmol, 10 eq). Step 3: Boc-deprotected as described in General Procedure (G). Final 
yield not calculated. 1H NMR (500 MHz, Methanol-d4) δ 7.25 – 7.21 (m, 1H), 7.12 (d, J = 6.9 Hz, 
2H), 6.99 – 6.95 (m, 1H), 6.91 – 6.83 (m, 1H), 6.55 (d, J = 8.1 Hz, 1H), 6.52 (d, J = 8.0 Hz, 1H), 
6.46 (dd, J = 8.4, 5.7 Hz, 3H), 4.91 (d, J = 18.6 Hz, 1H), 4.54 (ddt, J = 12.4, 8.1, 4.6 Hz, 1H), 3.95 
– 3.81 (m, 1H), 3.82 – 3.74 (m, 4H), 3.75 – 3.66 (m, 0H), 3.26 – 3.20 (m, 1H), 3.23 – 3.13 (m, 
2H), 3.15 – 3.06 (m, 1H), 3.06 – 2.98 (m, 1H), 2.97 – 2.66 (m, 4H), 2.48 (d, J = 12.2 Hz, 1H), 2.31 
– 2.19 (m, 12H), 2.04 (d, J = 11.1 Hz, 1H), 1.69 (d, J = 11.5 Hz, 1H), 1.65 – 1.58 (m, 1H), 1.51 (d, 
J = 17.4 Hz, 1H), 1.49 (s, 1H).HPLC (gradient A): retention time = 25.2 min. ESI-MS 719.3[M + 
H]+ and 741.3 [M + Na]+. 
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Chapter 3: Dual Pharmacophores Explored via SAR Matrix 
3.1  Introduction 
Translating the pharmacophore models derived from bifunctional opioid peptides 
(described in Chapter 1) required replication of the Tyr1 and Phe4 moieties, separated by a spacer 
region—the THQ core. While some modifications to the Tyr1 moiety were investigated, much 
exploration went into the Phe4 binding pocket, which translates to C-6 on our peptidomimetic 
scaffold. A summary of the C-6 substitutions investigated by our lab is depicted in Fig. 14, though 
this is not a comprehensive listing. Coloring in Fig. 14 corresponds to in vivo activity, where blue 
indicates full antinociception in the previously described WWTW assay while yellow denotes 
partial activity and red denotes no activity. Those without any coloration were not tested in vivo.  
As illustrated in the first column of Fig. 14, various substitutions were probed at the ortho, 
meta, and para positions including methyl, nitro, fluoro, hydroxyl, and methoxy substitutions. The 
second column depicts other modifications to the monocyclic aryl ring, with the unsubstituted 
phenyl ring of lead peptidomimetic 1 (referred to as the benzyl pendant henceforth) being the only 
fully active compound of those tested. By expanding the size of the C-6 pendant to a bicyclic 
system, the pharmacological profile was improved, as this typically reduced DOR stimulation 
while generally maintaining MOR efficacy. Some key observations from the C-6 SAR expansion 
shown in Fig. 14 are described below. 
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1) Heteroatoms distal to the THQ core reduced MOR efficacy significantly.  
2) Basic amines near C-6 generally display high affinity and partial efficacy for KOR. 
3) Saturated rings display lower MOR efficacy and potency than aryl or semi-aryl bicyclics. 
4) Monocyclic rings sometimes elicited DOR agonism whereas bicyclics did not. 
5) All analogues displayed 10- to 200-fold MOR selectivity regardless of C-6 substitution.  
6) Antinociceptive activity was unpredictable and infrequent amongst these substitutions. 
These results suggested that aryl or semi-aryl bicyclic pendants offered the optimal MOR 
agonist/DOR antagonist profile but most displayed high MOR-selectivity and poor bioavailability. 
Figure 14. Abbreviated Catalogue of C-6 Substitutions Probing the Phe4 Binding Pocketa 
 
a Red coloration indicates no significant antinociceptive activity in the mouse WWTW assay. Yellow denotes partial 
activity whereas blue denotes full antinociception. No color indicates that the compound was not tested in the WWTW 
assay. Analogues presented here were synthesized primarily by A.M.B. and A.A.H. with help by A.F.N. and D.J.M. 
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 Concurrent with the exploration at C-6, a separate SAR project was aimed at modifying 
the N-1 position of the THQ core. The initial focus of this work was to remove or block the 
metabolic hotspot at C-2, alpha to the nitrogen atom in the THQ core. First, the nitrogen was 
replaced with a methylene unit, though this benzylic carbon could undergo radical oxidation and 
showed only partial in vivo activity. Substituting the C-1 position with a methyl group did not 
improve bioavailability, however a geminal dimethyl substitution (analogue 69) did achieve full 
antinociceptive activity. Unfortunately, this scaffold was prohibitively lipophilic (ClogP = 6.3), 
requiring us to seek out alternative methods of improving bioavailability. The core -NH- was then 
replaced with -O-, -S-, and -SO2-. The ether analogue showed 200-fold selectivity for MOR and 
was not pursued for in vivo testing. However, the thioether and sulfone—which showed 
comparable MOR selectivity to lead peptidomimetic 1—were carried forward with in vivo 
evaluation. While the thioether was fully efficacious in vivo, the sulfone showed no activity. 
Figure 15. Substitutions at the 1-Position of the Peptidomimetic Corea 
 
a Red coloration indicates no significant antinociceptive activity in the mouse WWTW assay. Yellow denotes partial 
activity whereas blue indicates full antinociception. No coloration indicates that the compound was not tested in the 
WWTW assay. Analogues presented here were synthesized by A.A.H. and A.M.B. 69 was synthesized by A.F.N.  
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 Although replacement of the THQ core -NH- with a -CH2-, -O-, -S-, or -SO2- gave 
analogues with 30- to 200-fold selectivity for MOR, it was found that acylating the N-1 position 
significantly improved DOR affinity and reduced MOR selectivity. A selection of the N-acyl 
substitutions investigated are presented in Table 7, adapted from Harland et. al., 2016.95 These 
results demonstrated a very promising approach to balanced MOR-/DOR-selective bifunctional 
ligands. However, while the N-acyl series was very effective at balancing affinities between MOR 
and DOR, all analogues except the N-benzoyl analogue showed considerable DOR efficacy. 
 
a Data table adapted from Harland et. al., 2016 (reference 95). b Binding affinities (Ki) were obtained by competitive 
displacement of radiolabeled [3H]-diprenorphine in membrane preparations. Functional data were obtained using 
agonist induced stimulation of [35S]-GTPγS binding. Potency is represented as EC50 (nM) and efficacy as percent 
maximal stimulation relative to standard agonist DAMGO (MOR), DPDPE (DOR), or U69,593 (KOR) at 10 μM. All 
values are expressed as the mean of three separate assays performed in duplicate with standard error of the mean in 
parentheses. “dns” = does not stimulate (<10% stim). c First reported in reference 93. d First reported in reference 94. 
Compounds in this table were synthesized by A.A.H. and A.M.B.  
Ki (nM) EC50 (nM) % stim
# N-1 Substitution MOR DOR KOR DOR Ki / MOR Ki
MOR DOR KOR MOR DOR KOR
1c H 0.22(0.02)
9.4
(0.8)
68
(2)
43 1.6
(0.3)
110
(6) >500
81
(2)
16
(2)
22
(2)
32d COCH3 0.13(0.02)
1.8
(0.1)
87
(11)
14 6.0
(1.3)
68
(2)
>500 76
(4)
26
(3)
29
(5)
33 COOMe 0.19(0.05)
0.51
(0.19)
29
(8)
2.7 0.78
(0.19)
14
(3)
250
(40)
95
(5)
40
(7)
28
(3)
34 COCH2OCH3
0.15
(0.04)
2.1
(0.7)
34
(4)
14 3.0
(0.5)
67
(22) >500
91
(1)
47
(8)
38
(4)
35 COiPr 0.38(0.10)
0.53
(0.14)
76
(12)
1.7 9.6
(2.6)
25
(16) >500
95
(4)
52
(2)
41
(4)
36 COcPr 0.10(0.03)
0.35
(0.01)
25
(5)
3.5 1.8
(0.3)
10
(2) >500
88
(3)
69
(6)
32
(1)
37 COcBu 0.23
(0.07)
0.15
(0.07)
56
(4)
0.7 2.1
(0.2)
5.1
(1.9)
dns 94
(5)
58
(4)
dns
38 COPh 0.08
(0.03)
0.24
(0.09)
40
(15)
3 2.6
(0.6)
dns >500 75
(7)
dns 16
(4)
Table 7. N-Acyl Analogues with Improved MOR/DOR
Affinity Balance, MOR Agonism/DOR Partial Agonisma, bNH2
HN
N
OH
O
R
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 The opposing effects of the C-6 and N-1 campaigns—MOR-selective MOR agonism/DOR 
antagonism and balanced MOR agonism/DOR partial agonism—led us to combine these 
approaches in a small sampling of dually substituted C-6/N-1 analogues. Several bicyclic 
analogues were N-acetylated with the hope of retaining both MOR agonism/DOR antagonism as 
well as high DOR affinity/decreased MOR selectivity. Two N-acetylated that succeeded in 
achieving this goal featured 2-naphthyl and 1-tetrahydroisoquinolinyl (THIQ) pendants. These 
were potent MOR agonists, displayed no DOR efficacy, were less than 10-fold selective for MOR, 
and produced a robust antinociceptive effect in vivo with a duration of action twice as long as our 
lead 1. More recently, these analogues were demonstrated to show significantly reduced analgesic 
tolerance compared to morphine. Additionally, the 2-naphthyl analogue showed no dependence 
(no naloxone-induced withdrawal symptoms) or reward (measured by conditioned place 
preference), validating this chemotype for the treatment of pain with reduced side effects.98 
These results suggested a highly promising method for achieving our desired in vitro and 
in vivo goals. Following this success, several bicyclic analogues were N-acetylated with the aim 
of reproducing the previously observed boost in bioavailability. However, the subsequent N-acetyl 
analogues were as unpredictable in vivo as the unsubstituted analogues in Fig. 14, with no others 
displaying full antinociception. At this time, chemists A.A.H. and A.M.B. left the Mosberg lab, 
leaving this chemotype open to further development. What follows is a summary of the continued 
investigation into the C-6/N-1 chemotype. At present, a manuscript describing these results in 
abbreviated form is undergoing editing and resubmission to the Journal of Medicinal Chemistry. 
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3.2  Rationale & Approach 
 As discussed, the C-6 pharmacophore had been explored fairly extensively in past SAR 
campaigns. Additionally, while position-1 heteroatom replacement did not improve the 
pharmacological profile, it was discovered the N-1 substitutions could in fact be utilized to 
modulate DOR affinity (and in some cases bioavailability), establishing this as a second 
pharmacophore worth exploiting. Prior analogues had established that some combinations of C-6 
and N-1 substitutions could achieve high-affinity, high-potency, non-selective MOR agonism and 
DOR antagonism. However, bioavailability was both uncommon and unpredictable. As such, it 
was hypothesized that more incremental changes to this validated chemotype could both fine-tune 
our understanding of the SAR resulting from both pharmacophore elements and might also deliver 
more in vivo hits around these islands of bioavailability.  
 Considering most C-6 pendants had been incorporated on the -NH- THQ core, and all N-1 
substitutions were explored in the context of the benzyl C-6 scaffold, it seemed advantageous to 
combine promising moieties from both pharmacophores into a series of dually-substituted 
analogues. In order to most reliably compare across analogues, we identified select substitutions 
from each pharmacophore and synthesized the dually-substituted analogue resulting from each 
combination. In doing so, we generated a 2D matrix of compounds, allowing us to observe trends 
in both the x and y dimensions corresponding to different C-6 and N-1 substitutions. For this 2D 
matrix, we selected six C-6 substitutions and five N-1 moieties, resulting in 30 dual-
pharmacophore analogues in the series. The C-6 substitutions were selected based on several 
criteria. Because of the delay between synthesis of a novel analogue and full pharmacological 
evaluation, all C-6 substitutions were selected from the list of previously synthesized and 
characterized analogues in Fig. 14. A similar approach was taken for the N-1 moieties, however 
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as will be discussed later, an additional (novel) N-1 substitution was incorporated into the matrix 
as well. In order to fully present the pharmacological data, tables are presented with the N-1 
substitution as the independent variable initially, and matrices of select properties are included 
later in this chapter. As a follow-up to this study, the C-6 substitutions described below were also 
incorporated into the thiochromane scaffold (where the THQ -NH- was replaced with -S-), as the 
initial analogue in that series displayed full in vivo activity as depicted in Fig. 15. That series will 
be addressed separately at the end of this chapter along with the bioavailable gem-demethyl 
analogue 69 also found in Fig. 15. 
 Selection of C-6 pendants began with the bioavailable peptidomimetic lead 1, which 
featured a benzyl pendant. The 2-naphthyl pendant (the first bicyclic pendant that displayed the 
desired MOR agonist/DOR antagonist profile in vitro and, when N-acetylated, showed activity in 
vivo) was the next clear candidate selected for inclusion in this series. In order to decrease the 
lipophilicity associated with the 2-naphthyl pendant while keeping heteroatoms near the THQ core 
for reasons discussed previously, a 3-quinolinyl pendant was selected as a naphthyl isostere. 
Additionally, despite its mild KOR activity, the THIQ pendant showed high MOR efficacy and 
was known to be bioavailable upon N-acetylation. Thus, the first four pendants explored the effects 
of ring conjugation, lipophilicity, basicity, and planarity in the context of the C-6 pendant. 
Additionally, the 6-benzo-1,4-dioxanyl pendant and 2-benzofuranyl pendants explored the effects 
of oxygen incorporation, both into a semi-saturated as well as a fully aromatic bicyclic system. 
Contrary to prior observations of distal heteroatoms reducing MOR efficacy, it was believed that 
the ethylenedioxy bridge sufficiently masked these heteroatoms as demonstrated by analogue 41 
in Table 8. Subsequent analogues featuring the benzodioxanyl pendant would prove that 
assumption to have been incorrect.  
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3.3  Synthesis of Analogues 39-69 
The synthesis of compounds presented in this work began with the commercially available 
p-toluidine. As described in Chapter 2, this aniline was acylated with a 3-bromoproprionyl 
chloride. Intramolecular cyclization to the b-lactam followed by Fries Rearrangement yielded the 
THQ core with a C-6 methyl substitution. In step D of Scheme 6, the N-1 position was acylated 
with Boc anhydride, acetic anhydride, cyclopropyl acyl chloride, or benzoyl chloride. The mesyl 
group was poorly tolerated for subsequent benzylic bromination, as was the unprotected amine, 
necessitating use of the Boc group for these syntheses. 
 
Scheme 6. Condensed Synthetic Scheme of C-6/N-1 Dual Pharmacophore Ligandsa 
 
a (A) 3-bromopropionyl chloride & K2CO3 in DCM. (B) NaOtBu in DMF. (C) TfOH in DCE. (D) Boc2O, Ac2O, 
cyclopropanecarbonyl chloride, or benzoyl chloride, DIPEA, DCM. (E) NBS, benzoyl peroxide, CCl4, reflux. (F) R2-
boronic acid pinacol ester, Pd(dppf)Cl2, K2CO3, 3:1 acetone/water, 80°C, or tetrahydroisoquinoline-HCl, K2CO3, 
DMF, r.t. (G) (R)-(+)-2-methyl-2-propanesulfinamide, Ti(OEt)4, THF, 0°C to reflux, then NaBH4, THF, -78°C to r.t. 
(H) HCl, 1,4-dioxane, r.t., then diBoc 2,6-dimethyl-L-tyrosine, PyBOP, DIPEA, DMF, r.t., then TFA, DCM, r.t. 
 
The C-6 methyl group of the 6-methyl THQ intermediate underwent radical benzylic 
bromination in step E, catalyzed by benzoyl peroxide and heat. The C-6 pharmacophore then 
replaced the benzylic bromide by either Suzuki coupling with an aryl boronic acid or via 
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nucleophilic substitution with THIQ under basic conditions. Reductive amination was performed 
as described in Chapter 2 using the chiral Ellman auxiliary115–117 (R)-(+)-2-methyl-2-
propanesulfinamide, Ti(OEt)4, and NaBH4 to achieve the desired (R) stereochemistry at C-4. The 
sulfinamide was cleaved with concentrated HCl, leaving an enantiomerically pure amine salt, 
which was carried forward without further characterization to amide coupling with Boc-protected 
L-2,6-dimethyltyrosine.97,102,118 Boc deprotection with trifluoroacetic acid gave final compounds 
described in Tables 8-12. Final compounds were purified by semi-preparative HPLC. Due to 
availability of common intermediates, the R1 group appearing in the final compound was often 
incorporated at different stages for each compound in a subset. As such, Scheme 6 offers only a 
general schematic of the synthetic steps. Full synthetic procedures can be found at the end of 
Chapter 3.    
In addition to the bicyclic analogues presented in this chapter, the synthesis of the gem-
dimethyl analogue 69 as well as a series of thiochromane analogues 65-68 (presented at the end of 
this chapter) are included here.  
Scheme 7. Synthesis of Gem-Dimethyl Analogue 69a 
 
a (A) AlCl3, benzene, 95°C. (B) NBS, H2SO4, 60°C (C) benzyl boronic acid pinacol ester, Pd(dppf)Cl2, K2CO3, 3:1 
acetone/water, 80°C (D) (R)-(+)-2-methyl-2-propanesulfinamide, Ti(OEt)4, THF, 0°C to reflux, then NaBH4, THF, -
78°C to r.t. (E) HCl, 1,4-dioxane, r.t., then diBoc 2,6-dimethyl-L-tyrosine, PyBOP, DIPEA, DMF, r.t., then TFA, 
DCM, r.t. 
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 The initial steps of Scheme 7 differ significantly from those of the prior syntheses. In step 
A of Scheme 7, a 5-membered lactone undergoes Friedel Crafts acylation with benzene, generating 
the substituted gem-dimethyl tetrahydronaphthalene (THN) core in one step. Due to the electronics 
of this core, bromination did not proceed under standard conditions (NBS in DCM). As such, this 
reaction was performed in concentrated sulfuric acid, which facilitated selective C-6 bromination 
in 53% yield. The following steps were carried out as previously described, utilizing Suzuki, 
Ellman, and amide coupling reactions to produce final compound 69.  
 
Scheme 8. Synthesis of Thiochromane Analogues 65-68a 
 
a (A) NBS, benzoyl peroxide, CCl4, reflux. (B) R2-boronic acid pinacol ester, Pd(dppf)Cl2, K2CO3, 3:1 acetone/water, 
80°C, or tetrahydroisoquinoline-HCl, K2CO3, DMF, r.t. (C) (R)-(+)-2-methyl-2-propanesulfinamide, Ti(OEt)4, THF, 
0°C to reflux, then NaBH4, THF, -78°C to r.t. (D) HCl, 1,4-dioxane, r.t., then diBoc 2,6-dimethyl-L-tyrosine, PyBOP, 
DIPEA, DMF, r.t., then TFA, DCM, r.t. 
 
 Synthesis of the thiochromane analogues in Scheme 8 followed the same steps outlined in 
Scheme 6 from a commercially available 6-methyl thiochromane core. Benzylic bromination of 
this scaffold gave lower yields than the THQ scaffold, likely due to oxidation of the thioether by 
benzoyl peroxide. Removal of benzoyl peroxide eliminated some side-reactions, providing better 
yields. Subsequent steps were carried out as previously described in Scheme 6. 
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3.4  In Vitro Pharmacology of Dual-Pharmacophore Ligands 
 
 
a Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [3H]-diprenorphine in membrane 
preparations. Functional data were obtained using agonist induced stimulation of [35S]-GTPγS binding. Potency is 
represented as EC50 (nM) and efficacy as percent maximal stimulation relative to standard agonist DAMGO (MOR), 
DPDPE (DOR), or U69,593 (KOR) at 10 μM. All values are expressed as the mean of three separate assays performed 
in duplicate with standard error of the mean in parentheses. dns = does not stimulate. b Reported in reference 83.             c 
Reported in reference 99. d Synthesized by A.M.B. Previously reported analogues were synthesized by those authors. 
 
 Bicyclic compounds in Table 8 featuring no N-substitution display the MOR agonist/DOR 
antagonist profile, though the monocyclic C-6 analogue 1 displays low DOR and KOR efficacy at 
relatively high concentration of ligand (EC50 = 110 nM). The primary limitation of this subset 
remains the high degree of MOR selectivity. While compounds 39 and 41 display 15:1 and 16:1 
MOR selectivities, the others in this subset are at least 40-fold selective for MOR. This selectivity 
was combatted by acylation of the N-1 position with an acetyl group in Table 9.  
Ki (nM) EC50 (nM) % stim
# R2 R1 MOR DOR KOR
DOR Ki / 
MOR Ki
MOR DOR KOR MOR DOR KOR
1b 0.22
(0.02)
9.4
(0.8)
68
(2)
43 1.6
(0.3)
110
(6)
>500
(70)
81
(2)
16
(2)
22
(2)
4b 0.08
(0.01)
10
(2)
54
(7)
125 0.53
(0.08)
dns dns 96
(3)
dns dns
39c 0.10
(0.02)
1.5
(0.2)
16
(4)
15 2.2
(0.9)
dns dns 84
(6)
dns dns
40c 0.03
(0.01)
3.1
(0.2)
2.2
(0.4)
103 0.4
(0.1)
dns 90
(65)
105
(6)
dns 25
(4)
41d 0.35
(0.11)
5.5
(0.8)
116
(65)
16 7.3
(1.8)
dns dns 88
(8)
dns dns
42d 0.11
(0.03)
5
(2)
40
(20)
44 1.1
(0.5)
dns dns 98
(1)
dns dns
Table 8. Bicyclic C-6 Pendant with Unsubstituted N-1 Affords
a MOR-Selective, MOR Agonist/DOR Antagonist Profilea
N
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a Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [3H]-diprenorphine in membrane 
preparations. Functional data were obtained using agonist induced stimulation of [35S]-GTPγS binding. Potency is 
represented as EC50 (nM) and efficacy as percent maximal stimulation relative to standard agonist DAMGO (MOR), 
DPDPE (DOR), or U69,593 (KOR) at 10 μM. All values are expressed as the mean of three separate assays performed 
in duplicate with standard error of the mean in parentheses. dns = does not stimulate. b Reported in reference 93. c 
Reported in reference 99. Previously reported analogues were synthesized by those authors. 
 
 N-Acetylation of the THQ core improves binding affinity at DOR for all compounds in this 
subset. Notably, the five bicyclic analogues 43-47 all display subnanomolar affinity at both MOR 
and DOR. The drastic reduction in MOR selectivity of compounds 43 and 45 (6:1 and 5:1 
respectively) compared to their unsubstituted analogues 4 and 40 (125:1 and 103:1) was consistent 
throughout this subset, yielding very balanced profiles across Table 9. As shown in Table 7, N-
substitutions paired with monocyclic pendants generally caused low-potency, low-efficacy DOR 
agonism. However, bicyclic analogues 44 and 47 also displayed some low-efficacy DOR agonism 
but now with nanomolar potency. In fact, compound 44 was a remarkably well-balanced MOR 
agonist/DOR partial agonist in terms of both affinity and potency.  
Ki (nM) EC50 (nM) % stim
# R2 R1 MOR DOR KOR
DOR Ki / 
MOR Ki
MOR DOR KOR MOR DOR KOR
32b 0.13
(0.02)
1.8
(0.1)
87
(10)
14 6
(1)
68
(2)
>500 76
(4)
26
(3)
29
(5)
43b 0.04
(0.01)
0.23
(0.02)
48
(20)
6 0.9
(0.2)
dns dns 87
(3)
dns dns
44. 0.15
(0.05)
0.20
(0.08)
53
(14)
1 1.1
(0.3)
5.8
(0.6)
dns 76
(4)
35
(4)
dns
45c 0.19
(0.08)
0.89
(0.21)
0.78
(0.10)
5 6
(2)
dns 190
(30)
96
(4)
dns 41
(6)
46 0.38
(0.11)
0.83
(0.03)
142
(23)
2 13
(5)
dns dns 45
(3)
dns dns
47 0.12
(0.03)
0.73
(0.22)
58
(9)
6 1.9
(0.3)
1.6
(0.9)
>500 86
(5)
30
(2)
33
(10)
Table 9. N-1 Acetylation Reduces MOR Selectivity, Achieves
Sub-Nanomolar DOR Affinity with Modest DOR Efficacya
N
R2
HN
O
NH2 OH
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O
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O
O
O
O
O
O
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a Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [3H]-diprenorphine in membrane 
preparations. Functional data were obtained using agonist induced stimulation of [35S]-GTPγS binding. Potency is 
represented as EC50 (nM) and efficacy as percent maximal stimulation relative to standard agonist DAMGO (MOR), 
DPDPE (DOR), or U69,593 (KOR) at 10 μM. All values are expressed as the mean of three separate assays performed 
in duplicate with standard error of the mean in parentheses. dns = does not stimulate. b Reported in reference 93. 
 
 The third N-1 motif explored in this SAR study was a cyclopropyl acyl moiety, shown in 
Table 10. The bioavailable N-acetyl analogues 43 and 45 had each shown significant increases in 
duration of action. It was hypothesized that by sterically masking the N-1 amide bond with a 
cyclopropyl group, this duration of action and bioavailability might further be improved. 
Additionally, due to its similarity in size and electronics to the acetyl group, it was hypothesized 
that the cyclopropyl analogues would display similar increases in DOR affinity. Indeed, all 
analogues in Table 10 display subnanomolar affinity at both MOR and DOR. Compounds 49 and 
51 displayed the best binding profile yet achieved in this series, with nearly equal binding at MOR 
and DOR paired with substantial selectivity over KOR. Unfortunately, these highly optimal 
binding profiles were not paired with the desired MOR agonist/DOR antagonist functional profile. 
Ki (nM) EC50 (nM) % stim
# R2 R1 MOR DOR KOR
DOR Ki / 
MOR Ki
MOR DOR KOR MOR DOR KOR
36b 0.10
(0.03)
0.35
(0.01)
25
(5)
4 1.8
(0.3)
10
(2)
>500 88
(3)
69
(6)
32
(1)
48 0.05
(0.02)
0.37
(0.20)
117
(56)
7 0.42
(0.16)
1.9
(0.9)
>500 85
(7)
32
(4)
38
(3)
49 0.05
(0.01)
0.08
(0.04)
84
(26)
2 0.34
(0.12)
0.71
(0.13)
dns 47
(4)
84
(4)
dns
50 0.12
(0.06)
0.88
(0.23)
40
(10)
7 0.52
(0.22)
dns dns 95
(5)
dns dns
51 0.28
(0.08)
0.19
(0.03)
412
(200)
0.7 6
(2)
dns dns 36
(7)
dns dns
52 0.05
(0.01)
0.26
(0.07)
98
(9)
5 0.9
(0.3)
3.7
(2.6)
dns 89
(4)
52
(7)
dns
Table 10. Cyclopropyl Acyl N-1 Substitution Further Improves
MOR and DOR Affinity, Increases DOR Efficacy & Potencya
N
R2
HN
O
NH2 OH
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O
O
O
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O
O
O
O
O
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Both compounds were only partial agonists at MOR while compound 49 was additionally a highly-
potent, full DOR agonist (greater than 70% stimulation). In fact, all four planar, aromatic pendants 
display 30% or greater DOR efficacy. Three of these pendants also showed DOR efficacy in the 
N-acetyl subset. Taken together, these results indicate that while a bicyclic C-6 pendant is 
sufficient to prevent DOR activation in the context of the unsubstituted THQ core, the DOR-
activating propensity of some N-1 modifications reverses this trend. As such, the planar bicyclic 
pendants may revert to displaying DOR agonism, but with the increased potency associated with 
this bicyclic C-6/N-1 series. Notably, the non-planar THIQ and benzodioxanyl pendants both 
maintained the DOR antagonist profile in analogues 50 and 51 respectively. Analogue 50 
combines the favorable binding profile of the cyclopropyl acyl subset with the favorable functional 
profile of the THIQ pendant, yielding an optimal in vitro profile. Compared to its N-acetyl 
analogue, 50 shows significantly better selectivity over KOR, displays no KOR efficacy, and offers 
a 12-fold improvement in MOR potency, making this a highlight of the cyclopropyl acyl subset.  
 As illustrated by the analogues in Tables 9 and 10, small acyl substitutions at the N-1 
position do indeed drastically improve the DOR binding for all analogues in this series. Of these 
12 compounds, 11 display subnanomolar affinity for both MOR and DOR, while most are highly 
selective over KOR. However, DOR efficacy does appear in several of the planar pendant 
analogues, restricting the achievement of an optimal in vitro profile to compounds 43 and 50. 
Between these two acyl subsets, the cyclopropyl acyl group offers greater MOR potency. In the 
case of the high-efficacy DOR agonists 36 and 49, the cyclopropyl group also offers greater DOR 
potency compared to their N-acetyl analogues. For investigators aiming to design highly potent 
MOR agonist/DOR agonist ligands, one might look to combinations of the 3-quinolinyl pendant 
with the N-1 methyl carbamate, isopropyl acyl, or cyclobutyl acyl groups.  
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a Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [3H]-diprenorphine in membrane 
preparations. Functional data were obtained using agonist induced stimulation of [35S]-GTPγS binding. Potency is 
represented as EC50 (nM) and efficacy as percent maximal stimulation relative to standard agonist DAMGO (MOR), 
DPDPE (DOR), or U69,593 (KOR) at 10 μM. All values are expressed as the mean of three separate assays performed 
in duplicate with standard error of the mean in parentheses. dns = does not stimulate. 
 
In Table 11, the N-acyl motif is replaced with a methyl sulfone, or “mesyl” group. This 
was chosen to mimic the amide functionality while increasing stability toward amidases or 
peptidases that might otherwise cleave the amide bond. Additionally, the S=O bonds mimic the H-
bond accepting capacity of the C=O bond of the acyl analogues. While the compounds in this 
subset did show improvements in DOR affinity relative to the unsubstituted analogues, the mesyl 
group does not elicit the same DOR affinity as was observed with the cyclopropyl acyl subset. 
MOR affinity remained high throughout the series, yielding more MOR-selective compounds than 
in the previous two subsets. Notably, the mesyl group showed no DOR efficacy amongst the 
bicyclic analogues, though the monocyclic analogue 53 showed mild DOR efficacy. Additionally, 
the mesyl group boosted both MOR potency and efficacy. With the exception of 57, all analogues 
Ki (nM) EC50 (nM) % stim
# R2 R1 MOR DOR KOR
DOR Ki / 
MOR Ki
MOR DOR KOR MOR DOR KOR
53 0.06
(0.02)
0.41
(0.16)
8
(4)
7 0.23
(0.06)
12
(1)
121
(24)
98
(1)
22
(2)
60
(9)
54 0.04
(0.01)
0.95
(0.25)
27
(10)
24 0.23
(0.04)
dns dns 102
(4)
dns dns
55 0.23
(0.08)
0.64
(0.24)
7
(1)
3 0.26
(0.07)
dns dns 96
(3)
dns dns
56 0.11
(0.02)
0.98
(0.13)
1.1
(0.3)
9 0.12
(0.04)
dns 45
(14)
114
(6)
dns 51
(5)
57 0.07
(0.01)
1.5
(0.5)
46
(4)
21 9
(1)
dns >500 47
(6)
dns 39
(4)
58 0.05
(0.01)
1.0
(0.2)
8
(3)
20 0.34
(0.11)
dns >500 102
(3)
dns 61
(7)
Table 11. Sulfonyl N-1 Moiety Increases MOR Selectivity,
MOR Potency & MOR Efficacy; Regains DOR Antagonisma
N
R2
HN
O
NH2 OH
R1
S OO
S OO
S OO
S OO
S OO
S OOO
O
O
N
N
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in this subset displayed a MOR EC50 of less than 0.4 nM paired with a MOR efficacy of at least 
95%. Three analogues displayed over 100% efficacy at MOR. Despite its 24-fold MOR selectivity, 
analogue 54 offers a highly potent MOR agonist/DOR antagonist profile. Meanwhile, the more 
balanced 3-quinolinyl pendant maintains its MOR/DOR affinity balance in analogue 55 and also 
achieves the highly potent MOR agonist/DOR antagonist profile. Additionally, analogues 56 and 
58 both display highly potent and efficacious MOR agonism (greater than 100%) with no DOR 
efficacy, though both also have some KOR agonism at high concentrations of ligand.  
 
 
 
a Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [3H]-diprenorphine in membrane 
preparations. Functional data were obtained using agonist induced stimulation of [35S]-GTPγS binding. Potency is 
represented as EC50 (nM) and efficacy as percent maximal stimulation relative to standard agonist DAMGO (MOR), 
DPDPE (DOR), or U69,593 (KOR) at 10 μM. All values are expressed as the mean of three separate assays performed 
in duplicate with standard error of the mean in parentheses. dns = does not stimulate. b Reported in reference 93, 
synthesized by A.A.H. c Synthesized by D.J.M. 
 
Ki (nM) EC50 (nM) % stim
# R2 R1 MOR DOR KOR
DOR Ki / 
MOR Ki
MOR DOR KOR MOR DOR KOR
38b 0.08
(0.03)
0.24
(0.09)
40
(15)
3 2.6
(0.6)
dns >500 75
(7)
dns 16
(4)
59c 0.26
(0.13)
0.46
(0.05)
160
(40)
2 7.9
(3.4)
dns dns 57
(1)
dns dns
60c 0.04
(0.02)
0.74
(0.23)
100
(10)
19 1.0
(0.2)
dns dns 43
(4)
dns dns
61c 0.37
(0.11)
4
(2)
160
(30)
11 4.2
(1.6)
dns dns 93
(2)
dns dns
62 1.5
(0.3)
0.22
(0.07)
240
(60)
0.15 dns dns >500 dns dns 60
(16)
63 0.35
(0.13)
0.64
(0.03)
100
(20)
2 12
(2)
dns dns 64
(4)
dns dns
Table 12. Benzoyl N-1 Substitution Maintains DOR
Antagonism, Reduces MOR Efficacy & Potencya
N
R2
HN
O
NH2 OH
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O
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The final substitution explored in this series was the N-benzoyl acyl group. Whereas the 
monocyclic analogues in each of the past subsets (1, 32, 36, and 53) displayed some DOR agonism, 
the monocyclic N-benzoyl analogue 38 was a DOR antagonist. Thus, the benzoyl moiety was 
selected as it was most likely to deliver the MOR agonist/DOR antagonist profile in subsequent 
bicyclic analogues. Unfortunately, the benzoyl group was also associated with a reduction in 
efficacy at MOR, as four of the analogues display only partial (less than 70%) efficacy. These 
analogues were also the least potent at MOR in the series. However, in terms of binding, these 
compounds were generally well-balanced. Four of the six compounds displayed 3-fold or less 
MOR selectivity, with one compound (62) actually favoring DOR 7-fold. Functionally, compound 
62 was an antagonist at both MOR and DOR.  
The benzoyl substitution, despite its beneficial effects on balancing MOR/DOR affinity 
and maintaining DOR antagonism, caused a significant increase in lipophilicity. In fact, 
compounds such 59 and 63 displayed a ClogP of greater than 5. Due to issues with solubility in 
aqueous media, the benzoyl moiety was the most lipophilic substitution deemed feasible for this 
study, considering the possibility of precipitation of the compound in vivo. 
 In order to more easily observe trends in SAR relating to both C-6 pendant as well as N-1 
motif, a series of 2D matrices were constructed highlighting specific trends. In these matrices, N-
1 substituents are placed on the x axis in columns 1-5 while the C-6 pendants are listed on the y 
axis in rows A-F. Desirable values are in white, while less favorable values are colored in shades 
of blue where increasingly darker shades correspond to the least favorable values. Data presented 
in these matrices are taken from Tables 8-12, wherein standard error, original references, and 
compound numbers can be found; these matrices are designed to more visually display trends in 
both the C-6 and N-1 dimensions.  
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Figure 16. SAR Matrices Highlight Trends in Potency & Efficacy at MOR & DORa 
 
aSAR matrices of potency and efficacy at MOR and DOR highlight favorable values (high MOR potency, dns at DOR) 
in white with low MOR potency and high DOR potency in increasingly darker shades of blue, corresponding to less 
favorable values. Similarly, high MOR efficacy and no DOR efficacy (dns) are most favorable, rendered in white 
while low MOR efficacy and high DOR efficacy (unfavorable) are shown in darker shades of blue.  
 
 Investigating the effects of C-6 and N-1 substitutions on MOR potency showed that 
subnanomolar potency was achieved in nine of the twelve analogues in the cyclopropyl acyl and 
mesyl subsets (Fig. 16A columns 3 and 4). Conversely, the N-acetyl and N-benzoyl substitutions 
(Fig. 16A columns 2 and 5) were generally less potent at MOR. Notably, analogues in row E of 
Fig. 16A are consistently the least potent in each subset. Looking at MOR efficacy in Fig. 16B, 
we see that row E is also consistently the least efficacious at MOR. On the other hand, analogues 
in the row above, row D, were consistently the most efficacious. In the vertical direction, column 
≤ 30 31 – 50 51 – 70 71 – 90 > 90 
B MOR Efficacy (% stim)
1 2 3 4 5
A 81 76 88 98 75
B 96 87 85 102 57
C 84 76 47 96 43
D 105 96 95 114 93
E 88 45 36 47 dns
F 98 86 89 102 58
H
O O O
S
O
O
N
N
O
O
O
≤ 30 31 – 50 51 – 70 71 – 90 > 90 
D DOR Efficacy (% stim)
1 2 3 4 5
A 16 26 69 22 dns
B dns dns 32 dns dns
C dns 35 84 dns dns
D dns dns dns dns dns
E dns dns dns dns dns
F dns 30 52 dns dns
H O O O
S
O
O
N
N
O
O
O
≤ 1.0 1.1 – 5.0 5.1 – 10 > 10 dns
A MOR Potency, EC50 (nM)
1 2 3 4 5
A 1.6 6 1.8 0.23 2.6
B 0.53 0.9 0.42 0.23 7.9
C 2.2 1.1 0.34 0.26 1.0
D 0.4 6 0.52 0.12 4.2
E 7.3 13 6 9 dns
F 1.1 1.9 0.9 0.34 12
H
O O O
S
O
O
N
N
O
O
O
≤ 1.0 1.1 – 5.0 5.1 – 10 > 10 dns
C                 DOR Potency, EC50 (nM)
1 2 3 4 5
A 110 68 10 12 dns
B dns dns 1.9 dns dns
C dns 5.8 0.71 dns dns
D dns dns dns dns dns
E dns dns dns dns dns
F dns 1.6 3.7 dns dns
H O O O
S
O
O
N
N
O
O
O
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4 (the mesyl subset) is the most efficacious subset at MOR. Unsurprisingly, the analogue at the 
intersection of these two high-efficacy functionalities in square 4-D (compound 56) displays the 
highest MOR efficacy of the series (114%) as well as the best MOR potency (Fig. 16A). 
Compounds in columns 1, 2, and 3 were generally full MOR agonists, whereas column 5—the N-
benzoyl subset—displayed the lowest efficacy. The compound at the intersection of the lowest-
efficacy functionalities in square 5-E (compound 62) was the only MOR antagonist throughout 
the series.  
 Focusing on DOR potency (Fig. 16C) and efficacy (Fig. 16D), most analogues in columns 
1, 4, and 5 are antagonists, as are analogues in rows B, D, and E. Conversely, the monocyclic 
benzyl pendant of row A is most commonly associated with DOR efficacy, though rows C and F 
each feature two DOR agonist ligands as well. In the vertical direction, the acetyl and cyclopropyl 
acyl substitutions (columns 2 and 3) display some DOR efficacy. Again, the combination of the 3-
quinolinyl pendant (row C) and cyclopropyl acyl group (column 3) yield the most potent (Fig. 
16C) and efficacious (Fig. 16D) DOR analogue in the series. In terms of targeting our desired 
MOR agonist/DOR antagonist profile, column 4 (the mesyl subset) is consistently the most potent 
and efficacious at MOR while maintaining DOR antagonism. Row 4 analogues B, C, D, and F 
(54, 55, 56, and 58 respectively) all display high-potency MOR agonism and DOR antagonism 
with varying selectivity profiles between 3:1 and 24:1 in favor of MOR (see Table 11). 
 SAR analysis of two pharmacophores via 2D matrices provides useful information that 
may not have been readily apparent from individual SAR campaigns at either C-6 or N-1 alone. 
Based on our initial monocyclic series, it seemed that DOR efficacy would be a consistent issue 
for most if not all N-substituted analogues. However, combining these N-1 modifications with 
bicyclic pharmacophore elements at C-6 has shown that, contrary to initial expectations, some N-
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substitutions (namely the mesyl group) offer reliable DOR antagonism despite the mild efficacy 
of the initial analogue in the series. Additionally, the matrix setup allows us to identify 
intersections of key trends, enhancing our ability to fine-tune specific profiles. Some exemplary 
intersections are 3-C (compound 49), a potent, high-efficacy DOR agonist; 4-D (compound 56), a 
potent, high-efficacy MOR agonist/DOR antagonist; and 5E (compound 62), a dual antagonist. 
Additionally, chemists looking to replicate these results in slightly altered forms could add to 
remove a carbon atom (THIQ to isoindoline, cyclopropyl to cyclobutyl, ethylenedioxy to 
methylenedioxy benzodioxane) generating very similar profiles in vitro to those reported above. 
This could be advantageous in expanding the net of optimized in vitro candidates for in vivo 
testing. As will be described in the next section, in vivo results have thus far been fairly 
unpredictable with small modifications causing large differences in bioavailability. As such, by 
incrementally modifying past bioavailable ligands, we may be able to generate novel ligands with 
optimized in vitro profiles and in vivo antinociceptive activity. 
3.5  In Vivo Pharmacology 
To determine whether the improved in vivo activity achieved by acetylating compounds 43 
and 45 translates to other N-substituted analogues, all compounds in this series with MOR agonist 
activity in vitro were evaluated for their antinociceptive activity in mice via the WWTW assay. Of 
the 21 novel analogues presented here, four reached the maximal possible effect (100% MPE) 
while six others showed partial activity (50-75% MPE); the remaining eleven compounds showed 
no significant difference from baseline (Table 13).  
Within the -NH- subset, only the lead compound 1 showed full antinociceptive activity, 
while two others were partially active (50% MPE). The acetyl and mesyl subsets showed the 
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greatest in vivo efficacy with 2 fully active, 2 partially active, and 2 inactive analogues each. The 
benzoyl subset also contained 2 fully active analogues, though the remaining 4 analogues had no 
significant antinociceptive activity. The cyclopropyl acyl subset offered only two partially active 
analogues (50-60% MPE).  
  
 
a Results from the mouse WWTW assay after cumulative dosing of test compound up to 10 mg/kg ip. Antinociceptive 
activity represented as percent maximum possible effect (% MPE), with MPE being a 20 s latency to tail withdrawal. 
Baseline tail withdrawal latency is ~5 s, or 25% MPE. “dns” indicates no stimulation of an antinociceptive response. 
b Reported in reference 83. c Reported in reference 99. d Synthesized by A.M.B. e Reported in reference 94. f Reported in 
reference 95. g Synthesized by D.J.M.  
# R2 R1 % MPE
1b 100
4b 50
39c dns
40c dns
41d dns
42d 50
32e dns
43e 100
44. 60
45c 100
46 75
47 dns
# R2 R1 % MPE
36f 50
48 dns
49 dns
50 60
51 dns
52 dns
53 100
54 dns
55 50
56 100
57 70
58 dns
# R2 R1 % MPE
38f dns
59g 100
60g 100
61g dns
62 dns
63 dns
Duration of Action (h)
43 4.5
45 4.5
53 1.5
56 1.5
59 3.0
60 2.5
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Table 13. Antinociceptive Activity of C-6/N-1 Analogues in
WWTWAssay Following Intraperitoneal Administrationa
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In the bottom right section of Table 13, N-acetyl analogues 43 and 45 displayed a duration 
of action greater than 4 hours, whereas the mesyl derivatives 53 and 56 displayed antinociceptive 
effects lasting less than 2 hours. The benzoyl analogues 59 and 60 showed a duration of action of 
approximately 3 hours. Of note, 60 displayed only 43% efficacy in vitro at MOR, yet elicited a 
full antinociceptive effect in the WWTW assay, indicating even partial agonists may elicit full 
activity in vivo. 
As was the case with the mono-substituted C-6 and N-1 campaigns, a clear relationship 
between structure and in vivo activity was not easily detectable. We are still working toward 
developing more exact predictors of in vivo efficacy, however comparison with ClogP does offer 
some (albeit limited) insight. Fig. 17 compares ClogP for each compound with its corresponding 
in vivo activity.  
 
Figure 17. In Vivo SAR Matrix Indicates Lower ClogP is Favorable for Bioavailabilitya 
 
a Comparison of Clog P with in vivo activity shows that compounds with ClogP of 3.3 or less, denoted by blue stars, 
are all partially or fully active in vivo.  
Antinociceptive Efficacy (% MPE)
1 2 3 4 5
A 100 dns 50 100 dns
B 50 100 dns dns 100
C dns 60 dns 50 100
D dns 100 60 100 dns
E dns 75 dns 70 dns
F 50 dns dns dns dns
H
O O O
S
O
O
N
N
O
O
O
≤ 30 31 – 50 51 – 70 71 – 90 > 90 ClogP
Active/Total
3.0 - 3.4
7/8
3.5 – 3.9
3/10
4.0 – 4.4
1/3
4.5 – 4.9
3/6
≥ 5.0
1/3 
ClogP
1 2 3 4 5
A 3.8 3.4 3.9 3.3 4.6
B 4.9 4.5 5.1 4.4 5.8
C 3.7 3.2 3.8 3.1 4.5
D 3.7 3.2 3.8 3.1 4.5
E 3.5 3.1 3.7 3.0 4.4
F 4.3 3.9 4.5 3.8 5.2
H
O O O
S
O
O
N
N
O
O
O
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 Splitting compounds into bins by their ClogP, we see that seven of eight compounds in the 
lowest ClogP bin have full or partial antinociceptive activity, where the one outlier is the highest 
ClogP analogue of the group. However, in the bins with ClogP greater than or equal to 3.5, 
approximately only one in three (8 of 22) have activity in vivo. Those low-ClogP, bioavailable 
ligands are denoted in Table 17 with a blue star. These data indicate a greater propensity for in 
vivo activity amongst low-ClogP compounds than those in the higher-ClogP bins. This effect may 
correspond to greater solubility in blood, and thus a greater ability to reach the target receptors 
(lower volume of distribution). Conversely, several analogues with high Clog P including 43, 59 
and 60 (ClogP = 4.5, 4.5, and 5.8 respectively) have a much higher ClogP and corresponding 
volume of distribution yet are still fully active in vivo. It is worth noting that the two THIQ 
compounds 45 and 56 are very similar structurally and differ by only 0.1 ClogP units yet have a 
3-hour difference in duration of action. From these data, duration of action seems most correlated 
to N-1 substitution rather than ClogP or C-6 pendant, though more data would be needed to draw 
a more meaningful conclusion.  
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Figure 18. Plotting ClogP Against In Vivo Activity 
 
 
 While in vivo activity does correlate with ClogP generally, the presence of clear outliers to 
this trend indicates the presence of other contributing factors as well (e.g., efflux, metabolism, 
distribution, elimination). Nonetheless, chemists looking to develop new, bioavailable analogues 
of this chemotype would be well-advised to strive for low ClogP, both to improve solubility but 
also to favor in vivo activity.  
3.6  SAR of the Thiochromane Analogues of the Bicyclic Series 
 As discussed previously, an additional subset of analogues built around a thiochromane 
core instead of the THQ core were designed for inclusion within this study. The thiochromane core 
replaces the THQ amine (-NH-) with a thioether (-S-). The initial analogue utilizing the 
0
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thiochromane core, which featured a monocyclic benzyl pendant at C-6, was one of the few 
scaffolds that maintained bioavailability in vivo. As this series was among the most recently 
synthesized, many data points are still missing, and in vivo testing has not yet been conducted. 
Nevertheless, the existing data points are included in Table 14 below. The standalone gem-
dimethyl tetrahydronaphthalene analogue 69 is also included in Table 14. 
 
 
a Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [3H]-diprenorphine in membrane 
preparations. Functional data were obtained using agonist induced stimulation of [35S]-GTPγS binding. Potency is 
represented as EC50 (nM) and efficacy as percent maximal stimulation relative to standard agonist DAMGO (MOR), 
DPDPE (DOR), or U69,593 (KOR). Values are expressed as the mean of three separate assays performed in duplicate 
with standard error of the mean in parentheses. dns = does not stimulate. b Synthesized by A.M.B. † n=2 ‡ n=1. 
 
Analogues in this series are more MOR-selective than those in the substituted THQ series. 
This is to be expected, as the acyl C=O (or S=O) bond is critical to achieving subnanomolar DOR 
affinity. Analogues 64, 65 and 67 display high MOR potency and efficacy while maintaining the 
Ki (nM) EC50 (nM) % stim
# R2 R1 MOR DOR KOR
DOR Ki / 
MOR Ki
MOR DOR KOR MOR DOR KOR
64b -S- 0.15
(0.04)
4.8
(1.1)
48
(23)
32 1.9
(0.5)
dns† dns 80
(8)
dns† dns
65 -S- 0.20
(0.09)
4.3†
(0.6)
--- 22 0.8
(0.6)
dns --- 79
(6)
dns ---
66 -S- 0.18
(0.09)
3.1
(0.4)
--- 17 0.7
†
(0.1)
15‡
(---)
--- 57
†
(6)
28‡
(---)
---
67 -S- 0.07
(0.02)
3.9
(0.7)
14
(4)
56 0.7
(0.4)
dns† 85
‡
(---)
93
(2)
dns† 40
‡
(---)
68 -S- 0.7
(0.2)
6.5‡
(---)
--- 9 26
†
(20)
dns† --- 25
†
(1)
dns† ---
69 -C(CH3)2- 0.36
(0.08)
6.5
(0.7)
27
(5)
2 16
(5)
>500 >500 75
(4)
16
(3)
75
(3)
O
O
N
N
R1
R2
HN
O
NH2 OH
Table 14. Thiochromane and Gem-Dimethyl Tetrahydro-
naphthalene Analogues Show High MOR Selectivitya
 148 
DOR antagonist profile. As was observed in some 3-quinolinyl analogues in the previous series, 
analogue 66 displayed low MOR efficacy and partial DOR efficacy. In addition to the high degree 
of MOR selectivity, a key drawback of this series is lipophilicity. Analogues in this series range 
in ClogP from 4.6 to 6.0, limiting our ability to test these compounds for antinociception due to 
solubility issues. At present, only analogue 64 (ClogP = 4.8) has been tested in vivo. Based on 
lipophilicity and in vitro profile, compound 67 (ClogP = 4.6) may be a suitable candidate for future 
in vivo screening, though its MOR selectivity could limit the positive effects of DOR antagonism. 
Due to the limiting factors of lipophilicity and MOR selectivity, this scaffold is unlikely to be 
utilized for future drug development. The standalone analogue 69 also suffered high MOR 
selectivity and lipophilicity (and associated solubility issues) while also displaying lower MOR 
potency. Due to these issues, this scaffold was not further explored despite its in vivo activity. 
3.7  Conclusions  
By combining advantageous C-6 and N-1 moieties from past SAR campaigns and 
expanding those with novel substituents at both positions, we have developed an SAR matrix of 
30 analogues that further expand the available toolkit of multifunctional opioid ligands. Although 
our goal was to explore the C-6/N-1 chemotype with a focus on the MOR agonist/DOR antagonist 
profile, this SAR study has also yielded strategies for creating highly potent multifunctional MOR 
agonists/DOR agonists as well. While most compounds in this series displayed the desired DOR 
antagonist profile, cyclopropyl acyl analogues 36 and 39 (Table 10) showed surprising DOR 
efficacy and could be useful in the study of the MOR agonist/DOR agonist profile, which also 
holds promise for reducing opioid-related tolerance while improving analgesic potency and 
efficacy.112,119 Other compounds of note include 50, 54, and 55, which reproduce the desired in 
vitro profile: subnanomolar values for MOR affinity, DOR affinity, and MOR potency as well as 
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high efficacy at MOR with no DOR or KOR activity. Four novel compounds from this series, 53, 
56, 59, and 60 (Table 13), showed full antinociceptive activity in mice, and will be carried forward 
for evaluation in tolerance and dependence models. Comparing these with the bioavailable bicyclic 
lead 43 (2-naphthyl/N-acetyl, ClogP = 4.5), we observed a significant improvement in aqueous 
solubility for analogues 53 (ClogP = 3.2) and 56 (ClogP = 3.1), while 59 (ClogP = 5.8) was 
significantly more lipophilic and 60 (ClogP = 4.5) showed no change. Duration of action in vivo 
was not positively impacted by the N-1 substitutions explored in this series, as the previously 
reported analogues 43 and 45 showed longer-lasting antinociception than 53, 56, 59 and 60.  
A key finding of this work is the development compound 56, which shows the highest 
efficacy at MOR and displays subnanomolar potency at both MOR and DOR. Additionally, 56 is 
fully efficacious in vivo after peripheral administration and has a drug-like ClogP of 3.1. However, 
selectivity over KOR and duration of action are significantly reduced compared to 43, indicating 
areas in need of further optimization. 
 
Figure 19. Summary Profiles of 2nd Generation Lead 43 and Optimized Analogue 56 
 
MOR agonist (114% stim, EC50 = 0.12 nM)
DOR antagonist (<10% stim, Ke = 0.85 nM)
MOR/DOR selectivity: 9:1
MOR/KOR selectivity: 10:1
Full antinociceptive activity (100% MPE)
Duration of action = 1.5 h; ClogP = 3.1
N
N
NH2
HN
O
OH
S
O
O
N
NH2
HN
O
OH
O
MOR agonist (87% stim, EC50 = 0.9 nM)
DOR antagonist (<10% stim, Ke = 2.0 nM)
MOR/DOR selectivity: 6:1
MOR/KOR selectivity: 1200:1
Full antinociceptive activity (100% MPE)
Duration of action = 4.5 h; ClogP = 4.5
5643
Previously Reported Bicyclic Lead Optimized Analogue from This Work
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In summary, we have further investigated the bicyclic C-6/N-1 chemotype established by 
43 and 45,94,99 expanding the published C-6 and N-1 chemical space. The various C-6 and N-1 
modifications reported here have been combined in an SAR matrix to further elucidate the 
chemical motifs that govern ligand binding and receptor activation in the context of the THQ 
peptidomimetic core. This SAR study reinforces previous findings and refines our ability to 
develop potent bifunctional opioid ligands with a range of mixed-efficacy profiles in order to 
further probe the unique pharmacology of the opioid receptor family. The N-acyl and N-sulfonyl 
series—when combined with a bicyclic C-6 pendant—display among the most favorable in vitro 
profiles yet discovered throughout all of our peptidomimetic investigations to date.  
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3.8  Experimental Procedures  
 
 
a Synthesis reported in reference 93. b Synthesis reported in reference 83. c Synthesis reported in 
reference 99. d Synthesis reported in reference 94. e Synthesis reported in reference 95. Syntheses of 
referenced compounds are not reproduced in this dissertation. 
 
General Procedures  153 
Syntheses of Common Intermediates 158 
Compound 41 and Preceding Intermediates 165 
Compound 42 and Preceding Intermediates 167 
Compound 44 and Preceding Intermediates 169 
Compound 46 and Preceding Intermediates 172 
Compound 47 and Preceding Intermediates 175 
R1 Moieties
C
-6
 P
en
da
nt
s
1a 32d 36e 53 38e 64 69
4b 43d 48 54 59 65 ---
39c 44. 49 55 60 66 ---
40c 45c 50 56 61 67 ---
41 46 51 57 62 68 ---
42 47 52 58 63 --- ---
N
N
O
O
O
N
H
N
O
N
O
N
S OO
N
O
S C
R1
R2
HN
O
NH2 OH
Table 15. Chapter 3 Compound Numbering
and Literature References
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Compound 48 and Preceding Intermediates 178 
Compound 49 and Preceding Intermediates 182 
Compound 50 and Preceding Intermediates 184 
Compound 51 and Preceding Intermediates 187 
Compound 52 and Preceding Intermediates 190 
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Compound 64 was synthesized by A.M.B, the details for which can be found in his dissertation.   
 153 
General Procedures 
General Procedure (A): Schotten-Bauman Acylation of a Commercially Available Aniline 
Starting Material. To a flame-dried round-bottom flask under Ar atmosphere was added aniline 
starting material (1.00 eq), followed by dichloromethane, then K2CO3 (1.2-3.0 eq.). After 10 
minutes, 3-bromopropionyl chloride (1.05 eq) was added slowly via syringe. Reaction was 
monitored by TLC in 40% ethyl acetate, 60% hexanes. Ninhydrin stain was used to help monitor 
disappearance of aniline starting material. After 1-3 h, reaction was quenched with deionized 
water. Organics were separated and dried over MgSO4, then filtered and concentrated under 
vacuum. Product was purified by crystallization or, when necessary, column chromatography.   
General Procedure (B): Intramolecular b-Lactam Cyclization. To a flame-dried round-bottom 
flask under Ar atmosphere was added sodium tert-butoxide (1.05 eq) followed by anhydrous DMF, 
then stirred 10 min before slowly adding a solution of  acyl bromide intermediate from step A 
(1.00 eq) dissolved in DMF at ambient temperature via syringe. Monitored reaction by TLC in 
40% ethyl acetate, 60% hexanes. Desired product showed a moderate decrease in Rf relative to 
starting material. After stirring 1-3 h, reaction mixture was concenctrated under vacuum, then 
resuspended in dichloromethane or ethyl acetate. Extracted reaction mixture with deionized water 
and aqueous sodium bicarbonate, then separated organics and dried over MgSO4. Filtered and 
reconcentrated organics onto silica, then purified by flash chromatography. 
General Procedure (C): Fries Rearrangement to Synthesize the THQ Core. To a round-
bottom flask containing b-lactam intermediate (1 eq) dissolved in dichloroethane under inert 
atmosphere was slowly added TfOH (3 eq). After 1 hour, TLC in 40% ethyl acetate, 60% hexanes 
showed a decrease in Rf. Reaction was quenched with deionized water and neutralized with 
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K2CO3, then diluted with dichloromethane. Separated organics and dried over MgSO4, then filtered 
and concentrated organics onto silica and purified by flash chromatography. 
General Procedure (D): N-Substitution of the THQ Core 
Boc protection of the tetrahydroquinoline (THQ) core. To a flame-dried round bottom flask 
under Ar was added tetrahydroquinolin-4-one intermediate (1.0 eq), Boc2O (1.5 eq), and DMAP 
(0.1 eq). The reaction vessel was placed under vacuum for 5 min, then anhydrous DCM was added 
via syringe and the solution stirred for 5 min under vacuum. The round bottom flask was flooded 
with Ar, and DIPEA (1.5 eq) was added via syringe. The reaction vessel was equipped with a 
condenser and placed in oil bath at 60°C. The reaction stirred at reflux for 12-16 h under Ar and 
was monitored by TLC. Once significant conversion to product was seen, the reaction was 
quenched using dI H2O (20 mL) and the layers were separated. The organic layer was washed with 
sat. NaHCO3 and sat. NaCl solutions then dried over MgSO4. Organics were filtered and 
concentrated under reduced pressure, then purified using silica gel chromatography.  
N-Acylation or Mesylation of the THQ core. To a round-bottom flask containing THQ 
intermediate (1.0 eq) under Ar atmosphere was added DCM. Reaction flask was then cooled to 
0°C before adding Et3N (1.2 eq), followed by acyl or sulfonyl chloride (1.2 eq). When starting 
material showed complete conversion to product by TLC, solvent was removed under reduced 
pressure and reaction mixture was purified by silica chromatography. 
General Procedure (E): Benzylic Bromination of the C-6 Methyl Group. To a round-bottom 
flask containing N-protected 6-methyl THQ intermediate (1.00 eq) under Ar atmosphere was 
added degassed, Ar-sparged CCl4, followed by N-bromosuccinimide (1.05 eq) and benzoyl 
peroxide (0.1 eq). Reaction was then heated to reflux, monitored by TLC. Quantitative conversion 
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of starting material was generally not observed, so reaction was halted when side-product began 
to form. Reaction was halted by cooling to -20°C, and precipitate was filtered from solution 
(washing with additional cold CCl4). Filtrate was then concentrated onto silica and purified by 
silica chromatography.  
General Procedure (F): Substitution of C-6 Benzylic Bromide with R2 
Suzuki Coupling of Benzylic Bromide to R2-Boronic Acid. To a round-bottom flask under Ar 
atmosphere was added 3:1 acetone/water and stirred under vacuum for 10 minutes. Next, Ar was 
bubbled through solvent for an additional 10 minutes before adding benzylic bromide intermediate 
(1.0 eq), boronic acid (1.2-2.0 eq), K2CO3 (3 eq) and Pd(dppf)Cl2 (0.1 eq). Reaction was heated to 
80°C for 6-12 hours, after which the reaction mixture was cooled and diluted with ethyl acetate 
and aqueous NaHCO3. Organics were separated and dried over MgSO4, then filtered and 
concentrated in vacuo onto silica. Product was purified by silica chromatography. 
Substitution of Benzylic Bromide with Tetrahydroisoquinline (THIQ). To a round-bottom 
flask under inert atmosphere was added DMF, followed by K2CO3 (1.2 eq) and THIQ (1.2 eq), 
then benzylic bromide (1.0 eq) stirring at ambient temperature. After 6-12 hours, solvent was 
removed under reduced pressure and residual oil was resuspended in ethyl acetate and sat. 
NaHCO3. Organics were separated and dried over MgSO4, then filtered and concentrated in vacuo 
onto silica. Product was purified by silica chromatography. 
General Procedure (G): Reductive Amination of THQ Ketone to Sulfinamide Using Ellman’s 
Sulfinamide. To a round bottom flask already containing desiccated THQ intermediate (1.0 eq) 
under Ar atmosphere was added (R)-2-methylpropane-2-sulfinamide (3.0 eq). Meanwhile, a reflux 
condenser was flame-dried under vacuum, and then flooded with Ar. Next, anhydrous THF (5-10 
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mL) was added to the reaction vessel containing starting reagents via syringe. The round bottom 
flask was placed in an ice bath and allowed to equilibrate to 0°C. Next, Ti(OEt)4 (6.0 eq) was 
added slowly via syringe. Once addition was complete, the reaction vessel was taken out of ice 
bath and placed in oil bath at 70°C-75°C, affixed condenser, and stirred for 16-48 h under Ar. The 
reaction was monitored by TLC for loss of ketone. Once sufficient conversion to the tert-
butanesulfinyl imine was observed, reaction vessel was taken out of oil bath and cooled to ambient 
temperature. Meanwhile, an additional round bottom flask was flame-dried under vacuum, then 
flooded with Ar. NaBH4 (6.0 eq) was added quickly, and anhydrous THF was added (5-10 mL). 
The round bottom flask was placed in dry ice/acetone bath and allowed to equilibrate to -78°C. 
Contents from the round bottom flask containing the imine intermediate were transferred to round 
bottom flask containing NaBH4 via cannula. Imine-containing flask was washed twice with 
minimal THF, which was also transferred to reducing flask via cannula under Ar. Once contents 
were completely added, the reaction was taken out of dry ice/acetone bath and was allowed to 
warm to room temperature. The reaction stirred at ambient temperature for 2-3 h. To quench, sat. 
NaCl solution was added. Reaction mixture was diluted with ethyl acetate and DI H2O and 
separated, washing with H2O until both layers were clear, indicating sufficient removal of titanium 
oxide by-product. Organics were then isolated and dried over MgSO4 and filtered through a fritted 
funnel. Organic extract was then concentrated onto silica and purified by silica chromatography. 
General Procedure (H): Conversion of Sulfinamide to Final Compound – Step 1: 
Sulfinamide Cleavage. To a round bottom flask containing sulfinamide (1.0 eq) was added 1,4-
dioxane, followed by conc. HCl (6.0 eq), cleaving the sulfinamide to the primary amine. The 
reaction stirred at RT for up to 3 h. Solvent was removed under reduced, and residue was re-
suspended in Et2O. The resultant white solid precipitate (the HCl salt of the amine) was isolated 
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by decanting and washing with Et2O up to three times. After desiccation, the solid residue was 
used without further purification. Step 2: Amide Coupling. To a pear-shaped flask under inert 
atmosphere containing amine salt (1.0 eq) was added di-Boc-Dmt (1.1 eq), PyBOP (1.1 eq), and, 
when specified, 6-Cl HOBt (1.1 eq), followed by DMF (10 mL) and DIPEA (10 eq) at ambient 
temperature. After stirring for 6 hours, solvent was removed under reduced pressure and residual 
oil was loaded onto silica. Boc-protected intermediate was purified by silica chromatography but 
was generally not characterized by NMR. Step 3: Boc Deprotection. Boc-protected intermediate 
was suspended in DCM (10 mL), then TFA (3-5 mL) was added. After 1 hour, solvent was 
removed under vacuum. Product was resuspended in a solution of 99.9% acetonitrile, 0.1% TFA, 
then diluted with deionized water. Final products were purified by reverse-phase semi-preparative 
HPLC. Final yield not calculated.  
General Procedure (I): Boc-Deprotection Boc-protected intermediate was suspended in DCM 
(10 mL), then TFA (3-5 mL) was added. After 1 hour, solvent was removed in vacuo, resuspended 
in DCM, then dry-loaded onto silica in vacuo and purified by flash chromatography. 
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Common Intermediates: Step A – 6-Methyl beta-Bromide 
 
6-Me beta-bromide. 3-bromo-N-(p-tolyl)propanamide. 6-Me beta-bromide intermediate was 
synthesized following General Procedure (A) from p-toluidine (5.0 g, 46.7 mmol, 1.00 eq), 
K2CO3 (19.4 g, 140.1 mmol, 3.0 eq). and 3-bromopropionyl chloride (4.94 mL, 49.0 mmol, 1.05 
eq). Yield: 10.76 g, 95%. 1H NMR (400 MHz, CDCl3) δ 7.33 – 7.28 (m, 2H), 7.05 (d, J = 8.1 Hz, 
2H), 3.63 (t, J = 6.6 Hz, 2H), 2.84 (t, J = 6.6 Hz, 2H), 2.24 (s, 3H). 13C NMR (126 MHz, CDCl3) 
δ 167.85, 134.78, 134.37, 129.49, 120.21, 40.58, 27.17, 20.86. 
 
Common Intermediates: Step B – 6-Methyl Beta-Lactam 
 
6-Me beta-lactam. 1-(p-tolyl)azetidin-2-one. 6-Me beta-lactam intermediate was synthesized 
following General Procedure (B) from 6-Me beta-bromide (10.76, 44.4 mmol, 1.00 eq) and 
NaOtBu (4.48 g, 46.7 mmol, 1.05 eq). Yield: 7.07 g, 99%. 1H NMR (400 MHz, CDCl3) δ 7.25 (d, 
J = 8.2 Hz, 2H), 7.13 (d, J = 8.1 Hz, 2H), 3.60 (m, 2H), 3.12 – 3.06 (m, 2H), 2.31 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 164.22, 136.12, 133.36, 129.56, 116.03, 37.95, 35.97, 20.87. 
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Common Intermediates: Step C – 6-Methyl THQ 
 
6-Me THQ 6-methyl-2,3-dihydroquinolin-4(1H)-one. 6-Me THQ intermediate was synthesized 
following General Procedure (C) from 6-Me beta-lactam (7.07 g, 43.9 mmol, 1 eq) and TfOH 
(11.6 mL, 131.6 mmol, 3 eq). Yield: 4.23 g, 60%. 1H NMR (400 MHz, CDCl3) δ 7.65 (d, J = 2.1 
Hz, 1H), 7.13 (dd, J = 8.3, 2.1 Hz, 1H), 6.61 (d, J = 8.3 Hz, 1H), 3.58 – 3.52 (m, 2H), 2.68 (dd, J 
= 7.5, 6.4 Hz, 2H), 2.24 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 193.85, 149.95, 136.34, 127.41, 
127.12, 119.34, 115.92, 42.55, 38.22, 20.24. 
 
Common Intermediates: Step D – N-Substituted THQ Cores 
 
6-Me N-Boc THQ tert-butyl 6-methyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate. 
Intermediate 6-Me N-Boc THQ was synthesized following General Procedure (D) from 6-Me 
THQ (2.25 g, 13.96 mmol, 1.0 equiv), Boc2O (6.09 g, 27.92 mmol, 2.0 eq), DMAP (171 mg, 1.40 
mmol, 0.1 eq), and DIPEA (4.88 mL, 27.92 mmol, 2.0 eq). Yield: 3.06 g, 84%. 1H-NMR (400 
MHz, CDCl3) δ 8.00 (d, J = 2.3 Hz, 1H), 7.80 (d, J = 8.7 Hz, 1H), 7.53 (dd, J = 8.7, 2.4 Hz, 1H), 
4.48 (s, 2H), 4.15 (t, J = 6.4 Hz, 2H), 2.77 (t, J = 6.4 Hz, 2H), 1.56 (s, 9H); 13C-NMR (101 MHz, 
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CDCl3) δ 193.66, 152.68, 144.20, 134.70, 133.40, 127.75, 124.87, 124.30, 82.64, 44.36, 38.90, 
32.49, 28.40. 
 
6-Me N-Ac THQ 1-acetyl-6-methyl-2,3-dihydroquinolin-4(1H)-one. Intermediate 6-Me N-Ac 
THQ was synthesized following a modified version of General Procedure (D) from intermediate 
6-Me THQ: To a round-bottom flask containing 6-Me THQ (318 mg, 1.97 mmol, 1.0 eq) under 
inert atmosphere was added acetic anhydride (10 mL, excess), then reaction was heated to 80°C. 
After 5 hours, solvent was removed under reduced pressure and reaction mixture was purified by 
flash chromatography. Yield: 355 mg, 89%. 1H NMR (500 MHz, Chloroform-d) δ 7.81 (s, 1H), 
7.36 (dd, J = 8.1, 2.2 Hz, 1H), 7.30 (br s, 1H), 4.22 (t, J = 6.3 Hz, 2H), 2.78 (t, J = 6.2 Hz, 2H), 
2.37 (s, 3H), 2.32 (s, 3H). 13C NMR (126 MHz, cdcl3) δ 135.07, 127.87, 124.13, 39.70, 23.21, 
20.91. 
 
6-Me N-cPr THQ 1-(cyclopropanecarbonyl)-6-methyl-2,3-dihydroquinolin-4(1H)-one. 
Intermediate 6-Me N-cPr THQ was synthesized following General Procedure (D) from 6-Me 
THQ (950 mg, 5.9 mmol, 1.0 eq), Et3N (1.64 mL, 11.8 mmol, 2.0 eq), and cyclopropanecarbonyl 
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chloride (1.07 mL, 11.8 mmol, 2.0 eq). Yield: 1.24 g, 92%. 1H NMR (500 MHz, Chloroform-d) δ 
7.81 (d, J = 2.2 Hz, 1H), 7.42 (d, J = 8.3 Hz, 1H), 7.34 (dd, J = 8.3, 2.1 Hz, 1H), 4.26 (t, J = 6.3 
Hz, 2H), 2.77 (td, J = 6.3, 1.9 Hz, 2H), 2.37 (d, J = 1.9 Hz, 3H), 2.01 (tt, J = 8.0, 4.5 Hz, 1H), 1.19 
(ddd, J = 4.7, 3.0, 1.8 Hz, 2H), 0.87 (dq, J = 7.1, 3.8 Hz, 2H). 13C NMR (126 MHz, cdcl3) δ 194.71, 
173.10, 141.97, 135.28, 134.90, 127.91, 125.85, 123.91, 43.65, 39.82, 20.85, 13.74, 9.80. 
 
 
6-Me N-Bz THQ 1-benzoyl-6-methyl-2,3-dihydroquinolin-4(1H)-one. Intermediate 6-Me N-Bz 
THQ was synthesized following General Procedure (D) from intermediate 6-Me THQ (1.0 g, 
6.20 mmol, 1.0 eq), Et3N (0.86 mL, 7.44 mmol, 1.2 eq), and benzoyl chloride (1.25 mL, 7.44 
mmol, 1.2 eq). Reaction mixture was purified by silica chromatography. Yield: 1.63 g, 99%. 1H 
NMR (500 MHz, Chloroform-d) δ 7.81 (d, J = 2.2 Hz, 1H), 7.48 (dd, J = 8.1, 1.3 Hz, 2H), 7.44 (t, 
J = 7.7 Hz, 1H), 7.35 (t, J = 7.6 Hz, 2H), 7.06 (dd, J = 8.4, 2.1 Hz, 1H), 6.79 (d, J = 8.4 Hz, 1H), 
4.31 (t, J = 6.3 Hz, 2H), 2.87 (t, J = 6.3 Hz, 2H), 2.31 (s, 3H).  
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Common Intermediates: Step E – Benzyl Bromides 
 
6-MeBr N-Boc THQ tert-butyl 6-(bromomethyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate. 
Intermediate 6-MeBr N-Boc THQ was synthesized following General Procedure (E) from 
intermediate 6-Me N-Boc THQ (588 mg, 2.25 mmol, 1.00 eq), NBS (420 mg, 2.36 mmol, 1.05 
eq) and benzoyl peroxide (55 mg, 0.23 mmol, 0.10 eq). Yield: 596 mg, 78%. 1H- NMR (400 MHz, 
CDCl3) δ 8.49 (d, J = 1.5 Hz, 1H), 8.47 (dd, J = 4.8, 1.6 Hz, 1H), 7.83 (d, J = 1.8 Hz, 1H), 7.72 
(d, J = 8.6 Hz, 1H), 7.46 (dt, J = 7.9, 2.0 Hz, 1H), 7.30 (dd, J = 8.6, 2.3 Hz, 1H), 7.21 (ddd, J = 
7.8, 4.8, 0.9 Hz, 1H), 4.14 (t, J = 6.4 Hz, 2H), 3.96 (s, 2H), 2.75 (t, J = 6.4 Hz, 2H), 1.55 (s, 9H); 
13C-NMR (101 MHz, CDCl3) δ 194.18, 152.79, 150.18, 147.99, 142.84, 136.35, 135.93, 135.56, 
134.55, 127.23, 124.98, 124.21, 123.60, 82.33, 44.37, 39.04, 38.37, 28.39. 
 
6-MeBr N-Ac THQ 1-acetyl-6-(bromomethyl)-2,3-dihydroquinolin-4(1H)-one. Intermediate 6-
Me N-Ac THQ was synthesized following General Procedure (E) from intermediate 6-MeBr 
N-Ac THQ (350 mg, 1.72 mmol, 1.00 eq), NBS (338 mg, 1.89 mmol, 1.10 eq) and benzoyl 
peroxide (42 mg, 0.17 mmol, 0.10 eq). Reaction was heated at reflux for 2 hours. Yield: 200 mg, 
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41%. 1H NMR (500 MHz, Chloroform-d) δ 8.00 (d, J = 2.2 Hz, 1H), 7.57 (dd, J = 8.4, 2.3 Hz, 
1H), 7.48 (s, 1H), 4.47 (s, 2H), 4.20 (t, J = 6.2 Hz, 2H), 2.78 (t, J = 6.3 Hz, 2H), 2.34 (s, 3H). 13C 
NMR (126 MHz, cdcl3) δ 193.38, 169.39, 143.77, 135.23, 134.73, 128.06, 126.01, 124.77, 44.20, 
39.39, 32.02, 23.33. 
 
8 6-(bromomethyl)-1-(cyclopropanecarbonyl)-2,3-dihydroquinolin-4(1H)-one. Intermediate 8 
was synthesized following General Procedure (C) from intermediate 4 (836 mg, 3.65 mmol, 1.00 
eq), NBS (714 mg, 4.01 mmol, 1.10 eq) and benzoyl peroxide (88 mg, 0.37 mmol, 0.10 eq). 
Reaction time: 3 hours. Yield: 460 mg, 41%. 1H NMR (500 MHz, Chloroform-d) δ 8.03 (d, J = 
1.9 Hz, 1H), 7.57 (d, J = 2.7 Hz, 2H), 4.50 (s, 2H), 4.29 (t, J = 6.3 Hz, 2H), 2.81 (t, J = 6.4 Hz, 
2H), 2.05 – 1.97 (m, 1H), 1.23 (dt, J = 6.7, 3.4 Hz, 2H), 0.93 (dq, J = 7.1, 3.8 Hz, 2H). 13C NMR 
(126 MHz, cdcl3) δ 193.82, 173.28, 144.23, 134.95, 134.65, 128.30, 125.88, 124.50, 43.69, 39.65, 
32.13, 14.07, 10.11. 
 
6-MeBr N-Bz THQ 1-benzoyl-6-(bromomethyl)-2,3-dihydroquinolin-4(1H)-one. Intermediate 6-
MeBr N-Bz THQ was synthesized following General Procedure (E) from intermediate 6-Me N-
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Bz THQ (1.20 g, 4.52 mmol, 1.0 eq), N-bromosuccinimide (821 mg, 4.61 mmol, 1.02 eq) and 
benzoyl peroxide (55 mg, 0.23 mmol, 0.05 eq). Reaction was heated for 4 hours at reflux. Yield: 
685 mg, 44%. 1H NMR (500 MHz, Chloroform-d) δ 8.02 (s, 1H), 7.53 – 7.47 (m, 2H), 7.47 (dd, J 
= 7.0, 1.5 Hz, 1H), 7.42 – 7.34 (m, 2H), 7.31 (dt, J = 8.5, 2.0 Hz, 1H), 6.98 (d, J = 8.6 Hz, 1H), 
4.43 (d, J = 3.7 Hz, 2H), 4.31 (t, J = 6.0 Hz, 2H), 2.87 (t, J = 6.3 Hz, 2H).  
 
6-MeBr Thiochromane 6-(bromomethyl)thiochroman-4-one. Intermediate 6-MeBr 
Thiochromane was synthesized following General Procedure (E) from intermediate 6-Me 
Thiochromane (1.00 g, 5.61 mmol, 1.00 eq) and NBS (1.05 g, 5.89 mmol, 1.05 eq). Yield: 559 
mg, 39%. 1H NMR (500 MHz, Chloroform-d) δ 8.11 (d, J = 1.7 Hz, 1H), 7.42 (dd, J = 8.3, 2.1 Hz, 
1H), 7.28 (d, J = 8.2 Hz, 1H), 4.47 (s, 2H), 3.25 (td, J = 6.6, 1.0 Hz, 2H), 2.99 (t, J = 6.5 Hz, 2H). 
13C NMR (126 MHz, cdcl3) δ 193.67, 133.98, 133.89, 130.34, 129.52, 128.64, 128.48, 39.48, 
32.64, 26.69. 
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Compound 41 
 
41-1 tert-butyl 6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-oxo-3,4-dihydroquinoline-
1(2H)-carboxylate. 41-1 was synthesized following General Procedure (F) from intermediate 6-
MeBr N-Boc THQ (300 mg, 0.88 mmol, 1.0 eq), 1,4-benzodioxane-6-boronic acid (238 mg, 1.32 
mmol, 1.5 eq), K2CO3 (365 mg, 2.64 mmol, 3.0 eq) and Pd(dppf)Cl2 (65 mg, 0.09 mmol, 0.1 eq). 
Reaction was heated 12 hours. Yield: 266 mg, 76%. 1H-NMR (500 MHz, CDCl3) δ 7.81 (d, J = 
2.2 Hz, 1H), 7.67 (d, J = 8.6 Hz, 1H), 7.30 (dd, J = 8.6, 2.3 Hz, 1H), 6.76 (d, J = 8.0 Hz, 1H), 6.67 
– 6.62 (m, 2H), 4.21 (s, 4H), 4.13 (t, J = 6.3 Hz, 2H), 3.84 (s, 2H), 2.74 (t, J = 6.3 Hz, 2H), 1.54 
(s, 9H); 13C-NMR (126 MHz, CDCl3) δ 194.34, 152.86, 143.53, 142.45, 142.12, 137.18, 134.68, 
133.86, 127.16, 124.90, 123.93, 121.81, 117.60, 117.34, 82.16, 64.47, 64.39, 44.38, 40.50, 39.10, 
28.40. 
 
41-2 tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-
yl)methyl)-3,4-dihydroquinoline-1(2H)-carboxylate. 41-2 was synthesized following General 
Procedure (G) from 41-1 (78 mg, 0.20 mmol, 1.0 eq), (R)-2-methyl-2-propanesulfinamide (72 
mg, 0.59 mmol, 3.0 eq), and Ti(OEt)4 (0.31 mL, 1.18 mmol, 6.0 eq), then NaBH4 (45 mg, 1.18 
mmol, 6.0 eq). Yield: 60 mg, 61%. 1H-NMR (500 MHz, CDCl3) δ 7.68 (d, J = 8.5 Hz, 1H), 7.15 
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(d, J = 2.1 Hz, 1H), 7.06 (dd, J = 8.6, 2.2 Hz, 1H), 6.76 (d, J = 8.1 Hz, 1H), 6.68 – 6.63 (m, 2H), 
4.52 (q, J = 3.6 Hz, 1H), 4.22 (s, 4H), 3.94 (dt, J = 12.9, 4.5 Hz, 1H), 3.80 (s, 2H), 3.57 (ddd, J = 
12.9, 11.3, 3.9 Hz, 1H), 3.29 (d, J = 1.1 Hz, 1H), 2.20 (dq, J = 14.0, 4.0 Hz, 1H), 2.00 – 1.89 (m, 
1H), 1.51 (s, 9H), 1.20 (s, 9H); 13C-NMR (126 MHz, CDCl3) δ 153.68, 143.48, 142.01, 136.92, 
136.63, 134.36, 128.99, 128.73, 128.69, 124.15, 121.85, 117.62, 117.25, 81.20, 64.47, 64.41, 
55.76, 50.48, 40.54, 40.15, 29.50, 28.46, 22.73. 
 
 
41 (S)-2-amino-N-((R)-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propenamide. 41 was synthesized 
following General Procedure (H) from intermediate 41-2. Step 1: Sulfinamide cleavage was 
carried out with 41-2 (60 mg, 0.12 mmol, 1.0 eq) and excess concentrated HCl (0.06 mL) 
precipitating product as a white solid (35 mg total, 23 mg of which was carried forward) which 
was used without further purification. Step 2: Amide coupling was performed with the aminium 
chloride salt of 41-2 (23 mg, 0.053 mmol, 1.0 eq), di-Boc-Dmt (22 mg, 0.053 mmol, 1.0 eq), 
PyBOP (28 mg, 0.053 mmol, 1.0 eq), and 6-Cl HOBt (9 mg, 0.053 mmol, 1.0 eq), followed by 
DIPEA (0.09 mL, 0.53 mmol, 10 eq). After purification by silica chromatography, product was 
carried forward to Step 3: TFA deprotection, followed by purification by reverse-phase semi-
preparative HPLC, as described in General Procedure (H). Final yield not calculated. 1H-NMR 
(126 MHz, CD3OD) δ 6.96 (d, J = 2.0 Hz, 1H), 6.93 (dd, J = 8.2, 2.0 Hz, 1H), 6.67 (dd, J = 8.1, 
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6.8 Hz, 2H), 6.58 – 6.54 (m, 2H), 6.48 (s, 2H), 4.96 (t, J = 4.6 Hz, 1H), 4.17 (s, 4H), 3.86 (dd, J = 
11.5, 5.1 Hz, 1H), 3.69 (s, 2H), 3.25 (dd, J = 13.6, 11.5 Hz, 1H), 3.07 (dt, J = 12.4, 4.5 Hz, 1H), 
3.02 (dd, J = 13.6, 5.1 Hz, 1H), 2.58 (td, J = 11.7. 2.7 Hz, 1H), 2.27 (s, 6H), 1.83 – 1.74 (m, 1H), 
1.58 – 1.50 (m, 1H). Calculated [M+H]+: 488.3. ESI-MS mass observed: 488.3 (M+H). Analytical 
HPLC retention time: 24.49 min. 
 
Compound 42 
 
42-1 tert-butyl 6-(benzofuran-2-ylmethyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate. 42-1 
was synthesized following General Procedure (F) from intermediate 6-MeBr N-Boc THQ (300 
mg, 0.88 mmol, 1.0 eq), 2-benzofuranylboronic acid MIDA ester (360 mg, 1.32 mmol, 1.5 eq), 
K2CO3 (365 mg, 2.64 mmol, 3.0 eq) and Pd(dppf)Cl2 (65 mg, 0.09 mmol, 0.1 eq). Reaction was 
heated 12 hours. Yield: 245 mg, 74%. 1H-NMR (500 MHz, CDCl3) δ 7.95 (d, J = 2.3 Hz, 1H), 
7.75 (d, J = 8.9 Hz, 1H), 7.50 – 7.42 (m, 2H), 7.39 (d, J = 7.7 Hz, 1H), 7.24 – 7.13 (m, 2H), 6.41 
(s, 1H), 4.14 (t, J = 6.2 Hz, 2H), 4.08 (s, 2H), 2.76 (t, J = 6.2 Hz, 2H), 1.56 (s, 9H); 13C-NMR (126 
MHz, CDCl3) δ 194.06, 156.92, 154.98, 152.72, 142.93, 134.55, 132.95, 128.68, 127.37, 124.89, 
123.99, 123.56, 122.59, 120.49, 110.91, 103.56, 82.20, 44.27, 38.93, 34.19, 28.30. 
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42-2 tert-butyl (R)-6-(benzofuran-2-ylmethyl)-4-(((R)-tert-butylsulfinyl)amino)-3,4-
dihydroquinoline-1(2H)-carboxylate. 42-2 was synthesized following General Procedure (G) 
from 42-1 (88 mg, 0.23 mmol, 1.0 eq), (R)-2-methyl-2-propanesulfinamide (85 mg, 0.70 mmol, 
3.0 eq), and Ti(OEt)4 (0.30 mL, 1.40 mmol, 6.0 eq), then NaBH4 (53 mg, 1.40 mmol, 6.0 eq). 
Yield: 78 mg, 70%. 1H-NMR (500 MHz, CDCl3) δ 7.74 (d, J = 8.5 Hz, 1H), 7.46 (d, J = 7.8 Hz, 
1H), 7.38 (d, J = 8.2 Hz, 1H), 7.30 (s, 1H), 7.22 – 7.12 (m, 3H), 6.41 (s, 1H), 4.55 (q, J = 3.7 Hz, 
1H), 4.04 (s, 2H), 3.95 (dt, J = 13.1, 5.0 Hz, 1H), 3.64 – 3.50 (m, 1H), 3.30 (s, 1H), 2.22 – 2.15 
(m, 1H), 2.02 – 1.92 (m, 1H), 1.51 (s, 9H), 1.19 (s, 9H); 13C-NMR (126 MHz, CDCl3) δ 157.38, 
154.93, 153.53, 137.16, 132.62, 129.10, 128.78, 128.75, 128.61, 124.16, 123.39, 122.49, 120.42, 
110.88, 103.34, 81.22, 55.66, 50.44, 40.12, 34.19, 29.50, 28.33, 22.58. 
 
42 (S)-2-amino-N-((R)-6-(benzofuran-2-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-
2,6-dimethylphenyl)propenamide. 42 was synthesized following General Procedure (H) from 42-
2. Step 1: Sulfinamide cleavage was carried out with 42-2 (78 mg, 0.16 mmol, 1.0 eq) and excess 
concentrated HCl (0.08 mL), precipitating product as a white solid (79 mg crude yield, 40 mg of 
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which was carried forward), which was used without further purification. Step 2: Amide coupling 
was performed with the aminium chloride salt of 42-2 (40 mg, 0.096 mmol, 1.0 eq), di-Boc-Dmt 
(39 mg, 0.096 mmol, 1.0 eq), PyBOP (50 mg, 0.096 mmol, 1.0 eq), and 6-Cl HOBt (16 mg, 0.096 
mmol, 1.0 eq), followed by DIPEA (0.17 mL, 0.96 mmol, 10 eq). After purification by silica 
chromatography, product was carried forward to Step 3: TFA deprotection, followed by 
purification by reverse-phase semi-preparative HPLC, as described in General Procedure (H). 
Final yield not calculated. 1H-NMR (500 MHz, CD3OD) δ 8.13 (d, J = 8.0 Hz, 1H), 7.44 (d, J = 
6.6 Hz, 1H), 7.31 (d, J = 7.9 Hz, 1H), 7.20 – 7.10 (m, 2H), 7.00 (s, 1H), 6.98 (d, J = 2.1 Hz, 1H), 
6.57 (d, J = 8.1 Hz, 1H), 6.48 (s, 2H), 6.34 (s, 1H), 4.97 – 4.93 (m, 1H), 3.98 – 3.87 (m, 2H), 3.85 
(dd, J = 11.5, 5.0 Hz, 1H), 3.25 (dd, J = 13.6, 11.6 Hz, 1H), 3.04 – 2.96 (m, 2H), 2.52 (td, J = 11.7, 
2.5 Hz, 1H), 2.27 (s, 6H), 1.77 – 1.69 (m, 1H), 1.56 – 1.49 (m, 1H). Calculated [M+H]+: 469.2. 
ESI-MS mass observed: 492.2 (M+Na). Analytical HPLC retention time: 30.3 min. 
 
Compound 44 
 
44-1 1-acetyl-6-(quinolin-3-ylmethyl)-2,3-dihydroquinolin-4(1H)-one. Intermediate 44-1 was 
synthesized following General Procedure (F) from intermediate 6-MeBr N-Ac THQ (200 mg, 
0.71 mmol, 1.0 eq), 3-quinoline boronic acid (246 mg, 1.42 mmol, 2.0 eq), K2CO3 (240 mg, 2.13 
mmol, 3.0 eq) and Pd(dppf)Cl2 (52 mg, 0.07 mmol, 0.1 eq). Reaction was heated 18 hours. Yield: 
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122 mg, 52%. 1H NMR (500 MHz, Chloroform-d) δ 8.79 (d, J = 2.2 Hz, 1H), 8.07 (dt, J = 8.5, 1.0 
Hz, 1H), 7.93 – 7.89 (m, 2H), 7.75 (dd, J = 8.1, 1.4 Hz, 1H), 7.68 (ddd, J = 8.4, 6.9, 1.5 Hz, 1H), 
7.53 (ddd, J = 8.1, 6.9, 1.3 Hz, 1H), 7.42 – 7.38 (m, 1H), 4.22 (t, J = 6.2 Hz, 2H), 4.18 (s, 2H), 
2.79 (t, J = 6.2 Hz, 2H), 2.32 (s, 3H). 13C NMR (126 MHz, cdcl3) δ 169.40, 151.87, 147.16, 142.66, 
137.52, 135.10, 134.70, 132.91, 129.35, 129.27, 128.15, 127.88, 127.59, 127.03, 126.26, 124.73, 
39.60, 38.72, 23.27. 
 
44-2 (R)-N-((R)-1-acetyl-6-(quinolin-3-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-
methylpropane-2-sulfinamide. 44-2 was synthesized following General Procedure (G) from 
intermediate 44-1 (112 mg, 0.34 mmol, 1.0 eq), (R)-2-methyl-2-propanesulfinamide (123 mg, 1.01 
mmol, 3.0 eq), and Ti(OEt)4 (0.42 mL, 2.03 mmol, 6.0 eq), then NaBH4 (77 mg, 2.03 mmol, 6.0 
eq). Yield: 47 mg, 32%. 1H NMR (500 MHz, Chloroform-d) δ 8.78 (dd, J = 6.1, 2.1 Hz, 1H), 8.07 
(dd, J = 8.6, 4.6 Hz, 1H), 7.96 – 7.92 (m, 1H), 7.76 (t, J = 7.9 Hz, 1H), 7.72 – 7.65 (m, 1H), 7.53 
(dtd, J = 8.1, 6.5, 5.8, 2.5 Hz, 1H), 7.35 (s, 1H), 7.15 (tq, J = 5.8, 3.8, 2.9 Hz, 1H), 4.52 (q, J = 4.6 
Hz, 1H), 4.14 (s, 2H), 3.88 (q, J = 6.4 Hz, 1H), 3.75 (td, J = 8.9, 4.6 Hz, 1H), 2.22 (s, 3H), 2.18 
(dd, J = 10.9, 6.1 Hz, 1H), 2.15 – 2.04 (m, 1H), 1.17 (d, J = 1.3 Hz, 9H). 13C NMR (126 MHz, 
cdcl3) δ 169.95, 151.88, 135.02, 134.33, 133.31, 129.08, 128.81, 128.61, 128.09, 127.49, 126.82, 
126.43, 125.35, 125.04, 124.71, 55.85, 51.33, 38.72, 30.69, 23.35, 22.55. 
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44 (S)-N-((R)-1-acetyl-6-(quinolin-3-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-amino-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide. 44 was synthesized following General Procedure (H) 
from intermediate 44-2. Step 1: Sulfinamide cleavage was carried out with excess concentrated 
HCl  precipitating product as a white solid which was carried forward without further purification. 
Step 2: Amide coupling was performed with the aminium chloride salt of 44-2 (39 mg, 0.11 mmol, 
1.0 eq), di-Boc-Dmt (48 mg, 0.12 mmol, 1.1 eq), PyBOP (60 mg, 0.12 mmol, 1.1 eq), and 6-Cl 
HOBt (20 mg, 0.12 mmol, 1.1 eq), followed by DIPEA (0.19 mL, 1.06 mmol, 10 eq). After 
purification by silica chromatography, product was carried forward to Step 3: TFA deprotection, 
followed by purification by reverse-phase semi-preparative HPLC, as described in General 
Procedure (H). Final yield not calculated. 1H NMR (500 MHz, Methanol-d4) δ 9.01 (s, 1H), 8.72 
(s, 1H), 8.21 (d, J = 8.3 Hz, 1H), 8.19 (d, J = 8.3 Hz, 1H), 8.15 (t, J = 9.1 Hz, 2H), 8.05 (ddd, J = 
8.3, 6.9, 1.3 Hz, 1H), 8.02 (ddd, J = 8.5, 7.0, 1.4 Hz, 1H), 7.89 (t, J = 7.6 Hz, 1H), 7.87 – 7.83 (m, 
1H), 6.51 (s, 2H), 4.95 (d, J = 6.1 Hz, 1H), 4.29 (s, 2H), 3.91 (dt, J = 11.3, 5.3 Hz, 2H), 3.30 – 
3.27 (m, 1H), 3.27 – 3.22 (m, 1H), 3.03 (ddd, J = 25.6, 13.8, 4.7 Hz, 2H), 2.27 (s, 6H), 2.20 (s, 
3H), 1.87 (ddt, J = 13.5, 8.1, 5.3 Hz, 1H), 1.47 (m, 1H). Calculated [M+H]+: 523.3. ESI-MS mass 
observed: 523.3 (M+H) and 545.3 (M+Na). Analytical HPLC retention time: 20.9 min. 
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Compound 46 
 
46-1 6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydroquinolin-4(1H)-one. 46-1 was 
synthesized following Genera Procedure (I) from intermediate 41-1 (266 mg, 0.67 mmol, 1.0 
eq). Clean product 46-1 crystallized and was not purified by chromatograpy. Yield: 199 mg, 100%. 
1H NMR (500 MHz, Chloroform-d) δ 7.68 (d, J = 2.1 Hz, 1H), 7.11 (dd, J = 8.4, 2.2 Hz, 1H), 6.75 
(d, J = 8.1 Hz, 1H), 6.65 – 6.61 (m, 2H), 6.59 (d, J = 8.4 Hz, 1H), 4.21 (s, 4H), 3.74 (s, 2H), 3.54 
(t, J = 7.4, 6.7 Hz, 2H), 2.68 (t, J = 7.7, 6.9 Hz, 2H). 13C NMR (126 MHz, cdcl3) δ 193.96, 150.72, 
143.47, 141.97, 136.19, 134.75, 131.12, 127.30, 121.75, 119.36, 117.52, 117.28, 116.34, 64.51, 
64.43, 42.56, 40.32, 38.31. 
 
46-2 1-acetyl-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydroquinolin-4(1H)-one. 
Intermediate 46-2 was synthesized following General Procedure (D) from intermediate 46-1 (97 
mg, 0.33 mmol, 1.0 eq). After removal of solvent, clean product crystallized and thus was not 
purified by chromatography. Yield: 107 mg, 98%. 1H NMR (500 MHz, Chloroform-d) δ 7.83 (s, 
1H), 7.35 (dt, J = 6.0, 2.3, 2.1 Hz, 1H), 7.29 (br s, 1H), 6.78 (d, J = 7.9 Hz, 1H), 6.65 (d, J = 7.9 
Hz, 2H), 4.23 (s, 4H), 4.22 (t, J = 5.9 Hz, 2H), 3.87 (s, 2H), 2.77 (t, J = 6.2 Hz, 2H), 2.32 (s, 3H). 
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13C NMR (126 MHz, cdcl3) δ 169.49, 143.63, 142.29, 134.73, 133.47, 127.71, 124.37, 121.89, 
117.66, 117.50, 64.52, 64.44, 40.62, 39.67, 23.22. 
 
46-3 (R)-N-((R)-1-acetyl-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-2-methylpropane-2-sulfinamide. Intermediate 46-3 was synthesized 
following General Procedure (G) from 46-2 (102 mg, 0.30 mmol, 1.0 eq), (R)-2-methyl-2-
propanesulfinamide (110 mg, 0.91 mmol, 3.0 eq), and Ti(OEt)4 (0.38 mL, 1.82 mmol, 6.0 eq), then 
NaBH4 (69 mg, 1.82 mmol, 6.0 eq). Yield: 103 mg, 77%. 1H NMR (500 MHz, Chloroform-d) δ 
7.22 (d, J = 1.9 Hz, 1H), 7.09 (dd, J = 8.2, 2.0 Hz, 1H), 6.77 (d, J = 7.9 Hz, 1H), 6.66 (d, J = 8.4 
Hz, 2H), 4.52 (q, J = 4.1 Hz, 1H), 4.22 (d, J = 0.8 Hz, 4H), 3.87 (dt, J = 11.8, 5.4 Hz, 1H), 3.83 (s, 
2H), 3.76 (ddd, J = 13.1, 9.4, 5.3 Hz, 1H), 3.30 (d, J = 3.2 Hz, 1H), 2.24 (dt, J = 13.9, 4.9 Hz, 1H), 
2.21 (s, 3H), 2.07 – 1.96 (m, 1H), 1.19 (d, J = 0.8 Hz, 9H). 13C NMR (126 MHz, cdcl3) δ 170.05, 
143.55, 142.15, 133.93, 128.71, 128.66, 124.93, 121.92, 117.66, 117.38, 110.12, 77.16, 64.50, 
60.51, 55.87, 40.68, 30.46, 22.70, 22.24. 
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46 (S)-N-((R)-1-acetyl-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propenamide. 46 was 
synthesized following General Procedure (H) from intermediate 46-3. Step 1: Sulfinamide 
cleavage was carried out with 46-3 (103 mg, 0.23 mmol, 1.0 eq) and excess concentrated HCl 
(0.10 mL), precipitating product as a white solid, which was used without further purification. 
Step 2: Amide coupling was performed with the aminium chloride salt of 46-3 (87 mg, 0.23 mmol, 
1.0 eq), di-Boc-Dmt (104 mg, 0.26 mmol, 1.1 eq), and PyBOP (132 mg, 0.26 mmol, 1.1 eq), 
followed by DIPEA (0.41 mL, 2.32 mmol, 10 eq). After purification by silica chromatography, 
product was carried forward to Step 3: TFA deprotection, followed by purification by reverse-
phase semi-preparative HPLC, as described in General Procedure (H). Final yield not calculated. 
1H NMR (500 MHz, Methanol-d4) δ 7.37 (s, 1H), 7.12 – 7.09 (m, 1H), 7.04 (d, J = 8.3 Hz, 1H), 
6.69 (d, J = 8.1 Hz, 1H), 6.63 – 6.56 (m, 2H), 6.50 (s, 2H), 4.94 (d, J = 6.1 Hz, 1H), 4.16 (d, J = 
0.8 Hz, 4H), 3.87 (dt, J = 11.6, 3.2 Hz, 1H), 3.78 (s, 2H), 3.25 (dd, J = 13.7, 11.5 Hz, 1H), 3.03 
(dd, J = 13.7, 5.1 Hz, 1H), 2.27 (s, 6H), 2.18 (s, 3H), 1.89 – 1.81 (m, 1H), 1.45 (s, 1H). 13C NMR 
(126 MHz, cd3od) δ 172.54, 157.45, 144.85, 143.43, 140.07, 135.44, 129.28, 125.76, 123.25, 
122.55, 118.34, 118.05, 116.48, 111.42, 65.63, 65.53, 53.50, 49.00, 47.07, 41.38, 31.97, 20.43. 
Calculated [M+H]+: 530.3. ESI-MS mass observed: 530.3 (M+H) and 552.3 (M+Na). Analytical 
HPLC retention time: 31.1 min. 
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Compound 47 
 
47-1 6-(benzofuran-2-ylmethyl)-2,3-dihydroquinolin-4(1H)-one. Intermediate 47-1 was 
synthesized follow General Procedure (I) from 42-1 (245 mg, 0.65 mmol, 1.0 eq) and 1:1 
DCM/TFA (10 mL, excess), yielding clean product 47-1 without further purification. Yield: 180 
mg, 100%. 1H NMR (500 MHz, Chloroform-d) δ 7.80 (d, J = 2.1 Hz, 1H), 7.46 (dd, J = 7.3, 1.7 
Hz, 1H), 7.39 (d, J = 8.2 Hz, 1H), 7.25 (dd, J = 6.4, 2.0 Hz, 1H), 7.20 (td, J = 7.6, 1.6 Hz, 1H), 
7.16 (td, J = 7.3, 1.3 Hz, 1H), 6.64 (d, J = 8.4 Hz, 1H), 6.36 (t, J = 0.9 Hz, 1H), 3.99 (s, 2H), 3.56 
(td, J = 7.1, 6.2, 1.4 Hz, 3H), 2.69 (t, J = 6.9 Hz, 2H). 13C NMR (126 MHz, cdcl3) δ 193.78, 157.97, 
155.08, 151.10, 136.05, 128.92, 127.71, 123.50, 122.62, 120.53, 116.41, 111.02, 103.32, 42.47, 
38.22, 34.14, 28.41. 
 
47-2 1-acetyl-6-(benzofuran-2-ylmethyl)-2,3-dihydroquinolin-4(1H)-one. Intermediate 47-2 was 
synthesized following General Procedure (G) from intermediate 47-1 (100 mg, 0.36 mmol, 1.0 
eq) and neat Ac2O (5 mL, excess) yielding clean product 47-1. Yield: 112 mg, 97%. 1H NMR (500 
MHz, Chloroform-d) δ 7.96 (d, J = 2.1 Hz, 1H), 7.49 (td, J = 7.6, 6.8, 1.9 Hz, 2H), 7.40 (d, J = 8.0 
Hz, 1H), 7.22 (td, J = 7.7, 1.6 Hz, 1H), 7.18 (tt, J = 7.4, 0.9 Hz, 1H), 6.44 (t, J = 0.9 Hz, 1H), 4.23 
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(t, J = 6.3 Hz, 2H), 4.12 (s, 2H), 2.79 (t, J = 6.2 Hz, 2H), 2.33 (s, 3H). 13C NMR (126 MHz, cdcl3) 
δ 194.01, 169.46, 156.51, 155.14, 142.81, 134.73, 128.72, 127.98, 124.56, 123.85, 122.82, 120.70, 
111.09, 103.88, 39.63, 34.43, 23.27. 13C NMR (126 MHz, cdcl3) δ 170.08, 157.03, 155.09, 128.79, 
125.08, 123.68, 122.73, 120.63, 111.05, 103.68, 60.53, 55.93, 51.06, 34.47, 30.64, 22.70, 22.24. 
 
47-3 (R)-N-((R)-1-acetyl-6-(benzofuran-2-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-
methylpropane-2-sulfinamide. 47-3 was synthesized following General Procedure (G) from 47-
2 (110 mg, 0.34 mmol, 1.0 eq), (R)-2-methyl-2-propanesulfinamide (125 mg, 1.03 mmol, 3.0 eq), 
and Ti(OEt)4 (0.43 mL, 2.07 mmol, 6.0 eq), then NaBH4 (78 mg, 2.07 mmol, 6.0 eq). Yield: 90 
mg, 62%. 1H NMR (500 MHz, Chloroform-d) δ 7.48 (dd, J = 7.3, 1.7 Hz, 1H), 7.39 (dd, J = 8.3, 
1.1 Hz, 1H), 7.38 – 7.37 (m, 1H), 7.23 (dd, J = 8.2, 2.3 Hz, 1H), 7.20 (dd, J = 7.8, 1.8 Hz, 1H), 
7.17 (td, J = 7.4, 1.3 Hz, 1H), 6.45 (s, 1H), 4.55 (q, J = 4.3 Hz, 1H), 4.08 (s, 2H), 3.90 (dt, J = 
11.7, 5.4 Hz, 1H), 3.76 (ddd, J = 12.9, 9.4, 5.3 Hz, 1H), 3.34 (d, J = 3.4 Hz, 1H), 2.23 (s, 3H), 2.28 
– 2.18 (m, 1H), 2.11 – 2.00 (m, 2H), 1.19 (s, 9H). 
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47 (S)-N-((R)-1-acetyl-6-(benzofuran-2-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-amino-3-(4-
hydroxy-2,6-dimethylphenyl)propenamide. 47 was synthesized following General Procedure (H) 
from intermediate 47-3. Step 1: Sulfinamide cleavage was carried out with 47-3 (90 mg, 0.21 
mmol, 1.0 eq) and excess concentrated HCl (0.10 mL) precipitating product as a white solid, which 
was used without further purification. Step 2: Amide coupling was performed with the aminium 
chloride salt of 47-3 (76 mg, 0.21 mmol, 1.0 eq), di-Boc-Dmt (94 mg, 0.23 mmol, 1.1 eq), and 
PyBOP (122 mg, 0.23 mmol, 1.1 eq), followed by DIPEA (0.37 mL, 2.13 mmol, 10 eq). After 
purification by silica chromatography, product was carried forward to Step 3: TFA deprotection, 
followed by purification by reverse-phase semi-preparative HPLC, as described in General 
Procedure (H). Final yield not calculated. 1H NMR (500 MHz, Methanol-d4) δ 7.46 – 7.43 (m, 
1H), 7.32 (dq, J = 8.4, 0.9 Hz, 1H), 7.23 (s, 1H), 7.20 (dd, J = 8.1, 1.8 Hz, 1H), 7.17 (dd, J = 7.9, 
1.6 Hz, 1H), 7.14 (td, J = 7.4, 1.2 Hz, 1H), 6.51 (s, 2H), 6.42 (d, J = 1.0 Hz, 1H), 4.96 (t, J = 6.1 
Hz, 1H), 4.07 – 4.05 (m, 2H), 3.87 (dd, J = 11.5, 5.0 Hz, 1H), 3.78 (s, 1H), 3.25 (dd, J = 13.7, 11.6 
Hz, 1H), 3.21 – 3.12 (m, 2H), 3.04 (dd, J = 13.7, 5.1 Hz, 1H), 2.27 (s, 6H), 2.19 (s, 3H), 1.86 (ddt, 
J = 13.5, 8.0, 5.3 Hz, 1H), 1.46 (s, 1H). 13C NMR (126 MHz, cd3od) δ 172.56, 158.85, 157.42, 
156.35, 140.07, 130.10, 129.34, 125.90, 124.61, 123.67, 123.29, 121.49, 116.46, 111.52, 104.22, 
53.50, 49.00, 46.99, 34.99, 31.93, 23.38, 20.42. Calculated [M+H]+: 512.2. ESI-MS mass 
observed: 512.2 (M+H) and 534.2 (M+Na). Analytical HPLC retention time: 35.3 min. 
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Compound 48 
 
48-1 tert-butyl 6-(naphthalen-2-ylmethyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate. 
Intermediate 48-1 was synthesized following General Procedure (F) from intermediate 6-MeBr 
N-Boc THQ (500 mg, 1.47 mmol, 1.0 eq), naphthalene-2-boronic acid (505 mg, 2.94 mmol, 2.0 
eq), K2CO3 (609 mg, 0.82 mmol, 3.0 eq) and Pd(dppf)Cl2 (100 mg, 0.15 mmol, 0.1 eq). Reaction 
was heated 18 hours. Yield: 471 mg, 83%. 1H NMR (500 MHz, Chloroform-d) δ 7.90 (d, J = 2.2 
Hz, 1H), 7.81 – 7.73 (m, 3H), 7.69 (d, J = 8.7 Hz, 1H), 7.63 (s, 1H), 7.49 – 7.40 (m, 2H), 7.35 (dt, 
J = 8.6, 1.8 Hz, 1H), 7.30 (dt, J = 8.4, 1.5 Hz, 1H), 4.16 – 4.10 (m, 4H), 2.75 (t, J = 6.4 Hz, 2H), 
1.54 (s, 9H). 13C NMR (126 MHz, cdcl3) δ 194.26, 152.75, 142.47, 137.89, 136.72, 134.71, 133.58, 
132.13, 128.24, 127.61, 127.54, 127.35, 127.31, 127.25, 127.08, 126.78, 126.05, 125.46, 124.82, 
123.87, 82.12, 77.25, 77.20, 77.00, 76.75, 44.28, 41.33, 38.99, 28.29. 
 
48-2 6-(naphthalen-2-ylmethyl)-2,3-dihydroquinolin-4(1H)-one. Intermediate 48-2 was 
synthesized following General Procedure (I) from intermediate 48-1 (220 mg, 0.57 mmol, 1.0 
eq) and 1:1 DCM/TFA (10 mL, excess). Yield: 135 mg, 83%. 1H NMR (500 MHz, Chloroform-
d) δ 7.80 – 7.72 (m, 4H), 7.61 (d, J = 1.8 Hz, 1H), 7.47 – 7.39 (m, 2H), 7.30 (dd, J = 8.4, 1.8 Hz, 
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1H), 7.15 (dd, J = 8.4, 2.2 Hz, 1H), 6.59 (d, J = 8.4 Hz, 1H), 4.31 (s, 1H), 4.02 (s, 2H), 3.59 – 3.51 
(m, 2H), 2.72 – 2.66 (m, 2H). 13C NMR (126 MHz, cdcl3) δ 193.66, 138.64, 136.34, 136.11, 
133.56, 132.05, 128.11, 127.58, 127.51, 127.40, 127.36, 127.20, 126.87, 125.95, 125.31, 77.00, 
42.41, 41.14, 38.08. 
 
48-3 1-(cyclopropanecarbonyl)-6-(naphthalen-2-ylmethyl)-2,3-dihydroquinolin-4(1H)-one. 
Intermediate 48-3 was synthesized following General Procedure (D) from intermediate 48-2 (100 
mg, 0.35 mmol, 1.0 eq), Et3N (0.10 mL, 0.70 mmol, 2.0 eq), and cyclopropanecarbonyl chloride 
(0.06 mL, 0.70 mmol, 2.0 eq). Yield: 65 mg, 52%. 1H NMR (500 MHz, Chloroform-d) δ 7.95 (d, 
J = 2.2 Hz, 1H), 7.83 – 7.76 (m, 3H), 7.65 (s, 1H), 7.49 – 7.42 (m, 3H), 7.38 (dd, J = 8.3, 2.2 Hz, 
1H), 7.31 (dd, J = 8.4, 1.8 Hz, 1H), 4.28 (t, J = 6.3 Hz, 2H), 4.15 (s, 2H), 3.48 (s, 1H), 2.78 (t, J = 
6.3 Hz, 2H), 2.00 (tt, J = 7.9, 4.6 Hz, 1H), 1.21 – 1.16 (m, 2H), 0.87 (dq, J = 7.2, 3.8 Hz, 2H). 13C 
NMR (126 MHz, cdcl3) δ 194.56, 173.16, 142.61, 138.55, 137.69, 134.67, 133.71, 132.30, 128.53, 
127.90, 127.78, 127.66, 127.42, 127.31, 126.31, 125.97, 125.73, 124.22, 43.63, 41.56, 39.80, 
21.09, 13.85, 9.88, 7.57. 
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48-4 (R)-N-((R)-1-(cyclopropanecarbonyl)-6-(naphthalen-2-ylmethyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-2-methylpropane-2-sulfinamide. 48-4 was synthesized following 
General Procedure (G) from intermediate 48-3 (65 mg, 0.18 mmol, 1.0 eq), (R)-2-methyl-2-
propanesulfinamide (66 mg, 0.55 mmol, 3.0 eq), and Ti(OEt)4 (0.23 mL, 1.10 mmol, 6.0 eq), then 
NaBH4 (42 mg, 1.10 mmol, 6.0 eq). Yield: 41 mg, 49%. 1H NMR (500 MHz, Chloroform-d) δ 
7.79 (td, J = 8.2, 7.6, 5.7 Hz, 3H), 7.68 – 7.64 (m, 1H), 7.49 – 7.40 (m, 2H), 7.39 – 7.31 (m, 3H), 
7.13 (dd, J = 8.3, 2.0 Hz, 1H), 4.56 (q, J = 4.3 Hz, 1H), 4.12 (s, 2H), 3.97 (ddd, J = 12.8, 6.2, 4.9 
Hz, 1H), 3.75 (ddd, J = 12.9, 9.3, 5.6 Hz, 1H), 3.32 (d, J = 3.6 Hz, 1H), 2.23 (dq, J = 14.8, 5.1 Hz, 
1H), 2.10 – 1.99 (m, 1H), 1.92 (tt, J = 7.9, 4.7 Hz, 1H), 1.65 (s, 2H), 1.18 (s, 9H), 1.16 – 1.04 (m, 
2H), 0.80 – 0.73 (m, 2H). 13C NMR (126 MHz, cdcl3) δ 173.47, 138.51, 138.22, 136.97, 133.74, 
132.27, 128.78, 128.63, 128.40, 127.76, 127.69, 127.63, 127.28, 126.23, 125.62, 125.01, 55.94, 
51.31, 41.74, 39.93, 30.80, 22.70, 13.70, 9.36. 
 
48 (R)-N-((R)-1-(cyclopropanecarbonyl)-6-(naphthalen-2-ylmethyl)-1,2,3,4-tetrahydroquinolin-
4-yl)-2-methylpropane-2-sulfinamide. Final compound 48 was synthesized following General 
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Procedure (H) from intermediate 48-4. Step 1: Sulfinamide cleavage was carried out with 48-4 
(41 mg, 0.09 mmol, 1.0 eq) and excess concentrated HCl (0.06 mL) precipitating product as a 
white solid, which was used without further purification. Step 2: Amide coupling was performed 
with the aminium chloride salt of 48-4 (35 mg, 0.09 mmol, 1.0 eq), di-Boc-Dmt (40 mg, 0.10 
mmol, 1.1 eq), PyBOP (51 mg, 0.10 mmol, 1.1 eq), and 6-Cl HOBt (17 mg, 0.10 mmol, 1.1 eq), 
followed by DIPEA (0.16 mL, 0.89 mmol, 10 eq). After purification by silica chromatography, 
product was carried forward to Step 3: TFA deprotection, followed by purification by reverse-
phase semi-preparative HPLC, as described in General Procedure (H). Final yield not calculated. 
1H NMR (500 MHz, Methanol-d4) δ 7.81 – 7.76 (m, 1H), 7.74 (d, J = 8.1 Hz, 2H), 7.61 (s, 1H), 
7.46 – 7.38 (m, 3H), 7.29 (dd, J = 8.4, 1.7 Hz, 1H), 7.24 (d, J = 2.0 Hz, 1H), 7.14 (dd, J = 8.2, 2.1 
Hz, 1H), 6.51 (s, 2H), 4.97 (t, J = 6.3 Hz, 1H), 4.10 (s, 2H), 3.94 – 3.83 (m, 2H), 3.30 – 3.21 (m, 
2H), 3.04 (dd, J = 13.7, 5.1 Hz, 1H), 2.27 (s, 6H), 1.96 (td, J = 8.2, 4.2 Hz, 1H), 1.86 (dq, J = 13.0, 
6.0 Hz, 1H), 1.43 (dq, J = 12.9, 6.4 Hz, 1H), 1.37 (dd, J = 6.7, 4.1 Hz, 2H), 1.09 – 0.91 (m, 1H), 
0.91 – 0.78 (m, 2H). Calculated [M+H]+: 548.3. ESI-MS mass observed: 548.3 (M+H) and 570.3 
(M+Na). Analytical HPLC retention time: 42.9 min. 
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Compound 49 
 
49-1 1-(cyclopropanecarbonyl)-6-(quinolin-3-ylmethyl)-2,3-dihydroquinolin-4(1H)-one. 
Intermediate 49-1 was synthesized following General Procedure (F) from 6-MeBr N-cPr THQ 
(85 mg, 0.28 mmol, 1.0 eq), 3-quinoline boronic acid (72 mg, 0.41 mmol, 1.5 eq), K2CO3 (113 
mg, 0.82 mmol, 3.0 eq) and Pd(dppf)Cl2 (22 mg, 0.03 mmol, 0.1 eq). Yield: 53 mg, 54%. 1H NMR 
(500 MHz, Chloroform-d) δ 8.79 (d, J = 2.1 Hz, 1H), 8.08 (d, J = 8.5 Hz, 1H), 7.93 (dd, J = 6.4, 
2.0 Hz, 2H), 7.76 (dd, J = 8.2, 1.4 Hz, 1H), 7.68 (ddd, J = 8.3, 6.9, 1.4 Hz, 1H), 7.56 – 7.53 (m, 
1H), 7.53 – 7.48 (m, 1H), 7.38 (dd, J = 8.4, 2.2 Hz, 1H), 7.26 (s, 0H), 4.28 (t, J = 6.3 Hz, 2H), 4.19 
(s, 2H), 2.79 (t, J = 6.3 Hz, 2H), 2.00 (tt, J = 8.1, 4.7 Hz, 1H), 1.69 (s, 1H), 1.19 (dt, J = 6.5, 3.5 
Hz, 2H), 0.88 (dq, J = 7.1, 3.9 Hz, 2H). 13C NMR (126 MHz, cdcl3) δ 194.39, 173.17, 151.89, 
142.98, 137.18, 135.11, 134.53, 132.99, 129.37, 129.28, 127.99, 127.59, 127.05, 126.09, 124.48, 
112.06, 96.17, 43.67, 39.79, 38.75, 13.90, 9.94. 
 
49-2 (R)-N-((R)-1-(cyclopropanecarbonyl)-6-(quinolin-3-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-
yl)-2-methylpropane-2-sulfinamide. Intermediate 49-2 was synthesized following General 
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Procedure (G) from intermediate 49-1 (53 mg, 0.15 mmol, 1.0 eq), (R)-2-methyl-2-
propanesulfinamide (54 mg, 0.45 mmol, 3.0 eq), and Ti(OEt)4 (0.19 mL, 0.90 mmol, 6.0 eq), then 
NaBH4 (34 mg, 0.90 mmol, 6.0 eq). Yield: 32 mg, 46%. 1H NMR (500 MHz, Chloroform-d) δ 
8.09 (d, J = 8.4 Hz, 1H), 8.01 (s, 1H), 7.87 (dd, J = 8.3, 6.5 Hz, 1H), 7.79 (d, J = 8.2 Hz, 1H), 7.73 
– 7.66 (m, 1H), 7.58 – 7.51 (m, 1H), 7.44 – 7.37 (m, 2H), 7.12 (dt, J = 8.4, 2.6 Hz, 1H), 4.54 (q, J 
= 4.6 Hz, 1H), 4.15 (s, 2H), 3.98 (dt, J = 12.1, 5.7 Hz, 1H), 3.75 (ddd, J = 13.5, 8.9, 5.8 Hz, 1H), 
2.21 (dq, J = 15.5, 5.3 Hz, 1H), 2.08 (dq, J = 13.9, 5.5, 4.1 Hz, 1H), 1.90 (tq, J = 8.3, 4.4 Hz, 1H), 
1.18 (s, 9H), 1.13 – 1.07 (m, 2H), 0.78 (dd, J = 7.9, 3.0 Hz, 2H). 13C NMR (126 MHz, cdcl3) δ 
173.50, 140.00, 136.94, 133.60, 131.75, 129.42, 128.87, 128.82, 128.63, 128.55, 128.46, 128.01, 
127.67, 127.13, 125.21, 56.00, 51.62, 40.08, 38.87, 31.01, 22.71, 22.69, 13.72, 9.35. 
 
49 (S)-2-amino-N-((R)-1-(cyclopropanecarbonyl)-6-(quinolin-3-ylmethyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propenamide. Final compound 49 was 
synthesized following General Procedure (H) from intermediate 49=2. Step 1: Sulfinamide 
cleavage was carried out with 49-2 (32 mg, 0.07 mmol, 1.0 eq) and excess concentrated HCl (0.06 
mL) precipitating product as a white solid, which was used without further purification. Step 2: 
Amide coupling was performed with the aminium chloride salt of 49-2 (28 mg, 0.07 mmol, 1.0 
eq), di-Boc-Dmt (40 mg, 0.10 mmol, 1.3 eq), PyBOP (47 mg, 0.09 mmol, 1.3 eq), and 6-Cl HOBt 
(16 mg, 0.09 mmol, 1.3 eq), followed by DIPEA (0.14 mL, 0.81 mmol, 12 eq). Yield not 
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calculated. After purification by silica chromatography, product was carried forward to Step 3: 
TFA deprotection, followed by purification by reverse-phase semi-preparative HPLC, as described 
in General Procedure (H). Final yield not calculated. 1H NMR (500 MHz, Methanol-d4) δ 9.02 
(d, J = 1.8 Hz, 1H), 8.73 (d, J = 5.8 Hz, 1H), 8.19 – 8.13 (m, 2H), 8.02 (tq, J = 8.4, 7.1, 1.4 Hz, 
1H), 7.89 – 7.83 (m, 1H), 7.48 (d, J = 8.3 Hz, 1H), 7.32 (d, J = 2.0 Hz, 1H), 7.20 (dd, J = 8.4, 2.1 
Hz, 1H), 6.51 (s, 2H), 4.97 (q, J = 6.2 Hz, 1H), 4.30 (s, 2H), 3.96 – 3.87 (m, 2H), 3.30 – 3.22 (m, 
2H), 3.07 (dd, J = 13.7, 5.0 Hz, 1H), 2.28 (s, 6H), 1.96 (ddd, J = 7.8, 6.2, 3.9 Hz, 1H), 1.86 (ddt, 
J = 13.1, 7.3, 5.5 Hz, 1H), 1.44 (tt, J = 13.1, 6.2 Hz, 1H), 1.09 – 1.01 (m, 1H), 0.98 – 0.92 (m, 1H), 
0.92 – 0.79 (m, 2H). 13C NMR (500 MHz, CD3OD) δ 175.52, 157.43, 140.55, 140.05, 138.42, 
137.14, 134.40, 130.61, 130.26, 129.77, 129.41, 126.25, 123.31, 121.22, 118.90, 116.45, 53.57, 
47.11, 42.38, 38.73, 31.93, 31.32, 20.42, 14.43, 9.90, 9.48. Calculated [M+H]+: 549.3. ESI-MS 
mass observed: 549.3 (M+H) and 571.3 (M+Na). Analytical HPLC retention time: 24.6 min. 
 
Compound 50 
 
50-1 1-(cyclopropanecarbonyl)-6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-2,3-
dihydroquinolin-4(1H)-one. Intermediate 50-1 was synthesized following General Procedure (F) 
from intermediate 6-MeBr N-cPr THQ (140 mg, 0.45 mmol, 1.0 eq), K2CO3 (76 mg, 0.55 mmol, 
1.2 eq) and THIQ (0.07 mL, 0.55 mmol, 1.2 eq). Yield: 145 mg, 88%. 1H NMR (500 MHz, 
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Chloroform-d) δ 7.99 (d, J = 2.1 Hz, 1H), 7.64 (dd, J = 8.4, 2.1 Hz, 1H), 7.52 (d, J = 8.4 Hz, 1H), 
7.14 – 7.07 (m, 3H), 6.99 – 6.95 (m, 1H), 4.30 (t, J = 6.3 Hz, 2H), 3.69 (s, 2H), 3.63 (s, 2H), 2.91 
(t, J = 5.9 Hz, 2H), 2.78 (dt, J = 16.0, 6.1 Hz, 4H), 2.07 – 2.00 (m, 1H), 1.24 – 1.19 (m, 2H), 0.90 
(dq, J = 7.1, 3.8 Hz, 2H). 13C NMR (126 MHz, cdcl3) δ 194.52, 173.18, 143.40, 135.96, 134.78, 
134.65, 134.31, 128.82, 128.12, 126.64, 126.32, 125.75, 125.69, 124.11, 61.92, 56.07, 50.88, 
43.67, 39.80, 29.24, 13.90, 9.92. 
 
50-2 (R)-N-((R)-1-(cyclopropanecarbonyl)-6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-2-methylpropane-2-sulfinamide. 50-2 was synthesized following 
General Procedure (G) from 50-1 (120 mg, 0.33 mmol, 1.0 eq), (R)-2-methyl-2-
propanesulfinamide (121 mg, 1.00 mmol, 3.0 eq), and Ti(OEt)4 (0.42 mL, 2.00 mmol, 6.0 eq), then 
NaBH4 (76 mg, 2.00 mmol, 6.0 eq). Yield: 91 mg, 59%. Characterized by NMR after sulfinamide 
cleavage in next step (see Final Compound 50 Step 1). 
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50 (S)-2-amino-N-((R)-1-(cyclopropanecarbonyl)-6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-
1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propanamide. Final 
compound 50 was synthesized following General Procedure (H) from intermediate 50-2. Step 
1: Sulfinamide cleavage was carried out with 50-2 (91 mg, 0..20 mmol, 1.0 eq) and excess 
concentrated HCl, precipitating product as a white solid, which was used without further 
purification. 1H NMR (500 MHz, Methanol-d4) δ 7.87 (s, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.69 (td, 
J = 8.1, 2.4 Hz, 1H), 7.32 – 7.27 (m, 1H), 7.28 – 7.23 (m, 2H), 7.21 (t, J = 7.5 Hz, 1H), 4.72 (q, J 
= 6.6 Hz, 1H), 4.59 (s, 2H), 4.47 (s, 2H), 4.07 (ddd, J = 12.9, 7.6, 5.1 Hz, 1H), 3.99 (ddd, J = 13.1, 
7.1, 5.1 Hz, 1H), 3.52 – 3.46 (m, 4H), 2.46 (tq, J = 12.8, 7.2 Hz, 1H), 2.22 – 2.14 (m, 1H), 2.09 
(dtd, J = 26.0, 7.8, 4.0 Hz, 1H), 1.09 (dq, J = 8.4, 4.7, 4.1 Hz, 2H), 0.95 (qd, J = 8.0, 7.3, 3.2 Hz, 
2H). 13C NMR (126 MHz, cd3od) δ 175.70, 141.71, 133.22, 132.59, 132.21, 130.39, 129.84, 
129.41, 128.84, 128.18, 127.88, 127.02, 126.82, 60.07, 53.91, 53.64, 50.80, 48.20, 41.82, 29.55, 
14.80, 10.07. Step 2: Amide coupling was performed with the aminium chloride salt of 50-2 (76 
mg, 0.17 mmol, 1.0 eq), di-Boc-Dmt (78 mg, 0.19 mmol, 1.1 eq), PyBOP (99 mg, 0.19 mmol, 1.1 
eq), and 6-Cl HOBt (32 mg, 0.19 mmol, 1.1 eq), followed by DIPEA (0.30 mL, 1.74 mmol, 10 
eq). Yield not calculated. After purification by silica chromatography, product was carried forward 
to Step 3: TFA deprotection, followed by purification by reverse-phase semi-preparative HPLC, 
as described in General Procedure (H). Final yield not calculated. 1H NMR (500 MHz, Methanol-
d4) δ 7.70 (d, J = 8.4 Hz, 1H), 7.47 – 7.40 (m, 2H), 7.34 – 7.29 (m, 1H), 7.29 – 7.24 (m, 2H), 7.16 
(d, J = 7.6 Hz, 1H), 6.53 (s, 2H), 5.01 (t, J = 5.8 Hz, 1H), 4.46 – 4.39 (m, 2H), 4.39 – 4.32 (m, 
4H), 3.94 (dt, J = 12.6, 5.9 Hz, 1H), 3.88 (dd, J = 11.6, 5.0 Hz, 1H), 3.30 – 3.25 (m, 1H), 3.17 (s, 
1H), 3.07 (dd, J = 13.7, 5.1 Hz, 1H), 2.29 (s, 6H), 2.00 (td, J = 8.0, 3.9 Hz, 1H), 1.92 – 1.85 (m, 
1H), 1.52 (d, J = 7.4 Hz, 1H), 1.28 (d, J = 10.3 Hz, 1H), 1.05 (m, 2H), 0.97 – 0.85 (m, 2H). 
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Calculated [M+H]+: 553.3. ESI-MS mass observed: 553.3 (M+H) and 575.3 (M+Na). Analytical 
HPLC retention time: 24.6 min. 
 
Compound 51 
 
51-1 1-(cyclopropanecarbonyl)-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-
dihydroquinolin-4(1H)-one. Intermediate 51-1 was synthesized following General Procedure (F) 
from 6-MeBr N-cPr THQ (100 mg, 0.32 mmol, 1.0 eq), 1,4-benzodioxane-6-boronic acid (88 
mg, 0.49 mmol, 1.5 eq), K2CO3 (133 mg, 0.96 mmol, 3.0 eq) and Pd(dppf)Cl2 (24 mg, 0.03 mmol, 
0.1 eq). Reaction was heated 18 hours. Yield: 109 mg, 92%. 1H NMR (500 MHz, Chloroform-d) 
δ 7.85 (d, J = 2.2 Hz, 1H), 7.44 (d, J = 8.3 Hz, 1H), 7.34 (dd, J = 8.4, 2.2 Hz, 1H), 6.81 – 6.77 (m, 
1H), 6.66 (d, J = 7.5 Hz, 2H), 4.27 (t, J = 6.3 Hz, 2H), 4.23 (s, 4H), 3.87 (s, 2H), 2.77 (t, J = 6.3 
Hz, 2H), 2.02 (tt, J = 7.8, 5.2 Hz, 1H), 1.22 – 1.17 (m, 2H), 0.88 (dq, J = 7.1, 3.8 Hz, 2H). 13C 
NMR (126 MHz, cdcl3) δ 194.61, 173.16, 143.64, 142.53, 142.30, 138.87, 134.56, 133.55, 127.81, 
125.98, 124.17, 121.91, 117.66, 117.51, 64.54, 64.44, 43.62, 40.63, 39.84, 13.85, 9.90. 
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51-2 (R)-N-((R)-1-(cyclopropanecarbonyl)-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-
1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-sulfinamide. Intermediate 51-2 was 
synthesized following General Procedure (G) from 51-1 (104 mg, 0.29 mmol, 1.0 eq), (R)-2-
methyl-2-propanesulfinamide (104 mg, 0.87 mmol, 3.0 eq), and Ti(OEt)4 (0.36 mL, 1.72 mmol, 
6.0 eq), then NaBH4 (65 mg, 1.72 mmol, 6.0 eq). Yield: 123 mg, 92%. 1H NMR (500 MHz, 
Chloroform-d) δ 7.34 (d, J = 8.2 Hz, 1H), 7.25 (d, J = 1.9 Hz, 1H), 7.08 (dd, J = 8.1, 2.0 Hz, 1H), 
6.78 (dt, J = 7.7, 1.1 Hz, 1H), 6.68 (d, J = 1.4 Hz, 1H), 4.54 (q, J = 4.2 Hz, 1H), 4.22 (d, J = 1.5 
Hz, 4H), 3.99 – 3.91 (m, 1H), 3.83 (s, 2H), 3.74 (ddd, J = 14.9, 10.0, 6.3 Hz, 1H), 3.32 (d, J = 3.3 
Hz, 1H), 2.24 (dq, J = 14.7, 5.1 Hz, 1H), 1.97 – 1.89 (m, 1H), 1.84 (d, J = 13.6 Hz, 1H), 1.19 (d, 
J = 1.3 Hz, 9H), 1.12 – 1.08 (m, 2H), 0.80 – 0.74 (m, 2H). 13C NMR (500 MHz, cdcl3) δ 173.43, 
143.54, 142.14, 138.74, 136.85, 133.99, 128.61, 128.52, 124.96, 121.92, 117.65, 117.38, 64.50, 
64.41, 55.90, 51.18, 40.71, 39.83, 30.60, 22.70, 13.66, 9.31. 
 
51 (S)-2-amino-N-((R)-1-(cyclopropanecarbonyl)-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-
yl)methyl)-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propanamide. Final 
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compound 51 was synthesized following General Procedure (H) from intermediate 51-2. Step 
1: Sulfinamide cleavage was carried out with 51-2 (123 mg, 0..26 mmol, 1.0 eq) and excess 
concentrated HCl, precipitating product as a white solid, which was used without further 
purification. Step 2: Amide coupling was performed with the aminium chloride salt of 51-2 105 
mg, 0.26 mmol, 1.0 eq), di-Boc-Dmt (118 mg, 0.29 mmol, 1.1 eq), and PyBOP (151 mg, 0.29 
mmol, 1.1 eq), followed by DIPEA (0.46 mL, 2.62 mmol, 10 eq). After purification by silica 
chromatography (Yield: 121 mg, 61%), uncharacterized product was carried forward to Step 3: 
TFA deprotection, followed by purification by reverse-phase semi-preparative HPLC, as described 
in General Procedure (H). Final yield not calculated. 1H NMR (500 MHz, Methanol-d4) δ 8.18 
(d, J = 8.2 Hz, 0H), 7.36 (d, J = 8.3 Hz, 1H), 7.15 (d, J = 2.0 Hz, 1H), 7.03 (dd, J = 8.2, 2.0 Hz, 
1H), 6.68 (d, J = 8.0 Hz, 1H), 6.60 (dd, J = 10.0, 1.6 Hz, 2H), 6.50 (s, 2H), 4.94 (t, J = 6.3 Hz, 
1H), 4.15 (s, 4H), 3.89 (dt, J = 12.9, 5.3 Hz, 2H), 3.78 (s, 2H), 3.29 – 3.21 (m, 2H), 3.06 (dd, J = 
13.7, 5.1 Hz, 1H), 2.27 (s, 6H), 1.95 (tt, J = 8.1, 4.6 Hz, 1H), 1.84 (dq, J = 13.1, 5.8 Hz, 1H), 1.40 
(dq, J = 12.9, 6.8 Hz, 1H), 1.06 – 1.00 (m, 1H), 0.94 (tt, J = 9.0, 4.1 Hz, 1H), 0.87 (qd, J = 7.6, 
6.4, 4.0 Hz, 1H), 0.81 (qd, J = 9.0, 8.1, 2.8 Hz, 1H). 13C NMR (500 MHz, cd3od) δ 175.46, 157.41, 
144.83, 143.41, 140.05, 137.45, 135.46, 129.25, 129.16, 125.66, 123.27, 122.56, 118.33, 118.04, 
116.45, 65.61, 65.51, 53.52, 47.03, 42.23, 41.40, 31.98, 31.51, 20.44, 14.44. Calculated [M+H]+: 
556.3. ESI-MS mass observed: 556.3 (M+H) and 578.3 (M+Na). Analytical HPLC retention time: 
35.8 min. 
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Compound 52 
 
52-1 6-(benzofuran-2-ylmethyl)-1-(cyclopropanecarbonyl)-2,3-dihydroquinolin-4(1H)-one. 
Intermediate 52-1 was synthesized following General Procedure (F) from 6-MeBr N-cPr THQ 
(110 mg, 0.36 mmol, 1.0 eq), 2-benzofuranylboronic acid MIDA ester (146 mg, 0.54 mmol, 1.5 
eq), K2CO3 (149 mg, 1.08 mmol, 3.0 eq) and Pd(dppf)Cl2 (27 mg, 0.04 mmol, 0.1 eq). Reaction 
was heated 18 hours. Yield: 99 mg, 80%. 1H NMR (500 MHz, Chloroform-d) δ 7.98 (d, J = 2.0 
Hz, 1H), 7.53 – 7.45 (m, 3H), 7.40 (d, J = 8.0 Hz, 1H), 7.24 – 7.16 (m, 2H), 6.45 (s, 1H), 4.28 (t, 
J = 6.3 Hz, 2H), 4.13 (s, 2H), 2.79 (t, J = 6.3 Hz, 2H), 2.02 (dd, J = 8.0, 4.2 Hz, 1H), 1.23 – 1.18 
(m, 2H), 0.89 (dq, J = 7.2, 3.9 Hz, 2H). 13C NMR (126 MHz, cdcl3) δ 194.34, 173.17, 156.57, 
155.13, 143.09, 134.72, 134.52, 128.72, 128.06, 126.03, 124.29, 123.83, 122.81, 120.69, 111.07, 
103.85, 43.64, 39.78, 34.40, 13.89, 9.94. 
 
52-2 (R)-N-((R)-6-(benzofuran-2-ylmethyl)-1-(cyclopropanecarbonyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-2-methylpropane-2-sulfinamide. Intermediate 52-2 was synthesized 
following General Procedure (G) from 52-1 (85 mg, 0.25 mmol, 1.0 eq), (R)-2-methyl-2-
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propanesulfinamide (90 mg, 0.74 mmol, 3.0 eq), and Ti(OEt)4 (0.31 mL, 1.48 mmol, 6.0 eq), then 
NaBH4 (56 mg, 1.48 mmol, 6.0 eq). Yield: 90 mg, 81%. 1H NMR (500 MHz, Chloroform-d) δ 
7.49 (dd, J = 7.3, 1.8 Hz, 1H), 7.43 – 7.39 (m, 3H), 7.23 (dd, J = 8.7, 1.9 Hz, 2H), 7.21 – 7.16 (m, 
1H), 6.47 (d, J = 1.1 Hz, 1H), 4.58 (q, J = 4.3 Hz, 1H), 4.10 (s, 2H), 3.99 (ddd, J = 12.8, 6.2, 4.9 
Hz, 1H), 3.76 (ddd, J = 12.9, 9.3, 5.6 Hz, 1H), 3.34 (d, J = 3.6 Hz, 1H), 2.25 (dq, J = 14.7, 5.1 Hz, 
1H), 1.94 (tt, J = 7.9, 4.6 Hz, 1H), 1.68 (d, J = 11.3 Hz, 1H), 1.20 (s, 9H), 1.17 – 1.08 (m, 1H), 
0.79 (dq, J = 7.9, 1.8 Hz, 2H). 13C NMR (126 MHz, cdcl3) δ 173.51, 157.10, 155.10, 137.51, 
134.63, 128.84, 128.80, 128.61, 125.10, 123.69, 122.75, 120.65, 111.06, 103.67, 55.96, 51.30, 
39.95, 34.50, 30.79, 22.71, 13.73, 9.41, 9.37. 
 
52 (S)-2-amino-N-((R)-6-(benzofuran-2-ylmethyl)-1-(cyclopropanecarbonyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propenamide. Final compound 52 was 
synthesized following General Procedure (H) from intermediate 52-2. Step 1: Sulfinamide 
cleavage was carried out with 52-2 (90 mg, 0.20 mmol, 1.0 eq) and excess concentrated HCl (0.09 
mL) precipitating product as a white solid, which was used without further purification. Step 2: 
Amide coupling was performed with the aminium chloride salt of 52-2 (75 mg, 0.20 mmol, 1.0 
eq), di-Boc-Dmt (90 mg, 0.22 mmol, 1.1 eq), and PyBOP (114 mg, 0.22 mmol, 1.1 eq), followed 
by DIPEA (0.34 mL, 1.96 mmol, 10 eq). After purification by silica chromatography, product was 
carried forward to Step 3: TFA deprotection, followed by purification by reverse-phase semi-
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preparative HPLC, as described in General Procedure (H). Final yield not calculated. 1H NMR 
(500 MHz, Methanol-d4) δ 8.21 (d, J = 8.2 Hz, 1H), 7.47 – 7.41 (m, 2H), 7.32 (dq, J = 8.3, 0.9 Hz, 
1H), 7.27 (d, J = 2.0 Hz, 1H), 7.21 (dd, J = 8.3, 2.1 Hz, 1H), 7.17 (td, J = 7.7, 1.6 Hz, 1H), 7.14 
(td, J = 7.4, 1.3 Hz, 1H), 6.50 (s, 2H), 6.43 (d, J = 1.0 Hz, 1H), 4.97 (t, J = 6.2 Hz, 1H), 4.07 (s, 
2H), 3.93 – 3.86 (m, 2H), 3.29 – 3.22 (m, 2H), 3.05 (dd, J = 13.7, 5.0 Hz, 1H), 2.27 (s, 6H), 1.96 
(tt, J = 7.9, 4.7 Hz, 1H), 1.86 (ddt, J = 13.1, 7.4, 5.4 Hz, 1H), 1.42 (tt, J = 13.0, 6.1 Hz, 1H), 1.28 
(s, 1H), 1.05 (dddd, J = 9.7, 6.6, 4.6, 3.1 Hz, 1H), 0.95 (dddd, J = 9.5, 6.8, 4.7, 3.2 Hz, 1H), 0.91 
– 0.85 (m, 1H), 0.82 (qd, J = 9.2, 8.3, 3.0 Hz, 1H). 13C NMR (500 MHz, cd3od) δ 175.51, 169.39, 
158.87, 157.43, 156.35, 140.05, 138.12, 136.00, 130.11, 129.52, 129.26, 125.82, 124.61, 123.67, 
123.26, 121.50, 116.45, 111.52, 104.24, 53.55, 47.10, 42.29, 35.02, 31.97, 31.47, 20.43, 14.47, 
9.91, 9.50. Calculated [M+H]+: 538.3. ESI-MS mass observed: 538.3 (M+H) and 560.3 (M+Na). 
Analytical HPLC retention time: 40.1 min. 
 
Compound 53 
 
53-1 6-benzyl-1-(methylsulfonyl)-2,3-dihydroquinolin-4(1H)-one. Intermediate 53-1 was 
synthesized from intermediate 8-4, the synthesis of which can be found in Chapter 2. Intermediate 
53-1 was synthesized following General Procedure (D) with intermediate 8-4 (200 mg, 0.84 
mmol, 1.0 eq), Et3N (0.23 mL, 1.68 mmol, 2.0 eq), and methanesulfonyl chloride (0.13 mL, 1.68 
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mmol, 2.0 eq). Yield: 178 mg, 67%. 1H NMR (400 MHz, Chloroform-d) δ 7.91 (d, J = 2.3 Hz, 
1H), 7.64 (d, J = 8.5 Hz, 1H), 7.38 (dd, J = 8.5, 2.3 Hz, 1H), 7.30 (tt, J = 6.9, 1.0 Hz, 2H), 7.26 (s, 
1H), 7.26 – 7.18 (m, 1H), 7.18 (d, J = 8.0 Hz, 1H), 4.17 (t, J = 6.5 Hz, 2H), 3.98 (s, 2H), 3.04 (s, 
3H), 2.84 (dd, J = 7.0, 5.9 Hz, 2H). 13C NMR (101 MHz, cdcl3) δ 192.71, 148.67, 140.72, 140.11, 
138.45, 135.74, 133.96, 128.95, 128.81, 128.36, 126.60, 124.99, 122.19, 46.12, 41.23, 40.10, 
38.16. 
 
53-2  (R)-N-((R)-6-benzyl-1-(methylsulfonyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-
2-sulfinamide. Intermediate 53-2 was synthesized following General Procedure (G) from 53-1 
(104 mg, 0.33 mmol, 1.0 eq), (R)-2-methyl-2-propanesulfinamide (120 mg, 0.99 mmol, 3.0 eq), 
and Ti(OEt)4 (0.42 mL, 1.98 mmol, 6.0 eq), then NaBH4 (75 mg, 1.98 mmol, 6.0 eq). Yield: 61 
mg, 43%. 1H NMR (400 MHz, Chloroform-d) δ 7.70 (d, J = 8.8 Hz, 1H), 7.31 – 7.25 (m, 3H), 7.23 
– 7.16 (m, 3H), 7.12 (dd, J = 8.6, 2.2 Hz, 1H), 4.57 (q, J = 3.5 Hz, 1H), 4.09 (dt, J = 13.3, 3.7 Hz, 
1H), 3.93 (s, 2H), 3.67 (ddd, J = 13.6, 11.4, 2.9 Hz, 1H), 2.93 (d, J = 0.8 Hz, 3H), 2.18 (dq, J = 
14.3, 3.9 Hz, 1H), 2.09 – 1.98 (m, 1H), 1.20 (d, J = 0.8 Hz, 9H). 13C NMR (101 MHz, cdcl3) δ 
140.65, 138.03, 135.31, 130.73, 129.84, 128.95, 128.72, 127.67, 126.42, 121.72, 55.84, 49.91, 
41.76, 41.21, 38.88, 28.77, 22.71. 
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53 (S)-2-amino-N-((R)-6-benzyl-1-(methylsulfonyl)-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide. Final compound 53 was synthesized following 
General Procedure (H) from intermediate 53-2. Step 1: Sulfinamide cleavage was carried out 
with 53-2 (61 mg, 0.15 mmol, 1.0 eq) and excess concentrated HCl (0.08 mL) precipitating product 
as a white solid, which was used without further purification. Step 2: Amide coupling was 
performed with the aminium chloride salt of 53-2 (45 mg, 0.13 mmol, 1.0 eq), di-Boc-Dmt (58 
mg, 0.14 mmol, 1.1 eq), PyBOP (73 mg, 0.14 mmol, 1.1 eq), and 6-Cl HOBt (24 mg, 0.14 mmol, 
1.1 eq), followed by DIPEA (0.23 mL, 1.30 mmol, 10 eq). After purification by silica 
chromatography, product was carried forward to Step 3: TFA deprotection, followed by 
purification by reverse-phase semi-preparative HPLC, as described in General Procedure (H). 
Final yield not calculated. 1H NMR (500 MHz, Methanol-d4) δ 7.60 (d, J = 8.6 Hz, 1H), 7.27 – 
7.21 (m, 2H), 7.18 – 7.11 (m, 4H), 7.06 (dd, J = 8.6, 2.2 Hz, 1H), 6.50 (s, 2H), 4.98 (t, J = 4.9 Hz, 
1H), 3.88 (s, 2H), 3.86 – 3.76 (m, 2H), 3.25 (dd, J = 13.6, 11.6 Hz, 1H), 3.02 (dd, J = 13.7, 5.2 Hz, 
1H), 2.93 (ddd, J = 13.5, 10.6, 2.7 Hz, 1H), 2.86 (s, 3H), 2.27 (s, 6H), 1.89 (dddd, J = 14.0, 10.6, 
5.2, 3.5 Hz, 1H), 1.56 – 1.48 (m, 1H). 13C NMR (500 MHz, cd3od) δ 140.02, 138.89, 138.40, 
136.72, 130.27, 129.76, 129.50, 127.98, 127.20, 122.91, 116.48, 46.65, 43.64, 41.91, 38.82, 31.88, 
29.21, 20.45. Calculated [M+H]+: 508.3. ESI-MS mass observed: 508.3 (M+H) and 530.3 
(M+Na). Analytical HPLC retention time: 34.8 min. 
N
HN
O
NH2 OH
N
HN
53-2
S
O
S
H
53
S OO OO
 195 
Compound 54 
 
54-1 1-(methylsulfonyl)-6-(naphthalen-2-ylmethyl)-2,3-dihydroquinolin-4(1H)-one. Intermediate 
54-1 was synthesized following General Procedure (D) from intermediate 48-2 (120 mg, 0.42 
mmol, 1.0 eq), Et3N (0.12 mL, 0.84 mmol, 2.0 eq), and methanesulfonyl chloride (0.06 mL, 0.84 
mmol, 2.0 eq). Yield: 100 mg, 66%. 1H NMR (500 MHz, Chloroform-d) δ 7.96 (d, J = 2.2 Hz, 
1H), 7.78 (ddd, J = 13.2, 8.0, 2.5 Hz, 3H), 7.67 – 7.62 (m, 2H), 7.49 – 7.40 (m, 3H), 7.29 (dd, J = 
8.5, 1.7 Hz, 1H), 4.16 (t, J = 5.8 Hz, 2H), 4.13 (s, 2H), 3.02 (d, J = 1.1 Hz, 3H), 2.83 (t, J = 6.5 
Hz, 2H). 13C NMR (126 MHz, cdcl3) δ 192.66, 140.80, 138.28, 137.59, 135.80, 133.69, 132.28, 
128.52, 128.39, 127.76, 127.66, 127.36, 127.27, 126.31, 125.73, 125.01, 122.21, 46.09, 41.40, 
40.05, 38.14. 
 
54-2  (R)-2-methyl-N-((R)-1-(methylsulfonyl)-6-(naphthalen-2-ylmethyl)-1,2,3,4-
tetrahydroquinolin-4-yl)propane-2-sulfinamide. Intermediate 54-2 was synthesized following 
General Procedure (G) from 54-1 (100 mg, 0.27 mmol, 1.0 eq), (R)-2-methyl-2-
propanesulfinamide (100 mg, 0.82 mmol, 3.0 eq), and Ti(OEt)4 (0.35 mL, 1.64 mmol, 6.0 eq), then 
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NaBH4 (62 mg, 1.64 mmol, 6.0 eq). Yield: 74 mg, 57%. 1H NMR (500 MHz, Chloroform-d) δ 
7.81 – 7.74 (m, 3H), 7.70 (d, J = 8.6 Hz, 1H), 7.65 – 7.63 (m, 1H), 7.47 – 7.40 (m, 2H), 7.33 (d, J 
= 2.2 Hz, 1H), 7.31 (dd, J = 8.4, 1.8 Hz, 1H), 7.16 (dd, J = 8.6, 2.2 Hz, 1H), 4.57 (q, J = 3.7 Hz, 
1H), 4.08 (s, 2H), 4.06 (td, J = 4.0, 2.0 Hz, 1H), 3.68 (ddd, J = 13.2, 11.3, 2.9 Hz, 1H), 3.25 (d, J 
= 2.4 Hz, 1H), 2.92 (s, 3H), 2.18 (dddd, J = 14.3, 4.9, 3.8, 2.9 Hz, 1H), 2.08 – 1.99 (m, 1H), 1.18 
(s, 9H). 13C NMR (126 MHz, cdcl3) δ 138.16, 137.89, 135.39, 133.71, 132.24, 130.81, 129.87, 
128.36, 127.78, 127.73, 127.66, 127.49, 127.17, 126.20, 125.60, 121.75, 55.83, 50.04, 41.84, 
41.41, 38.86, 28.88, 22.68. 
 
54 (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-1-(methylsulfonyl)-6-(naphthalen-2-
ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)propenamide. Final compound 54 was synthesized 
following General Procedure (H) from 54-2. Step 1: Sulfinamide cleavage was carried out with 
54-2 (74 mg, 0.16 mmol, 1.0 eq) and excess concentrated HCl (0.09 mL) precipitating product as 
a white solid, which was used without further purification. Step 2: Amide coupling was performed 
with the aminium chloride salt of 54-2 (60 mg, 0.15 mmol, 1.0 eq), di-Boc-Dmt (67 mg, 0.16 
mmol, 1.1 eq), PyBOP (85 mg, 0.16 mmol, 1.1 eq), and 6-Cl HOBt (28 mg, 0.16 mmol, 1.1 eq), 
followed by DIPEA (0.26 mL, 1.49 mmol, 10 eq). Yield: 102 mg, 90%. Carried forward without 
characterization. Step 3: TFA deprotection, followed by purification by reverse-phase semi-
preparative HPLC, as described in General Procedure (H). Final yield not calculated. 1H NMR 
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(500 MHz, Methanol-d4) δ 7.78 (d, J = 7.8 Hz, 1H), 7.74 (d, J = 8.1 Hz, 2H), 7.65 – 7.59 (m, 2H), 
7.46 – 7.38 (m, 2H), 7.28 (dd, J = 8.6, 1.6 Hz, 1H), 7.18 (d, J = 2.0 Hz, 1H), 7.16 – 7.13 (m, 1H), 
6.50 (s, 2H), 4.99 (t, J = 5.0 Hz, 1H), 4.06 (s, 2H), 3.80 (td, J = 10.6, 9.7, 4.4 Hz, 2H), 3.24 (dd, J 
= 13.6, 11.6 Hz, 1H), 3.01 (dd, J = 13.7, 5.3 Hz, 1H), 2.95 (ddd, J = 13.0, 10.5, 2.3 Hz, 1H), 2.87 
(d, J = 1.0 Hz, 3H), 2.26 (s, 6H), 1.94 – 1.85 (m, 1H), 1.58 – 1.49 (m, 1H). Calculated [M+H]+: 
558.3. ESI-MS mass observed: 558.3 (M+H) and 580.3 (M+Na). Analytical HPLC retention time: 
41.4 min. 
 
Compound 55 
 
55-1 tert-butyl 4-oxo-6-(quinolin-3-ylmethyl)-3,4-dihydroquinoline-1(2H)-carboxylate. 
Intermediate 55-1 was synthesized following General Procedure (F) from intermediate 6-MeBr 
N-Boc THQ (250 mg, 0.73 mmol, 1.0 eq), 3-quinoline boronic acid (190 mg, 1.10 mmol, 1.5 eq), 
K2CO3 (302 mg, 2.19 mmol, 3.0 eq) and Pd(dppf)Cl2 (51 mg, 0.07 mmol, 0.1 eq). Reaction was 
heated 24 hours. Yield: 248 mg, 87%. 1H NMR (500 MHz, Chloroform-d) δ 8.80 (d, J = 2.2 Hz, 
1H), 8.09 – 8.05 (m, 1H), 7.90 – 7.88 (m, 2H), 7.76 – 7.71 (m, 2H), 7.67 (ddd, J = 8.4, 6.9, 1.5 Hz, 
1H), 7.52 (ddd, J = 8.0, 6.8, 1.2 Hz, 1H), 7.35 (dd, J = 8.6, 2.3 Hz, 1H), 4.16 (s, 2H), 4.15 (t, J = 
6.6, 6.0 Hz, 2H), 2.76 (dd, J = 6.8, 5.8 Hz, 2H), 1.54 (s, 9H). 13C NMR (126 MHz, cdcl3) δ 192.68, 
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152.86, 152.01, 142.96, 135.01, 134.69, 129.38, 129.14, 127.62, 127.48, 126.94, 125.11, 124.29, 
82.42, 44.43, 39.10, 38.66, 28.44. 
 
55-2 6-(quinolin-3-ylmethyl)-2,3-dihydroquinolin-4(1H)-one. Intermediate 55-2 was synthesized 
following General Procedure (I) from intermediate 55-1 (248 mg, 0.64 mmol, 1.0 eq) and 1:3 
TFA/DCM (12 mL, excess). Yield: 184 mg, 100%. 1H NMR (500 MHz, Chloroform-d) δ 8.79 (d, 
J = 2.2 Hz, 1H), 8.08 (dd, J = 8.5, 1.1 Hz, 1H), 7.96 (d, J = 2.2 Hz, 1H), 7.90 (dd, J = 2.3, 1.0 Hz, 
1H), 7.80 (s, 1H), 7.75 (dd, J = 8.2, 1.3 Hz, 1H), 7.70 – 7.65 (m, 1H), 7.54 (ddd, J = 8.1, 6.9, 1.2 
Hz, 1H), 7.49 (dd, J = 8.5, 2.3 Hz, 1H), 4.24 – 4.20 (m, 4H), 2.89 (t, J = 6.2 Hz, 2H).13C NMR 
(126 MHz, cdcl3) δ 192.05, 151.81, 147.24, 135.14, 134.99, 132.64, 129.41, 129.33, 128.15, 
127.99, 127.61, 127.08, 126.77, 45.70, 39.40, 38.80. 
 
55-3 1-(methylsulfonyl)-6-(quinolin-3-ylmethyl)-2,3-dihydroquinolin-4(1H)-one. Intermediate 55-
2 was synthesized following General Procedure (D) from intermediate 55-2 (184 mg, 0.64 mmol, 
1.0 eq), Et3N (0.27 mL, 1.92 mmol, 3.0 eq), and methanesulfonyl chloride (0.10 mL, 1.28 mmol, 
2.0 eq). Yield: 151 mg, 65%. 1H NMR (500 MHz, Chloroform-d) δ 8.76 (t, J = 1.8 Hz, 1H), 8.05 
(d, J = 8.4 Hz, 1H), 7.92 (d, J = 2.2 Hz, 1H), 7.88 (d, J = 2.1 Hz, 1H), 7.75 – 7.72 (m, 1H), 7.68 – 
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7.63 (m, 2H), 7.50 (ddt, J = 7.8, 6.6, 1.5 Hz, 1H), 7.40 (dt, J = 8.6, 2.0 Hz, 1H), 4.14 (t, J = 6.5 
Hz, 2H), 4.14 (s, 2H), 3.03 (d, J = 1.6 Hz, 3H), 2.82 (t, J = 6.4 Hz, 2H). 13C NMR (126 MHz, 
cdcl3) δ 192.43, 151.77, 147.07, 141.09, 136.82, 135.57, 134.97, 132.85, 129.25, 129.19, 128.37, 
128.06, 127.53, 126.96, 125.04, 122.30, 46.01, 40.04, 38.48, 38.06. 
 
55-4 (R)-2-methyl-N-((R)-1-(methylsulfonyl)-6-(quinolin-3-ylmethyl)-1,2,3,4-tetrahydroquinolin-
4-yl)propane-2-sulfinamide. Intermediate 55-4 was synthesized following General Procedure 
(G) from intermediate 55-3 (70 mg, 0.19 mmol, 1.0 eq), (R)-2-methyl-2-propanesulfinamide (70 
mg, 0.57 mmol, 3.0 eq), and Ti(OEt)4 (0.24 mL, 1.15 mmol, 6.0 eq), then NaBH4 (44 mg, 1.15 
mmol, 6.0 eq). Yield: 47 mg, 52%. Intermediate 55-4 not characterized by NMR until after 
sulfinamide cleavage (see Final Compound 55 Step 1). 
 
55 (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-1-(methylsulfonyl)-6-(quinolin-3-
ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)propenamide. Final compound 55 was synthesized 
following General Procedure (H) from intermediate 55-4. Step 1: Sulfinamide cleavage was 
carried out with 55-4 (47 mg, 0.10 mmol, 1.0 eq) and excess concentrated HCl (0.06 mL) 
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precipitating product as a white solid, which was used without further purification. 1H NMR (500 
MHz, Methanol-d4) δ 9.25 (d, J = 2.0 Hz, 1H), 9.14 – 9.11 (m, 1H), 8.35 – 8.32 (m, 1H), 8.26 (d, 
J = 8.7 Hz, 1H), 8.15 (ddd, J = 8.5, 7.0, 1.3 Hz, 1H), 7.97 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H), 7.79 (d, 
J = 8.7 Hz, 1H), 7.66 – 7.62 (m, 1H), 7.43 (dd, J = 8.7, 2.2 Hz, 1H), 4.65 (t, J = 5.7 Hz, 1H), 4.44 
(s, 2H), 4.03 (ddd, J = 13.9, 6.9, 3.6 Hz, 1H), 3.86 – 3.78 (m, 1H), 3.09 (s, 2H), 2.46 – 2.33 (m, 
1H), 2.23 – 2.15 (m, 1H). Step 2: Amide coupling was performed with the aminium chloride salt 
of 55-4 (40 mg, 0.10 mmol, 1.0 eq), di-Boc-Dmt (49 mg, 0.12 mmol, 1.2 eq), and PyBOP (63 mg, 
0.12 mmol, 1.2 eq), followed by DIPEA (0.18 mL, 1.00 mmol, 10 eq). Yield: 102 mg, 90%. Carried 
forward without characterization. Step 3: TFA deprotection, followed by purification by reverse-
phase semi-preparative HPLC, as described in General Procedure (H). Final yield not calculated. 
1H NMR (500 MHz, Methanol-d4) δ 8.85 (d, J = 3.9 Hz, 1H), 8.45 (s, 1H), 8.07 (d, J = 8.7 Hz, 
1H), 8.02 (d, J = 9.1 Hz, 1H), 7.90 (d, J = 8.6 Hz, 1H), 7.74 (t, J = 7.5 Hz, 1H), 7.66 (d, J = 8.7 
Hz, 1H), 7.24 (d, J = 2.2 Hz, 1H), 7.18 (dd, J = 8.7, 2.2 Hz, 1H), 6.50 (s, 2H), 5.01 (t, J = 5.1 Hz, 
1H), 4.20 (s, 2H), 3.87 – 3.76 (m, 2H), 3.25 (dd, J = 13.6, 11.6 Hz, 1H), 3.06 – 2.94 (m, 2H), 2.90 
(s, 3H), 2.26 (s, 6H), 1.89 (ddt, J = 14.2, 9.4, 4.3 Hz, 1H), 1.53 (dt, J = 13.8, 7.0 Hz, 1H). Calculated 
[M+H]+: 559.3. ESI-MS mass observed: 559.3 (M+H) and 581.3 (M+Na). Analytical HPLC 
retention time: 23.6 min. 
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Compound 56 
 
56-1 tert-butyl 6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-4-oxo-3,4-dihydroquinoline-1(2H)-
carboxylate. 56-1 was synthesized following General Procedure (F) from intermediate 6-MeBr 
N-Boc THQ (500 mg, 1.47 mmol, 1.0 eq), K2CO3 (243 mg, 1.76 mmol, 1.2 eq) and THIQ (0.23 
mL, 1.76 mmol, 1.2 eq). Yield: 519 mg, 90%. 1H NMR (500 MHz, Chloroform-d) δ 7.95 (d, J = 
2.2 Hz, 1H), 7.75 (d, J = 8.6 Hz, 1H), 7.59 (dd, J = 8.6, 2.2 Hz, 1H), 7.10 (tdd, J = 8.8, 4.6, 2.4 
Hz, 3H), 6.97 (dd, J = 7.8, 1.7 Hz, 1H), 4.19 – 4.14 (m, 2H), 3.66 (s, 2H), 3.62 (s, 2H), 2.89 (t, J 
= 5.9 Hz, 2H), 2.80 – 2.71 (m, 4H), 1.56 (s, 9H). 13C NMR (126 MHz, cdcl3) δ 194.41, 152.92, 
143.39, 134.95, 134.85, 134.43, 128.83, 127.68, 126.70, 126.27, 125.73, 124.70, 123.88, 82.34, 
61.97, 56.15, 50.74, 44.48, 39.14, 29.27, 28.46. 
 
56-2 tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-
3,4-dihydroquinoline-1(2H)-carboxylate. Intermediate 56-2 was synthesized following General 
Procedure (G) from 56-1 (244 mg, 0.62 mmol, 1.0 eq), (R)-2-methyl-2-propanesulfinamide (225 
mg, 1.86 mmol, 3.0 eq), and Ti(OEt)4 (0.78 mL, 3.73 mmol, 6.0 eq), then NaBH4 (141 mg, 3.73 
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mmol, 6.0 eq). Yield: 281 mg, 91%. 1H NMR (500 MHz, Chloroform-d) δ 7.82 (dd, J = 12.9, 8.6 
Hz, 1H), 7.43 (dd, J = 4.8, 2.1 Hz, 1H), 7.25 – 7.20 (m, 2H), 7.19 – 7.14 (m, 2H), 7.05 – 6.98 (m, 
1H), 4.57 (dq, J = 7.2, 3.7 Hz, 1H), 4.06 – 3.88 (m, 5H), 3.58 (ddt, J = 12.8, 11.2, 3.7 Hz, 1H), 
3.30 – 3.19 (m, 2H), 3.15 – 2.94 (m, 2H), 2.21 (tq, J = 12.5, 4.2 Hz, 1H), 1.99 (tt, J = 10.3, 3.2 Hz, 
1H), 1.52 (d, J = 1.3 Hz, 9H), 1.22 (d, J = 4.2 Hz, 9H). 13C NMR (126 MHz, cdcl3) δ 139.11, 
138.45, 136.54, 134.47, 132.41, 132.18, 131.16, 128.61, 127.28, 126.72, 125.92, 123.11, 63.64, 
62.69, 57.30, 54.85, 50.36, 40.26, 29.25, 28.30, 24.72, 22.60. 
 
56 (S)-2-amino-N-((R)-6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1-(methylsulfonyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propanamide. 56 was synthesized 
following General Procedures (I), (H) and (D) from intermediate 56-2. Intermediate 56-2 (150 
mg, 0.30 mmol) was Boc deprotected with 1:1 TFA/DCM (15 mL) as described in General 
Procedure (I). Crude product was carried forward without further characterization. General 
Procedure (H) Step 1: Sulfinamide cleavage was carried out with Boc-deprotected 56-2 and 
excess concentrated HCl, precipitating product as a white solid, a portion of which was used 
without further purification in subsequent steps. Step 2: Amide coupling was performed with the 
aminium chloride salt of 56-2 (29 mg, 0.08 mmol, 1.0 eq), di-Boc-Dmt (39 mg, 0.10 mmol, 1.2 
eq), and PyBOP (50 mg, 0.10 mmol, 1.2 eq), followed by DIPEA (0.14 mL, 0.78 mmol, 10 eq). 
Product was purified by silica chromatography, yielding 22 mg (0.03 mmol) of amide-coupled 
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product, which was then sulfonylated following General Procedure (D) with methanesulfonyl 
chloride (0.03 mL, 0.04 mmol, 1.2 eq) and Et3N (0.06 mL, 0.04 mmol, 1.2 eq). Sulfonylated, di-
Boc-Dmt coupled product was then purified by silica chromatography before Step 3: Boc-
deprotecting with 1:1 TFA/DCM (5 mL). Final compound 56 was purified by reverse-phase semi-
preparative HPLC, as described in General Procedure (H). Final yield not calculated. 1H NMR 
(500 MHz, Methanol-d4) δ 7.81 (d, J = 8.7 Hz, 1H), 7.47 – 7.43 (m, 1H), 7.40 (dd, J = 8.7, 2.2 Hz, 
1H), 7.33 – 7.28 (m, 1H), 7.28 – 7.23 (m, 2H), 7.15 (d, J = 7.7 Hz, 1H), 6.51 (s, 2H), 5.04 (t, J = 
5.3 Hz, 1H), 4.41 (s, 2H), 4.37 (s, 2H), 3.89 – 3.80 (m, 2H), 3.29 – 3.23 (m, 1H), 3.18 (s, 2H), 3.11 
– 3.01 (m, 2H), 3.00 (s, 3H), 2.28 (s, 6H), 1.90 (ddt, J = 14.3, 9.3, 4.7 Hz, 1H), 1.60 – 1.52 (m, 
1H). Calculated [M+H]+: 563.3. ESI-MS mass observed: 563.3 (M+H) and 585.3 (M+Na). 
Analytical HPLC retention time: 23.9 min. 
 
Compound 57 
 
57-1 6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-1-(methylsulfonyl)-2,3-dihydroquinolin-
4(1H)-one. 57-1 was synthesized following General Procedure (D) from 46-1 (100 mg, 0.34 
mmol, 1.0 eq), Et3N (0.10 mL, 0.68 mmol, 2.0 eq), and methanesulfonyl chloride (0.05 mL, 0.68 
mmol, 2.0 eq). Yield: 70 mg, 56%. 1H NMR (500 MHz, Chloroform-d) δ 7.88 (d, J = 2.3 Hz, 1H), 
7.64 (d, J = 8.5 Hz, 1H), 7.37 (dd, J = 8.6, 2.3 Hz, 1H), 6.78 (d, J = 8.9 Hz, 1H), 6.65 (s, 1H), 4.23 
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(s, 4H), 4.17 (t, J = 6.4 Hz, 2H), 3.86 (s, 2H), 3.04 (s, 3H), 2.84 (t, J = 6.5 Hz, 2H). 13C NMR (126 
MHz, cdcl3) δ 192.70, 142.31, 140.71, 138.70, 135.76, 133.46, 128.30, 125.03, 122.24, 121.88, 
117.65, 117.51, 64.54, 64.45, 46.16, 40.49, 40.11, 38.18. 
 
57-2 (R)-N-((R)-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-1-(methylsulfonyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-2-methylpropane-2-sulfinamide. Intermediate 57-2 was synthesized 
following General Procedure (G) from 57-1 (70 mg, 0.19 mmol, 1.0 eq), (R)-2-methyl-2-
propanesulfinamide (66 mg, 0.56 mmol, 3.0 eq), and Ti(OEt)4 (0.23 mL, 1.12 mmol, 6.0 eq), then 
NaBH4 (42 mg, 1.12 mmol, 6.0 eq). Yield: 65 mg, 72%. 1H NMR (500 MHz, Chloroform-d) δ 
7.69 (d, J = 8.6 Hz, 1H), 7.23 (d, J = 2.1 Hz, 1H), 7.10 (dd, J = 8.6, 2.2 Hz, 1H), 6.77 (d, J = 8.9 
Hz, 1H), 6.68 – 6.62 (m, 2H), 4.57 (q, J = 4.4 Hz, 3H), 4.23 (s, 4H), 4.09 (dt, J = 13.2, 4.3 Hz, 
1H), 3.81 (s, 2H), 3.66 (ddd, J = 13.6, 11.5, 2.9 Hz, 1H), 2.93 (s, 3H), 2.23 – 2.14 (m, 1H), 2.09 – 
1.98 (m, 1H), 1.21 (s, 9H). 13C NMR (126 MHz, cdcl3) δ 143.56, 138.19, 135.30, 133.99, 130.66, 
129.85, 127.63, 124.34, 121.87, 121.72, 117.62, 117.39,  64.45, 55.85, 49.90, 41.76, 40.43, 38.87, 
28.72, 22.74. 
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57 (S)-2-amino-N-((R)-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-1-(methylsulfonyl)-
1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propenamide. 57 was 
synthesized following General Procedure (H) from intermediate 57-2. Step 1: Sulfinamide 
cleavage was carried out with 57-2 (65 mg, 0.13 mmol, 1.0 eq) and excess concentrated HCl (0.06 
mL) precipitating product as a white solid, which was used without further purification. Step 2: 
Amide coupling was performed with the aminium chloride salt of 57-2 (56 mg, 0.14 mmol, 1.0 
eq), di-Boc-Dmt (61 mg, 0.15 mmol, 1.1 eq), and PyBOP (78 mg, 0.15 mmol, 1.1 eq), followed 
by DIPEA (0.24 mL, 1.36 mmol, 10 eq). After purification by silica chromatography, product was 
carried forward to Step 3: TFA deprotection, followed by purification by reverse-phase semi-
preparative HPLC, as described in General Procedure (H). Final yield not calculated. 1H NMR 
(500 MHz, Methanol-d4) δ 7.58 (d, J = 8.6 Hz, 1H), 7.09 (d, J = 2.1 Hz, 1H), 7.02 (dd, J = 8.6, 2.2 
Hz, 1H), 6.70 – 6.67 (m, 1H), 6.59 (d, J = 7.7 Hz, 2H), 6.49 (s, 2H), 4.97 (q, J = 5.1 Hz, 1H), 4.16 
(s, 4H), 3.85 (dd, J = 11.5, 5.1 Hz, 1H), 3.77 (ddd, J = 14.0, 6.1, 3.6 Hz, 1H), 3.74 (s, 2H), 3.25 
(dd, J = 13.6, 11.6 Hz, 1H), 3.04 (dd, J = 13.7, 5.2 Hz, 1H), 2.93 (ddd, J = 13.5, 10.5, 2.7 Hz, 1H), 
2.84 (s, 3H), 2.26 (s, 6H), 1.87 (dddd, J = 14.0, 10.6, 5.4, 3.5 Hz, 1H), 1.51 (dddd, J = 13.7, 5.9, 
4.6, 2.7 Hz, 1H). 13C NMR (500 MHz, cd3od) δ 168.91, 168.83, 157.41, 144.81, 143.40, 140.04, 
139.18, 136.58, 135.40, 131.53, 130.15, 127.93, 123.27, 122.83, 122.54, 118.32, 118.05, 116.44, 
111.39, 65.60, 65.50, 53.37, 49.00, 46.65, 43.67, 41.13, 38.76, 31.84, 29.18, 20.45. Calculated 
[M+H]+: 566.2. ESI-MS mass observed: 566.2 (M+H) and 588.2 (M+Na). Analytical HPLC 
retention time: 34.1 min. 
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Compound 58 
 
58-1 6-(benzofuran-2-ylmethyl)-1-(methylsulfonyl)-2,3-dihydroquinolin-4(1H)-one. 58-1 was 
synthesized following General Procedure (D) from 47-1 (80 mg, 0.29 mmol, 1.0 eq), Et3N (0.09 
mL, 0.58 mmol, 2.0 eq), and methanesulfonyl chloride (0.05 mL, 0.58 mmol, 2.0 eq). Yield: 31 
mg, 30%. 1H NMR (500 MHz, Chloroform-d) δ 8.01 (d, J = 2.3 Hz, 1H), 7.70 (d, J = 8.6 Hz, 1H), 
7.52 (dd, J = 8.6, 2.4 Hz, 1H), 7.48 (dd, J = 7.7, 1.5 Hz, 1H), 7.39 (d, J = 8.3 Hz, 1H), 7.21 (dd, J 
= 7.9, 1.6 Hz, 1H), 7.19 (dd, J = 7.4, 1.2 Hz, 1H), 6.44 (s, 1H), 4.19 (t, J = 6.3 Hz, 2H), 4.11 (s, 
2H), 3.06 (s, 3H), 2.86 (t, J = 6.5 Hz, 2H). 13C NMR (126 MHz, cdcl3) δ 192.49, 176.33, 156.49, 
141.30, 135.74, 134.54, 128.60, 125.08, 123.86, 122.83, 122.27, 120.71, 111.09, 103.87, 46.15, 
40.15, 38.17, 34.31, 28.43. 
 
 
58-2 (R)-N-((R)-6-(benzofuran-2-ylmethyl)-1-(methylsulfonyl)-1,2,3,4-tetrahydroquinolin-4-yl)-
2-methylpropane-2-sulfinamide. 58-2 was synthesized following General Procedure (G) from 
58-1 (31 mg, 0.09 mmol, 1.0 eq), (R)-2-methyl-2-propanesulfinamide (32 mg, 0.26 mmol, 3.0 eq), 
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and Ti(OEt)4 (0.11 mL, 0.52 mmol, 6.0 eq), then NaBH4 (20 mg, 0.52 mmol, 6.0 eq). Yield: 38 
mg, 95%. 1H NMR (500 MHz, Chloroform-d) δ 7.74 (d, J = 8.6 Hz, 1H), 7.50 – 7.44 (m, 1H), 7.38 
(q, J = 2.9, 1.7 Hz, 2H), 7.24 (dd, J = 8.6, 2.2 Hz, 1H), 7.20 (td, J = 7.7, 1.7 Hz, 1H), 7.18 (dd, J 
= 7.4, 1.3 Hz, 1H), 6.43 (d, J = 1.0 Hz, 1H), 4.59 (q, J = 3.7 Hz, 1H), 4.09 (dt, J = 13.3, 4.4 Hz, 
1H), 4.06 (s, 2H), 3.68 (ddd, J = 13.2, 11.4, 2.9 Hz, 1H), 2.94 (s, 3H), 2.19 (ddd, J = 14.3, 7.8, 3.4 
Hz, 1H), 2.05 (ddt, J = 14.8, 11.1, 4.0 Hz, 1H), 1.20 (s, 9H). 13C NMR (126 MHz, cdcl3) δ 157.00, 
155.08, 135.93, 134.04, 130.89, 129.88, 128.80, 127.82, 123.69, 122.74, 121.78, 120.64, 115.06, 
111.03, 103.60, 77.16, 55.89, 50.03, 41.82, 38.90, 34.23, 28.84, 22.25. 
 
58 (S)-2-amino-N-((R)-6-(benzofuran-2-ylmethyl)-1-(methylsulfonyl)-1,2,3,4-tetrahydroquinolin-
4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propenamide. 58 was synthesized following General 
Procedure (H) from intermediate 58-2. Step 1: Sulfinamide cleavage was carried out with 58-2 
(38 mg, 0.08 mmol, 1.0 eq) and excess concentrated HCl (0.05 mL) precipitating product as a 
white solid, which was used without further purification. Step 2: Amide coupling was performed 
with the aminium chloride salt of 58-2 (32 mg, 0.081 mmol, 1.0 eq), di-Boc-Dmt (37 mg, 0.089 
mmol, 1.1 eq), and PyBOP (47 mg, 0.089 mmol, 1.1 eq), followed by DIPEA (0.14 mL, 0.81 
mmol, 10 eq). After purification by silica chromatography, product was carried forward to Step 3: 
TFA deprotection, followed by purification by reverse-phase semi-preparative HPLC, as described 
in General Procedure (H). Final yield not calculated. 1H NMR (500 MHz, Methanol-d4) δ 7.66 
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(d, J = 8.5 Hz, 1H), 7.48 – 7.43 (m, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.22 (s, 1H), 7.20 (dd, J = 8.4, 
2.0 Hz, 1H), 7.17 (dd, J = 7.9, 1.6 Hz, 1H), 7.14 (td, J = 7.4, 1.1 Hz, 1H), 6.49 (s, 2H), 6.43 (d, J 
= 1.0 Hz, 1H), 5.01 (t, J = 5.0 Hz, 1H), 4.03 (d, J = 5.0 Hz, 2H), 3.81 (td, J = 10.9, 10.4, 4.3 Hz, 
2H), 3.26 – 3.21 (m, 1H), 3.02 (dd, J = 13.7, 5.2 Hz, 1H), 2.96 (ddd, J = 13.4, 10.4, 2.7 Hz, 1H), 
2.88 (s, 3H), 2.26 (s, 6H), 1.89 (ddd, J = 14.2, 9.4, 4.6 Hz, 1H), 1.56 – 1.50 (m, 1H). Calculated 
[M+H]+: 548.2. ESI-MS mass observed: 548.2 (M+H) and 570.2 (M+Na). Analytical HPLC 
retention time: 38.7 min. 
 
Compound 59 
 
59-1 1-benzoyl-6-(naphthalen-2-ylmethyl)-2,3-dihydroquinolin-4(1H)-one. Intermediate 59-1 was 
synthesized following General Procedure (D) from intermediate 48-2 (45 mg, 0.158 mmol, 1.0 
eq) and benzoyl chloride (0.04 mL, 0.31 mmol, 2.0 eq). Yield: 38 mg, 62%. 1H NMR (500 MHz, 
CDCl3) δ 7.92 (d, J = 2.2 Hz, 1H), 7.79 (dd, J = 7.5, 1.7 Hz, 1H), 7.76 (d, J = 7.9 Hz, 2H), 7.60 (s, 
1H), 7.49 (m, 2H), 7.43 (m, 3H), 7.36 (m, 2H), 7.26 (dd, J = 8.3, 2.0 Hz, 1H), 7.13 (dd, J = 8.5, 
2.2 Hz, 1H), 6.89 (d, J = 8.5 Hz, 1H), 4.30 (t, J = 6.1 Hz, 2H), 4.09 (s, 2H), 2.85 (t, J = 6.4 Hz, 
2H). 13C NMR (126 MHz, CDCl3) δ 193.88, 170.23, 142.81, 138.09, 137.62, 135.18, 134.52, 
133.66, 132.26, 131.17, 128.63, 128.61, 128.43, 127.74, 127.63, 127.61, 127.37, 127.26, 126.25, 
125.67, 125.00, 124.83, 45.44, 41.43, 39.64. 
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59-2 (R)-N-((R)-1-benzoyl-6-(naphthalen-2-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-
methylpropane-2-sulfinamide. Intermediate 59-2 was synthesized following General Procedure 
(G) from intermediate 59-1 (38 mg, 0.10 mmol, 1.0 eq), (R)-2-methyl-2-propanesulfinamide (35 
mg, 0.29 mmol, 3.0 eq), and Ti(OEt)4 (0.12 mL, 0.58 mmol, 6.0 eq), then NaBH4 (15 mg, 0.04 
mmol, 4.0 eq). Yield: 25 mg, 52%. 1H NMR (500 MHz, CDCl3) δ 7.78 (m, 3H), 7.61 (s, 1H), 7.45 
(m, 2H), 7.39 (m, 3H), 7.32 (m, 3H), 7.28 (dd, J = 8.6, 1.7 Hz, 1H), 6.89 (m, 2H), 4.62 (q, J = 4.1 
Hz, 1H), 4.06 (s, 2H), 4.01 (dt, J = 12.9, 5.1 Hz, 1H), 3.81 (ddd, J = 13.0, 10.0, 4.9 Hz, 1H), 3.45 
(m, 1H), 2.29 (dq, J = 14.0, 4.7 Hz, 1H), 2.10 (ddt, J = 14.5, 10.0, 5.1 Hz, 1H), 1.18 (s, 9H). 13C 
NMR (126 MHz, CDCl3) δ 170.44, 138.20, 138.11, 136.95, 136.11, 133.70, 132.22, 130.55, 
130.12, 128.98, 128.60, 128.53, 128.43, 128.30, 127.73, 127.66, 127.57, 127.21, 126.81, 125.57, 
55.96,50.88, 41.56, 41.57, 30.41, 22.70 
 
59 (S)-2-amino-N-((R)-1-benzoyl-6-(naphthalen-2-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-3-
(4-hydroxy-2,6-dimethylphenyl)propenamide. Final compound 59 was synthesized following 
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General Procedure (H) from intermediate 59-2. Step 1: Sulfinamide cleavage was carried out 
with 59-2 (25 mg, 0.05 mmol, 1.0 eq) and excess concentrated HCl, precipitating product as a 
white solid, which was used without further purification. Step 2: Amide coupling was performed 
with the aminium chloride salt of 59-2 (21 mg, 0.05 mmol, 1.0 eq), di-Boc-Dmt (21 mg, 0.05 
mmol, 1.05 eq), 6-Cl HOBt (8 mg, 0.05 mmol, 1.0 eq), and PyBOP (25 mg, 0.05 mmol, 1.0 eq), 
followed by DIPEA (0.07 mL, 0.49 mmol, 10 eq). After purification by silica chromatography, 
uncharacterized product was carried forward to Step 3: TFA deprotection, followed by purification 
by reverse-phase semi-preparative HPLC, as described in General Procedure (H). Final yield not 
calculated. 1H NMR (500 MHz, Methanol-d4) δ 8.26 (d, J = 8.3 Hz, 1H), 7.78 (dd, J = 7.6, 1.2 Hz, 
1H), 7.73 (d, J = 8.8 Hz, 2H), 7.55 (s, 1H), 7.40 (m, 7H), 7.25 (dd, J = 8.3, 1.5 Hz, 1H), 7.21 (s, 
1H), 6.87 (br. s, 2H), 6.49 (s, 2H), 5.05 (m, 1H), 4.04 (s, 2H), 3.87 (m, 2H), 3.36 (m, 1H), 3.25 
(dd, J = 13.7, 11.7 Hz, 1H), 3.05 (dd, J = 13.7, 5.4 Hz, 1H), 2.27 (s, 6H), 1.94 (m, 1H), 1.50 (m, 
1H). Calculated [M+H]+: 584.3. ESI-MS mass observed: 584.3. (M+H). Analytical HPLC 
retention time: 45.0 min. 
 
Compound 60 
 
60-1 tert-butyl (R)-4-(((R)-tert-butylsulfinyl)amino)-6-(quinolin-3-ylmethyl)-3,4-
dihydroquinoline-1(2H)-carboxylate. Intermediate 60-1 was synthesized following General 
N
Boc
O
N
HN
G
55-1 60-1
NN
S
O
Boc
 211 
Procedure (G) from intermediate 55-1 (135 mg, 0.35 mmol, 1.0 eq), (R)-2-methyl-2-
propanesulfinamide (127 mg, 1.04 mmol, 3.0 eq), and Ti(OEt)4 (0.44 mL, 2.09 mmol, 6.0 eq), then 
NaBH4 (53 mg, 1.39 mmol, 4.0 eq). Yield: 11 mg, 8%. 1H NMR (500 MHz, Chloroform-d) δ 9.05 
– 9.01 (m, 1H), 8.90 (d, J = 8.9 Hz, 1H), 8.24 (d, J = 2.1 Hz, 1H), 7.90 – 7.84 (m, 2H), 7.78 (d, J 
= 8.7 Hz, 1H), 7.69 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H), 7.29 (d, J = 2.1 Hz, 1H), 7.09 (dd, J = 8.6, 2.2 
Hz, 1H), 4.54 (q, J = 4.0 Hz, 1H), 4.13 (d, J = 1.6 Hz, 2H), 3.95 (dt, J = 12.9, 4.7 Hz, 1H), 3.61 
(ddd, J = 13.1, 10.9, 4.0 Hz, 1H), 2.17 (dq, J = 13.4, 4.4 Hz, 1H), 2.00 (ddt, J = 14.4, 10.0, 4.3 Hz, 
1H), 1.52 (s, 9H), 1.19 (s, 9H).  
 
60 (S)-2-amino-N-((R)-1-benzoyl-6-(quinolin-3-ylmethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide. 60 was synthesized following General Procedures 
(H) and (D) from intermediate 60-1. Step 1: Sulfinamide cleavage was carried out with 60-1 (11 
mg, 0.028 mmol) and excess concentrated HCl, precipitating product as a white solid, which was 
used without further purification. Step 2: Amide coupling was performed with the aminium 
chloride salt of 60-1 (9 mg, 0.028 mmol, 1.00 eq), di-Boc-Dmt (12 mg, 0.029 mmol, 1.05 eq), 6-
Cl HOBt (5 mg, 0.028 mmol, 1.00 eq), and PyBOP (15 mg, 0.028 mmol, 1.00 eq), followed by 
DIPEA (0.04 mL, 0.28 mmol, 10 eq). Product was benzoylated as described in General Procedure 
(D). Crude product was carried forward to Step 3: Boc-deprotection with 1:1 TFA/DCM (2 mL), 
followed by purification by reverse-phase semi-preparative HPLC, as described in General 
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Procedure (H). Final yield not calculated. 1H NMR (500 MHz, Methanol-d4) δ 8.70 (s, 1H), 8.15 
(s, 1H), 8.00 (d, J = 8.5 Hz, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.77 (t, J = 7.7 Hz, 1H), 7.64 (t, J = 7.5 
Hz, 1H), 7.45 (t, J = 7.0 Hz, 1H), 7.41 – 7.34 (m, 4H), 7.24 (s, 1H), 6.93 (s, 2H), 6.49 (s, 2H), 5.06 
(t, J = 6.2 Hz, 1H), 4.14 (s, 2H), 3.86 (dt, J = 14.1, 6.9 Hz, 2H), 3.36 (dd, J = 1.0, 0.5 Hz, 1H), 
3.29 – 3.22 (m, 1H), 3.04 (dd, J = 13.7, 5.1 Hz, 1H), 2.27 (s, 6H), 2.00 – 1.90 (m, 1H), 1.49 (dt, J 
= 12.9, 6.4 Hz, 1H). Calculated [M+H]+: 584.3. ESI-MS mass observed: 584.3 (M+H). Analytical 
HPLC retention time: 27.9 min. 
 
Compound 61 
 
61-1 1-benzoyl-6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-2,3-dihydroquinolin-4(1H)-one. 
Intermediate 61-1 was synthesized following General Procedure (F) from intermediate 6-MeBr 
N-Bz THQ (100 mg, 0.29 mmol, 1.0 eq), K2CO3 (48 mg, 0.35 mmol, 1.2 eq), and THIQ (0.044 
mL, 0.35 mmol, 1.2 eq). Yield: 112 mg, 97%. 1H NMR (500 MHz, Chloroform-d) δ 7.98 (d, J = 
2.0 Hz, 1H), 7.52 – 7.47 (m, 2H), 7.47 – 7.42 (m, 1H), 7.36 (td, J = 6.8, 5.7, 3.1 Hz, 3H), 7.10 (d, 
J = 6.4 Hz, 2H), 6.95 (t, J = 7.3 Hz, 2H), 4.32 (td, J = 6.1, 1.8 Hz, 2H), 3.61 (d, J = 25.1 Hz, 2H), 
2.87 (t, J = 6.2 Hz, 4H), 2.72 (dd, J = 6.7, 5.0 Hz, 2H).  
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61-2 (R)-N-((R)-1-benzoyl-6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-2-methylpropane-2-sulfinamide. Intermediate 61-2 was synthesized 
following General Procedure (G) from intermediate 61-1 (112 mg, 0.28 mmol, 1.0 eq), (R)-2-
methyl-2-propanesulfinamide (103 mg, 0.85 mmol, 3.0 eq), and Ti(OEt)4 (0.36 mL, 1.69 mmol, 
6.0 eq), then NaBH4 (43 mg, 1.13 mmol, 4.0 eq). Yield: 123 mg, 87%. 1H NMR (500 MHz, 
Chloroform-d) δ 7.43 (d, J = 1.9 Hz, 1H), 7.40 – 7.35 (m, 3H), 7.29 (t, J = 7.5 Hz, 2H), 7.10 – 7.03 
(m, 4H), 6.95 – 6.89 (m, 2H), 4.63 (q, J = 4.3 Hz, 1H), 4.01 (dt, J = 12.9, 5.2 Hz, 1H), 3.87 – 3.77 
(m, 1H), 3.59 (dd, J = 23.3, 11.8 Hz, 4H), 2.86 (t, J = 5.9 Hz, 2H), 2.71 (q, J = 6.0, 4.6 Hz, 2H), 
2.27 (dq, J = 14.3, 4.9 Hz, 1H), 2.10 (ddt, J = 14.3, 9.8, 5.5 Hz, 1H), 1.18 (d, J = 1.4 Hz, 9H).  
 
61 (S)-2-amino-N-((R)-1-benzoyl-6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propenamide. Final compound 61 was 
synthesized following General Procedure (H) from intermediate 61-2. Step 1: Sulfinamide 
cleavage was carried out with intermediate 61-2 (123 mg, 0.25 mmol) and excess concentrated 
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HCl (0.50 mL), precipitating product as a white solid, a portion of which was used without further 
purification in subsequent steps. Step 2: Amide coupling was performed with the aminium 
chloride salt of 61-2 (36 mg, 0.077 mmol, 1.00 eq), di-Boc-Dmt (33 mg, 0.081 mmol, 1.05 eq), 6-
Cl HOBt (13 mg, 0.77 mmol, 1.00 eq), and PyBOP (40 mg, 0.077 mmol, 1.00 eq), followed by 
DIPEA (0.11 mL, 0.77 mmol, 10 eq). Crude product was carried forward to Step 3: Boc-
deprotection with 1:1 TFA/DCM (3 mL), followed by purification by reverse-phase semi-
preparative HPLC, as described in General Procedure (H). Final yield not calculated. 1H NMR 
(500 MHz, Methanol-d4) δ 7.68 (s, 1H), 7.51 – 7.43 (m, 4H), 7.42 – 7.37 (m, 2H), 7.31 (t, J = 7.3, 
5.9 Hz, 1H), 7.26 (t, J = 7.1 Hz, 2H), 7.20 (t, J = 11.6, 10.5 Hz, 1H), 7.14 (t, J = 7.4 Hz, 2H), 6.49 
(s, 2H), 5.07 (t, J = 6.3 Hz, 1H), 4.42 (d, J = 25.6 Hz, 2H), 4.35 (d, J = 22.3 Hz, 2H), 3.90 (dd, J 
= 11.7, 4.9 Hz, 1H), 3.88 – 3.79 (m, 1H), 3.42 (d, J = 17.8 Hz, 1H), 3.26 (d, J = 12.2 Hz, 1H), 3.18 
(s, 2H), 3.07 (dd, J = 13.7, 4.9 Hz, 1H), 2.28 (s, 6H), 1.94 (q, J = 7.1, 6.5 Hz, 1H), 1.51 (td, J = 
12.0, 6.9 Hz, 1H). Calculated [M+H]+: 589.3. ESI-MS mass observed: 589.3 (M+H). Analytical 
HPLC retention time: 27.7 min. 
 
Compound 62 
 
62-1 1-benzoyl-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-2,3-dihydroquinolin-4(1H)-one. 
Intermediate 62-1 was synthesized following General Procedure (D) from intermediate 46-1 (101 
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mg, 0.34 mmol, 1.0 eq), Et3N (0.10 mL, 0.68 mmol, 2.0 eq), and benzoyl chloride (0.08 mL, 0.68 
mmol, 2.0 eq). After 12 hours, added additional equivalents of Et3N (0.15 mL, 1.08 mmol, 3.2 eq) 
and benzoyl chloride (0.10 mL, 0.86 mmol, 2.5 eq). After another two hours, TLC indicated 
complete consumption of product. Yield: 128 mg, 94%. 1H NMR (500 MHz, Chloroform-d) δ 7.83 
(d, J = 2.1 Hz, 1H), 7.49 – 7.46 (m, 2H), 7.44 (t, J = 7.6 Hz, 1H), 7.36 (t, J = 7.6 Hz, 2H), 7.07 
(dd, J = 8.5, 2.2 Hz, 1H), 6.85 (d, J = 8.5 Hz, 1H), 6.76 (d, J = 7.9 Hz, 1H), 6.61 (d, J = 8.3 Hz, 
2H), 4.30 (t, J = 6.3 Hz, 2H), 4.22 (s, 4H), 3.82 (s, 2H), 2.85 (t, J = 6.3 Hz, 2H). 13C NMR (126 
MHz, cdcl3) δ 193.75, 170.01, 142.61, 142.09, 138.28, 135.12, 134.27, 133.33, 131.00, 128.51, 
128.50, 127.33, 124.83, 124.62, 121.71, 117.50, 117.28, 64.36, 64.28, 45.26, 40.36, 39.55. 
 
62-2 (R)-N-((R)-1-benzoyl-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-1,2,3,4-
tetrahydroquinolin-4-yl)-2-methylpropane-2-sulfinamide. 62-2 was synthesized following 
General Procedure (G) from intermediate 62-1 (125 mg, 0.31 mmol, 1.0 eq), (R)-2-methyl-2-
propanesulfinamide (114 mg, 0.94 mmol, 3.0 eq), and Ti(OEt)4 (0.39 mL, 1.88 mmol, 6.0 eq), then 
NaBH4 (71 mg, 1.88 mmol, 6.0 eq). Yield: 130 mg, 82%. 1H NMR (500 MHz, Chloroform-d) δ 
7.39 (td, J = 5.4, 4.9, 2.6 Hz, 3H), 7.34 – 7.29 (m, 2H), 7.20 (s, 1H), 6.83 (s, 2H), 6.76 (d, J = 7.9 
Hz, 1H), 6.62 (d, J = 8.4 Hz, 2H), 4.62 (q, J = 3.9 Hz, 1H), 4.23 (s, 4H), 4.01 (dt, J = 12.8, 5.1 Hz, 
1H), 3.85 – 3.79 (m, 1H), 3.79 (s, 2H), 2.30 (dq, J = 13.9, 4.6 Hz, 1H), 2.09 (ddt, J = 14.5, 10.0, 
5.0 Hz, 1H), 1.21 (s, 9H). 13C NMR (126 MHz, cdcl3) δ 170.40, 138.44, 136.89, 136.20, 133.99, 
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130.52, 130.07, 128.74, 128.54, 128.44, 125.54, 121.91, 117.68, 117.34, 77.16, 64.52, 64.45, 
55.91, 50.75, 41.56, 40.59, 30.29, 22.75. 
 
62 (S)-2-amino-N-((R)-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-1-(methylsulfonyl)-
1,2,3,4-tetrahydroquinolin-4-yl)-3-(4-hydroxy-2,6-dimethylphenyl)propenamide. 62 was 
synthesized following General Procedure (H) from intermediate 62-2. Step 1: Sulfinamide 
cleavage was carried out with 62-2 (130 mg, 0.26 mmol, 1.0 eq) and excess concentrated HCl, 
precipitating product as a white solid, which was used without further purification. Step 2: Amide 
coupling was performed with the aminium chloride salt of 62-2 (113 mg, 0.26 mmol, 1.0 eq), di-
Boc-Dmt (115 mg, 0.28 mmol, 1.1 eq), and PyBOP (146 mg, 0.28 mmol, 1.1 eq), followed by 
DIPEA (0.45 mL, 2.59 mmol, 10 eq). After purification by silica chromatography, which yielded 
99 mg (48% yield), uncharacterized product was carried forward to Step 3: TFA deprotection, 
followed by purification by reverse-phase semi-preparative HPLC, as described in General 
Procedure (H). Final yield not calculated. 1H NMR (500 MHz, Methanol-d4) δ 7.44 (tt, J = 6.0, 
2.7 Hz, 1H), 7.36 (d, J = 6.0 Hz, 4H), 7.11 (d, J = 1.8 Hz, 1H), 6.78 (t, J = 11.4 Hz, 2H), 6.67 (d, 
J = 8.2 Hz, 1H), 6.59 – 6.51 (m, 2H), 6.49 (s, 2H), 5.04 (t, J = 6.2 Hz, 1H), 4.16 (s, 4H), 3.88 (dd, 
J = 11.5, 5.2 Hz, 1H), 3.84 (dd, J = 7.8, 4.8 Hz, 1H), 3.73 (s, 2H), 3.38 – 3.33 (m, 1H), 3.26 (dd, 
J = 13.7, 11.5 Hz, 1H), 3.05 (dd, J = 13.7, 5.1 Hz, 1H), 2.27 (s, 6H), 1.94 (dq, J = 13.8, 5.7 Hz, 
1H), 1.47 (dtd, J = 13.7, 7.2, 4.3 Hz, 1H). 13C NMR (126 MHz, cd3od) δ 157.49, 140.04, 135.41, 
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131.73, 129.51, 129.40, 128.93, 126.25, 123.17, 122.49, 118.27, 118.01, 116.46, 65.63, 65.53, 
53.55, 49.00, 46.87, 41.31, 31.99, 31.43, 20.45. Calculated [M+H]+: 592.3. QTOF high-resolution 
MS mass observed: 592.2795 (M+H). Analytical HPLC retention time: 38.0 min. 
Compound 63 
 
63-1 6-(benzofuran-2-ylmethyl)-1-benzoyl-2,3-dihydroquinolin-4(1H)-one. Intermediate 63-1 was 
synthesized following General Procedure (D) from intermediate 47-1 (87 mg, 0.31 mmol, 1.0 
eq), Et3N (0.09 mL, 0.63 mmol, 2.0 eq), and BzCl (0.07 mL, 0.63 mmol, 2.0 eq). After 12 hours, 
added additional equivalents of Et3N (0.15 mL, 1.08 mmol, 3.5 eq) and BzCl (0.10 mL, 0.86 mmol, 
2.8 eq). After another two hours, TLC indicated complete consumption of product. Yield: 117 mg, 
98%. 1H NMR (500 MHz, Chloroform-d) δ 7.96 (d, J = 2.2 Hz, 1H), 7.51 – 7.43 (m, 4H), 7.37 (dt, 
J = 8.6, 6.5 Hz, 3H), 7.21 (ddt, J = 8.0, 3.6, 2.2 Hz, 2H), 7.17 (td, J = 7.4, 1.2 Hz, 1H), 6.92 (d, J 
= 8.5 Hz, 1H), 6.39 (d, J = 1.0 Hz, 1H), 4.31 (t, J = 6.3 Hz, 2H), 4.07 (s, 2H), 2.86 (t, J = 6.3 Hz, 
2H). 13C NMR (126 MHz, cdcl3) δ 193.69, 170.24, 156.60, 155.13, 143.36, 135.19, 134.37, 134.30, 
131.26, 128.74, 128.72, 128.68, 127.77, 125.08, 124.93, 123.81, 122.80, 120.67, 111.07, 103.84, 
77.16, 45.48, 39.67, 34.35. 
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63-2 (R)-N-((R)-6-(benzofuran-2-ylmethyl)-1-benzoyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-
methylpropane-2-sulfinamide. Intermediate 63-2 was synthesized following General Procedure 
(G) from 63-1 (115 mg, 0.30 mmol, 1.0 eq), (R)-2-methyl-2-propanesulfinamide (110 mg, 0.90 
mmol, 3.0 eq), and Ti(OEt)4 (0.38 mL, 1.80 mmol, 6.0 eq), then NaBH4 (68 mg, 1.80 mmol, 6.0 
eq). Yield: 89 mg, 60%. 1H NMR (500 MHz, Chloroform-d) δ 7.50 – 7.45 (m, 1H), 7.42 – 7.39 
(m, 3H), 7.37 (dd, J = 8.6, 1.9 Hz, 2H), 7.32 (dd, J = 8.4, 6.7 Hz, 2H), 7.19 (dtd, J = 18.0, 7.3, 1.3 
Hz, 2H), 6.97 (dd, J = 8.5, 2.0 Hz, 1H), 6.40 (d, J = 1.1 Hz, 1H), 4.65 (q, J = 3.8 Hz, 1H), 4.07 – 
3.99 (m, 4H), 3.81 (ddd, J = 13.1, 10.0, 4.9 Hz, 1H), 2.29 (dq, J = 14.1, 4.8 Hz, 1H), 2.11 (ddt, J 
= 14.6, 10.1, 5.1 Hz, 1H), 1.20 (s, 10H). 13C NMR (126 MHz, cdcl3) δ 137.54, 136.09, 134.30, 
130.63, 128.95, 128.56, 128.50, 125.67, 123.67, 122.72, 120.62, 111.05, 103.64, 77.16, 64.12, 
60.54, 55.95, 50.86, 41.65, 34.43, 30.46, 22.74. 
 
63 (S)-2-amino-N-((R)-6-(benzofuran-2-ylmethyl)-1-benzoyl-1,2,3,4-tetrahydroquinolin-4-yl)-3-
(4-hydroxy-2,6-dimethylphenyl)propenamide. 63 was synthesized following General Procedure 
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(H) from intermediate 63-2. Step 1: Sulfinamide cleavage was carried out with 63-2 (89 mg, 0.18 
mmol, 1.0 eq) and excess concentrated HCl, precipitating product as a white solid, which was used 
without further purification. Step 2: Amide coupling was performed with the aminium chloride 
salt of 63-2 (77 mg, 0.18 mmol, 1.0 eq), di-Boc-Dmt (82 mg, 0.20 mmol, 1.1 eq), and PyBOP (104 
mg, 0.20 mmol, 1.1 eq), followed by DIPEA (0.32 mL, 1.84 mmol, 10 eq). After purification by 
silica chromatography, which yielded 76 mg (54% yield), uncharacterized product was carried 
forward to Step 3: TFA deprotection, followed by purification by reverse-phase semi-preparative 
HPLC, as described in General Procedure (H). Final yield not calculated. 1H NMR (500 MHz, 
Methanol-d4) δ 7.46 – 7.43 (m, 2H), 7.42 – 7.33 (m, 4H), 7.34 – 7.28 (m, 1H), 7.24 (d, J = 1.9 Hz, 
1H), 7.18 (td, J = 7.7, 1.6 Hz, 1H), 7.14 (td, J = 7.4, 1.2 Hz, 1H), 6.95 (d, J = 8.2 Hz, 1H), 6.90 (s, 
1H), 6.49 (s, 2H), 6.37 (d, J = 1.0 Hz, 1H), 5.07 (t, J = 6.3 Hz, 1H), 4.01 (d, J = 4.2 Hz, 2H), 3.88 
(d, J = 5.0 Hz, 1H), 3.86 (d, J = 5.3 Hz, 1H), 3.34 (h, J = 1.7 Hz, 1H), 3.26 (dd, J = 13.7, 11.5 Hz, 
1H), 3.04 (dd, J = 13.7, 5.2 Hz, 1H), 2.27 (s, 6H), 1.98 – 1.91 (m, 1H), 1.53 – 1.45 (m, 1H). 
Calculated [M+H]+: 574.3. QTOF high-resolution MS mass observed: 574.2692 (M+H).  
Analytical HPLC retention time: 42.1 min. 
 
Compound 65 
 
65-1 6-(naphthalen-2-ylmethyl)thiochroman-4-one. Intermediate 65-1 was synthesized following 
General Procedure (F) from 6-MeBr Thiochromane (103 mg, 0.40 mmol, 1.0 eq), 2-
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naphthylboronic acid (138 mg, 0.80 mmol, 2.0 eq), K2CO3 (166 mg, 1.20 mmol, 3.0 eq) and 
Pd(dppf)Cl2 (30 mg, 0.04 mmol, 0.1 eq). Yield: 54 mg, 44%. 1H NMR (500 MHz, Chloroform-d) 
δ 8.04 (d, J = 1.8 Hz, 1H), 7.80 – 7.73 (m, 4H), 7.61 (d, J = 1.8 Hz, 1H), 7.47 – 7.39 (m, 2H), 7.27 
(dd, J = 8.5, 1.8 Hz, 1H), 7.22 (dd, J = 8.2, 2.1 Hz, 1H), 7.18 (d, J = 8.1 Hz, 1H), 4.09 (s, 2H), 3.20 
(t, J = 6.6 Hz, 2H), 2.95 (t, J = 6.7, 6.1 Hz, 2H). 13C NMR (126 MHz, cdcl3) δ 194.31, 140.01, 
138.28, 137.96, 134.31, 133.69, 132.26, 131.01, 129.47, 128.41, 128.04, 127.74, 127.67, 127.42, 
127.20, 126.21, 125.62, 77.16, 41.60, 39.78, 26.76. 
 
65-2 (R)-2-methyl-N-((R)-6-(naphthalen-2-ylmethyl)thiochroman-4-yl)propane-2-sulfinamide. 
65-2 was synthesized following General Procedure (G) from intermediate 65-1 (54 mg, 0.18 
mmol, 1.0 eq), (R)-2-methyl-2-propanesulfinamide (65 mg, 0.53 mmol, 3.0 eq), and Ti(OEt)4 (0.22 
mL, 1.06 mmol, 6.0 eq), then NaBH4 (40 mg, 1.06 mmol, 6.0 eq). Yield: 56 mg, 78%. 1H NMR 
(500 MHz, Chloroform-d) δ 7.78 (d, J = 9.1 Hz, 1H), 7.74 (d, J = 8.8 Hz, 1H), 7.62 (s, 1H), 7.46 
– 7.40 (m, 2H), 7.29 (dd, J = 8.4, 1.8 Hz, 1H), 7.26 (d, J = 1.7 Hz, 1H), 7.26 (s, 1H), 7.04 (d, J = 
8.1 Hz, 1H), 7.00 (dd, J = 8.2, 1.9 Hz, 1H), 4.61 (q, J = 3.2 Hz, 1H), 4.05 (s, 2H), 3.28 (td, J = 
12.6, 2.8 Hz, 1H), 3.18 (s, 1H), 2.79 (dt, J = 12.5, 4.0 Hz, 1H), 2.45 (dtd, J = 14.2, 4.5, 3.0 Hz, 
1H), 2.06 – 1.95 (m, 1H), 1.21 (s, 9H). 13C NMR (126 MHz, cdcl3) δ 138.49, 137.83, 133.73, 
132.75, 132.23, 131.90, 131.31, 129.38, 128.29, 127.73, 127.69, 127.57, 127.12, 127.10, 126.13, 
125.51, 77.16, 55.76, 50.98, 41.59, 28.22, 22.76, 21.19. 
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65 (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(naphthalen-2-
ylmethyl)thiochroman-4-yl)propanamide. 65 was synthesized following General Procedure (H) 
from intermediate 65-2. Step 1: Sulfinamide cleavage was carried out with 65-2 (56 mg, 0.14 
mmol, 1.0 eq) and excess concentrated HCl, precipitating product as a white solid, which was used 
without further purification. Step 2: Amide coupling was performed with the aminium chloride 
salt of 65-2 (40 mg, 0.12 mmol, 1.0 eq), di-Boc-Dmt (53 mg, 0.13 mmol, 1.1 eq), and PyBOP (67 
mg, 0.13 mmol, 1.1 eq), followed by DIPEA (0.21 mL, 1.20 mmol, 10 eq). Crude product was 
carried forward to Step 3: TFA deprotection, followed by purification by reverse-phase semi-
preparative HPLC, as described in General Procedure (H). Final yield not calculated. 1H NMR 
(500 MHz, Methanol-d4) δ 7.77 (dd, J = 7.9, 1.6 Hz, 1H), 7.74 – 7.70 (m, 2H), 7.57 (s, 1H), 7.45 
– 7.37 (m, 2H), 7.25 (dd, J = 8.4, 1.7 Hz, 1H), 7.08 (d, J = 1.8 Hz, 1H), 6.99 (dd, J = 8.2, 1.8 Hz, 
1H), 6.94 (d, J = 8.1 Hz, 1H), 6.49 (s, 2H), 5.04 (q, J = 4.3 Hz, 1H), 4.00 (s, 2H), 3.85 (dd, J = 
11.6, 5.1 Hz, 1H), 3.24 (dd, J = 13.6, 11.6 Hz, 1H), 3.00 (dd, J = 13.7, 5.1 Hz, 1H), 2.52 (dt, J = 
13.3, 4.3 Hz, 1H), 2.27 (s, 6H), 2.22 (td, J = 12.7, 2.9 Hz, 1H), 1.86 (dq, J = 13.0, 4.4 Hz, 1H), 
1.81 – 1.73 (m, 1H). Calculated [M+H]+: 497.2. ESI-MS mass observed: 497.2 (M+H) and 519.2 
(M+Na). Analytical HPLC retention time: 45.0 min. 
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Compound 66 
 
66-1 6-(quinolin-3-ylmethyl)thiochroman-4-one. Intermediate 66-1 was synthesized following 
General Procedure (F) from 6-MeBr Thiochromane (80 mg, 0.31 mmol, 1.0 eq), 3-quinoline 
boronic acid (107 mg, 0.62 mmol, 2.0 eq), K2CO3 (128 mg, 0.93 mmol, 3.0 eq) and Pd(dppf)Cl2 
(23 mg, 0.03 mmol, 0.1 eq). Yield: 66 mg, 70%. 1H NMR (500 MHz, Chloroform-d) δ 8.78 (d, J 
= 2.2 Hz, 1H), 8.07 (d, J = 8.6 Hz, 1H), 8.04 (d, J = 1.7 Hz, 1H), 7.89 – 7.86 (m, 1H), 7.74 (dd, J 
= 8.1, 1.4 Hz, 1H), 7.67 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.52 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 7.24 
(d, J = 1.2 Hz, 2H), 4.14 (s, 2H), 3.26 – 3.20 (m, 2H), 3.01 – 2.95 (m, 2H). 13C NMR (126 MHz, 
cdcl3) δ 151.92, 135.05, 134.13, 129.52, 129.32, 129.19, 128.34, 127.61, 126.97, 77.16, 39.73, 
38.79, 26.77. 
 
66-2 (R)-2-methyl-N-((R)-6-(quinolin-3-ylmethyl)thiochroman-4-yl)propane-2-sulfinamide. 66-2 
was synthesized following General Procedure (G) from intermediate 66-1 (66 mg, 0.22 mmol, 
1.0 eq), (R)-2-methyl-2-propanesulfinamide (79 mg, 0.65 mmol, 3.0 eq), and Ti(OEt)4 (0.27 mL, 
1.30 mmol, 6.0 eq), then NaBH4 (49 mg, 1.30 mmol, 6.0 eq). Yield: 71 mg, 80%. 1H NMR (500 
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MHz, Chloroform-d) δ 8.77 (d, J = 2.2 Hz, 1H), 8.06 (d, J = 8.5, 0.9 Hz, 1H), 7.90 (s, 1H), 7.75 
(d, J = 8.1 Hz, 1H), 7.65 (td, J = 8.2, 1.5 Hz, 1H), 7.51 (td, J = 8.1, 1.0 Hz, 1H), 7.28 (d, J = 2.0 
Hz, 1H), 7.06 (d, J = 8.2 Hz, 1H), 6.99 (dd, J = 8.2, 2.0 Hz, 1H), 4.60 (q, J = 3.3 Hz, 1H), 4.08 (s, 
2H), 3.27 (td, J = 12.6, 2.8 Hz, 1H), 3.21 – 3.14 (m, 1H), 2.81 (dt, J = 12.7, 4.0 Hz, 1H), 2.44 (dtd, 
J = 14.2, 4.6, 3.0 Hz, 1H), 2.05 – 1.97 (m, 1H), 1.21 (s, 9H). 
 
66 (S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)-N-((R)-6-(quinolin-3-ylmethyl)thiochroman-4-
yl)propanamide. 66 was synthesized following General Procedure (H) from intermediate 66-2. 
Step 1: Sulfinamide cleavage was carried out with 66-2 (71 mg, 0.17 mmol, 1.0 eq) and excess 
concentrated HCl, precipitating product as a white solid, which was used without further 
purification. Step 2: Amide coupling was performed with the aminium chloride salt of 66-2 (21 
mg, 0.07 mmol, 1.0 eq), di-Boc-Dmt (31 mg, 0.08 mmol, 1.1 eq), and PyBOP (39 mg, 0.08 mmol, 
1.1 eq), followed by DIPEA (0.12 mL, 0.69 mmol, 10 eq). Crude product was carried forward to 
Step 3: TFA deprotection, followed by purification by reverse-phase semi-preparative HPLC, as 
described in General Procedure (H). Final yield not calculated. 1H NMR (500 MHz, Methanol-
d4) δ 8.88 (d, J = 2.2 Hz, 1H), 8.54 (s, 1H), 8.29 (d, J = 8.2 Hz, 1H), 8.10 (d, J = 8.7 Hz, 1H), 8.07 
(d, J = 8.3 Hz, 1H), 7.95 (t, J = 7.8 Hz, 1H), 7.79 (t, J = 7.7 Hz, 1H), 7.16 (d, J = 2.0 Hz, 1H), 7.05 
(dd, J = 8.2, 1.9 Hz, 1H), 7.01 (d, J = 8.1 Hz, 1H), 6.50 (s, 2H), 5.06 (s, 1H), 4.18 (s, 2H), 3.86 
(dd, J = 11.6, 5.0 Hz, 1H), 3.26 (dd, J = 13.6, 11.7 Hz, 1H), 3.02 (dd, J = 13.6, 5.0 Hz, 1H), 2.55 
(dt, J = 13.3, 4.3 Hz, 1H), 2.28 (s, 6H), 2.25 (d, J = 12.9 Hz, 1H), 1.86 (d, J = 14.3 Hz, 1H), 1.78 
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(t, J = 12.9 Hz, 1H). Calculated [M+H]+: 498.2. ESI-MS mass observed: 498.2 (M+H) and 520.2 
(M+Na). Analytical HPLC retention time: 26.2 min. 
 
Compound 67 
 
67-1 6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)thiochroman-4-one Intermediate 67-1 was 
synthesized following General Procedure (F) from 6-MeBr Thiochromane (88 mg, 0.34 mmol, 
1.0 eq), THIQ (55 mg, 0.41 mmol, 1.2 eq), and K2CO3 (57 mg, 0.41 mmol, 3.0 eq). Yield: 63 mg, 
60%. 1H NMR (500 MHz, Chloroform-d) δ 8.07 (d, J = 2.0 Hz, 1H), 7.49 (dd, J = 8.2, 2.0 Hz, 
1H), 7.27 – 7.24 (m, 1H), 7.12 – 7.07 (m, 3H), 6.97 (dd, J = 7.7, 1.8 Hz, 1H), 3.65 (s, 2H), 3.61 
(s, 2H), 3.24 (t, J = 6.5 Hz, 2H), 2.98 (t, J = 6.5 Hz, 2H), 2.89 (t, J = 5.9 Hz, 2H), 2.73 (t, J = 5.9 
Hz, 2H). 13C NMR (126 MHz, cdcl3) δ 194.27, 141.00, 135.83, 134.80, 134.39, 134.34, 130.76, 
129.64, 128.80, 127.92, 126.67, 126.25, 125.71, 77.16, 62.07, 56.10, 50.72, 39.77, 29.26, 26.78. 
 
67-2 (R)-N-((R)-6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)thiochroman-4-yl)-2-
methylpropane-2-sulfinamide. 67-2 was synthesized following General Procedure (G) from 
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intermediate 67-1 (63 mg, 0.20 mmol, 1.0 eq), (R)-2-methyl-2-propanesulfinamide (74 mg, 0.61 
mmol, 3.0 eq), and Ti(OEt)4 (0.26 mL, 1.22 mmol, 6.0 eq), then NaBH4 (46 mg, 1.22 mmol, 6.0 
eq). Yield: 27 mg, 32%. NMR was taken, but indicated presence of impurity. Carried forward as 
crude mixture. 
 
67 (S)-2-amino-N-((R)-6-((3,4-dihydroisoquinolin-2(1H)-yl)methyl)thiochroman-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide. 67 was synthesized following General Procedure (H) 
from intermediate 67-2. Step 1: Sulfinamide cleavage was carried out with 67-2 (27 mg, 0.07 
mmol, 1.0 eq) and excess concentrated HCl, precipitating product as a white solid, which was used 
without further purification. Step 2: Amide coupling was performed with the aminium chloride 
salt of 67-2 (23 mg, 0.07 mmol, 1.0 eq), di-Boc-Dmt (33 mg, 0.08 mmol, 1.1 eq), and PyBOP (42 
mg, 0.08 mmol, 1.1 eq), followed by DIPEA (0.13 mL, 0.74 mmol, 10 eq). Crude product was 
carried forward to Step 3: TFA deprotection, followed by purification by reverse-phase semi-
preparative HPLC, as described in General Procedure (H). Final yield not calculated. 1H NMR 
(500 MHz, Methanol-d4) δ 7.32 (d, J = 5.3 Hz, 1H), 7.32 – 7.27 (m, 1H), 7.29 – 7.22 (m, 3H), 7.17 
(d, J = 8.2 Hz, 1H), 7.15 (d, J = 7.7 Hz, 1H), 6.51 (s, 2H), 5.10 (d, J = 4.4 Hz, 1H), 4.36 (q, J = 
16.6, 14.8 Hz, 4H), 3.86 (dd, J = 11.7, 4.9 Hz, 1H), 3.74 (s, 2H), 3.29 – 3.23 (m, 1H), 3.23 – 3.09 
(m, 2H), 3.04 (dd, J = 13.6, 4.9 Hz, 1H), 2.69 – 2.60 (m, 1H), 2.37 – 2.31 (m, 1H), 1.91 – 1.75 (m, 
2H). Calculated [M+H]+: 502.3. ESI-MS mass observed: 502.3 (M+H) and 524.3 (M+Na). 
Analytical HPLC retention time: 26.0 min. 
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Compound 68 
 
68-1 6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)thiochroman-4-one. Intermediate 68-1 was 
synthesized following General Procedure (F) from 6-MeBr Thiochromane (105 mg, 0.41 
mmol, 1.0 eq), 1,4-benzodioxan-6-boronic acid (180 mg, 0.61 mmol, 1.5 eq), K2CO3 (168 mg, 
1.22 mmol, 3.0 eq) and Pd(dppf)Cl2 (30 mg, 0.04 mmol, 0.1 eq). Yield: 83 mg, 65%. 1H NMR 
(500 MHz, Chloroform-d) δ 7.96 (dt, J = 1.5, 0.8 Hz, 1H), 7.20 – 7.18 (m, 2H), 6.79 – 6.75 (m, 
1H), 6.63 (dd, J = 8.9, 1.4 Hz, 2H), 4.22 (s, 4H), 3.83 (s, 2H), 3.24 – 3.18 (m, 2H), 2.99 – 2.93 (m, 
2H). 13C NMR (126 MHz, cdcl3) δ 194.35, 143.58, 142.18, 139.85, 138.63, 134.22, 133.87, 130.99, 
129.33, 128.00, 121.83, 117.60, 117.42, 77.16, 64.52, 64.44, 40.69, 39.84, 26.80. 
 
68-2 (R)-N-((R)-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)thiochroman-4-yl)-2-
methylpropane-2-sulfinamide. 68-2 was synthesized following General Procedure (G) from 
intermediate 68-1 (82 mg, 0.26 mmol, 1.0 eq), (R)-2-methyl-2-propanesulfinamide (96 mg, 0.79 
mmol, 3.0 eq), and Ti(OEt)4 (0.33 mL, 1.57 mmol, 6.0 eq), then NaBH4 (59 mg, 1.57 mmol, 6.0 
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eq). Yield: 42 mg, 39%. 1H NMR (500 MHz, Chloroform-d) δ 7.16 (d, J = 1.9 Hz, 1H), 7.03 (d, J 
= 8.1 Hz, 1H), 6.96 (dd, J = 8.1, 1.9 Hz, 1H), 6.76 (d, J = 8.0 Hz, 1H), 6.64 (d, J = 8.5 Hz, 2H), 
4.60 (q, J = 3.0 Hz, 1H), 4.22 (s, 4H), 3.78 (s, 2H), 3.28 (td, J = 12.6, 2.8 Hz, 1H), 3.16 (s, 1H), 
2.78 (dt, J = 12.5, 4.0 Hz, 1H), 2.48 – 2.42 (m, 1H), 2.05 – 1.96 (m, 1H), 1.22 (s, 9H). 13C NMR 
(126 MHz, cdcl3) δ 143.50, 142.04, 138.10, 134.36, 132.61, 131.70, 131.14, 129.26, 127.04, 
121.81, 117.57, 117.31, 77.16, 64.50, 64.43, 55.74, 50.85, 40.61, 28.09, 22.78, 21.12. 
 
68 (S)-2-amino-N-((R)-6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)thiochroman-4-yl)-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide. 68 was synthesized following General Procedure (H) 
from intermediate 68-2. Step 1: Sulfinamide cleavage was carried out with 68-2 (42 mg, 0.10 
mmol, 1.0 eq) and excess concentrated HCl, precipitating product as a white solid, which was used 
without further purification. Step 2: Amide coupling was performed with the aminium chloride 
salt of 68-2 (36 mg, 0.10 mmol, 1.0 eq), di-Boc-Dmt (45 mg, 0.11 mmol, 1.1 eq), and PyBOP (57 
mg, 0.11 mmol, 1.1 eq), followed by DIPEA (0.18 mL, 1.03 mmol, 10 eq). Crude product was 
carried forward to Step 3: TFA deprotection, followed by purification by reverse-phase semi-
preparative HPLC, as described in General Procedure (H). Final yield not calculated. 1H NMR 
(500 MHz, Methanol-d4) δ 6.99 (d, J = 1.6 Hz, 1H), 6.92 – 6.90 (m, 2H), 6.70 – 6.66 (m, 1H), 6.56 
(d, J = 8.1 Hz, 2H), 6.49 (s, 2H), 5.02 (s, 1H), 4.17 (s, 4H), 3.85 (dd, J = 11.6, 5.1 Hz, 1H), 3.70 
(s, 2H), 3.25 (dd, J = 13.6, 11.7 Hz, 1H), 3.01 (dd, J = 13.6, 5.0 Hz, 1H), 2.51 (dt, J = 13.3, 4.4 
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Hz, 1H), 2.27 (s, 6H), 2.21 (td, J = 12.7, 2.8 Hz, 1H), 1.85 (dd, J = 10.4, 5.9 Hz, 1H), 1.81 – 1.73 
(m, 1H). Calculated [M+H]+: 505.2. ESI-MS mass observed: 505.2 (M+H) and 527.2 (M+Na). 
Analytical HPLC retention time: 38.5 min. 
 
Compound 69 
 
69-2 4,4-dimethyl-3,4-dihydronaphthalen-1(2H)-one (2). Intermediate 69-2 was synthesized by 
implementation of the following procedure: to a flame-dried reaction vessel was added 
commercially available lactone 69-1 (500 mg, 4.38 mmol, 1 eq) in anhydrous benzene solvent 
under inert atmosphere. AlCl3 (2.04 g, 15.3 mmol, 3.0 eq) was then added to a separate flame-
dried reaction vessel containing anhydrous benzene under inert atmosphere and was cooled to 0oC. 
The solution of lactone was transferred via cannula to the flask containing AlCl3 and heated at 
reflux (95oC) for 2.5 h. Reaction was quenched by pouring over HCl/ice slurry. Reaction mixture 
was separated with DCM/H2O. Product was dried over magnesium sulfate and filtered. Organic 
solvent was removed under reduced pressure. Purified by silica column in 1:4 ethyl 
acetate/hexanes. Title compound 69-2 was recovered in 73% yield. 1H NMR (500 MHz, 
Chloroform-d) δ 8.01 (td, J = 7.8, 1.7 Hz, 1H), 7.53 – 7.46 (m, 1H), 7.41 (td, J = 8.0, 1.3 Hz, 1H), 
7.30 – 7.23 (m, 1H), 2.76 – 2.67 (m, 2H), 2.05 – 1.96 (m, 2H), 1.47 – 1.28 (m, 6H). 13C NMR (126 
O
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MHz, cdcl3) δ 198.17, 198.14, 152.12, 133.71, 133.68, 131.04, 127.16, 126.13, 125.70, 77.25, 
77.00, 76.98, 76.75, 36.96, 35.00, 33.78, 29.74, 29.62. 
 
69-3 7-bromo-4,4-dimethyl-3,4-dihydronaphthalen-1(2H)-one. Intermediate 69-3 was synthesized 
by implementation of the following procedure: Intermediate 69-2 (552 mg, 3.17 mmol, 1 eq) was 
dissolved in concentrated sulfuric acid, then added NBS (662 mg, 3.80 mmol, 1.2 eq) 
incrementally. Solution was heated at 60oC until side-product was observed by TLC (30 min). 
Reaction was quenched reaction with addition of H2O on ice bath to minimize generation of excess 
heat. Reaction was extracted with DCM/H2O, rinsed with brine, and dried over magnesium sulfate. 
Filtrate was concentrated under reduced pressure and purified by silica column in 1:9 ethyl 
acetate/hexanes. Title compound 69-3 was recovered in 53% yield. 1H NMR (500 MHz, 
Chloroform-d) δ 8.13 (d, J = 2.2 Hz, 1H), 7.62 (ddd, J = 8.5, 2.3, 1.1 Hz, 1H), 7.33 – 7.28 (m, 1H), 
2.76 – 2.69 (m, 2H), 2.02 (q, J = 6.9 Hz, 2H), 1.39 (d, J = 9.3 Hz, 6H). 13C NMR (126 MHz, cdcl3) 
δ 196.93, 150.97, 136.52, 133.80, 132.68, 130.08, 127.90, 127.27, 126.23, 125.78, 120.48, 77.25, 
77.00, 76.75, 37.05, 36.76, 35.09, 34.93, 33.89, 33.79, 29.71, 29.55. 
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69-4 7-benzyl-4,4-dimethyl-3,4-dihydronaphthalen-1(2H)-one. Intermediate 69-4 was synthesized 
following a modified form* of General Procedure (D) from intermediate 69-3 (100 mg, 0.40 
mmol, 1 eq) benzylboronic acid pinacol ester (172 mg, 0.79 mmol, 2.0 eq), K2CO3 (164 mg, 1.18 
mmol, 3.0 eq) and Pd(dppf)Cl2 (30 mg, 0.04 mmol, 0.1 eq). Yield: 82 mg, 75%. *Modification: 
reaction was done in microwave reactor at 110oC for 30 minutes. 1H NMR (500 MHz, Chloroform-
d) δ 7.33 (t, J = 1.2 Hz, 2H), 7.30 – 7.25 (m, 4H), 7.23 – 7.17 (m, 3H), 3.98 (s, 2H), 2.74 – 2.69 
(m, 3H), 2.00 (td, J = 6.9, 1.2 Hz, 2H), 1.38 (dd, J = 16.6, 1.0 Hz, 8H). 13C NMR (126 MHz, cdcl3) 
δ 198.50, 150.15, 140.57, 139.26, 134.42, 131.13, 128.86, 128.53, 127.31, 127.30, 126.25, 126.21, 
126.11, 77.25, 77.00, 76.75, 41.42, 37.10, 37.07, 35.18, 35.11, 33.67, 29.73, 29.72, 24.70. 
 
69-5 (R)-N-((R)-7-benzyl-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-2-methylpropane-2-
sulfinamide. 69-5 was synthesized following General Procedure (G) from 69-4 (163 mg, 0.617 
mmol, 1 eq), (R)-2-methyl-2-propanesulfinamide (224 mg, 1.85 mmol, 3.0 eq), and Ti(OEt)4 (0.77 
mL, 3.70 mmol, 6.0 eq), then NaBH4 (140 mg, 3.70 mmol, 6.0 eq). Yield: 153 mg, 65%. 
Characterized by NMR after sulfinamide cleavage in next step (see Final Compound 69 Step 1). 
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69 (S)-2-amino-N-((R)-7-benzyl-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(4-hydroxy-
2,6-dimethylphenyl)propanamide. Final compound 69 was synthesized following General 
Procedure (H) from intermediate 69-4. Step 1: Sulfinamide cleavage was carried out with 69-4 
(153 mg, 0.56 mmol, 1 eq) and excess concentrated HCl, precipitating product as a white solid, 
which was used without further purification. 1H NMR (500 MHz, Chloroform-d) δ 8.76 (s, 4H), 
7.48 (d, J = 2.1 Hz, 1H), 7.20 (d, J = 4.4 Hz, 4H), 7.11 (p, J = 4.3 Hz, 1H), 7.09 – 7.04 (m, 1H), 
4.33 (d, J = 6.2 Hz, 1H), 3.83 (d, J = 2.7 Hz, 2H), 2.20 – 2.04 (m, 3H), 1.94 (t, J = 12.5 Hz, 1H), 
1.54 – 1.46 (m, 1H), 1.32 (s, 3H), 1.18 (s, 3H). Step 2: Amide coupling was performed with the 
aminium chloride salt of 69-4 (46 mg, 0.15 mmol, 1.0 eq), di-Boc-Dmt (69 mg, 0.17 mmol, 1.1 
eq), PyBOP (86 mg, 0.15 mmol, 1.0 eq), and 6-Cl HOBt (51 mg, 0.15 mmol, 1.0 eq), followed by 
DIPEA (0.21 mL, 1.52 mmol, 10 eq). Yield not calculated. After purification by silica 
chromatography, product was carried forward to Step 3: TFA deprotection, followed by 
purification by reverse-phase semi-preparative HPLC, as described in General Procedure (H). 
Final yield not calculated. 1H NMR (500 MHz, Methanol-d4) δ 7.94 (d, J = 8.0 Hz, 1H), 7.25 – 
7.10 (m, 5H), 7.03 – 6.98 (m, 2H), 6.49 (s, 2H), 3.87 (d, J = 14.7 Hz, 3H), 3.26 (dd, J = 13.6, 11.5 
Hz, 1H), 3.01 (dd, J = 13.7, 5.0 Hz, 1H), 2.27 (s, 6H), 1.72 (dddd, J = 13.5, 11.0, 4.9, 2.7 Hz, 1H), 
1.44 (dddd, J = 13.3, 7.8, 5.3, 2.7 Hz, 1H), 1.37 (ddd, J = 13.9, 7.4, 2.6 Hz, 1H), 1.24 – 1.18 (m, 
1H), 1.17 (d, J = 7.2 Hz, 6H). 13C NMR (126 MHz, cd3od) δ 171.84, 168.82, 165.07, 157.40, 
145.26, 142.67, 140.04, 139.89, 135.46, 130.38, 129.75, 129.70, 129.38, 128.05, 127.01, 123.16, 
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116.51, 53.52, 49.83, 49.00, 42.24, 35.88, 34.28, 32.00, 31.71, 31.64, 26.76, 20.49. Calculated 
[M+H]+: 457.3. ESI-MS mass observed: 457.3 (M+H) and 480.3 (M+Na). Analytical HPLC 
retention time: 45.6 min. 
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Chapter 4: Additional Projects 
 The previous chapters have discussed the novel exploration of substitutions at C-8 (Chapter 
2) and the effects of combined substitutions at C-6 and N-1 (Chapter 3). In the first two sections 
of Chapter 4, we will investigate cross-over projects, combining C-8 substitutions with each of the 
Chapter 3 pharmacophores previously explored. In the third section, efforts toward the further 
development of in vivo candidates—including both increasing the scale of synthesis and 
radiolabeling of analogue 43—will be discussed. These additional projects involved only a small 
number of compounds. When relevant, related analogues synthesized by other chemists will be 
included to provide greater context for these works. The projects discussed in Chapter 4 are in 
various stages of completion, and as such, have not been published.  
4.1  Bicyclic/C-8 Hybrid Peptidomimetics 
 As described in greater detail in Chapter 3, it was discovered that bicyclic pendants at the 
C-6 position of the THQ scaffold proved beneficial toward reducing DOR efficacy. On the other 
hand, the N-acyl and C-8 series—when combined with a monocyclic C-6 THQ core—typically 
displayed partial DOR agonism. However, when a bicyclic C-6 pendant was combined with an N-
acyl or N-sulfonyl motif, these analogues often maintained the DOR antagonist profile and 
increased MOR potency to subnanomolar levels. As described previously, some N-acyl motifs 
(namely the acetyl and cyclopropyl) did generate DOR efficacy with single-digit to sub-nanomolar 
potency. As such, it was inferred that both the C-6 and N-1 substitutions could impart effects on 
In vitro pharmacology data obtained by Nicholas Griggs, Thomas Fernandez, Tyler Trask, Jessica Anand, and others 
in the lab of John Traynor. In vivo data were obtained by Jessica Anand and others in the lab of Emily Jutkiewicz. 
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DOR efficacy. Early on in the C-8 campaign, the idea of combining an advantageous C-8 
substitution with a bicyclic C-6 pendant was explored. However, the most advantageous C-8 
pendants were also the most bulky and lipophilic. Incorporating two bulky, aryl substitutions at C-
6 and C-8 would result in undesirably lipophilic, amphipathic chemical matter. Indeed, compound 
8, which featured benzyl pendants at C-6 and C-8, displayed very poor aqueous solubility. 
Considering that the benzyl and ethylphenyl were initially our most advantageous substitutions, 
combining these with a bicyclic C-6 would yield an undesirably lipophilic core. Thus, this idea 
was shelved at an early stage.  
 Further synthetic and SAR development at the C-8 position provided renewed interest in 
combining advantageous C-8 and C-6 substitutions. It was discovered that a small, polar carbonyl-
containing motif such as the dimethyl amide moiety found in analogue 20 could not only elicit 
DOR antagonism, but also reduced ClogP from 3.1 (no C-8 substitution) to 2.2. Furthermore, it 
had been shown that this low-ClogP analogue (20) maintained antinociceptive activity in vivo, 
whereas all other bioactive analogues in the C-8 series increased lipophilicity. Lastly, the carbonyl 
motif could be incorporated after installation of the C-6 pendant, simplifying the synthesis of this 
analogue. The first proof-of-concept bicyclic/C-8 hybrid peptidomimetic featured a 2-naphthyl 
pendant at C-6. The synthesis of this 2-naphthyl/C-8 dimethyl amide analogue 70 can be found in 
Scheme 9. Starting with the commercially available p-toluidine, this synthesis involves 15 steps, 
described in further detail below. 
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Scheme 9. De Novo Synthesis of Analogue 70 
 
 
 The synthesis of analogue 70 utilized methodologies previously developed and described 
in Chapters 2 and 3. Acylation, cyclization, and Fries Rearrangement proceed in fairly high yields 
to give the THQ core, which can be N-Boc protected prior to benzylic bromination of the C-6 
methyl position. Suzuki coupling and Boc removal give the C-6 naphthyl THQ scaffold, which 
undergoes facile, selective aryl bromination at the C-8 position with exceptional yields. Palladium-
catalyzed carbonylation with carbon monoxide (generated in situ) in DMF/H2O produces the 
carboxylic acid at C-8. Amide coupling installs the C-8 dimethyl amide prior to reductive 
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amination. Upon cleaving the sulfinamide, the Dmt moiety is installed through another amide 
coupling. Final Boc deprotection and HPLC purification yields final compound 70. While 
incorporation of the dimethyl amide prior to C-6 substitution would facilitate further 
diversification, the branched C-8 moiety sterically hinders Boc protection which is necessary for 
benzylic bromination of the C-6 position. As such, no other analogues have yet been synthesized 
of this type. However, as Table 16 indicates, the in vitro profile is highly favorable (discussed 
below) and could merit further research around this chemotype. Further C-6 bicyclic pendants 
would need to be tolerant of bromination and carbonylation conditions if further analogues are 
synthesized following Scheme 9. 
 
Table 16. Bicyclic/C-8 Hybrid Peptidomimetic 70 Compared to Parent Analogues 20 & 43a 
 
a Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [3H]-diprenorphine in membrane 
preparations. Functional data were obtained using agonist induced stimulation of [35S]-GTPγS binding. Potency is 
represented as EC50 (nM) and efficacy as percent maximal stimulation relative to standard agonist DAMGO (MOR), 
DPDPE (DOR), or U69,593 (KOR). Values are expressed as the mean of three separate assays performed in duplicate 
with standard error of the mean in parentheses. dns = does not stimulate. b Synthesized by A.A.H., see reference 94. 
Ki (nM) EC50 (nM) % stim
# MOR DOR KOR DOR Ki / MOR Ki
MOR DOR KOR MOR DOR KOR ClogP
20 0.23(0.08)
1.3
(0.2)
80
(50) 6
9
(3) dns >500
58
(1) dns
25
(4) 2.2
70 0.15
(0.01)
0.73
(0.03)
28
(3)
5 1.8(0.7) dns dns
92
(8) dns dns 3.7
43b 0.04
(0.01)
0.23
(0.02)
48
(20)
6 0.9
(0.2)
dns dns 87
(3)
dns dns 4.5
N
H
HN
O
NH2 OH
ON
N
HN
O
NH2 OH
O
N
H
HN
O
NH2 OH
ON 20 4370
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By translocating and inverting the tertiary amide moiety of analogue 43 from the N-1 to 
the C-8 position, analogue 70 maintains high MOR and DOR affinity but decreases ClogP from 
4.5 to 3.7. Additionally, the preferred MOR agonist/DOR antagonist profile is maintained, with 
only a 2-fold reduction in MOR potency (though the high error associated with this value could 
negate or amplify this change in potency). Analogue 70 shows subnanomolar affinity for MOR 
and DOR with 5-fold MOR selectivity, consistent with the parent analogues 20 and 43. This hybrid 
shows higher affinity for KOR, though selectivity for MOR over KOR is still approximately 200:1. 
A profile summary of analogue 70 is provided below in Fig. 20.  
 
Figure 20. Profile Summary of Bicyclic/C-8 Hybrid Peptidomimetic 70 
 
Moving forward, analogue 70 is a prime candidate for further in vivo studies, as the in vitro 
profile meets our desired characteristics. However, due to recency of this ligand’s synthesis, it still 
awits in vivo testing.  
While analogue 70 is the only analogue to date utilizing a bicyclic C-6/carbonyl C-8 
substitution pattern, it represents a promising means toward further diversifying the chemical 
motifs that maintain (or improve) our desired MOR agonist/DOR antagonist profile. Translocating 
the carbonyl moiety to C-8 and removing the H-bond donating capacity of the amide decreases the 
70
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ClogP of 70 relative to 43 while retaining most of the favorable in vitro properties. Additional 
analogues of this type should be further investigated, exploring different modifications to both the 
bicyclic C-6 and carbonyl C-8 substitutions. Based on the currently available data, analogue 70 
represents a novel, if incremental diversification of the THQ-based peptidomimetic series that 
opens up new opportunities for drug development in the field of bifunctional MOR-/DOR-
selective ligands. 
4.2  N-Acetyl/C-8 Hybrid Peptidomimetics  
Prior to the expanded investigation into combined bicyclic C-6/N-1 substitutions detailed 
in Chapter 3, N-acetylation of analogues was still a newly identified strategy for increasing DOR 
affinity and potentially improving bioavailability. This modification could typically be 
incorporated at a late stage in the synthesis, making these analogues easily accessible synthetically. 
Following this practice, several C-8 substituted analogues were N-acetylated in order to boost 
DOR affinity and bioavailability. However, given the proximity between the C-8 and N-1 
substitutions, it was uncertain as to which motif would most strongly influence the 
pharmacological profile associated with these dually substituted ligands. In order to determine 
which substitution was most important and whether N-acetylation could reliably improve 
bioavailability, the compounds presented in Table 17 were synthesized and evaluated in vitro and 
in vivo. 
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Table 17. N-Acetyl/C-8 Hybrid Peptidomimetics 71-77 Mimic Parent N-Acetyl Analogue 32a 
 
a Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [3H]-diprenorphine in membrane 
preparations. Functional data were obtained using agonist induced stimulation of [35S]-GTPγS binding. Potency is 
represented as EC50 (nM) and efficacy as percent maximal stimulation relative to standard agonist DAMGO (MOR), 
DPDPE (DOR), or U69,593 (KOR). Values are expressed as the mean of three separate assays performed in duplicate 
with standard error of the mean in parentheses. dns = does not stimulate. † n=2 ‡ n=1. b Synthesized by A.A.H. c First 
reported in reference 94. 
 
 The analogues in Table 17 show highly similar in vitro profiles to that of the parent 
analogue 32 featuring an N-acetyl moiety and no C-8 substitution. Generally, this series showed 
0.1 to 0.2 nM affinity at MOR, 1 to 2 nM affinity at DOR, and double-digit nanomolar affinity at 
KOR, though KOR affinity varied considerably more than MOR or DOR, ranging between 10 and 
100 nM affinity. The C-8 benzyl analogue 77 was somewhat of an outlier, displaying lower MOR 
Ki (nM) EC50 (nM) % stim
# R MOR DOR KOR DOR Ki / MOR Ki
MOR DOR KOR MOR DOR KOR
32b, c H 0.13(0.02)
1.8
(0.1)
87
(11)
14 6.0
(1.3)
68
(2) >500
76
(4)
26
(3)
29
(5)
71b F 0.15
(0.02)
0.9
(0.4)
30
(6)
6 1.4
(0.2)
77
(8)
>500 98
(2)
48
(5)
47
(3)
72 CH3
0.18
(0.04)
1.9
(0.5)
80
(20)
10 7
(2)
24
(1)
>500 85
(3)
31
(3)
31
(2)
73 CF3
0.19
(0.02)
1.3
(0.8)
49
(16)
7 11
(5)
30
(12)
>500† 68
(3)
47
(3)
28
(1)
74 Br 0.25
(0.11)
1.2
(0.5)
27
(6)
5 6
†
(3)
1.0†
(0.1)
>500‡ 79
(5)
44
(5)
51‡
(---)
75b OCH3
0.14
(0.01)
2.2
(1)
45
(17)
15 0.78
(0.2)
5
(2)
>500 96
(10)
45
(4)
16
(6)
76 n-Propyl
0.19
(0.02)
0.9
(0.5)
36
(7)
2 2.9
†
(0.8)
7
(3)
dns‡ 103
†
(6)
29
(4)
dns‡
77 Benzyl
0.40
(0.08)
0.39
(0.15)
20
(8)
1 12
(3)
1.5
(0.2)
dns 71
(4)
34
(4)
dns
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affinity and higher DOR affinity than those general trends previously stated. The decreased MOR 
affinity and increased DOR affinity combined to yield a perfectly balanced 1:1 MOR/DOR binding 
profile. Functionally, all analogues displayed MOR agonism with partial DOR agonism. MOR 
potency typically varied between 1 and 10 nM with no clearly discernible trends. On the other 
hand, DOR potency did show some dependence on the size of the C-8 substitution, with larger C-
8 moieties (analogues 74-77) displaying single-digit nanomolar potency and smaller C-8 motifs 
(analogues 32, 71-73) showing doubled-digit nanomolar potency. KOR efficacy was only 
observed at concentrations above 500 nM.  
 Aside from analogue 77, all N-acetyl/C-8 hybrids in Table 17 are pharmacologically 
indistinguishable from the unsubstituted parent analogue 32. Due to the spatial proximity between 
C-8 and N-1, it appears that any meaningful interaction between these ligands and the opioid 
receptors are primarily mediated by the N-1 acetyl group. However, in the case of the C-8 benzyl 
analogue 77 where the benzyl group is significantly larger than the N-1 moiety, one can observe a 
departure from the common profile observed for others in this series. Notably, 77 displays more 
balanced binding and greater potency at DOR compared to most in this series. Additionally, MOR 
potency is the poorest for 77, though only by a slight margin. This short series of analogues 
efficiently answered the question of which motif was most likely to influence the in vitro profile 
of a dually C-8/N-1 substituted analogue. This dependence on N-1 to dictate pharmacological 
profile, comparatively independent of C-8, is consistent with the flat binding SAR discussed in the 
C-8 substituted series of Chapter 2. Because the C-8 moieties likely occupy a flexible or solvent-
exposed pocket of the opioid receptors, it is unsurprising that the N-1 motif influences ligand 
binding more strongly. N-acetylation of the C-8 ethyl ester analogue 26 was also attempted, 
seeking to determine whether DOR antagonism could be reestablished despite the masking effect 
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of the N-acetyl moiety. However, synthesis of this analogue was unsuccessful, as acetylation of N-
1 was sterically occluded by the rigid, branched carbonyl at C-8. 
 Concerning bioavailability, most analogues in Table 17 were evaluated in vivo, probing 
whether N-acetylation did indeed improve bioavailability for this series. These results are depicted 
in Table 18, where N-acetyl analogues are compared with their unacetylated counterparts. 
 
Table 18. Investigating the Effect of N-Acetylation on Bioavailability for C-8 Substituted Ligandsa 
 
a Results from the mouse WWTW assay after cumulative dosing of test compound up to 10 mg/kg ip. Antinociceptive 
activity represented as percent maximum possible effect (% MPE), with MPE being a 20 s latency to tail withdrawal. 
Baseline tail withdrawal latency is ~5 s, or 25% MPE. “dns” indicates no stimulation of an antinociceptive response. 
b Reported in reference 83. c Synthesized by A.A.H. d Reported in reference 94. 
N-H C-8 Analogues
# C-8 R Group % MPE
1b H 100
14c F dns
9 CH3 100
15 CF3 dns
16 Br 50
78c OCH3 ---
11 n-Propyl dns
8 Benzyl dns
N-Acetyl C-8 Analogues
# C-8 R Group % MPE
32c, d H dns
71c F dns
72 CH3 100
73 CF3 50
74 Br ---
75c OCH3 ---
76 n-Propyl dns
77 Benzyl dns
N
H
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O
NH2 OH
R
N
HN
O
NH2 OH
OR
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Of the analogues tested in the WWTW assay for antinociception, only the C-8 methyl 
analogue 72 (within the N-acetyl series) displayed full antinociceptive activity. Correspondingly, 
the unacetylated C-8 methyl analogue 9 was also fully active in vivo. The N-acetyl analogue 72 
did show a slightly improved duration of action of 2.0 h compared to 1.5 h for 9. Additionally, the 
trifluoromethyl analogue went from inactive (analogue 15) to partially active (73) when acetylated. 
Conversely, N-acetylation actually eliminated the bioavailability of the lead peptidomimetic 1 as 
seen in analogue 32. It may be informative to evaluate the N-acetyl C-8 bromo analogue 74 in vivo, 
as the unacetylated 16 showed partial activity. However, on the whole it can be surmised that while 
N-acetylation may improve bioavailability, it does so only sporadically and unpredictably.  
 In this short series of analogues, we observed that N-acetylation dictates the in vitro profile 
more significantly than the small C-8 substitutions investigated here. However, in the case of the 
larger benzyl pendant of 77, the MOR/DOR balancing effect associated with the C-8 benzyl 
substitution can be observed, as 77 displayed a 1:1 binding ratio at MOR and DOR. Functionally, 
all ligands in this series were partial DOR agonists. Unfortunately, it was not synthetically tractable 
to incorporate a C-8 carbonyl substitution as well as an N-acetyl substitution, as these branched 
substitutions caused insurmountable allylic (A1,3) strain. As such, C-8 substitutions evaluated in 
this series were limited to small or unbranched motifs. Bioavailability for this series of compounds 
showed no reliable improvement relative to the unsubstituted analogues, consistent with other N-
acetylated/non-acetylated pairs synthesized previously. From the work presented in this chapter 
and those preceding, N-1 and C-8 substitutions show highly favorable profiles when combined 
with a C-6 bicyclic pendant. However, when both are implemented in the context of a monocyclic 
C-6 benzyl pendant, the benefits are minor. While these results support previous observations, this 
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series did not substantially improve in vitro or in vivo parameters and is unlikely to be utilized in 
further ligand design. 
4.3  Scaled Syntheses of In Vivo Candidates & Radiosynthetic Approaches 
 The main focus of the preceding chapters has been the design and synthesis of novel ligands 
to further probe SAR and generate new leads for opioid drug design with the aim of eliminating 
analgesic tolerance and opioid dependence. In this section, projects focused less on chemical 
novelty and more on the further evaluation of select candidates in vivo. In particular, this section 
will detail two projects necessitating the increased scale of synthesis of analogues 43, 45, 64, and 
20 shown in Fig. 21. The first project involved the scaled synthesis of all four aforementioned 
analogues for evaluation in in vivo assays including those for tolerance, dependence, and 
conditioned place preference (CPP) among others. The second project involved the attempted 
radiosynthesis of [11C]43. The results of the first project were reported in part in a 2018 manuscript 
published in the British Journal of Pharmacology.98 Unfortunately, the second project stalled at 
radiosynthesis and has not been further pursued at present.   
 
Figure 21. In Vivo Candidates and Amounts of Compound Synthesized  
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 Novel peptidomimetic ligands—requiring in vitro and in some cases in vivo evaluation—
are typically synthesized with a target yield of five to ten milligrams of final compound. However, 
compounds showing robust antinociceptive activity—especially those with a long duration of 
action and favorable in vitro profile—may be selected for further evaluation in chronic 
antinociceptive tolerance, physical dependence, and CPP models. Descriptions of these assays and 
the resultant data for compounds 43, 45, and 64 are detailed below. Compound 20 has been 
synthesized but is yet to be evaluated in the assay for chronic tolerance, dependence, or CPP. 
To test for chronic tolerance, mice were given twice daily injections ip of saline or test 
compound at escalating doses, such that on day one, mice received two 10 mg/kg doses of test 
compound, and by day five, mice received two 50 mg/kg injections of test compound. Following 
five days of escalating treatment with a test compound, animals were evaluated in the WWTW 
assay on day six. When using morphine as a test compound, a significant rightward shift in the 
dose-response curve was observed on day six compared to WWTW dose-response performed prior 
to chronic drug exposure. However, compounds 43, 45, and 64 showed no significant rightward 
shift in dose-response curve after chronic drug exposure, indicating these compounds produce 
significantly less antinociceptive tolerance than morphine.98 Fig. 22, adapted from Anand et. al., 
2018, shows the results of the chronic tolerance assay for 43, 45, and morphine—64 was evaluated 
subsequent to the publication of these results and is not included in Fig. 22. Showing no significant 
analgesic tolerance, 43, 45 and 64 were then advanced into dependence models.  
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Figure 22. Chronic Antinociceptive Tolerance Evaluation of 43, 45, and morphinea 
 
a Mice were given test compound or saline in escalating doses over a 5-day regimen and were tested in the WWTW 
assay using test compound on days 1 and 6. After 5 days of saline, no tolerance is observed for any compound. After 
5 days of morphine, tolerance develops indicated by the rightward shift in dose-response curve. No tolerance develops 
for analogues 43 or 45. BL = baseline. Figure adapted from Anand et. al., 2018 (reference 98). 
 
Dependence models utilized the same escalating dosing regimen as tolerance, where mice 
were exposed to increasing doses of test compound (or saline) for five days and were evaluated on 
day six. Following five days of chronic opioid exposure, mice were given naltrexone, an opioid 
antagonist, to precipitate withdrawal symptoms. Chronic treatment with morphine, followed by 
naltrexone, induced significant withdrawal jumps compared to chronic saline treatment (baseline). 
However, compounds 43 and 64 showed no difference in withdrawal jumps compared to saline, 
suggesting these compounds do not produce significant opioid dependence. On the other hand, 
compound 45 looked similar to morphine in this assay, indicating 45 did induce physical 
dependence.98 These results, as well as those for CPP evaluation, are displayed below in Fig. 23.   
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Figure 23. Compounds 43 and 64 Show No Physical Dependence; Only 43 Shows No CPPa 
 
a To test for physical dependence, mice were given test compound or saline in escalating doses over a 5-day regimen. 
On day 6, mice were given naltrexone to precipitate opioid-induced withdrawal jumps. Compound 45 showed 
comparable withdrawal symptoms to morphine while 43 and 64 showed significantly less dependence. In the two-
chambered CPP apparatus, mice preferred the morphine-paired side while saline and 45 induced no significant 
preference. 64 was not significantly different from either saline or morphine. Results adapted from data prepared by 
J.P.A. and reported in part in reference 98.  
 
The final assay discussed here, evaluation of CPP as a proxy for “drug-seeking” or 
“reward,” uses a two-chambered apparatus. One chamber is paired with test compound whereas 
the other is paired with saline. After five days of conditioning, mice are free to inhabit either 
chamber. In this model, rewarding drugs such as morphine cause mice to preferentially occupy the 
drug-paired side, whereas the negative control (where saline is paired with both chambers) induces 
no significant preference for either chamber. Only compounds 43 and 64—which showed 
significantly less physical dependence than morphine—were evaluated in the CPP assay. 
Compound 43 showed significantly less CPP than morphine, mimicking the negative control, 
saline. However, compound 64 showed intermediate levels of CPP, not statistically different from 
either saline or morphine.98 Dr. Jessica Anand (J.P.A.), was the lead pharmacologist who oversaw 
or performed the aforementioned assays. Figs. 22 and 23 were adapted from the manuscript98 and 
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data presentations prepared by J.P.A. Compounds for these experiments were synthesized by 
A.F.N. and D.J.M. 
At present, compound 20 is awaiting evaluation in tolerance models to determine whether 
this analogue should be carried forward with dependence and CPP assays. The twice-daily dosing 
regimen utilized for morphine, 43, 45, and 64 was not suitable for the short-acting analogue 20 
(2.0 h), as mice would be below the therapeutic threshold during much of the drug exposure period. 
As such, methodological development was required in order to evaluate shorter-acting analogues 
for tolerance, dependence, and CPP. Methods are currently in development using fentanyl—a 
short-acting MOR agonist known to induce tolerance and dependence—as a positive control. Once 
these protocols are established and functioning reliably, compound 20 will be evaluated for the 
aforementioned assays. 
Due to the cumulative dosing and number of trials (n=6 mice for each compound), the 
amount of final compound required for these assays was substantial. As such, the scale of syntheses 
were increased by one to two orders of magnitude. In addition to tolerance, dependence, and CPP, 
the in vivo candidates shown in Fig. 21 (as well as others not shown, but also synthesized in lesser, 
20 to 60 mg quantities) were required for various other in vivo experiments including but not 
limited to the following: evaluation of antinociception in rats as well as MOR-knockout and PGP-
knockout mice, evaluation of antinociception after pretreatment with the non-specific opioid 
antagonist naltrexone (affirming opioid-mediated antinociception) or the PGP-inhibitor elacridar 
(to determine if these ligands are PGP substrates), evaluation of DOR antagonism in vivo by pre-
treatment with ligand followed by the DOR agonist SNC-80, evaluation for constipation and 
locomotion, and various other in vivo assays. Because these compounds were synthesized on-
demand, the quantities listed in Fig. 21 represent cumulative totals and not yields synthesized in a 
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single batch. The largest single batch of compound produced was 280 mg of 43, followed by two 
batches of 180 mg each for compound 64.  
 Advancement of in vivo candidates through preclinical animal models has validated 43 as 
a bioavailable analgesic with significantly reduced tolerance, dependence and CPP compared to 
morphine. More generally, these results support the bifunctional MOR agonist/DOR antagonist 
approach as a viable strategy for reducing side effects associated with classical opioid treatment. 
Moving forward, the Mosberg lab and collaborators were interested in gathering further data 
concerning the pharmacokinetics of 43. In order to track 43 through the phases of absorption, 
distribution, metabolism and excretion, effort was made toward radiolabeling 43 with a 11C nuclide 
which can be tracked via positron emission tomography (PET) in vivo. Though at longer-lasting 
nuclide such as 18F would provide more information over a longer duration, no fluorinated 
analogues of the peptidomimetic series have demonstrated robust in vivo activity. Importantly, 
despite the short half-life of the 11C nuclide, an [11C]43 ligand could confirm whether or not 43 
gains access to the central nervous system (CNS), further substantiating the notion that our 
peptidomimetic was centrally-acting. In order to bolster the novelty of 43 as a CNS-active opioid 
devoid of tolerance and dependence, visual demonstration (in addition to pharmacological 
evidence) of CNS access via PET would be instrumental. With this goal in mind, we aimed to 
incorporate an 11C nuclide into the acetyl group of 43 as described in Scheme 10. The synthesis 
of unlabeled precursor and HPLC standards was performed by A.F.N., while radiolabeling was 
performed by Dr. Allan Brooks and Dr. Xia Shao as a collaborative project with Dr. Peter Scott’s 
laboratory. 
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Scheme 10. Attempted Radiolabeling of [11C]43 
 
 
 Synthesis of [11C]43 was attempted using a Boc-protected unacetylated precursor of 43 and 
[11C]acetyl chloride, derived from [11C]CO2 which is converted to [11C]acetate by methyl 
Grignard. Treatment of the acetate with thionyl chloride gives the activated acid chloride, which 
was successfully incorporated into the peptidomimetic molecule with 4.5% conversion. However, 
subsequent Boc-deprotection methodologies using TFA or HCl both removed the 11C-labeled 
acetyl group. This was unexpected, as acetyl removal had not been observed previously with 
unlabeled compounds. Nonetheless, the desired [11C]43 product was not observed by HPLC. Due 
to expense and time constraints, radiosynthesis was not further pursued at this time.  
 Although the design and synthesis of novel chemical matter is a major focus of any 
synthetic chemist working in drug development, the importance of resynthesizing or incrementally 
modifying chemical hits should not be understated. In order to proceed further, or to redirect efforts 
in more fruitful directions, it is often necessary to halt novel chemical exploration in favor of 
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deeper exploration of chemical guideposts. In this chapter, considerable effort was dedicated to 
further evaluating compound 43 for both pharmacological effects as well as pharmacokinetic 
properties. Through this deeper investigation, it was discovered that not all MOR agonist/DOR 
antagonist compounds with in vivo activity are effective at reducing tolerance and dependence, as 
was the case of compound 45. At present, the reason for why some analogues are more effective 
than others are reducing side-effects is unknown. However, the work detailed in this section 
provided critical proof-of-concept data in support of the bifunctional MOR agonist/DOR 
antagonist approach. Furthermore, this work bolsters the bicyclic C-6/N-1 research described in 
Chapter 3 which builds incrementally from the chemotype of in vivo candidates 43 and 45. 
Through this collaborative work, we have demonstrated that the bifunctional, bicyclic C-6/N-1 
THQ-based peptidomimetics may indeed (but do not necessarily) offer the target pharmacological 
profile both in vitro and in vivo. Future directions in this field of research, in the context of the 
work described in the preceding chapters, will be discussed further in Chapter 5.  
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4.4  Experimental Procedures  
 
Figure 24. Structures of Analogues 32, 70-77 Discussed in Chapter 4 
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*Analogues 32, 71 and 75 were synthesized by A.A.H. See her thesis for synthetic details.  
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General Procedure (A): N-Acylation or Mesylation of the THQ core. To a round-bottom flask 
containing THQ intermediate (1.0 eq) was added acetic anhydride (excess) and heated to 100°C. 
When starting material showed complete conversion to product by TLC, solvent was removed 
under reduced pressure and reaction mixture was purified by silica chromatography. When noted, 
product was isolated by crystallization and was used without further purification.   
General Procedure (B): Reductive Amination of THQ Ketone Intermediate to a Sulfinamide 
Using Ellman’s Chiral Auxilliary. To a round bottom flask already containing desiccated THQ 
intermediate (1.0 eq) under Ar atmosphere was added (R)-2-methylpropane-2-sulfinamide (3.0 
eq). Meanwhile, a reflux condenser was flame-dried under vacuum, and then flooded with Ar. 
Next, anhydrous THF (5-10 mL) was added to the reaction vessel containing starting reagents via 
syringe. The round bottom flask was placed in an ice bath and allowed to equilibrate to 0°C. Next, 
Ti(OEt)4 (6.0 eq) was added slowly via syringe. Once addition was complete, the reaction vessel 
was taken out of ice bath and placed in oil bath at 70°C-75°C, affixed condenser, and stirred for 
16-48 h under Ar. The reaction was monitored by TLC for loss of ketone. Once sufficient 
conversion to the tert-butanesulfinyl imine was observed, reaction vessel was taken out of oil bath 
and cooled to ambient temperature. Meanwhile, an additional round bottom flask was flame-dried 
under vacuum, then flooded with Ar. NaBH4 (6.0 eq) was added quickly, and anhydrous THF was 
added (5-10 mL). The round bottom flask was placed in dry ice/acetone bath and allowed to 
equilibrate to -78°C. Contents from the round bottom flask containing the imine intermediate were 
transferred to round bottom flask containing NaBH4 via cannula. Imine-containing flask was 
washed twice with minimal THF, which was also transferred to reducing flask via cannula under 
Ar. Once contents were completely added, the reaction was taken out of dry ice/acetone bath and 
was allowed to warm to room temperature. The reaction stirred at ambient temperature for 2-3 h. 
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To quench, sat. NaCl solution was added. Reaction mixture was diluted with ethyl acetate and DI 
H2O and separated, washing with H2O until both layers were clear, indicating sufficient removal 
of titanium oxide by-product. Organics were then isolated and dried over MgSO4 and filtered 
through a fritted funnel. Organic extract was then concentrated onto silica and purified by silica 
chromatography. 
General Procedure (C): Conversion of Sulfinamide to Final Compound. Step 1: To a round 
bottom flask containing sulfinamide (1.0 eq) was added 1,4-dioxane, followed by conc. HCl (6.0 
eq), cleaving the sulfinamide to the primary amine. The reaction stirred at RT for up to 3 h. Solvent 
was removed under reduced, and residue was re-suspended in Et2O. The resultant white solid 
precipitate (the HCl salt of the amine) was isolated by decanting and washing with Et2O up to three 
times. After desiccation, the solid residue was used without further purification. Step 2: To a pear-
shaped flask under inert atmosphere containing amine salt (1.0 eq) was added di-Boc-Dmt (1.1 
eq), PyBOP (1.1 eq), and, when specified, 6-Cl HOBt (1.1 eq), followed by DMF and DIPEA (10 
eq) at ambient temperature. After stirring for 6 hours, solvent was removed under reduced pressure 
and residual oil was loaded onto silica. Boc-protected intermediate was purified by silica 
chromatography but was generally not characterized by NMR. Step 3: Boc-protected intermediate 
was suspended in DCM (10 mL), then TFA (3-5 mL) was added. After 1 hour, solvent was 
removed under vacuum. Product was resuspended in a solution of 99.9% acetonitrile, 0.1% TFA, 
then diluted with deionized water. Final products were purified by reverse-phase semi-preparative 
HPLC. Final yield not calculated.  
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Compound 70 
 
70-1 8-bromo-6-(naphthalen-2-ylmethyl)-2,3-dihydroquinolin-4(1H)-one. Intermediate 70-1 was 
synthesized from intermediate 48-2, whose synthesis was described in Section 3.8 Experimental 
Procedures. To a round-bottom flask containing intermediate 48-2 (275 mg, 0.96 mmol, 1.00 eq), 
dissolved in dichloromethane under inert atmosphere was added N-bromosuccinimide (178 mg, 
1.00 mg, 1.05 eq) at ambient temperature. After 5 minutes, TLC in 40% ethyl acetate, 60% hexanes 
showed complete conversion. Reaction was concentrated onto silica in vacuo and was purified by 
flash chromatography. Yield: 290 mg, 88%. 1H NMR (500 MHz, Chloroform-d) δ 7.79 (d, J = 8.3 
Hz, 1H), 7.77 (s, 1H), 7.76 (d, J = 4.9 Hz, 1H), 7.61 (d, J = 1.8 Hz, 1H), 7.48 – 7.41 (m, 3H), 7.43 
(s, 1H), 7.28 (dd, J = 8.4, 1.6 Hz, 1H), 4.90 (s, 1H), 4.01 (s, 2H), 3.66 – 3.59 (m, 2H), 2.71 (t, J = 
6.9 Hz, 2H). 13C NMR (126 MHz, cdcl3) δ 193.14, 147.49, 138.67, 138.14, 133.72, 132.29, 
131.25, 128.45, 127.77, 127.71, 127.40, 127.19, 127.13, 126.22, 125.63, 120.35, 110.44, 41.98, 
40.99, 37.61. 
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70-2 6-(naphthalen-2-ylmethyl)-4-oxo-1,2,3,4-tetrahydroquinoline-8-carboxylic acid. 70-2 was 
synthesized using the following procedure: To a flame-dried pear-shaped flask under Ar 
atmosphere was added intermediate 70-1 (310 mg, 0.85 mmol, 1.0 eq), K2CO3 (175 mg, 1.27 
mmol, 1.5 eq) and Pd(dppf)Cl2 (62 mg, 0.09 mmol, 0.1 eq), followed by 5:1 DMF/H2O (12 mL). 
To a separate 30 mL pressure tube under Ar atmosphere was added 2M NaOH (15 mL), then 
evacuated, flushed with Ar, and bubbled Ar through base solution for 15 min. To the bottom of 
the tube containing stirring base solution was added, via syringe, oxalyl chloride (1 mL in aliquots 
of 0.1 to 0.2 mL). Carbon monoxide generated in situ from the decomposition of oxalyl chloride 
was cannulated to the reaction mixture. Reaction was heated at 80°C for 8 hours, monitored by 
TLC. When TLC indicated conversion of starting material to new product, reaction was cooled to 
ambient temperature and reaction solvents were removed under vacuum. Residual oil was 
resuspended in ethyl acetate and water, and acid/base extraction was performed. Organics were 
isolated, dried with MgSO4, filtered, and reconcentrated onto silica in vacuo. Reaction was purified 
by flash chromatography. Reaction yielded 190 mg pure 70-2, 82%. An additional 120 mg of 
impure material containing 70-2 was isolated and was carried forward separately. 1H NMR (500 
MHz, Chloroform-d) δ 9.78 (s, 1H), 8.47 (s, 1H), 8.03 (d, J = 2.2 Hz, 1H), 7.82 – 7.79 (m, 1H), 
7.78 (dd, J = 7.8, 2.4 Hz, 2H), 7.65 – 7.61 (m, 1H), 7.52 (d, J = 2.3 Hz, 1H), 7.50 – 7.40 (m, 2H), 
7.29 (dd, J = 8.4, 1.8 Hz, 1H), 4.08 (s, 2H), 3.68 (td, J = 7.2, 2.5 Hz, 2H), 2.77 – 2.70 (m, 2H). 13C 
NMR (126 MHz, cdcl3) δ 193.57, 192.56, 151.31, 143.15, 137.99, 135.06, 133.73, 132.33, 128.57, 
128.52, 127.80, 127.70, 127.33, 127.16, 126.32, 125.72, 120.68, 120.15, 77.16, 40.82, 40.68, 
37.12. 
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70-3 N,N-dimethyl-6-(naphthalen-2-ylmethyl)-4-oxo-1,2,3,4-tetrahydroquinoline-8-carboxamide. 
Intermediate 70-3 was synthesized by the following procedure: To a pear-shaped flask containing 
intermediate 70-2 (91 mg, 0.27 mmol, 1.0 eq) dissolved in DMF under inert atmosphere was added 
PyBOP (157 mg, 0.30 mmol, 1.1 eq), dimethylamine hydrochloride (45 mg, 0.55 mmol, 2.0 eq) 
and DIPEA (0.48 mL, 2.74 mmol, 10 eq), then stirred at ambient temperature. Reaction was 
monitored by TLC. After 5 hours, solvent was removed under reduced pressure and reconcentrated 
residue onto silica in vacuo. Crude reaction mixture was combined with a previously run trial 
reaction which used impure starting material. The combined reactions were purified by flash 
chromatography, giving a combined overall yield of 125 mg, or 38% of the theoretical combined 
yield. 1H NMR (500 MHz, Chloroform-d) δ 7.85 (d, J = 2.2 Hz, 1H), 7.79 (dd, J = 7.4, 1.8 Hz, 
1H), 7.77 – 7.72 (m, 2H), 7.59 (s, 1H), 7.44 (pd, J = 6.8, 1.5 Hz, 2H), 7.26 (dd, J = 8.4, 1.7 Hz, 
1H), 7.08 (d, J = 2.2 Hz, 1H), 5.92 (s, 1H), 4.03 (s, 2H), 3.54 (t, J = 7.0 Hz, 2H), 2.97 (s, 7H), 2.67 
(t, J = 7.0 Hz, 2H). 13C NMR (126 MHz, cdcl3) δ 193.60, 170.09, 149.64, 138.42, 134.94, 133.69, 
132.24, 129.57, 128.67, 128.36, 127.75, 127.64, 127.43, 127.09, 126.21, 125.58, 120.46, 120.37, 
77.16, 46.42, 46.38, 41.59, 41.00, 37.69, 26.50, 26.44. 
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70-4 (R)-4-(((R)-tert-butylsulfinyl)amino)-N,N-dimethyl-6-(naphthalen-2-ylmethyl)-1,2,3,4-
tetrahydroquinoline-8-carboxamide. Intermediate 70-4 was synthesized following General 
Procedure (B) from intermediate 70-3 (125 mg, 0.35 mmol, 1.0 eq), (R)-2-methyl-2-
propanesulfinamide (127 mg, 1.05 mmol, 3.0 eq), and Ti(OEt)4 (0.44 mL, 2.10 mmol, 6.0 eq), then 
NaBH4 (80 mg, 2.10 mmol, 6.0 eq). Yield: 45 mg, 23%. 1H NMR (500 MHz, Chloroform-d) δ 
7.78 (d, J = 7.7 Hz, 2H), 7.74 (dd, J = 10.7, 8.0 Hz, 2H), 7.60 (s, 1H), 7.43 (pd, J = 6.9, 1.6 Hz, 
2H), 7.28 (s, 1H), 7.19 (d, J = 2.1 Hz, 1H), 6.82 (d, J = 2.1 Hz, 1H), 4.53 (d, J = 3.0 Hz, 1H), 3.99 
(d, J = 2.8 Hz, 2H), 3.37 (td, J = 11.9, 2.9 Hz, 1H), 3.22 (td, 1H), 2.96 (s, 6H), 2.05 (dd, J = 13.7, 
3.3 Hz, 1H), 1.88 (t, J = 12.9 Hz, 1H), 1.21 (s, 9H). 
 
70 (R)-4-((S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanamido)-N,N-dimethyl-6-
(naphthalen-2-ylmethyl)-1,2,3,4-tetrahydroquinoline-8-carboxamide. 70 was synthesized 
following General Procedure (C) from intermediate 70-4. Step 1: Sulfinamide cleavage was 
carried out with 70-4 (45 mg, 0.10 mmol, 1.0 eq) and excess concentrated HCl, precipitating 
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product as a white solid, which was used without further purification. Step 2: Amide coupling was 
performed with the aminium chloride salt of 70-4 (54 mg, 0.14 mmol, 1.0 eq), di-Boc-Dmt (61 
mg, 0.15 mmol, 1.1 eq), and PyBOP (78 mg, 0.15 mmol, 1.1 eq), followed by DIPEA (0.24 mL, 
1.36 mmol, 10 eq). Crude product was carried forward to Step 3: TFA deprotection, followed by 
purification by reverse-phase semi-preparative HPLC, as described in General Procedure (C). 
Final yield not calculated. 1H NMR (500 MHz, Methanol-d4) δ 8.21 (d, J = 7.8 Hz, 1H), 7.77 (d, 
J = 7.8 Hz, 1H), 7.75 – 7.69 (m, 2H), 7.57 (s, 1H), 7.44 – 7.37 (m, 2H), 7.25 (dd, J = 8.5, 1.8 Hz, 
1H), 6.99 (d, J = 2.0 Hz, 1H), 6.84 (d, J = 2.1 Hz, 1H), 6.47 (d, J = 6.8 Hz, 2H), 4.95 – 4.89 (m, 
1H), 3.94 (s, 2H), 3.81 (dd, J = 11.5, 5.1 Hz, 1H), 3.28 – 3.20 (m, 1H), 3.02 – 2.85 (m, 6H), 2.41 
(t, J = 12.3 Hz, 1H), 2.26 (s, 6H), 1.70 – 1.61 (m, 1H), 1.51 (dt, J = 13.5, 3.7 Hz, 1H). Analytical 
HPLC retention time: 36.8 min. 
Compound 72 
 
72-1 1-acetyl-6-benzyl-8-methyl-2,3-dihydroquinolin-4(1H)-one. Intermediate 72-1 was 
synthesized following General Procedure (A) from intermediate 9-6 (570 mg, 2.27 mmol, 1.0 
eq), and Ac2O (15 mL, excess). Yield not calculated. NMR identified two rotomers, which was 
supported by HSQC NMR. 1H NMR (500 MHz, Chloroform-d) δ 7.68 (d, J = 2.3 Hz, 1H), 7.28 
(d, J = 7.9 Hz, 3H), 7.18 (d, J = 7.2 Hz, 3H), 5.06 (dd, J = 13.4, 5.8 Hz, 1H), 4.26 (t, J = 9.1 Hz, 
0.5H), 3.95 (d, J = 10.1 Hz, 2H), 3.88 – 3.77 (m, 0.5H), 3.32 (td, J = 13.1, 3.4 Hz, 0.5H), 2.91 (td, 
N
H
O
N
A
 9-6 72-1
O
O
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J = 13.7, 10.4, 4.8 Hz, 0.5H), 2.89 – 2.80 (m, 0.5H), 2.72 (d, J = 18.0 Hz, 0.5H), 2.60 (d, J = 17.9 
Hz, 0.5H), 2.38 – 2.34 (m, 1.5H), 1.97 (d, J = 2.5 Hz, 1.5H). 13C NMR (126 MHz, cdcl3) δ 195.57, 
194.25, 171.04, 168.87, 141.84, 141.11, 140.14, 139.92, 139.45, 137.53, 137.16, 136.98, 135.06, 
134.71, 133.11, 131.22, 129.45, 128.87, 128.69, 128.59, 128.08, 127.67, 126.50, 126.32, 125.89, 
125.76, 125.05, 115.38, 44.12, 41.32, 40.04, 39.51, 24.83, 22.61, 21.64. 
 
 
72-2 (R)-N-((R)-1-acetyl-6-benzyl-8-methyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-
sulfinamide. Intermediate 72-2 was synthesized following General Procedure (B) from 
intermediate 72-1 (90 mg, 0.31 mmol, 1.0 eq), (R)-2-methyl-2-propanesulfinamide (112 mg, 0.92 
mmol, 3.0 eq), and Ti(OEt)4 (0.39 mL, 1.84 mmol, 6.0 eq), then NaBH4 (70 mg, 1.84 mmol, 6.0 
eq). Yield: 121 mg, 98%. 1H NMR (500 MHz, Chloroform-d) δ 7.32 – 7.28 (m, 2H), 7.21 (d, J = 
7.0 Hz, 3H), 7.08 (s, 1H), 6.99 (s, 1H), 4.52 (dt, J = 4.7, 2.5 Hz, 1H), 3.94 (d, J = 20.2 Hz, 2H), 
2.99 (ddd, J = 13.3, 9.1, 4.4 Hz, 1H), 2.84 (tt, J = 10.2, 4.5 Hz, 1H), 2.54 (dddd, J = 14.0, 9.4, 4.4, 
2.8 Hz, 1H), 1.88 (d, J = 1.6 Hz, 3H), 1.81 (dq, J = 14.0, 8.8 Hz, 1H), 1.21 (d, J = 1.7 Hz, 9H). 13C 
NMR (126 MHz, cdcl3) δ 171.05, 140.13, 137.44, 135.28, 134.08, 131.76, 130.33, 128.96, 128.63, 
128.53, 126.37, 126.29, 123.22, 51.71, 41.45, 39.48, 39.11, 28.61, 22.60, 22.12. 
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72 (S)-N-((R)-1-acetyl-6-benzyl-8-methyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-amino-3-(4-hydroxy-
2,6-dimethylphenyl)propanamide. 72 was synthesized following General Procedure (C) from 
intermediate 72-2. Step 1: Sulfinamide cleavage was carried out with 72-2 (83 mg, 0.21 mmol, 
1.0 eq) and excess concentrated HCl, precipitating product as a white solid, which was used 
without further purification. Step 2: Amide coupling was performed with the aminium chloride 
salt of 72-2 (37 mg, 0.11 mmol, 1.0 eq), di-Boc-Dmt (51 mg, 0.12 mmol, 1.1 eq), and PyBOP (64 
mg, 0.12 mmol, 1.1 eq), followed by DIPEA (0.20 mL, 1.12 mmol, 10 eq). Crude product was 
carried forward to Step 3: TFA deprotection, followed by purification by reverse-phase semi-
preparative HPLC, as described in General Procedure (C). Final yield not calculated. 1H NMR (500 
MHz, Methanol-d4) δ 7.27 – 7.20 (m, 2H), 7.16 (dq, J = 7.5, 4.6, 2.9 Hz, 3H), 7.03 (d, J = 6.2 Hz, 
1H), 7.01 – 6.96 (m, 1H), 6.94 (s, 0H), 6.52 (d, J = 3.3 Hz, 2H), 4.66 – 4.49 (m, 1H), 3.98 (dd, J = 
11.3, 4.8 Hz, 0.5H), 3.94 (s, 1H), 3.88 (d, J = 15.7 Hz, 1H), 3.83 – 3.78 (m, 0.5H), 3.31 (s, 2H), 3.26 
(dd, J = 13.7, 11.6 Hz, 1H), 3.09 (dd, J = 14.0, 4.7 Hz, 1H), 2.72 (ddd, J = 13.6, 9.2, 5.2 Hz, 0.5H), 
2.33 – 2.26 (m, 6H), 2.02 (d, J = 6.3 Hz, 1.5H), 1.88 (d, J = 8.3 Hz, 1.5H), 1.48 – 1.28 (m, 0.5H), 1.21 
– 1.10 (m, 0.5H). Calculated [M+H]+: 486.28. ESI-MS mass observed: 486.3 (M+H) and 508.3 
(M+Na). Analytical HPLC retention time: 34.6 min. 
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Compound 73 
 
73-1 1-acetyl-6-benzyl-8-(trifluoromethyl)-2,3-dihydroquinolin-4(1H)-one. Intermediate 73-1 was 
synthesized following General Procedure (A) from intermediate 15-6 (175 mg, 0.57 mmol, 1.0 
eq), and Ac2O (12 mL, excess). Yield: 45 mg, 23%. NMR identified two rotomers, supported by 
HSQC NMR. 1H NMR (500 MHz, Chloroform-d) δ 8.01 (d, J = 5.8 Hz, 1H), 7.72 – 7.65 (m, 1H), 
7.32 (dd, J = 11.3, 7.3 Hz, 2H), 7.29 – 7.22 (m, 1H), 7.19 (t, J = 6.0 Hz, 2H), 5.08 (dd, J = 13.4, 
6.2 Hz, 0.5H), 4.32 (dd, J = 14.5, 5.4 Hz, 0.5H), 4.05 (d, J = 15.3 Hz, 2H), 3.90 (td, J = 14.0, 3.9 
Hz, 0.5H), 3.40 (td, J = 13.2, 3.8 Hz, 0.5H), 2.97 (ddd, J = 19.2, 13.1, 6.3 Hz, 0.5H), 2.86 (td, J = 
13.0, 6.6 Hz, 0.5H), 2.82 – 2.75 (m, 0.5H), 2.64 (dd, J = 18.6, 3.7 Hz, 0.5H), 2.37 (s, 1.5H), 1.95 
(s, 1.5H). 13C NMR (126 MHz, cdcl3) δ 194.23, 171.41, 141.68, 133.27, 131.63, 131.23, 129.12, 
129.00, 127.12, 126.93, 46.69, 44.54, 41.38, 39.88, 39.40, 22.35, 22.06. 
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73-2 (R)-N-((R)-1-acetyl-6-benzyl-8-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-
methylpropane-2-sulfinamide Intermediate 73-2 was synthesized following General Procedure 
(B) from intermediate 73-1 (45 mg, 0.13 mmol, 1.0 eq), (R)-2-methyl-2-propanesulfinamide (47 
mg, 0.39 mmol, 3.0 eq), and Ti(OEt)4 (0.17 mL, 0.78 mmol, 6.0 eq), then NaBH4 (30 mg, 0.78 
mmol, 6.0 eq). Yield: 52 mg, 90%. Carried forward without NMR characterization. 
 
73 (S)-N-((R)-1-acetyl-6-benzyl-8-(trifluoromethyl)-1,2,3,4-tetrahydroquinolin-4-yl)-2-amino-3-
(4-hydroxy-2,6-dimethylphenyl)propanamide. 73 was synthesized following General Procedure 
(C) from intermediate 73-2. Step 1: Sulfinamide cleavage was carried out with 73-2 (40 mg, 0.09 
mmol, 1.0 eq) and excess concentrated HCl, precipitating product as a white solid, which was used 
without further purification. Step 2: Amide coupling was performed with the aminium chloride 
salt of 73-2 (32 mg, 0.08 mmol, 1.0 eq), di-Boc-Dmt (38 mg, 0.09 mmol, 1.1 eq), 6-Cl HOBt (16 
mg, 0.09 mmol, 1.1 eq), and PyBOP (48 mg, 0.09 mmol, 1.1 eq), followed by DIPEA (0.15 mL, 
0.83 mmol, 10 eq). Crude product was carried forward to Step 3: TFA deprotection, followed by 
purification by reverse-phase semi-preparative HPLC, as described in General Procedure (C). 
Final yield not calculated. 1H NMR (500 MHz, Methanol-d4) δ 7.46 (d, J = 4.2 Hz, 1H), 7.38 (dd, 
J = 20.8, 11.2 Hz, 1H), 7.27 (q, J = 6.9 Hz, 3H), 7.18 (d, J = 7.3 Hz, 4H), 6.59 (t, J = 7.2 Hz, 1H), 
6.53 (s, 2H), 4.80 (dd, J = 11.9, 6.7 Hz, 0.5H), 4.74 – 4.66 (m, 0.5H), 4.55 (dd, J = 11.3, 6.6 Hz, 
1H), 4.07 (d, J = 5.4 Hz, 2H), 4.02 (s, 1H), 3.99 – 3.93 (m, 1H), 3.25 (d, J = 12.0 Hz, 1H), 3.10 
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(dd, J = 14.3, 5.4 Hz, 1H), 2.75 – 2.68 (m, 0.5H), 2.28 (s, 6H), 1.84 (d, J = 5.2 Hz, 3H), 1.32 (s, 
0.5H), 1.18 (s, 0.5H). Calculated [M+H]+: 540.25. QTOF high-res mass observed: 540.2467 
(M+H). Analytical HPLC retention time: 38.1 min. 
 
Compound 74 
 
74-1 1-acetyl-6-benzyl-8-bromo-2,3-dihydroquinolin-4(1H)-one. Intermediate 74-1 was 
synthesized following General Procedure (A) from intermediate 8-5 (158 mg, 0.50 mmol, 1.0 
eq), and Ac2O (10 mL, excess). Yield: 63 mg, 34%. 1H NMR (500 MHz, Chloroform-d) δ 7.79 (d, 
J = 2.0 Hz, 1H), 7.65 (d, J = 2.0 Hz, 1H), 7.32 (t, J = 7.5 Hz, 2H), 7.26 (d, J = 7.2 Hz, 1H), 7.21 – 
7.16 (m, 2H), 5.07 (s, 1H), 3.98 (s, 2H), 3.36 (s, 1H), 2.90 (s, 1H), 2.64 (d, J = 19.1 Hz, 1H), 2.14 
(s, 2H). 13C NMR (126 MHz, cdcl3) δ 138.98, 128.88, 128.86, 127.19, 126.80, 44.18, 41.06, 39.42, 
22.71. 
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74-2 (R)-N-((R)-1-acetyl-6-benzyl-8-bromo-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-
sulfinamide Intermediate 74-2 was synthesized following General Procedure (B) from 
intermediate 74-1 (63 mg, 0.17 mmol, 1.0 eq), (R)-2-methyl-2-propanesulfinamide (60 mg, 0.49 
mmol, 3.0 eq), and Ti(OEt)4 (0.21 mL, 0.99 mmol, 6.0 eq), then NaBH4 (38 mg, 0.99 mmol, 6.0 
eq). Yield not calculated. 1H NMR (500 MHz, Chloroform-d) δ 7.45 (d, J = 1.9 Hz, 1H), 7.33 (dt, 
J = 10.6, 7.6 Hz, 4H), 7.22 (d, J = 8.1 Hz, 2H), 7.12 (d, J = 1.8 Hz, 1H), 4.52 (dt, J = 4.3, 2.8 Hz, 
1H), 3.95 (s, 2H), 3.04 (ddd, J = 13.2, 9.2, 4.2 Hz, 0.5H), 2.88 (td, J = 10.9, 8.8, 5.2 Hz, 0.5H), 
2.61 – 2.53 (m, 0.5H), 2.49 (dt, J = 12.5, 6.3 Hz, 0.5H), 2.04 (s, 3H), 1.88 – 1.79 (m, 0.5H), 1.57 
(d, J = 13.1 Hz, 0.5H), 1.20 (s, 9H). 13C NMR (126 MHz, cdcl3) δ 142.18, 137.57, 133.93, 129.14, 
128.97, 128.86, 127.97, 126.87, 126.69, 55.74, 55.30, 52.07, 47.33, 41.29, 39.45, 28.96, 24.97, 
22.72, 22.65. 
 
 
74 (S)-N-((R)-1-acetyl-6-benzyl-8-bromo-1,2,3,4-tetrahydroquinolin-4-yl)-2-amino-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide. 74 was synthesized following General Procedure (C) 
from intermediate 74-2. Step 1: Sulfinamide cleavage was carried out with 74-2 and excess 
concentrated HCl, precipitating product as a white solid, which was used without further 
purification. Step 2: Amide coupling was performed with the aminium chloride salt of 74-2 (58 
mg, 0.14 mmol, 1.0 eq), di-Boc-Dmt (57 mg, 0.14 mmol, 1.0 eq), 6-Cl HOBt (26 mg, 0.15 mmol, 
N
HN
O
NH2 OH
N
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O
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1.1 eq), and PyBOP (79 mg, 0.15 mmol, 1.1 eq), followed by DIPEA (0.24 mL, 1.4 mmol, 10 eq). 
Crude product was carried forward to Step 3: TFA deprotection, followed by purification by 
reverse-phase semi-preparative HPLC, as described in General Procedure (C). Final yield not 
calculated. Calculated [M+H]+: 550.17. ESI-MS mass observed: 550.2 (79Br M+H) ,552.2 (81Br 
M+H), 572.2 (79Br M+Na), and 574.2 (81Br M+H). Analytical HPLC retention time: 36.0 min. 
 
Compound 76 
 
76-1 1-acetyl-6-benzyl-8-propyl-2,3-dihydroquinolin-4(1H)-one. Intermediate 76-1 was 
synthesized following General Procedure (A) from intermediate 11-6 (202 mg, 0.72 mmol, 1.0 
eq), and Ac2O (8 mL, excess). Yield: 180 mg, 78%. 1H NMR (500 MHz, Chloroform-d) δ 7.67 (d, 
J = 2.1 Hz, 1H), 7.33 – 7.29 (m, 2H), 7.27 (d, J = 13.4 Hz, 1H), 7.24 – 7.20 (m, 1H), 7.20 – 7.16 
(m, 2H), 5.07 (ddd, J = 12.9, 6.2, 1.2 Hz, 1H), 3.97 (d, J = 10.0 Hz, 2H), 3.31 (td, J = 13.1, 3.7 
Hz, 1H), 2.92 (ddd, J = 19.0, 13.2, 6.1 Hz, 1H), 2.69 – 2.63 (m, 1H), 2.60 (ddd, J = 18.6, 3.7, 1.3 
Hz, 1H), 2.49 (ddd, J = 14.3, 8.7, 5.4 Hz, 2H), 1.95 (s, 3H), 1.69 – 1.44 (m, 2H), 0.87 (t, J = 7.3 
Hz, 3H). 13C NMR (126 MHz, cdcl3) δ 195.73, 171.29, 141.67, 140.53, 140.07, 138.03, 136.08, 
135.76, 128.95, 128.81, 128.70, 126.60, 126.43, 125.90, 125.32, 44.27, 41.56, 39.55, 33.03, 24.22, 
21.98, 13.80. 
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76-2 (R)-N-((R)-1-acetyl-6-benzyl-8-propyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-
sulfinamide. Intermediate 76-2 was synthesized following General Procedure (B) from 
intermediate 76-1 (180 mg, 0.56 mmol, 1.0 eq), (R)-2-methyl-2-propanesulfinamide (204 mg, 1.68 
mmol, 3.0 eq), and Ti(OEt)4 (0.70 mL, 3.36 mmol, 6.0 eq), then NaBH4 (127 mg, 3.36 mmol, 6.0 
eq). Yield not calculated. 1H NMR (500 MHz, Chloroform-d) δ 7.31 (qd, J = 8.0, 3.8 Hz, 3H), 
7.24 – 7.19 (m, 3H), 7.11 (d, J = 2.0 Hz, 1H), 6.99 (d, J = 2.1 Hz, 1H), 4.88 – 4.79 (m, 0.5H), 4.76 
(ddd, J = 13.0, 9.0, 6.6 Hz, 0.5H), 4.52 (dt, J = 4.6, 2.4 Hz, 1H), 3.95 (s, 2H), 2.95 (ddd, J = 13.3, 
9.2, 4.5 Hz, 0.5H), 2.81 (ddd, J = 13.4, 9.1, 5.2 Hz, 0.5H), 2.56 (dtdd, J = 24.1, 11.1, 8.9, 6.2 Hz, 
2H), 2.42 (tdd, J = 10.9, 5.3, 1.9 Hz, 1H), 1.87 (s, 3H), 1.85 – 1.78 (m, 0.5H), 1.63 – 1.43 (m, 2H), 
1.23 (s, 9H), 0.84 (td, J = 7.3, 3.2 Hz, 3H). 13C NMR (126 MHz, cdcl3) δ 140.42, 138.96, 135.47, 
130.71, 129.29, 129.09, 128.76, 128.65, 126.47, 126.32, 55.54, 51.83, 41.71, 39.75, 32.82, 28.76, 
24.06, 22.74, 22.68, 22.24, 13.91. 
 
76 (S)-N-((R)-1-acetyl-6-benzyl-8-propyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-amino-3-(4-
hydroxy-2,6-dimethylphenyl)propanamide. 76 was synthesized following General Procedure (C) 
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from intermediate 76-2. Step 1: Sulfinamide cleavage was carried out with 76-2 and excess 
concentrated HCl, precipitating product as a white solid, which was used without further 
purification. Step 2: Amide coupling was performed with the aminium chloride salt of 76-2 (60 
mg, 0.17 mmol, 1.0 eq), di-Boc-Dmt (75 mg, 0.18 mmol, 1.1 eq), 6-Cl HOBt (31 mg, 0.18 mmol, 
1.1 eq), and PyBOP (93 mg, 0.18 mmol, 1.1 eq), followed by DIPEA (0.29 mL, 1.67 mmol, 10 
eq). Crude product was carried forward to Step 3: TFA deprotection, followed by purification by 
reverse-phase semi-preparative HPLC, as described in General Procedure (C). Final yield not 
calculated. Calculated [M+H]+: 514.31. ESI-MS mass observed: 514.3 (M+H) and 536.3 (M+Na). 
Analytical HPLC retention time: 39.2 min. 
 
Compound 77 
 
77-1 1-acetyl-6,8-dibenzyl-2,3-dihydroquinolin-4(1H)-one. Intermediate 77-1 was synthesized 
following General Procedure (A) from intermediate 8-6 (310 mg, 0.95 mmol, 1.0 eq), and Ac2O 
(15 mL, excess). Yield: 158 mg, 45%. NMR identified multiple rotational states. 1H NMR (500 
MHz, Chloroform-d) δ 7.70 (dd, J = 14.0, 2.2 Hz, 2H), 7.27 (d, J = 7.1 Hz, 7H), 7.21 (d, J = 6.6 
Hz, 4H), 7.15 (d, J = 7.7 Hz, 2H), 7.12 (d, J = 7.6 Hz, 2H), 7.04 (d, J = 7.4 Hz, 4H), 5.00 (dd, J = 
13.0, 6.1 Hz, 0.5H), 4.01 – 3.94 (m, 0.5H), 3.94 (d, J = 3.5 Hz, 4H), 3.49 (td, J = 14.1, 3.4 Hz, 
0.5H), 3.17 (td, J = 13.1, 3.7 Hz, 0.5H), 2.93 (ddd, J = 19.2, 13.2, 6.1 Hz, 0.5H), 2.81 (ddd, J = 
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19.2, 13.8, 5.7 Hz, 0.5H), 2.67 (dd, J = 17.9, 3.8 Hz, 0.5H), 2.58 (dd, J = 18.7, 3.6 Hz, 0.5H), 2.21 
(s, 1.5H), 2.05 (s, 1.5H). 13C NMR (126 MHz, cdcl3) δ 195.16, 193.85, 170.70, 168.53, 141.27, 
140.49, 140.33, 139.98, 139.74, 139.52, 139.47, 139.17, 137.86, 136.87, 136.72, 136.56, 128.82, 
128.65, 128.60, 128.57, 128.54, 128.48, 128.42, 128.37, 128.31, 128.29, 128.25, 128.16, 128.01, 
126.27, 126.19, 126.04, 126.02, 125.85, 125.45, 77.00, 46.34, 43.69, 41.04, 39.60, 39.05, 38.71, 
37.04, 22.22, 21.63. 
 
77-2 (R)-N-((R)-1-acetyl-6,8-dibenzyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-methylpropane-2-
sulfinamide. Intermediate 77-2 was synthesized following General Procedure (B) from 
intermediate 77-1 (158 mg, 0.43 mmol, 1.0 eq), (R)-2-methyl-2-propanesulfinamide (155 mg, 1.28 
mmol, 3.0 eq), and Ti(OEt)4 (0.56 mL, 2.56 mmol, 6.0 eq), then NaBH4 (98 mg, 2.56 mmol, 6.0 
eq). Yield not calculated. H NMR not available. 
 
 
77 (S)-N-((R)-1-acetyl-6,8-dibenzyl-1,2,3,4-tetrahydroquinolin-4-yl)-2-amino-3-(4-hydroxy-2,6-
dimethylphenyl)propanamide. 77 was synthesized following General Procedure (C) from 
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intermediate 77-2. Step 1: Sulfinamide cleavage was carried out with 77-2 and excess 
concentrated HCl, precipitating product as a white solid, which was used without further 
purification. Step 2: Amide coupling was performed with the aminium chloride salt of 77-2 (63 
mg, 0.15 mmol, 1.0 eq), di-Boc-Dmt (69 mg, 0.17 mmol, 1.1 eq), 6-Cl HOBt (26 mg, 0.15 mmol, 
1.0 eq), and PyBOP (80 mg, 0.15 mmol, 1.0 eq), followed by DIPEA (0.26 mL, 1.5 mmol, 10 eq). 
Crude product was carried forward to Step 3: TFA deprotection, followed by purification by 
reverse-phase semi-preparative HPLC, as described in General Procedure (C). Final yield not 
calculated. Calculated [M+H]+: 562.3. ESI-MS mass observed: 562.3 (M+H) and 584.3 (M+Na). 
Analytical HPLC retention time: 42.4 min. 
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Chapter 5: Conclusions & Future Directions 
5.1  Observations at C-8 
 The endogenous opioid peptides such as the enkephalins, endorphins, and dynorphins share 
the N-terminal Tyr1-Gly2-Gly3-Phe4-X5 sequence, where X is either Met or Leu, highlighting an 
importance for the conserved tetrapeptide N-terminus. As indicated by pharmacophore models, the 
di-glycine residues primarily act as a flexible spacer region between two key aryl pharmacophores, 
Tyr1 and Phe4. The first peptidomimetic series reported by our lab, synthesized by L.Y.M., A.A.H. 
and A.M.B., exchanged Tyr1 for the dimethyl analogue Dmt and explored the effects of five aryl 
Phe4 bioisosteres located at the C-6 position of our scaffold. Subsequent work continued to probe 
C-6, and eventually branched to N-1. Recently, that exploration has expanded to include 
modifications to the C-8 position, which was the focus of Chapter 2. The 24 substitutions 
investigated here varied widely in length, bulk, lipophilicity, and polarity and included the 
following motifs: alkanes, halogens, amides, esters, acids, saturated heterocycles, flexible and 
inflexible aromatics, H-bond donors, H-bond acceptors, as well as nitrile and amino acid 
substitutions. An intentional emphasis was placed on diversity of chemical matter throughout this 
SAR campaign so as to thoroughly explore the chemical space with a minimal number of 
analogues.  
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 One major issue with prior analogues focusing exclusively on C-6 modifications was a 
high degree of selectivity for MOR over DOR. Though it is not known what specific binding ratio 
is optimal between MOR and DOR, the 20:1 to 200:1 selectivity for MOR limited the bifunctional 
aspect of these compounds. Based on the first fifteen compounds synthesized in the C-8 series, the 
flexible aryl C-8 substitutions of compounds 8 (C-8 = benzyl) and 18 (ethylphenyl) provided the 
best increase in DOR affinity with a modest decrease in MOR affinity, yielding significantly more 
balanced profiles (2:1 and 4:1 respectively). However, all analogues in this series also elicited low-
potency partial DOR agonism whereas the target had been DOR antagonism.  
Subsequent synthetic development allowed access to a C-8 carbonyl motif as in the case of 
the amides, esters, and acid analogues 20-27. These carbonyl-featuring analogues consistently 
displayed the desired DOR antagonist profile. Additionally, the flexible, lipophilic ethyl ester of 
analogue 26 retained the MOR/DOR affinity balance achieved by the flexible aryl C-8 pendants 
(4:1 MOR/DOR), achieving a highly favorable in vitro profile. This favorability was bolstered by 
the in vivo antinociceptive activity of analogue 26, solidifying this as a noteworthy improvement 
over the unsubstituted C-8 lead peptidomimetic 1. This success was replicated with a less flexible, 
less lipophilic dimethyl amide analogue 20. 20 not only retained the optimal functional profile 
(MOR agonist/DOR antagonist), but also maintained an only 6-fold selectivity for MOR over DOR 
in terms of binding affinity. Significantly, analogue 20 reduced ClogP to 2.2 compared to 3.1 for 
the lead 1 and 4.3 for the ethyl ester analogue 26 and maintained antinociceptive activity. These 
two compounds were featured as highlights of the C-8 series in Fig. 13, replicated below with the 
added comparison to analogue 1 for convenience in Fig. 25. The only detraction of 20 is the loss 
of MOR potency—9 nM compared to 1.6 nM for lead 1 and 4.9 for ethyl ester analogue 26. 
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Figure 25. Summary Profiles of Top C-8 In Vivo Candidates 20 and 26 Compared to Lead 1 
 
 Based on the library of C-8 substituted compounds 8-31 discussed at length in Chapter 2, 
the author notes the following observations: 
1. C-8 substituted analogues, with the exception of the saturated amino heterocycles, display 
better binding balance between MOR and DOR (closer to 1:1) than lead peptidomimetic 1. 
 
2. Most substitutions elicit low-potency DOR agonism, though carbonyl motifs reverse this 
trend and reliably provide DOR antagonism.  
 
3. Small, non-polar alkyl chains and non-H-bond-donating carbonyl substituents are well-
tolerated in vivo (i.e. dimethyl amide and esters fully active, secondary amides inactive). 
 
4. Halogens and amines were also poorly tolerated in vivo and offered limited benefit in vitro. 
 
5. C-8 substituted analogues display 1 to 10 nM MOR potency, though deep, lipophilic n-
propyl, n-butyl, ethylphenyl and benzofuranyl substitutions diverge from this trend, 
displaying double-digit nanomolar potency. 
 
6. DOR and KOR potency is consistently 10 nM or higher, with most in the 100 nM range. 
 
7. Duration of action is not significantly improved by C-8 modifications—the longest-acting 
analogues display a 2.5 h duration of action compared to 2.0 h for lead peptidomimetic 1. 
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DOR antagonist (<10% stim, Ke = 43 nM)
MOR/DOR selectivity: 4:1
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DOR antagonist (<10% stim), Ke not yet tested
MOR/DOR selectivity: 6:1
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Full antinociceptive activity (100% MPE)
Duration of action = 2.0 h; ClogP = 2.2
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MOR agonist (81% stim, EC50 = 1.6 nM)
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Presently, analogue 20 is the only compound from this series under further investigation 
for in vivo tolerance and/or dependence. However, 26 may also be a viable candidate for further 
evaluation. 
Chapter 4 discussed the combined effects of N-acetyl and C-8 moieties, which were 
evaluated in vitro and in vivo via a short series of compounds (71-77). These analogues all showed 
highly similar in vitro profiles, with MOR affinity between 0.1 and 0.2 nM and DOR affinity 
ranging from 1 to 2 nM. The one exception, 77, showed a much more balanced 1:1 binding profile 
with 0.4 nM affinity at both MOR and DOR. Functionally, all compounds evaluated were MOR 
agonists/partial DOR agonists. The only analogue showing full antinociceptive activity was the C-
8 methyl analogue 72. Based on this short series of analogues, the pharmacological profile 
associated with these combined N-acetyl/C-8 substitutions is most heavily impacted by the N-
acetyl motif. All analogues in this series are nearly indistinguishable from the N-acetyl/C-8 H lead 
32. As such, these combined substitutions offer no discernible improvement either in vitro or in 
vivo relative to the C-8/N-H analogues. Furthermore, the N-acetyl group sterically precludes a 
number of advantageous C-8 motifs from being incorporated. Specifically, the carbonyl analogues 
which showed the most favorable in vitro profile could not be incorporated in tandem with an N-
acetyl motif. As such, it is recommended that further investigations at C-8 be done in the absence 
of an N-1 modification.  
5.2  Future Directions for C-8 Utilization  
 Moving forward, the C-8 position could be an advantageous position to exploit in order to 
advance various projects yet undeveloped. The first of these potential future directions involves a 
follow-up to the previously unsuccessful 11C-radiolabeling project discussed in Chapter 4. Based 
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on the bioavailability of the small, non-H-bonding carbonyl motifs at C-8 tested thus far, the 
synthesis of a methyl ester at C-8 is suggested (see Fig. 26, analogue 79). Not only will this 
analogue decrease ClogP relative to the bioavailable ethyl ester (ClogP = 3.7 for 79 vs. 4.3 for 26), 
it is predicted that this will maintain bioavailability if existing trends hold true. Furthermore, 79 is 
likely to maintain the MOR agonist/DOR antagonist profile of the carbonyl series, offering an 
additional compound with favorable in vitro pharmacology. 
 
Figure 26. Structures of Proposed Compound 79 and its Radiolabeled Analogue [11C]79 
 
 Should analogue 79 demonstrate the predicted in vivo activity, a radiolabeled analogue 
[11C]79 could then be synthesized and evaluated via PET to observe CNS penetrance. An 
immediately apparent liability of this approach is the positioning of the radiolabel on an ester 
moiety, as esters are notoriously susceptible to hydrolysis. Hydrolysis of the radiolabel would 
increase background signal and limit resolution. However, a similar model is currently used in the 
field of PET for labeling opioid receptors. The radioligand [11C]carfentanil, the synthesis and 
utilization of which has been widely reported in the literature120–131 (including by those in the Peter 
Scott lab at the University of Michigan132–134), also employs a 11C-labeled methyl ester. Using this 
radioligand as a model should facilitate the synthesis and evaluation of the methyl ester 
peptidomimetic [11C]79. Additionally, as demonstrated by the wealth of studies utilizing 
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[11C]carfentanil, hydrolysis of the radioligand is not likely to be a limiting factor in the PET 
analysis of the proposed peptidomimetic radioligand.  
 The radiosynthesis of [11C]79, outlined in Scheme 11, is designed based on the updated 
[11C]carfentanil radiosynthesis recently reported by members of the Scott lab133 and utilizes input 
from Dr. Allan Brooks of said research group. The Boc-protected desmethyl precursor (Boc-25) 
has been synthesized in half-gram quantities and is presently available for utilization, should the 
prerequisite synthesis and pharmacology be executed and yield favorable results.  
 
Scheme 11. Proposed radiosynthesis of [11C]79 
 
 An additional future direction utilizing the C-8 position aims to improve bioavailability by 
incorporation of a glucoserine moiety. Our lab and others have previously reported on the use of a 
glycosylated amino acid residue to boost transport into the CNS.82,108,111 Fig. 27 shows the cyclic 
peptide KSK-103 developed by our lab, which gained in vivo activity via glucoserine attachment 
(VRP-26). By comparison, the unglycosylated peptide showed no activity in vivo. In Fig. 27, one 
can see the overlap between the spatial orientation of the glucoserine motif (shown in blue) of 
VRP-26 and of the proposed compound 80 in relation to the Tyr1 and Phe4 isosteres. 
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Figure 27. Structures of the Unglycosylated Peptide KSK-103, the Bioavailable VRP-26, and 80 
  
 
 As described in Chapter 2 as well as the above C-8 observations, substitutions at the C-8 
position were well-tolerated and had little impact on binding. Despite carbonyl moieties impacting 
the functional profiles of C-8 substituted compounds, even the larger C-8 substitutions show 
similar binding profiles to their smaller or unsubstituted counterparts. Highlighted in Table 19 are 
the in vitro profiles of analogues 1, 30, and 31. The notable similarity between the unsubstituted, 
piperazine-substituted, and Dmt-piperazine-substituted analogues suggests that even the larger 
moieties at this position are well-tolerated, as substitutions at this position are likely able to adopt 
a solvent-accessible conformation. Using this to our advantage, it may be possible to increase BBB 
permeability and solubility with a similarly-sized glucoserine moiety without significantly 
impacting binding at MOR and DOR. Additionally, if this analogue should prove promising, the 
chemistry is presently established to replace the C-6 benzyl pendant with a 2-naphthyl pendant, 
which may improve the in vitro profile.  
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Table 19. Large, Hydrophilic C-8 Substitution Show Limited Impact on Binding Affinity 
  
a Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [3H]-diprenorphine in membrane 
preparations. Functional data were obtained using agonist induced stimulation of [35S]-GTPγS binding. Potency is 
represented as EC50 (nM) and efficacy as percent maximal stimulation relative to standard agonist DAMGO (MOR), 
DPDPE (DOR), or U69,593 (KOR) at 10 μM. All values are expressed as the mean of three separate assays performed 
in duplicate with standard error of the mean in parentheses. dns = does not stimulate. † indicates n=2. 
 
 The synthesis of analogue 80 was recently attempted as outlined in Scheme 12. However, 
synthesis stalled at the amide coupling between the peptidomimetic acid and glucoserine amine.   
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Ki (nM) EC50 (nM) % stim
# C-8 R Group MOR DOR KOR DOR Ki / MOR Ki
MOR DOR KOR MOR DOR KOR
1 H 0.22(0.02)
9.4
(0.8)
68
(2)
43 1.6
(0.3)
110
(6)
>500 81
(2)
16
(2)
22
(2)
30 piperazine 0.35(0.18)
15
(3)
1.9
(0.5)
43 8.2
(3.5)
290
(100)
170
(67)
60
(2)
18
(1)
17
(1)
31 piperazine-Dmt 0.31(0.16)
2.6
(0.5)
7
(2)
20 5.9
(0.7) dns
† dns 86(8) dns
† dns
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Scheme 12. Full Synthetic Scheme of Glucoserine Conjugated Peptidomimetic 80 
 
 
 
 The attempted synthesis of 80 begins as previously described for analogue 25. The key 
intermediate Boc-25 was synthesized in 9 steps as outlined in Scheme 12. This key intermediate, 
useful for both the glucoserine conjugate analogue 80 as well as the proposed radioligand [11C]79 
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described above, has been synthesized in half-gram quantities. The glucoserine component was to 
be incorporated using resin-bound peptide chemistry. The glucoserine free acid, available on-hand 
due to the prior synthesis of VRP-26, was loaded onto a Rink resin after Fmoc deprotection of the 
resin. A Rink resin was selected because after ligand cleavage from the resin, the carboxylate is 
converted to a terminal carboxamide which is more CNS penetrant than the carboxylic acid. 
Glucoserine loading onto the resin and subsequent Fmoc deprotection proceeded as expected, 
confirmed by ninhydrin stain and HPLC at each step. Unfortunately, amide coupling between the 
peptidomimetic carboxylate and glucoserine amine—attempted three times using different 
coupling reagents—failed to produce the desired product. There was concern that the sterics of the 
Rink resin could inhibit the amide coupling. Thus, in a fourth attempt, after loading the glucoserine 
onto the resin and removing the Fmoc group, the glucoserine moiety was cleaved with TFA, 
yielding the C-terminal carboxamide and free amine. Unfortunately, the attempted solution-phase 
peptide coupling yielded only a non-volatile oily substance with no relevant peaks in the UV 
spectrum as observed by HPLC. Again, the peptidomimetic component failed to couple to the 
glucoserine amine. Due to time constraints as well as the cost of starting materials, a fifth synthesis 
was not attempted.  
 Reasons for the lack of success of the synthesis outlined in Scheme 12 are elusive. The 
consistent result of an oily substance devoid of any appreciable UV activity is perplexing. This 
oily substance adhered to the HPLC column and was only removed after excessive washing, 
limiting the ability to inject higher concentrations of the unidentified substance. Organic/aqueous 
extraction and vacuum desiccation were unsuccessful at isolating any UV-active product, and TLC 
showed only uncoupled peptidomimetic fragment. It may be the case that the carboxylic acid, after 
reductive amination of the ketone, is significantly less reactive than the THQ carboxylate. Amide 
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couplings were generally low-yielding at the THQ stage and increasing electron density by 
removal of the ketone may further deactivate the acid. Further synthetic optimization may indeed 
prove fruitful toward developing analogue 80, however at present, this project is no longer being 
actively pursued.  
5.3  C-8 Conclusions 
 A diverse set of substitutions at C-8 have been investigated and reported in part in a 2018 
article in the journal ACS Chemical Neuroscience. This SAR campaign has demonstrated that C-
8 substitutions, with only two exceptions, serve to balance the relative affinities at MOR and DOR, 
reducing MOR selectivity. Additionally, while most substitutions demonstrate MOR and DOR 
agonism, carbonyl-substituted ligands decreased efficacy at both receptors yielding MOR 
agonist/DOR antagonist or, in some cases, MOR partial agonist/DOR antagonist ligands. In vivo, 
7 of the 24 ligands featuring C-8 modifications demonstrated full antinociceptive activity while 
two others were partially active. As outlined in section 5.1, some rules governing bioavailability 
in the context of C-8 substitutions have been observed, though further in vivo SAR development 
is needed to bolster these observations. At present, this SAR campaign has shown the greatest 
propensity for maintaining bioavailability of any SAR campaigns explored by our lab, with nearly 
one-third of all compounds showing full antinociceptive activity. The bioavailability of this series, 
paired with the ability to reduce MOR selectivity and to modulate functionality to fit the desired 
MOR agonist/DOR antagonist profile, sets this campaign apart as a successful area of exploration 
in the field of THQ-based bifunctional peptidomimetics. Two key analogues to come from the C-
8 campaign, 20 and 26, have been highlighted in Figs. 13 and 25 noting improvements in several 
areas of drug development. Moving forward, plans are underway for analogue 20 to be evaluated 
for antinociceptive tolerance in vivo. 
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 Two projects that have been partially developed were outlined in section 5.2, presently in 
the category of “future directions.” The background and supporting chemical context for both 
projects are well-founded and both are, by this author’s estimation, high-quality candidates for 
further research. The C-8 position is additionally viable as a useful chemical handle due to its 
predicted access to bulk solvent when bound to the opioid receptors. Based on the limited impact 
of large chemical motifs at C-8 on binding, this position could be utilized in other areas requiring 
a solvent-exposed handle. C-8 may be further functionalized to design fluorescent, proximity-
based (FRET or BRET) probes in an attempt to observe dimerization between opioid receptors 
and other proposed dimer pairs. Additionally, the C-8 position could serve as a branch for linking 
two (bifunctional) pharmacophores in a bivalent ligand. Appropriately spaced bivalent 
peptidomimetics would in theory show increased binding affinity to dimers of opioid receptors 
compared to monovalent ligands. Furthermore, computational modeling indicates the presence of 
a conserved lysine residue near C-8 which could be targeted by C-8 substituted lysine-targeting 
covalent ligands. The need for these chemical probes is not presently well-established; however, 
these potential applications for C-8 substituted ligands highlights the functionality of this position 
on the THQ core. Even so, if none of the aforementioned future directions are further pursued, this 
previously unexplored position has been successfully exploited in a number of bioavailable in vivo 
candidates that may yet provide benefits in the treatment of pain with the promise of reduced side-
effects due to their bifunctional nature.  
5.4  Observations Based on Combined Bicyclic C-6 and N-1 or C-8 Motifs  
 Early peptide-based and peptidomimetic SAR studies had demonstrated that bicyclic 
substitutions at C-6 (or analogously positioned bicyclics in the peptide series) preferentially bound 
to the active-state receptor conformation of MOR and to the inactive-state conformation of DOR. 
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By utilizing a bicyclic C-6 pendant, it was possible to elicit the MOR agonist/DOR antagonist 
profile which was hypothesized to be advantageous for reducing tolerance and dependence while 
maintaining antinociceptive activity in vivo. A limitation of the C-6 bicyclic approach was the high 
degree of binding selectivity for MOR over DOR, which limits the bifunctional aspect of these 
ligands. Chemists previously working on this project (A.A.H. and A.M.B.) had established that N-
acylation could increase DOR affinity, thereby reducing MOR selectivity and achieving a more 
optimal in vitro profile. Furthermore, two notable N-acetylated/bicyclic C-6 analogues (43 and 45) 
had demonstrated a boost in bioavailability whereby both analogues showed robust antinociceptive 
activity. These promising results were expanded upon as described in Chapter 3 by pairing five 
bicyclic C-6 pendants with four N-acyl and N-sulfonyl moieties. The monocyclic benzyl pendant 
and unsubstituted N-H core were included in this series for reference, giving a 6x5 matrix of 30 
analogues—20 of which could be classified as bicyclic/N-substituted analogues. Of these 20 
bicyclic/N-substituted analogues, 14 displayed partial or full MOR agonism and DOR antagonism. 
Based on the results of the study described in Chapter 3, the following observations were made: 
1. Subnanomolar affinity at MOR and DOR can be consistently achieved via N-substitution. 
 
2. The N-mesyl substitution has the most beneficial effect on functional profile, combining DOR 
antagonism with superior MOR potency and efficacy. 
 
3. N-Acetyl and cyclopropyl acyl substitutions provide the best binding profiles (closest to 1:1 
between MOR and DOR), but often elicit partial DOR agonism—especially with planar, fully 
aromatic pendants. 
 
4. Heteroatoms distal to the THQ core are poorly tolerated at MOR (poor potency and efficacy). 
 
5. The THIQ pendant is most effective at achieving the MOR agonist/DOR antagonist profile, 
but also displays high KOR affinity and sporadic KOR efficacy. 
 
6. Bioavailability is unpredictable, though a ClogP < 3.5 is generally preferred. 
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The in vitro profiles achieved through the combination of C-6 and N-1 substitutions 
investigated in Chapter 3 are among the most favorable throughout the peptidomimetic series. 
These typically display less than 10-fold selectivity for MOR over DOR with subnanomolar 
affinity at both receptors. Additionally, specific motifs (THIQ, N-mesyl) could reliably produce 
the desired MOR agonist/DOR antagonist profile with subnanomolar potency at MOR. 
Furthermore, clear functional trends showed ways in which both MOR and DOR efficacy could 
be increased or attenuated. Some highlighted analogues featuring the bicyclic motif at C-6 are 
displayed in Fig. 28.  
 
Figure 28. Bicyclic Leads Displaying MOR Agonism/DOR Antagonism with <10:1 MOR/DOR 
Selectivity & >10:1 MOR/KOR Selectivitya 
 
a Analogues 43 and 59 synthesized by A.A.H. and D.J.M. respectively.  
MOR agonist (92% stim, EC50 = 1.8 nM)
DOR antagonist (<10% stim, Ke = N/A)
MOR/DOR selectivity: 5:1
MOR/KOR selectivity: 200:1
Antinociceptive activity: N/A
Duration of action = N/A ; ClogP = 3.7
MOR agonist (96% stim, EC50 = 0.26 nM)
DOR antagonist (<10% stim, Ke = N/A)
MOR/DOR selectivity: 3:1
MOR/KOR selectivity: 30:1
Antinociceptive activity: 50% MPE
Duration of action = N/A; ClogP = 3.1
MOR agonist (87% stim, EC50 = 0.9 nM)
DOR antagonist (<10% stim, Ke = 2.0 nM)
MOR/DOR selectivity: 6:1
MOR/KOR selectivity: 1200:1
Full antinociceptive activity (100% MPE)
Duration of action = 4.5 h; ClogP = 4.5
MOR agonist (114% stim, EC50 = 0.12 nM)
DOR antagonist (<10% stim, Ke = 0.85 nM)
MOR/DOR selectivity: 9:1
MOR/KOR selectivity: 10:1
Full antinociceptive activity (100% MPE)
Duration of action = 1.5 h; ClogP = 3.1
MOR agonist (95% stim, EC50 = 0.52 nM)
DOR antagonist (<10% stim, Ke = N/A)
MOR/DOR selectivity: 3:1
MOR/KOR selectivity: 300:1
Antinociceptive activity: 60% MPE
Duration of action = N/A; ClogP = 3.8
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 Fig. 28 includes six analogues that display the desired MOR agonist/DOR antagonist 
profile with less than 10-fold selectivity for MOR over DOR as well as 10-fold or more selectivity 
for MOR over KOR. Notably, analogue 70 does not incorporate an N-1 substitution but features 
an analogous carbonyl motif at the proximal C-8 position. Analogues 43, 59, and 56 all display 
full antinociceptive activity, but display at least one limiting characteristic. 43 and 59 both display 
a ClogP of 4.5 or greater, which is associated with poor aqueous solubility. Analogue 56 improves 
ClogP to 3.1, but shows a diminished duration of action of only 1.5 h. Furthermore, the binding 
profile of 56 is less optimal than most others included in Fig. 28, displaying approximately 10-
fold selectivity for MOR over both DOR and KOR. Functionally, 56 is the most efficacious and 
potent at MOR, and displays a subnanomolar Ke at DOR, indicating high potency as an antagonist. 
Analogues in the bottom row display highly favorable in vitro profiles, but either have not yet been 
evaluated in vivo (70) or only show partial activity (55 and 50). These three analogues display 
greater than 90% efficacy at MOR and single-digit to sub-nanomolar potency paired with DOR 
antagonism. In terms of binding, all show 5:1 or less MOR selectivity over DOR, while 70 and 50 
are both 200-fold selective over KOR. These analogues demonstrate the types of favorable in vitro 
profiles achieved through incorporation of bicyclic C-6 pendants in tandem with a carbonyl (or 
sulfonyl) motif at N-1 or C-8. As illustrated in Fig. 28, the specific chemical moieties can vary at 
both positions, however a general pattern of bicyclic C-6 pendant paired with a H-bond acceptor 
at the bottom face of the THQ core is consistent throughout all six analogues.  
5.5  Future Directions of the Bicyclic C-6 Chemotype 
 Utilizing the insights obtained from the SAR study discussed in Chapter 3 and above, one 
can re-evaluate past analogues from the C-6 and N-1 series to guide future ligand design. Following 
the success that the THIQ pendant had offered (potent, high-efficacy MOR agonism and DOR 
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antagonism), an analogous pendant that may afford similar success is the isoindoline pendant 
shown in Fig. 29 in analogues 83, 85 and 86. Removal of a single carbon is unlikely to drastically 
affect the pharmacological profile in vitro, however as has been demonstrated, even very subtle 
changes can have significant effects in vivo. As such, this pendant may be useful for replicating 
the in vitro profile attained by the THIQ pendant while also increasing bioavailability. 
Additionally, this pendant was selected for its low lipophilicity. As discussed, existent in vivo data 
indicate a preference for analogues with a ClogP of less than 3.5 (ideally 3.3 or less). Analogues 
83, 85, and 86 all fit within that optimal window, offering the best opportunity for in vivo activity. 
These three analogues utilize N-1 substitutions including the previously unexplored methyl 
carbamate (83) as well as the cyclopropyl acyl moiety (85) that showed the greatest benefit in 
binding as well as the mesyl moiety (86) which demonstrated optimal functionality. Similar to 56, 
one might predict that 86 will also display high KOR affinity due to the N-mesyl group as well as 
the basic amine at C-6. Nevertheless, synthesis and evaluation of 86 could confirm or aid in the 
refinement of in vitro SAR predictions.  
 
Figure 29. Proposed Bicyclic Analogues 81-86 
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 The methyl carbamate moiety of 83 has been previously reported by A.A.H. and, in the 
context of the C-6 benzyl pendant (33), showed full antinociceptive activity in vivo.95 In fact, it 
was additionally paired with two bicyclic pendants, the 2-naphthyl (87) and isoindanyl (88) 
pendants, shown in Table 20 (all three of which were synthesized by A.A.H.). Unforutnately, the 
bicyclic analogues were both inactive in vivo.  
 
 
a Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [3H]-diprenorphine in membrane 
preparations. Functional data were obtained using agonist induced stimulation of [35S]-GTPγS binding. Potency is 
represented as EC50 (nM) and efficacy as percent maximal stimulation relative to standard agonist DAMGO (MOR), 
DPDPE (DOR), or U69,593 (KOR) at 10 μM. All values are expressed as the mean of three separate assays performed 
in duplicate with standard error of the mean in parentheses. dns = does not stimulate. b Synthesized by A.A.H.  
 
The methyl carbamate is comparable in lipophilicity to the cyclopropyl acyl group discussed 
previously. As such, the bicyclic C-6 pendants proposed for analogues 81-83 are all heterocycles 
which, can negate some of the added lipophilicity. Analogues 81-83 range in lipophilicity between 
3.1 and 3.6 as indicated in Fig. 28. These proposed compounds are predicted to display the 
Ki (nM) EC50 (nM) % stim
# R2 R1 MOR DOR KOR
DOR Ki / 
MOR Ki
MOR DOR KOR MOR DOR KOR
33b 0.19
(0.05)
0.51
(0.19)
29
(8)
3 0.78
(0.19)
14
(3)
250
(40)
95
(5)
40
(7)
28
(3)
87b 0.32
(0.08)
0.46†
(0.08)
140†
(70)
2 0.39
(0.21)
dns† dns† 106
(6)
dns† dns†
88b 0.10
(0.02)
0.32
(0.07)
7†
(3)
3 0.39
(0.05)
14†
(3)
170†
(40)
94
(8)
40†
(7)
26†
(3)
81 --- --- --- --- --- --- --- --- --- ---
82 --- --- --- --- --- --- --- --- --- ---
83 --- --- --- --- --- --- --- --- --- ---
Table 20. N-1 Methyl Carbamate Leads 32, 87, & 88,
and Proposed C-6 Heterocyclic Analogues 81-83a
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favorable profile of the leads 32, 87, and 88, however one might expect 81 to display some DOR 
agonism, as the 3-quinolinyl pendant was often a partial DOR agonist when paired with the N-
acetyl and N-cyclopropyl acyl moieties. Additionally, 87 shows some DOR agonism suggesting 
the methyl carbamate may display similar DOR-activating propensity to that of the cyclopropyl 
acyl motif.  
The final analogue proposed in Fig. 29, 84, also incorporates the 3-quinolinyl pendant. 
However, as observed with prior C-8 carbonyl analogues, it is predicted that the dimethyl amide 
motif would maintain the DOR antagonist profile. Analogue 84 is largely designed to mimic the 
2-naphthyl analogue 70 which has shown promise in vitro but displays a ClogP of 3.7 which may 
be unfavorably high. The 3-quinolinyl analogue 84 displays a lower ClogP (2.1) comparable to 
that of the C-6 benzyl/C-8 dimethyl amide analogue 20 which previously showed full activity in 
vivo. Analogue 20 displayed a comparatively poor MOR potency of 9 nM, whereas the bicyclic 
analogue 70 was 5-fold more potent, with an EC50 of 1.8 nM. It is predicted that this increase in 
potency associated with the bicyclic series would also translate to the 3-quinolinyl analogue 84.  
The proposed analogues above represent incremental changes upon a chemotype proven to 
display an optimal or near-optimal in vitro pharmacological profile. As highlighted in Fig. 28, 
analogues featuring a bicyclic C-6 pendant with a carbonyl moiety at the bottom face (N-1/C-8) of 
the THQ core typically show high-potency MOR agonism and DOR antagonism, though in vivo 
activity and duration of action are less predictable. Thus, the goal of the analogues proposed in 
Fig. 29 is to achieve an optimal in vitro profile while targeting low (<3.5) ClogP. As the library of 
analogues displaying related but slightly modified structures and chemical properties expands, it 
may be possible to better predict which motifs will be favored and which are not. Four novel 
bicyclic analogues in Chapter 3 displayed full antinociceptive activity. Analogues 81-86 aim to 
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expand the number of bioavailable ligands so as to better understand correlations between 
structure, chemical properties, in vivo activity, and duration of action. The bicyclic analogues 
discussed thus far have shown promising result in vitro and may yet yield further analogues with 
in vivo profiles comparable to 43. The data presented above and in the preceding chapters merit 
further research into compounds of the bicyclic/N-1 or bicyclic/C-8 carbonyl type.   
5.6 Bicyclic C-6 Conclusions 
 The structural paradigm established by analogues 43 and 45 of two conjugated, aryl or 
semi-aryl rings at C-6 paired with an N-1 acetyl moiety has proven widely successful at achieving 
high affinity at MOR and DOR in tandem with potent, efficacious MOR agonism and DOR 
antagonism. Several analogues replicating this chemotype have demonstrated optimal or near-
optimal in vitro profiles spanning a range of characteristics. Following this structural paradigm, 
efficacious have spanned the range of <10% to 114% at MOR and <10% to 84% at DOR. 
Furthermore, by strategically pairing sets of C-6 and N-1 motifs with one another in a 2D matrix 
setup, trends have emerged that facilitate the design of ligands with tailorable profiles including 
dual agonists, dual antagonists, and anywhere between. This capacity is instrumental in the 
continued evaluation of bifunctional opioid profiles and what impact those have in vivo. Presently, 
the duration of antinociceptive activity achieved by 43 and 45 is yet to be rivaled. However, the 
number of ligands achieving a full antinociceptive effect, albeit for a shorter duration, has 
increased from 2 to 6, with plans for further analogues detailed above. A reliable predictor of 
bioavailability based on in vitro pharmacology, structural traits, or physicochemical properties 
remains elusive. Yet, preliminary data within this series indicates low lipophilicity (ClogP < 3.5) 
is a fair correlate of bioavailability. Further investigation of this chemotype could yield novel 
analogues that reproduce the in vitro and in vivo success observed for 43 outlined in Chapter 4.  
 289 
 In addition to combining bicyclic C-6 pendants with N-acyl or N-sulfonyl motifs, the recent 
analogue 70 has demonstrated that the carbonyl moiety can effectively be translocated to C-8 
(described in Chapter 2), replicating the in vitro profile achieved by 43. Furthermore, by inversion 
of the tertiary amide moiety of 43 as in analogue 70, lipophilicity is decreased considerably (ClogP 
of 4.3 for 43 is reduced to 3.7 for 70). At present, analogue 70 is a prime candidate for evaluation 
in vivo for antinociception.  
5.7 Concluding Remarks 
 As a result of the work presented here, the number of fully active in vivo candidates has 
been expanded by 11. Seven of the in vivo candidates come from the C-8 campaign described in 
Chapter 2 while four come from the bicyclic project of Chapter 3. It should be noted that credit for 
the synthesis of two of those bicyclic analogues (59 and 60) belongs to chemist D.J.M. who also 
contributed to the bicyclic project. These analogues cover a range of in vitro profiles. The further 
evaluation of said in vivo candidates for tolerance and dependence may aid in the identification of 
which pharmacological descriptors best predict reductions in tolerance, dependence, and CPP. 
This work additionally has yielded numerous compounds displaying optimal in vitro profiles—
potent, efficacious MOR agonism and DOR antagonism with similar affinity at both receptors (and 
100-fold selectivity over KOR). The SAR research described here has laid strong foundations for 
future development of analogues in both the C-8 and bicyclic series. It is now established that 
carbonyl C-8 moieties and sulfonyl N-1 motifs (when combined with bicyclic C-6 pendants) can 
reliably achieve the desired MOR agonist/DOR antagonist profile. Additionally, compounds of 
both types of shown robust antinociceptive activity after peripheral administration, suggesting both 
approaches are viable for the development of future analgesics.  
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 Plans for the continued utilization of C-8, bicyclic C-6/N-1, and C-6/C-8 substitution 
patterns have been laid out in this chapter. C-8 may serve as a functional handle for radiolabeling 
and glucoserine conjugation, while proposed C-6/N-1 and C-6/C-8 analogues hold promise for 
further optimization of physicochemical properties as well as in vitro and in vivo pharmacology. 
The work presented here was made possible by foundational SAR work performed by chemists 
Larisa Yeomans, Aubrie Harland, and Aaron Bender. Should future chemists carry on in this field 
of research, it is hoped by this author that the work described herein will provide a similarly strong 
foundation for continued opioid drug discovery.  
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